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at amino acid residue 101. 
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PVDF Polyvinylidine fluoride 
QuIC Quaking-induced conversion assay 
recPrP Recombinant PrP 
RNA Ribonucleic acid 
RML Murine scrapie strain; Rocky Mountain Laboratories 
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RT Room temperature 
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SAF Scrapie associated fibrils 
SD50 Seeding dose or serial dilution at which 50% of animals/wells were positive 
for TSE disease 
SDS Sodium dodecyl sulphate 
SELDI Surface-enhanced laser desorption/ionization 
SEM Standard Error of the Mean 
sPMCA serial protein misfolding cyclic amplification 
sPrP
Sc
 PK-sensitive form of PrP
Sc 
TBE Tris borate EDTA buffer 
TBS Tris buffered saline 
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TBST Tris buffered saline with Tween 20 
Tg Transgenic 
TOF-MS Time of flight mass spectrometry 
TME Transmissible mink encephalopathy 
TSE Transmissible spongiform encephalopathy 
UV Ultraviolet light 
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Transmissible spongiform encephalopathies (TSEs) are a group of fatal, neurodegenerative 
diseases that can affect both humans and animals. TSEs can be sporadic, familial, or 
acquired diseases. The prion hypothesis states that a misfolded form of the host glycoprotein, 
PrP
C
, acts as the infectious agent in TSE disease. The misfolded form, PrP
Sc
, is increased in 
β-sheet content, detergent insoluble and partially resistant to proteinase K (PK) digestion. 
Based on the prion hypothesis, most current post-mortem diagnostic tests rely on the 
presence of PrP
Sc
 as indicative of TSE disease. However, recently experimental cases of TSE 
disease have been identified where no PrP
Sc
 deposition is evident. 
One example of this is a murine transgenic model of Gerstmann Sträussler Scheinker (GSS) 
disease. GSS is a familial TSE disease, caused by a number of different mutations in human 
PrP including a point mutation from proline to leucine at residue 102. A murine model of 
GSS disease, produced through gene-targeting, contains the same point mutation at the 
equivalent residue, 101, in murine PrP. These mice do not develop spontaneous disease 
during their lifespan, but when inoculated intra-cerebrally with either human P102L GSS 
(101LL/GSS) or hamster 263K scrapie (101LL/263K); develop a clinical disease and 
vacuolar TSE-related pathology. Upon biochemical and immunohistochemical analysis, the 
brain tissues of these clinically ill mice contain little or no detectable PrP
Sc
. However 




IU/g of brain tissue. 
Standard PK digestion (at 37°C), NaPTA precipitation and isolation of PrP
Sc
 through 
detergent insolubility and differential centrifugation all confirmed the observation of little or 
no detectable PK-resistant PrP (PrP-res)
 
in the 101LL/GSS and 101LL/263K brain tissues, 
despite the high levels of TSE infectivity.  
The presence of PrP
Sc
 and/or TSE infectivity in the spleen during disease pathogenesis is 
dependent upon TSE agent strain and host species. Previous studies utilising wild-type mice 
infected with ME7, have shown that the levels of infectivity observed in spleen tissue are 2-
3log10 lower than those observed in the brain tissue of the same mice. However, experiments 
conducted as part of this thesis showed that sub-passage of both the brain and spleen tissue 
from clinically ill 101LL/GSS and 101LL/263K mice into 101LL mice by intra-cerebral 
inoculation result in short incubation periods, indicating that infectivity levels were similarly 
high in both tissues. Biochemical analysis of the primary spleen tissue identified the 
presence of PrP-res, albeit at lower levels than those observed in wild-type spleens infected 
with a standard laboratory TSE strain, ME7 or 79A. However, the presence of PrP-res 
xiii 
 
indicates that the spleen has a role in disease pathogenesis, which will require further 
investigation. Additionally, the spleen tissue maintains the discrepancy between PrP-res and 
TSE infectivity that is observed in the brain tissue of these models and further questions the 
prion hypothesis.   
As little or no PrP-res was detectable in the brain tissues of 101LL/GSS and 101LL/263K 
mice by standard biochemical and immunohistochemical techniques, it was hypothesised 
that an in vitro amplification technique, protein misfolding cyclic amplification (PMCA) 
could amplify PrP
Sc
 to detectable levels. A series of optimisation experiments were 
performed to produce a reliable positive control for amplification of mouse PrP
Sc
 from a 
standard laboratory mouse TSE strain, 79A or ME7, with a  normal wild-type mouse brain 
homogenate substrate. While a wide range of technical and experimental conditions were 
investigated, consistent and reproducible amplification of mouse PrP
Sc
 was not achieved and 
therefore amplification of PrP
Sc
 from 101LL/GSS and 101LL/263K tissues could not be 
performed as interpretation of results would be complicated without the presence of a 
positive control. Previous research has shown that while other commercial assays, e.g. 
TeSeE (BioRad), identified tissues from these models as borderline positive or negative for 
TSE disease, one TSE diagnostic assay, the IDEXX HerdChek kit, that utilises the Seprion 
ligand, identified both the brain and spleen tissue from 101LL/GSS and 101LL/263K clinical 
mice as positive for TSE disease. In order to identify if TSE infectivity is associated with the 
target of the Seprion ligand, brain tissue homogenates from 101LL/GSS, 101LL/263K and a 
positive control wild-type/79A homogenate were depleted of the Seprion ligand target 
utilising a PAD-beads kit (Microsens Biotechnologies), which incorporates the Seprion 
ligand as the capture agent, in combination with magnetic beads. Upon inoculation, a single 
depletion of the homogenates produced no significant reduction in incubation period to 
clinical disease in either the depleted homogenates or the wash buffers produced, in 
comparison to a non-depleted brain homogenate. This result indicates that a single depletion 
with the Seprion ligand, did not remove enough of the aggregated protein to significantly 
alter the level of infectivity in the depleted homogenate and that any infectious agent, which 
was initially bound to the Seprion ligand due to non-specific interactions, was then released 
during the wash steps of the procedure.  Proteomic differences between all components 
produced during a single depletion of an infected brain homogenate, wild-type/79A, or a 
normal uninfected brain homogenate were assessed to potentially identify the target of the 
Seprion ligand.  
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In conclusion, these murine models of TSE disease, 101LL/GSS and 101LL/263K, which 
contain both high infectivity levels with little or no PrP-res in the brain tissue and similar 
high levels of infectivity with low levels of PrP-res in the spleen, questions the accepted 
correlation between levels of infectivity and PrP-res or PrP
Sc
 as proposed by the prion 
hypothesis. It is hypothesised that either an alternative form of PrP, which has not yet been 
identified is the infectious agent in these disease models, or that the TSE infectious agent is a 
component which associates with PrP
Sc
 rather than being PrP
Sc
 itself.  The eventual 
identification of the infectious agent present in these unusual disease models will increase 
our understanding of these diseases, potentially offer improved diagnostics for infectivity, 





1. An Introduction to Transmissible Spongiform 
Encephalopathies 
1.1. Introduction 
Transmissible spongiform encephalopathies (TSEs) are a group of fatal neurodegenerative 
diseases that can affect both humans and animals. Transmission is possible either within or 
between species, depending on the infectious strain and host species. For example, BSE is 
transmissible between cattle but can also transmit across the species barrier to humans, 
causing variant Creutzfeldt-Jakob disease (vCJD), to cats causing feline spongiform 
encephalopathy and to sheep causing ovine BSE. TSE diseases can be sporadic, acquired; by 
various routes including ingestion and intravenous inoculation or familial; due to a genetic 
mutation of the PRNP gene in humans. Examples of the TSE diseases and the species that 
they affect are listed in Table 1-1. 
TSE Disease Affected Species 
Bovine Spongiform Encephalopathy (BSE) Cattle 
Scrapie Sheep and Goats 
Chronic Wasting Disease (CWD) Deer, Elk and Moose 
Transmissible Mink Encephalopathy (TME) Mink 
Feline Spongiform Encephalopathy (FSE) Cats 
Creutzfeldt-Jakob Disease (CJD) Human 
Kuru Human 
Fatal Familial Insomnia (FFI) Human 
Gerstmann-Straussler-Scheinker (GSS) Human 
Table 1-1: TSE diseases and the affected species 
These diseases are characterised by long asymptomatic incubation periods that develop into 
clinical symptoms including behavioural changes, cognitive impairment and insomnia. The 
neuropathological changes of TSE diseases include spongiform degeneration, vacuolation, 
gliosis, abnormal protein (PrP
Sc
) deposition, and neuronal loss that will eventually lead to 
neurodegeneration and inevitably death. Although the infectious agent remains unknown, the 
widely accepted prion hypothesis identifies an abnormal misfolded form (PrP
Sc
) of the 
normal cellular host glycoprotein (PrP
C
) as the TSE infectious agent (Prusiner 1982).  
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1.1.1. The normal cellular protein, PrPC 
PrP
C
 is a 38kDa glycoprotein (Figure 1-1) encoded by the PRNP gene on the short arm of 
chromosome 20 in humans and by the Prnp gene on chromosome 2 in mice. PrP
C
 is 
expressed in many different organs including brain, heart, lungs, kidney and in lymphoid 
cells but has the highest expression levels in neurons (Westergard, Christensen et al. 2007). 
Murine PrP
C
 is a 253 amino acid protein that is synthesised in the rough endoplasmic 
reticulum and then post-translationally processed with the addition of oligosaccharide side 
chains at two amino acids, 180 and 196. Differential glycoslyation results in the PrP
C
 
produced in un-, mono-, or di-glycosylated states. A 22 amino acid signal peptide, located at 
the amino terminus, targets the protein to the endoplasmic reticulum where it is then cleaved. 
PrP
C
 locates to the outer leaflet of the lipid bilayer in regions rich in cholesterol known as 
lipid rafts within the cell membrane, where the protein attaches via its glycosyl-
phosphatidylinositol (GPI) anchor present at the carboxyl-terminus (Stahl, Borchelt et al. 
1987). PrP
C
 contains an N-terminal flexible, random coil region that is unstructured and 
contains five copies of an octapeptide repeat region. The C-terminal globular domain of PrP
C
 
contains 3 alpha-helix structures comprising 42% of the protein, with only 3% beta-sheet 
structure (Pan et al., 1993). Alpha-helixes 2 and 3 are stabilized by the presence of a 























Figure 1-1: Cartoon of murine PrP
C
 
1.1.2. PrP null mice 
PrP null mice, Prnp
o/o 





produced developed normally (Büeler, Fischer et al. 1992) but were shown to be resistant to 
scrapie infection (Bueler, Aguzzi et al. 1993, Prusiner, Groth et al. 1993, Manson, Clarke et 
al. 1994) indicating an essential role of PrP
C
 in TSE infection. Upon inoculation, the Prnp
o/o 
mice did not develop any TSE associated vacuolation or PrP-res deposition. Further no 
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clinical disease developed from the sub-passage of Prnp
o/o 
mouse brain into wild-type CD-1 
mice, indicating the infectious agent had not been replicated during the primary passage 
(Prusiner, Groth et al. 1993). Mice that were heterozygous for Prnp
o/+
 showed enhanced 
resistance to disease, with extended incubation periods to clinical disease indicating a dose-
dependent effect of Prnp expression. The heterozygous expression of Prnp
o/+
 did not affect 
the distribution of either TSE associated vacuolation or PrP
Sc
 deposition observed at the 
clinical stage of the disease (Prusiner, Groth et al. 1993, Manson, Clarke et al. 1994). The 
level of PrP
C
 expression therefore affects the length of incubation period in a dose-dependent 
manner. Thus host PrP
C
 is required to support TSE infection, but the function remains 
elusive. 
1.1.3. PrPC function 
A number of studies have identified possible functions of the normal cellular protein, PrP
C
, 
such as involvement in cell adhesion and promotion of neuronal growth and survival. Indeed, 
PrP
C 
is located on the cell-membrane and has been shown to act as a receptor for laminin, 
binding to the laminin γ-1 chain that then through an unknown intracellular signalling 
pathway promotes neuronal growth (Graner, Mercadante et al. 2000). In addition to binding 
laminin directly, both the 37kDa laminin receptor precursor and the 67kDa laminin receptor 
have been identified as endocytic receptors for PrP
C
 on the cell surface that mediate the 
internalization and recycling of PrP
C
 through clathrin coated pits (Rieger, Edenhofer et al. 
1997, Gauczynski, Peyrin et al. 2001). Further evidence for the role of PrP
C
 in cell adhesion 
was gained from research with zebrafish, which have two PrP genes that are structurally 
similar to mammalian PrP, called PrP1 and PrP2. The PrP1 proteins on adjacent cells have 
been shown to interact, serving as a homophilic adhesion molecules (Biasini, Turnbaugh et 
al. 2011). Other research shows that PrP
C
 binds the neural cell adhesion molecule within the 
lipid rafts, promoting activation of the fyn kinase pathway and therefore enhancing neuronal 
growth (Santuccione, Sytnyk et al. 2005). PrP
C
 has also been shown to initiate other 
transmembrane signalling processes involving neuronal survival, neurite outgrowth and 
neurotoxicity. PrP
C
 has been shown to interact with cell-surface stress inducible protein 1 
and the interaction mediates neuritogenesis and neuroprotection of hippocampal neurons 
(Zanata, Lopes et al. 2002), where both proteins are highly expressed. This protective effect 
was shown to be dependent on the cAMP/protein kinase A signalling pathway (Chiarini, 
Freitas et al. 2002). Another possible neuroprotective function of PrP
C 
is through an anti-
apoptotic activity by inhibiting Bax-mediated neuronal death (Bounhar, Zhang et al. 2001, 
Zomosa-Signoret, Arnaud et al. 2008). Indeed, one study showed that some of the mutations 
that are associated with CJD, FFI (D178N) and GSS disease; P102L, P105V, Y145stop and 
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Q212P, lose the ability to prevent Bax-mediated apoptosis whilst others; GSS A117V 
retained the anti-Bax function. (Jodoin, Misiewicz et al. 2009). Other possible functions of 
PrP
C
 could depend on the ability of the octapeptide repeat region of the PrP
C
 protein to bind 
copper ions, although the implications of this metal ion binding to the protein are poorly 
understood with conflicting data (Westergard, Christensen et al. 2007). Elucidating the 
function(s) of PrP
C
 may help to determine if symptoms of TSE disease are caused by loss of 





.    
1.1.4. Genetics of TSE disease – polymorphisms and mutations 
The presence of a gene controlling scrapie incubation time was first identified in 1968 using 
classical genetics and was initially termed the sinc gene, denoting scrapie incubation period 
(Dickinson, Meikle et al. 1968). Two alleles of the gene were detected that influenced the 
incubation period of disease, p7 and s7. Following the identification of PrP in 1982, it was 
shown by molecular genetic analysis that PrP and Sinc could encode the same gene (Hunter, 
Hope et al. 1987). Polymorphic variation of PrP was known to control susceptibility to 
different TSE diseases and contain mutations that can cause familial inherited forms of the 
diseases. In mice, two PrP alleles were identified in inbred laboratory strains of mice that 
have polymorphisms present at codons 108 and 189. Prnp
a 
encodes 108L, 189T whilst Prnp
b
 
encodes 108F, 189V.  These genes appeared to correlate with the sinc s7 and p7 alleles. 
Studies using knock-in transgenic mice that introduced the 108F and 189V polymorphisms 
into the Prnp
a
 allele proved that these polymorphisms were the major factors controlling 
TSE incubation time in mice, and that Prnp and sinc were the same gene (Barron, Baybutt et 
al. 2005). In sheep, polymorphisms at codons 136, 154 and 171 in ovine PrP are important in 
determining the susceptibility of the host to classical scrapie, with VRQ/VRQ homozygote 
sheep highly susceptible to infection, whilst ARR/ARR homozygote sheep are identified as 
resistant to classical scrapie disease (Goldmann 2008). In human prion disease, the 
metionine/valine polymorphism at codon 129 influences disease susceptibility and 
phenotype, with all case of definite vCJD to date homozygous for methionine.  
Germ-line mutations that occur within the PRNP gene are thought to lead to familial forms 
of prion disease in humans. A number of different mutations associate with different familial 
forms of the disease; eleven single point mutations are associated with familial CJD, a single 
point mutation D178N is associated with FFI syndrome, whilst other familial forms of 
human TSE disease are caused by insertion and deletion mutations within the PrP gene. 
Several different point mutations are known to cause the GSS phenotype (Figure 1-2), the 
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severity of which can alter depending on the polymorphism present at codon 129. The 



















, Y218N, Y226X, Q227X and M232T (Liberski and Budka 2004, 
Imran and Mahmood 2011) (Figure 1-2). GSS is defined as an autosomal dominant disorder 
characterised clinically by progressive ataxia followed by a late onset of dementia and 
neuropathologically by encephalopathy and multicentric PrP plaques (Liberski 2012). The 
P102L mutation is the most common GSS mutation and results in substitution of proline 
(CCG) by leucine (CTG), creating an additional DdeI site within exon 3 of the PRNP gene. 
Disease symptoms appear in P102L GSS patients aged 20-60 and the disease duration can 
range from a few months to a few years. P102L GSS disease has been shown to be infectious 
through transmission to nonhuman primates including squirrel monkeys, spider monkeys and 
marmosets (Masters, Gajdusek et al. 1981, Tateishi, Kitamoto et al. 1988, Baker, Duchen et 
al. 1990) although to date no cases of GSS disease caused by human to human  transmission 
have been reported (Liberski 2012). Other research has transmitted a Japanese case of GSS 
disease to wild-type mice and rats producing a TSE disease that was transmissible to other 
rodents, a strain known as Fukuoka-1 (Tateishi, Ohta et al. 1979, Tateishi, Sato et al. 1980).  
 
Figure 1-2: Human PrP
C
 with pathogenic mutations that are associated with GSS indicated.  
1.1.5. Strains of TSE agent 
The existence of different strains of TSE agent in most species susceptible to TSE disease 
has been well documented, often by transmission to mice. After multiple serial passages of a 
TSE agent, a stable strain is obtained that will produce reproducible strain characteristics on 
further sub-passage in the same host species. In mice, TSE strains are differentiated based on 
the incubation period to disease, clinical symptoms and the neuropathology when passaged 
in a panel of wild-type mice. Dickinson et al, (Fraser and Dickinson 1968) first proposed the 
stain typing of TSE strains in mice based on the severity of vacuolation in different brain 
areas. Nine grey matter and three white matter brain areas from at least six mice are scored 
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on a scale of 0-5 by experienced personnel, the average values are calculated and graphed to 
produce a lesion profile that is individual for each TSE strain based on the severity and 
pattern of vacuolation of each strain. Strain typing was utilised to show that vCJD was 
caused by the same agent that caused BSE in cattle as well as FSE in cats (Bruce, Will et al. 
1997). Further strain differentiation can be performed through analysis of the PrP
Sc
 
deposition pattern, with different strains targeting different brain areas that are detected 
through immunohistochemical analysis with anti-PrP antibodies. Biochemically, different 
fragment sizes and glycoform patterns of PrP-res on an immunoblot can be used to help 
identify TSE strains. PrP can either be un-, mono- or di-glycosylated during post-
translational modification and the different sizes and ratios of these three isoforms following 
PK digestion of PrP produces individual banding patterns on immunoblots that can be 
utilised to differentiate between strains. Indeed, different types of CJD are identified by the 
detection of either „type 1‟ or „type 2‟ PrP-res that differ by fragment size and glycoform 
ratio. However, the identification of co-occurrence cases, where both glycoforms of PrP-res 
were present in one individual (Yull, Ritchie et al. 2006) complicates the interpretation of 
strain typing through glycoform patterns. Alternatively, variations in the conformation of 
PrP
Sc
 can be identified through conformation dependent immunoassays (CDI) through 
unfolding in increasing concentrations of GdnHCl. This technique was utilised to distinguish 
eight different hamster scrapie strains (Safar, Wille et al. 1998) and will be discussed in more 
detail later (Section 1.2.4).  
The ability of the TSE infectious agent to transmit strain-specific information in the absence 
of an identifiable nucleic acid component is a major weakness of the prion hypothesis 
(Section 1.2.1). Speculation suggests that each TSE strain represents a specific conformation 
of PrP
Sc
 that is transferred to the PrP
C 
protein upon conversion and encodes for the strain 
specific phenotypes observed.  
1.1.6. The use of rodent models of TSE disease 
Rodents are popular models for TSE research as they are cheap, easy to maintain and allow 
discrimination between strains. Mice, hamsters and more recently bank voles are frequently 
utilised for TSE disease research. Transgenic murine models have shown a correlation 
between increased expression level of PrP
C
 and a decrease in incubation period to disease 
(Scott, Foster et al. 1989, Manson, Clarke et al. 1994). Indeed, over-expression of PrP
C
 can 
lead to spontaneous disease in some transgenic mouse models (Westaway, DeArmond et al. 
1994). The phenomenon of the species barrier results in prolonged incubation periods to 
disease when disease is transmitted to a different species, with a second passage in the new 
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host species reducing the length of the incubation period. To overcome the species barrier 
effect, transgenic mice have been created that express a different species of PrP
C
, such as 
bovine, ovine, caprine, human, cervid, or hamster to alter the susceptibility of the transgenic 
mice to different species and strains of TSE agent. Further, specific PrP polymorphisms 
within a species that have different susceptibilities to disease have been modelled in 
transgenic mice, e.g. mice have been created that express human PrP that are either 
homozygous or heterozygous for methionine or valine at codon 129 (Bishop, Hart et al. 
2006). The majority of transgenic lines created and used today are produced on a Prnp
o/o 
background to avoid confounding effects of the host species PrP
C
. Transgenic  mice can be 
produced through two different approaches (i) by gene-targeting (knock-in) that introduces 
the gene of interest at the same location, under the same promoters as endogenous PrP 
producing the same expression level, (ii) random insertion of multiple copies of the PrP gene 
of interest at random locations throughout the genome, resulting in a different expression 
level. Transgenic mouse models that over-express PrP
C
 produce shorter incubation periods to 
disease decreasing experimental costs and provide results quicker but the interpretation of 
the results are complicated by the risk of the development of spontaneous disease. In 
comparison, the gene-targeted transgenics allow for more controlled assessment of the 
effects of mutations and polymorphisms on disease pathogenesis. Both over-expressors and 
gene-targeted transgenic models provide insights into TSE disease and have increased the 
understanding of these fatal diseases.  
1.2. Nature of the TSE agent 
1.2.1. Prion hypothesis 
The prion hypothesis defines a prion as a small proteinaceous infectious particle, composed 
largely if not exclusively of PrP
Sc
, that is resistant to inactivation by most procedures that 
modify nucleic acids (Prusiner 1982). According to this hypothesis the prion acts as the 









 have been shown to have the same amino acid 
sequence (Stahl, Baldwin et al. 1993) indicating they are the same protein differing in 
secondary, tertiary and quaternary structures. PrP
Sc
 has an increase in beta-sheet content 
(43%) and therefore less (30%) alpha-helix content than the protein in its normal 
conformation (Pan, Baldwin et al. 1993). This conformational change is thought to occur 
through a seeded-nucleation model where PrP
Sc
 acts as the template (Jarrett and Lansbury 
1993, Kocisko, Come et al. 1994). Conversion to the abnormal form results in protease-
resistance, insolubility in non-denaturing detergents and resistance of the protein to UV and 
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ionizing radiation. Other arguments that support the prion hypothesis are that the 
concentration of PrP
Sc
 was found to be directly proportional to the titre of the infectious 
agent in sucrose gradient fractions (McKinley, Bolton et al. 1983), infectivity levels were 
reduced by proteolytic digestion and other procedures that damage proteins, such as 
digestion with diethylpyrocarbonate (Prusiner, McKinley et al. 1981). Scrapie-associated 
fibrils (SAF), with amyloid-like properties were identified through negative staining 
techniques in mice and hamsters infected with TSEs (Merz, Somerville et al. 1981). SAF that 
were identified in hamster 263K disease models, were shown to co-purify with TSE 
infectivity (Hilmert and Diringer 1984). When an infected brain homogenate was digested 
with proteinase K (PK), the 33-35kDa protein was N-terminally cleaved to produce a 
resistant core that was 27-30kDa in size. As the normal form PrP
C
 was completely degraded 
by PK digestion, the presence of PrP-res, 27-30kDa, is taken as indicative of TSE disease. 
All forms of PrP
Sc
; PrP27-30, SAF and prion rods have only been identified from TSE-
infected brain tissue and the prion hypothesis suggests PrP
Sc
 is the infectious agent of TSE 
disease. However, one study identified the presence of low levels of detergent insoluble 
aggregated PrP and PrP-res in uninfected human brains using sedimentation and size 
exclusion chromatography (Yuan, Xiao et al. 2006) indicating PrP-res may be present in all 
brains at a low level. Further support of the prion hypothesis was shown through the 
discovery of yeast prions, defined as an infectious protein that behaves as a non-mendelian 
genetic element and can transmit biological information in the absence of a nucleic acid. 
These yeast prions have added support to the prion hypothesis, especially since yeast prions 
produced in vitro have the ability to transfer the prion phenotype to yeast cells in vivo (Soto 
and Castilla 2004) without the addition of any co-factors.  
1.2.2. Alternative hypothesis – the virus and virino hypothesis 
The long incubation period of TSE disease, led researchers to propose that a „slow virus‟ was 
the infectious agent of these fatal, neurodegenerative diseases. The virus hypothesis states 
that TSE diseases are caused by a slow virus particle that is 25-30nm in diameter and 
contains a double-stranded viral DNA genome of 1-4kb length (Manuelidis 2007). Previous 
research indicated that the infectious agent was able to pass through >20nm filters, was of 
roughly similar size to smaller viruses as indicated by sedimentation velocity and was 
sensitive to ionising radiation (Rohwer 1991). The scrapie agent was shown to be heat stable 
with a denaturation curve similar to that of double-stranded DNA (Millson, Hunter et al. 
1976). The TSE infectious agent has been shown to be resistant to UV irradiation which is 
often cited as evidence for the prion hypothesis but some small viruses are known to be UV-
resistant. A scrapie virus would be UV resistant if the nucleic acid present was a small 
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component of only around 20-30 bases (Rohwer 1991). The virus hypothesis proposes a 
facilitator role for cellular PrP
C
 to explain the correlation observed between PrP-res and 
infectivity and the requirement of PrP
C
 for disease. One of the main arguments against the 
prion hypothesis is the presence of different strains of TSE (Section 1.1.5), a phenomenon 
that could be explained by mutations in the viral genome.  
Alternatively, the virino hypothesis states that a small agent-specific informational molecule 
bound to and protected by PrP
C
, is the infectious agent in TSE diseases (Farquhar, 
Somerville et al. 1998). This virino hypothesis is supported by the lack of an immune 
response to a TSE infection, as the immune system recognises the PrP
C
 protective coating as 
host protein. In this proposal, the protein itself is not infectious but interacts with the 
infectious agent and determines the rate of pathogenesis (Dickinson and Meikle 1971). 
Similarly to the virus hypothesis, the presence of a nucleic acid could account for the strain-
specific information that is transmitted upon infection (Kimberlin 1982). 
However, both these alternative hypotheses require the discovery of an informational 
molecule, e.g. a nucleic acid, and until evidence of this molecule is discovered, these 
hypotheses remain unverified. Recent work has identified the presence of two circular 
plasmid-related DNA sequences from highly infectious N2a-22L scrapie cell gradient 
fractions, hamster 263K brain tissues and from FU-CJD infected mice. These SPHINX DNA 
sequences were present at 2500-fold greater level in TSE-infected cells compared to normal 
cells (Manuelidis 2011). Whether these indicate a TSE genome or are a pathological by-
product of endogenous circoviruses remains to be determined.  
1.2.3. Dissociation of PrP-res and TSE infectivity 
Although many cases of TSE disease have been reported with the presence of PrP-res 
identified through its partial resistance to protease digestion, an increasing number of cases 
have been reported where TSE disease is present in the absence of detectable PrP-res.  
One case of transmission of BSE to wild-type (C57BL6) mice resulted in 100% attack rate 
with all mice developing clinical symptoms of neurological disease, displaying hind-limb 
paralysis, tremors, hypersensitivity to stimulation, apathy and hunching. In 55% of the 
diseased mice, no PrP-res was detectable by western blotting. Upon sub-passage of PrP-res 
negative tissue, a TSE disease developed, with the absence of PrP-res in 38% of the mice 
inoculated. The transmission of a TSE agent through three passages without the presence of 
PrP-res indicates that TSE infectivity can exist in the absence of detectable PrP-res
 
(Lasmezas, Deslys et al. 1997). In another study (Race, Meade-White et al. 2002), the cross-
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species passage of hamster 263K scrapie into wild-type mice, appeared not to transmit, with 
the mice appearing clinically normal and no PrP-res was detectable. Sub-passage of brain 
tissue from a PrP-res
 
negative, clinically normal mouse to wild-type mice did not produce a 
clinical disease but PrP-res was detectable in the brain tissue with disease produced upon a 
secondary sub-passage. In contrast, primary sub-passage of the same PrP-res negative, 
clinically normal mouse brain tissue into hamsters produced a clinical TSE disease, 
indicating that the mice had replicated the scrapie infectious agent without the corresponding 
replication of PrP-res
 
(Race, Meade-White et al. 2002). In one murine transgenic model, 
mice that express a mutation associated with GSS disease P102L at the equivalent codon in 
murine PrP, denoted as 101LL, develop a clinical TSE disease with associated vacuolar 
pathology when inoculated with human GSS brain tissue (101LL/GSS) or hamster 263K 
brain tissue (101LL/263K). However upon biochemical and immunohistochemical analysis 





IU/g being identified by full titration bioassays (Barron, Campbell et al. 2007). More 
recently, a larger animal study was performed where cattle were inoculated orally with 
atypical BSE and developed a clinical disease. However, one cow presented with a clinical 
TSE disease in the absence of detectable PrP-res by standard biochemical techniques (Czub, 
S – personal communication). These studies have indicated that TSE infectivity can be 
present in the absence of detectable PrP-res.  
In contradiction to the models described above, the detection of PrP amyloid in the absence 
of TSE infectivity has also been shown to occur (Piccardo, Manson et al. 2007). The 
transgenic mouse model of GSS disease, 101LL, was inoculated with either a human P102L 
GSS case that had no spongiform degeneration and an 8kDa form of PrP-res (atypical GSS).  
The majority of the mice inoculated with 8kDa-GSS remained asymptomatic with no 
spongiform degeneration, with only one mouse developing neurological symptoms at 662 
dpi with spongiform degeneration detectable. This one 8kDa-inoculated mouse contained 
small PrP
Sc
 plaques as shown by immunohistochemistry of the brain tissue. Surprisingly, 
immunohistochemical analysis of the brain tissue from the 8kDa-inoculated, asymptomatic 
mice identified large PrP
Sc
 plaques in the corpus callosum and surrounding area, indicating 
the presence of PrP
Sc
 in the absence of a typical TSE disease. To assess if infectivity was 
present, the brain tissue from the asymptomatic 101LL/8kDa mice was sub-passaged into 
101LL and wild-type mice. Neither the transgenic nor the wild-type mice developed clinical 
disease or showed any spongiform degeneration on analysis. However, PrP
Sc
 plaques were 
again identified in the recipient 101LL brain tissue by immunohistochemistry. In summary, 
these mice inoculated with the atypical GSS brain homogenate containing an 8kDa-fragment 
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of PrP-res, did not develop clinical disease, spongiform degeneration or infectivity but did 
contain PrP
Sc
 amyloid plaques composed from murine PrP (Piccardo, Manson et al. 2007). 
Another study has shown that in a herd of goats that had endemic classical scrapie, a number 
of healthy goats were identified that had a single 12kDa PrP-res band that was similar but 
not identical to the low molecular weight PrP-res band observed in atypical scrapie 
(Bouzalas, Lortscher et al. 2011). The goats with the unique 12kDa band were healthy with 
no signs of clinical TSE disease at the time of culling. Infectivity studies are currently 
underway that will confirm if these goats are another case of PrP-res deposition without the 
presence of the infectious agent (Bouzalas, Lortscher et al. 2011).  
In another study a number of strains from classical and atypical scrapie and BSE were 
passaged in Tg338 mice that over-express ovine PrP. A range of sedimentation fractions 
were analysed to determine the distribution of PrP-res and infectivity through 
immunoblotting and mouse bioassay respectively (Tixador, Herzog et al. 2010). For two 
„fast‟ ovine strains, LA21K and 127S, inoculation of the fractions containing the most PrP-
res, resulted in a longer incubation period to disease than the fractions containing less PrP-
res, indicating dissociation between PrP-res and TSE infectivity. In contrast, three other 
strains; LA19K, Nor98 and ovine BSE, termed „slow‟ ovine strains showed that the fractions 
with the greatest PrP-res and TSE infectivity peak overlapped. Thus strain-specific 
differences were observed for the sedimentation profiles of PrP-res and TSE infectivity with 
a dissociation between PrP-res and TSE infectivity indicated for some strains (Tixador, 
Herzog et al. 2010).  
The experimental cases described here indicate a dissociation between PrP-res and TSE 
infectivity, indicating that PrP
Sc
 as defined by the prion hypothesis might not be the 
infectious agent. The reliance of diagnostic tests for the presence of PrP-res may result in 
false negatives upon disease diagnosis.  
1.2.4. Presence of PK-sensitive PrPSc (sPrPSc) 
Given the absence of typical PrP-res from a number of different natural and experimental 
cases, it was hypothesised that other forms of PrP
Sc
 exist in infected brains with varying 
sensitivities to PK digestion. The development of the conformational dependent 
immunoassay (CDI) (Safar, Wille et al. 1998), first identified the possibility of alternative 
forms of PrP
Sc
. The CDI utilises an anti-PrP antibody that binds to an epitope site that is 
hidden in the abnormal conformation of PrP but accessible in the normal conformation. 
When the protein is denatured, the epitope is revealed in the abnormal protein and the signal 
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increases indicating the presence of a form of PrP that was present in a different 
conformation. When homogenates were PK-digested prior to undergoing CDI, the 
denaturation-dependent signal was weakened. This indicated that the concentration of 
abnormal PrP was lowered by PK digestion but not completely removed (Safar, Wille et al. 




) fractions from sCJD 
patients, with approximately 90% of total PrP
Sc
 PK-sensitive (Safar, Geschwind et al. 2005). 
It has also been applied to scrapie-infected sheep (Thackray, Hopkins et al. 2007), ME7 and 




(Thackray, Hopkins et al. 2007) and both vCJD and sCJD cases (Choi, Gröner et al. 2011).  
The presence of sPrP
Sc
 was demonstrated in hamster Sc237 scrapie brain homogenates and 
in persistently scrapie-infected-N2a cells through gel filtration and sedimentation techniques 
that identified the sPrP
Sc
 aggregates as small aggregates of less than 600kDa size (Tzaban, 
Friedlander et al. 2002). Isolation of sPrP
Sc
 from hamster 263K scrapie brain homogenate 
was achieved through modification of an ultracentrifugation technique, to produce a 
supernatant containing sPrP
Sc
. The isolated sPrP
Sc
 was able to convert PrP
C
 to PrP-res in the 
protein misfolding cyclic amplification technique (PMCA), (Section 1.5.1) indicating that 
this isoform of sPrP
Sc
 retained converting activity, similar to PrP-res
 
(Pastrana, Sajnani et al. 
2006). Digestion of brain homogenates with either thermolysin or pronase E eliminates PrP
C
 
whilst leaving both sPrP
Sc
 and PrP-res for analysis and characterisation (Cronier, Gros et al. 
2008, D'Castro, Wenborn et al. 2010). Another assay, termed the conformational solubility 
and stability assay, measured the variation in PrP
Sc
 solubility with increasing GdnHCl 
concentrations. This immunoassay identified the presence of high levels of insoluble, sPrP
Sc
 
in Nor98 atypical scrapie cases that had a distinct denaturation profile in comparison to 
classical scrapie cases (Pirisinu, Di Bari et al. 2010). Limited or „cold‟ PK digestion 
performed at 4°C, could also be used to detect sPrP
Sc
. Tg196 mice, that over-express 101L 
PrP
C
 2-fold and eventually develop a spontaneous neurological disease, (Section 1.6) did not 
contain detectable PrP-res through standard PK digestion when inoculated with either an in 
vitro derived misfolded peptide of PrP or human GSS prions. However, a 22-24kDa sPrP
Sc
 
was detected through limited or „cold‟ PK digestion. These sPrP
Sc
 isoforms were absent from 
the brains of wild-type mice but were also present in Tg2866 spontaneously ill mice that 
over-express 101L mutant PrP
C
 8-fold (Tremblay, Ball et al. 2004). However, neither CDI 
nor cold PK digestion detected sPrP
Sc
 from the 101LL/GSS and 101LL/263K disease models 
(Barron, Campbell et al. 2007)(Section 1.2.3 and 1.6).  
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One study by Gambetti et al (Gambetti, Dong et al. 2008), identified 11 patients with a 
neurodegenerative disease characterised by the presence of insoluble PrP that was sensitive 
to protease digestion. A small amount of 6kDa PrP-res was just detectable in the temporal 
cortex of 3 of the patients studied by conventional methods but abundant sPrP
Sc
 was present 
with a ladder-like electrophoretic profile of PrP in all cases. These cases were termed as 
protease-sensitive prionopathy (PSPr) and account for 3% of sCJD cases and 16% of CJD 
cases that have the codon 129VV polymorphism (Gambetti, Dong et al. 2008). Later studies 
identified a further 15 cases of PSPr with cases identified in all codon 129 genotypes, MM, 
MV and VV (Zou, Puoti et al. 2010). As the levels of PrP-res in the newly identified cases 
were more variable dependent on genotype, the diseases were renamed „Variably protease-
sensitive prionopathy‟ (VPSPr). The ladder-like electrophoretic profile of the PrP, was 
present in all codon 129 genotypes, with the 5 major bands showing variation in the 
resistance to digestion by PK. Overall, all the cases had similar clinical symptoms, 
vacuolation levels and the PrP ladder-like electrophoretic pattern indicating the same disease 
was present (Zou, Puoti et al. 2010).  
The role of sPrP
Sc
 and its relationship with TSE infectivity remains to be determined, 
although one study has shown that in sCJD, longer disease durations are associated with 
stable form of sPrP
Sc
, whilst less stable forms of sPrP
Sc
 were associated with shorter disease 
durations (Kim, Haldiman et al. 2011) indicating sPrP
Sc
 levels and stability are related to the 
disease progression rate. Taken together, these data indicate that sPrP
Sc
 is a major fraction of 
total PrP
Sc
 in a number of TSE diseases in different species and it retains the ability to 
replicate both in vivo and in vitro. Further investigation is required to fully understand the 
role of sPrP
Sc
 in disease pathogenesis and the correlation with the TSE infectious agent  
1.2.5. Synthetic prions 
It was presumed that definite proof of the prion hypothesis would come from the production 
of in vitro derived infectious PrP
Sc
, produced from starting material that contained only 
protein with no additional co-factors. The debate about whether this has now been achieved 
through the production of synthetic prions from recombinant PrP is currently ongoing. 
Recombinant mouse PrP (89-230) fibrils were produced through either unseeded or seeded 
polymerisation, and upon inoculation in Tg9949 mice (over-express mouse PrP (89-230) at a 
level 16-fold greater than PrP
C
 in hamster wild-type brains and develop spontaneous late-
onset neurological dysfunction) produced a neurological disease. However, it is not known if 
these recombinant fibrils would be sufficient to produce disease in wild-type mice. Mice 
inoculated intra-cerebrally with the seeded recombinant amyloid contained greater amounts 
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of PrP-res deposition and vacuolation than the recipients of the recombinant amyloid that 
was produced without a seed, hence it was hypothesised that two different strains were 
created. The disease produced upon inoculation of the seeded recombinant fibrils was 
designated mouse synthetic prion strain 1 (MoSP1) and was shown to transmit to both wild-
type mice and Tg4053 mice (over-express mouse PrP
C
 at a level 8-fold greater than PrP
C
 in 
hamster wild-type brains) (Legname, Baskakov et al. 2004). Further experiments were 
performed, including transmission to wild-type mice, neuropathology, conformational 
stability and glycoform pattern on immunoblot that produced doublet bands instead of a 
single band for the unglycosylated band, to confirm MoSP1 was a novel strain (Legname, 
Baskakov et al. 2004, Legname, Nguyen et al. 2005). Since no PrP-res was detected in the 
brains of Tg9949 mice inoculated with unseeded recombinant fibrils despite the presence of 
a neurological disease similar to a TSE disease, an amyloid seeding assay (Section 1.5.2) 
was utilised to examine if sPrP
Sc
 was present. The assay determines if NaPTA precipitated 
PrP
Sc
 retains the ability to seed amyloid formation. The sPrP
Sc
 in Tg9949/unseeded fibril 
brain homogenates were able to seed the formation of amyloid (Colby, Zhang et al. 2007).  
Further synthetic strains were produced by altering the conditions utilised to produce the 
fibrils from the recombinant PrP, including urea concentration, pH and temperature. Mice 
(Tg4053) inoculated with three different recombinant fibril preparations; MoSP5, MoSP6 
and MoSP7, developed a TSE-like disease with the presence of PrP-res in the brain tissue 
that was protease-resistant. The vacuolation profiles and PrP-res deposition patterns were 
unique for each recombinant fibril indicating that three different strains had been produced. 
Data from these studies indicated that the conformational stability of the in vivo PrP-res was 
determined by the conformational stability of the in vitro produced recombinant fibrils 
inoculated and the fibrils produced with the higher stability resulted in longer incubation 
periods to disease (Colby, Giles et al. 2009). Further production of recombinant amyloid 2, 3 
and 4 fibrils in vitro produced disease upon bioassay in Tg9949 mice. However, no PrP-res 
was detected in the brains of the recipient mice but the brain homogenates were able to seed 
the amyloid seeding assay, indicating the presence of protease-sensitive amyloid. Disease 
was shown to be transmissible to Tg9949 mice with the synthetic strains termed MoSP2, 
MoSP3 and MoSP4 respectively (Colby, Wain et al. 2010). MoSP2 produced no clinical or 
pathological symptoms of  TSE disease in wild-type mice but Tg9949/MoSP2 mice were 
able to transmit to Tg4053 mice whilst maintaining the strain characteristics (Colby, Wain et 
al. 2010), indicating the protease-sensitive prions had been produced in vitro. However, 
production of a synthetic prion in vitro would need to be shown to be the cause of TSE 
disease in wild-type mice on primary passage, rather than initial passage through transgenic 
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mice that over-express PrP, before a truly novel synthetic prion can be assumed to have been 
produced.  
Other researchers have produced TSE infectivity in hamsters inoculated with recombinant 
hamster PrP in a beta-sheet conformation that was subjected to an annealing process in the 
presence of either normal brain homogenate (NBH), a process that produced a 16kDa PK-
resistant band, or BSA prior to inoculation. No clinical disease was observed on first passage 
into hamster despite the presence of PrP-res in some hamsters. Clinical disease was produced 
upon sub-passage from brains with or without the presence of PrP-res
 
following inoculation 
with the NBH-annealed fibrils. Surprisingly, long disease duration was observed on sub-pass 
with large amounts of PrP-res detected in the brain. Although disease developed upon sub-
passage, the lack of disease on primary passage suggests that disease was only produced 
once the recombinant amyloid fibrils had access to required co-factors (Supattapone 2010). 
None of the hamsters in the sub-passage that received brain homogenates from hamsters that 
received the BSA annealed fibrils developed clinical disease (Makarava, Kovacs et al. 2010).  
Another method, the PMCA technique (Section 1.5.1) was utilised to investigate whether 
recombinant PrP alone could convert into an infectious synthetic prion, through PMCA 
reactions in the presence of different lipids and/or RNA isolated from normal mouse liver. 
The PMCA product produced after 24 PMCA rounds, performed on recombinant PrP in the 
presence of a synthetic anionic phospholipid POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoglycerol) and RNA, was aggregated, PK-resistant, able to convert PrP
C
 to the PK-
resistant form and infectious to wild-type mice. Although the authors claim to have created a 
synthetic prion de novo, the presence of the lipid molecules and RNA, suggest a role for co-
factors, either in the production of infectivity or as a component in the infectious particle 
(Wang, Wang et al. 2010). 
Despite many claiming the prion hypothesis has been proven by the generation of these 
synthetic prions from re-folded recombinant PrP, a bona fide prion disease has not been 
produced on first passage of the recombinant fibrils in wild-type animals without the 
presence of a co-factor during the fibril production. Further research will continue to attempt 
to produce a prion disease in vitro and could identify a co-factor required for disease.   
1.3. Role of the periphery in disease 
PrP-res and TSE infectivity accumulate in the lymphoreticular system (LRS) that is 
composed of the spleen, lymph nodes, tonsil, appendix and other gut-associated lymphoid 
tissue, within a number of different species that are affected by TSE disease, including mice, 
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hamsters, sheep, deer and humans (vCJD) (Fraser and Dickinson 1970, Rubenstein, Merz et 
al. 1991, Somerville, Birkett et al. 1997, Race, Meade-White et al. 2007). However, not all 
cases of TSE disease have LRS involvement with both BSE in cattle, sporadic CJD and 
familial forms of TSE in humans occurring without pronounced and consistent 
lymphoreticular involvement (Somerville, Birkett et al. 1997, Lee, Kuo et al. 2005). The 
level of PrP-res deposition and infectivity in the LRS varies depending on host species, PrP 
genotype and strain of agent. This is clearly observed in sheep where VRQ/VRQ 
homozygote sheep have PrP-res deposition in the spleen whilst other genotypes, ARR/ARR 





et al. 2000). Based on the available data the European TSE regulation (Parliament 2001) 
includes the spleen as specified risk material for sheep and the tissue does not enter the 
human food chain.  
1.3.1. Presence of infectivity and PrP-res in spleen tissue 
In murine models of acquired TSE disease, infectivity levels in the spleen were shown to 
have an initial increase in titre within days of inoculation that then plateaus for the remainder 
of the disease duration long before infectivity was detected in the central nervous system 
(Dickinson and Fraser 1969, Dickinson, Meikle et al. 1969). In hamsters infected intra-
peritonally with 263K scrapie, the infectivity titre of the spleen at disease end-point was 
2x10
5
 LD50/ml whilst the infectivity titre of the brain tissue at disease end-point was higher 
at 3x10
8 
LD50/ml with different dilution kinetics for each tissue indicating that there was 
organ-specific modification of infectivity (Robinson, Cheevers et al. 1990). Lower titres of 
infectivity in the spleen tissue compared to the brain tissue was also observed in murine 
models of TSE disease regardless of the route of infection, with wild-type/139A spleens 
containing 2-3 log10 units less infectivity than the brains (Rubenstein, Merz et al. 1991). In 
correlation with the infectivity data, the levels of PrP-res in the spleen were 500-fold less 
than those observed in the brain tissue at terminal stage of disease (Rubenstein, Merz et al. 
1991). The molecular profiles of brain PrP-res and spleen PrP-res were similar for murine 
ME7 tissues, hamster 263K tissues but not murine 139A tissues, indicating that the PrP-res-
type could be organ-specific (Rubenstein, Merz et al. 1991). Indeed, sub-passage of ME7 
and 22L infected spleen tissue has been shown to maintain the same strain characteristics as 
observed from sub-passage of the brain tissue, based on incubation period to disease in three 
wild-type mouse strains and clinical symptoms. However, sub-passage of 139A spleen tissue 
produced shorter incubation periods to disease compared to brain tissue (Carp, Meeker et al. 
1997). The presence of both TSE infectivity and PrP-res in spleen tissue occurs in the 
absence of histopathological changes (Fraser and Dickinson 1970). If the LRS system is 
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involved in disease pathogenesis, the presence of both TSE infectivity and PrP-res are 
generally detectable in the spleen tissue before detection is possible in the brain tissue 
regardless of the route of infection.  
1.3.2. Role of the spleen in disease pathogenesis 
The role of the spleen in disease pathogenesis was first demonstrated through splenectomy of 
scrapie infected mice that prolonged the incubation period to disease when the mice were 
inoculated intra-peritoneally (Fraser and Dickinson 1970, Clarke and Haig 1971). However, 
when intra-cerebral or intra-ocular inoculation was utilised, no difference in incubation 
period to clinical disease was observed with a splenectomy (Fraser and Dickinson 1970, 
Clarke and Haig 1971, Fraser 1996). Similarly once infection was established in the CNS, a 
splenectomy had no effect on incubation period to disease (Fraser 1996).  Further indication 
of a role of the spleen in TSE disease pathogenesis is that unlike other viral infections that 
exploit the lack of a functioning immune system, TSEs with peripheral involvement during 
disease pathogenesis were prevented if a functioning immune system was absent. Indeed 
data has shown that a high dose peripheral inoculation of ME7 (10
-1
) causes disease in severe 
combined immunodeficient mice indicating that the high dose did not require replication of 
the agent in the spleen, whilst lower doses (10
-3-4
) were unable to cause disease (Fraser, 
Brown et al. 1996). Despite the involvement of the spleen, no innate immune response is 
observed possibly due to immune tolerance to PrP as a host protein. Studies on scrapie 
replication in immuno-deficient mice have demonstrated that PrP-res replication in the LRS 
depends on long-lived, radio-resistant, mitotically inactive cells (Fraser and Farquhar 1987) 
that are now known to be follicular dendritic cells (FDCs) which express high levels of PrP
C
. 
Indeed severe combined immunodeficiency mice that lack mature B and T cells and 
therefore FDCs do not succumb to TSE disease upon infection with ME7 and no PrP-res was 
detectable in the spleen (Fraser 1996). Other work has shown that expression of PrP
C
 
specifically on either B or T cells in Prnp
o/o 
mice was not efficient at supporting prion 
replication in the spleen tissue (Raeber, Montrasio et al. 2001). Recent research has 
confirmed the role of FDCs in replicating PrP
Sc
 in the spleen as a transgenic mouse model 
that expressed PrP
C 
only on the FDCs was able to support PrP
Sc
 replication whilst in contrast 
specifically removing the presence of PrP
C 
only from FDCs blocked PrP
Sc
 replication in the 




Once infection is established in the spleen tissue and lymph nodes, neuroinvasion spreads the 
infection to the CNS and the brain resulting in the neuropathological features of TSE disease. 
The most likely route of neuroinvasion appears to be from the lymphoid tissue, to the mid-
thoracic cord, along visceral sympathetic nerve fibres (Kimberlin and Walker 1989). 
Neuroinvasion is also hypothesised to occur along neuronal pathways, specifically along 
either the sympathetic celiac and mesenteric ganglion complex or the parasympathetic vagus 
nerve (McBride, Schulz-Schaeffer et al. 2001), although a role for haematogenous 
neuroinvasion cannot be ruled out.   
1.4. Disease diagnostics 
TSE diseases were historically diagnosed by the presence of TSE-related pathology in the 
brain tissue at post-mortem diagnosis. TSE-related pathology includes the presence of 
spongiform or vacuolation changes in the brain tissue and the deposition of the disease 
associated protein, PrP
Sc
. The gold standards for confirmation of disease are through 
immunohistochemistry or immunoblotting to detect PrP-res, both of which require an anti-
PrP antibody for detection. PrP-res is utilised as a marker of TSE disease despite the increase 
in research indicating that PrP-res might not be present in all cases of TSE disease (Section 
1.2.3). Confirmation of TSE infectivity requires a time-consuming bioassay although some 
cell-culture models are currently in development such as the scrapie cell assay (Mahal, 
Demczyk et al. 2008). The absence of an immune response to PrP
Sc
, due to the recognition 
by the host, prevents detection of disease by serological methods that are utilised to diagnose 
other infectious diseases.  
1.4.1. Current post-mortem diagnostics 
Current post-mortem diagnostics for the detection of TSE disease in cattle and small 
ruminants utilise rapid tests that provide results within 24 hours and are high-throughput but 
rely on the detection of PrP-res. Currently the European Commission have a number of rapid 
tests approved for use in the EU TSE monitoring program (Figure 1-3). Some of these kits, 
including Bio-Rad TeSeE and IDEXX HerdChek* are also licensed for screening in USA 




Figure 1-3: Rapid tests (results available within 24 hours) currently approved by the EU for 
monitoring TSE disease in the EU. List last updated 1 January 2011 (EFSA 2012). 
These assays are all performed on brain tissue taken at post-mortem and with the exception 





. Each test includes a step that denatures the PrP to allow its detection 
by an anti-PrP antibody (Grassi, Maillet et al. 2008). The majority of these rapid diagnostics 
utilise an ELISA format, except Prionics
®
-Check Western test and Prionics
®
-Check 
PrioSTRIP that utilise a western blot and lateral flow technology respectively. Further, the 
Roboscreen Beta Prion BSE enzyme-immunoassay test kit utilises two monoclonal 
antibodies against PrP epitopes present when the protein is highly unfolded in a 2-sided 
immunoassay (Gavier-Widén, Stack et al. 2005). The reliance of the majority of these assays 
to detect PrP-res means that disease cases without the presence of typical PrP-res might be 
falsely identified as negative. Indeed, atypical scrapie in sheep was detected utilising the 
BIO-RAD TeSeE assay but not the Enfer assay or the Prionics
®
 Check luminescence-
immunoassay, a result that indicated that the rapid tests approved by the EU may not have an 
appropriate sensitivity levels for the detection of atypical scrapie (Buschmann, Biacabe et al. 
2004). All tests previously approved for detection of TSE disease in small ruminants by the 
EU were re-evaluated to confirm their sensitivity and ability to detect atypical scrapie (EFSA 
2007), resulting in the approval of only the IDEXX HerdChek* and BIO-RAD TeSeE assays 
for detection of TSE disease in small ruminants. In the latest report (EFSA 2012) an 
additional rapid test, Prionics
®
 Check PrioSTRIP was approved for diagnostic testing of 
small ruminants, including the identification of atypical scrapie cases. Each positive or 
inconclusive result from a rapid test requires a confirmatory test to be performed for 
confirmation of disease and to provide detail on the strain of disease. The confirmatory test 
20 
 
must have a high specificity level and are often histological examination, 
immunohistochemical or western blotting analysis.  
In both human and animals, a small number of post-mortem tests are available that do not 
rely on the presence of PrP-res. For disease diagnosis in animals, only the IDEXX 
HerdChek* assay does not rely on the presence of PrP-res but utilises the Seprion ligand 
(Microsens Biotechnologies) as the capture agent which binds aggregated proteins. The 
captured aggregated protein is then detected with the use of a species-specific anti-PrP mAb. 
Another diagnostic assay, the conformational dependent immunoassay (CDI)(Section 1.2.4) 
has been utilised to confirm the presence of an abnormal conformer of PrP present in 
diseased tissue homogenate for both humans (Choi, Gröner et al. 2011) and animals 
including cattle and sheep (Safar, Scott et al. 2002, McCutcheon, Hunter et al. 2005).  
An alternative method for diagnosis is the creation of conformation-specific antibodies that 
specifically recognise disease-associated PrP
Sc
 in an immuno-precipitation assay. These 
antibodies specifically recognise the structural epitopes present on PrP
Sc
 that are absent from 
PrP
C
. The 15B3 antibody specifically precipitates PrP
Sc
 from bovine, murine and human 
samples by recognising three epitope sequences of PrP, 142-148, 162-170 and 214-226 that 
are hypothesised to be aggregated into a single continuous binding site (Korth, Stierli et al. 
1997). This PrP
Sc
 specific anitbody was utilised to identify PrP
Sc 
from spontaneous ill 
Tg(GSS)12 mice that over-express 101L PrP 12-fold but do not contain PrP-res as detected 
by standard biochemical methods. PrP
Sc
 was only immunoprecipitated just prior to the onset 
of spontaneous disease. However, PrP
Sc
 was not immunoprecipitated from Tg(GSS)2 mice 
culled at ~570 days that express PrP 0.5-1-fold (Nazor, Kuhn et al. 2005)(Section 1.6). 
Another motif-grafted antibody that recognises epitope sites 88-112 and 136-158 selectively 
binds PrP
Sc
 from mouse, human and hamster infected tissues (Moroncini, Kanu et al. 2004). 
These motif-grafted antibodies, did not bind any PrP
Sc
 from 101LL/GSS and 101LL/263K 
tissues (Barron, Campbell et al. 2007). Another conformational antibody P1:1 recognises the 
aggregated 106-126 epitope in human PrP
Sc
 and detects the aggregated form of PrP
Sc
 but not 
the normal cellular form. Through immunoprecipitation, this mAb P1.1 was able to 
selectively precipitate full-length PrP
Sc
 from vCJD, sCJD and GSS (P102L) brain 
homogenates. In contrast, PrP-res was only precipitated from sCJD brain homogenates that 
contained type 1 but not type 2 PrP
Sc
 glycoform and from GSS (P102L) brain homogenates 
(Jones, Wight et al. 2009).  
These assays; IDEXX HerdChek*, conformational dependent immunoassay and 
conformation-specific antibodies in combination with immunoprecipitation have the 
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advantage that in principle they allow the detection of both PrP-res and sPrP
Sc
 forms of 
PrP
Sc
, which is becoming increasingly important in the field.  
1.4.2. Pre-mortem diagnosis 
Currently, there is no pre-mortem diagnostic test that can identify the presence of TSE 
disease prior to the onset of clinical symptoms or after the development of early clinical 
symptoms. Often biopsy of the LRS, such as the tonsil tissue is performed to confirm the 
presence of disease. However, LRS is tissue is not readily accessible and can only be 
performed with a limited frequency. With the knowledge that bodily fluids, specifically 
blood have been shown to be infectious, through four cases of iatrogenic transmission of 
vCJD and in numerous animal models (Hunter, Foster et al. 2002, Lefrère and Hewitt 2009, 
McCutcheon, Alejo Blanco et al. 2011) the requirement of a pre-mortem test that can 
identify the presence of TSE disease during the asymptomatic stage of disease is essential. 
Any diagnostic test would be required to be high-throughput, low cost and with both high 
sensitivity and specificity. Due to the nature of TSE diseases, a typical diagnostic test for a 
viral infection is not possible as no immune response is observed to a TSE infection to allow 
detection of serological antibody and there is no known nucleic acid that could be detected. 
Attempts to detect PrP-res from bodily fluids are further complicated by the low 
concentrations of PrP-res thought to be as low as the pico-femtogram range in blood during 
the asymptomatic stage (Coste, Prowse et al. 2009) and the high background presence of 
PrP
C
. The low levels of PrP-res in blood despite the presence of infectivity, indicates the 
nature of the infectious agent may be different to PrP-res and therefore not picked up by tests 
that rely on proteinase K digestion.  
The development of a diagnostic test that can detect the presence of TSE disease from blood 
is a main focus of TSE research. A number of tests in developmental stages successfully 
identified blood spiked with infected brain homogenate through the detection of PrP
Sc
. One 
promising assay the epitope-protection assay (EP-vCJD™) developed by Amorfix, was 
based on the ability of the aggregated PrP
Sc
 to protect epitopes from chemical modification 
from free radicals due to its abnormal conformation whilst the epitopes of the PrP
C
 molecule 
were destroyed by the free radicals. Disaggregation of the PrP
Sc
 then allowed the recognition 
of previously protected epitopes by anti-PrP monoclonal antibodies to identify the presence 
of PrP
Sc
. This EP-vCJD™ assay was proposed to detect less than 10 femtogram of 
recombinant PrP
Sc
 (Working Group 2009) and was shown to be 100% specific with a 
sensitivity of 1:500,000 dilution of vCJD brain when trialled on 20,000 blood samples 
(Amorfix 2009). The EP-vCJD™ assay was able to detect TSE disease from both a pre-
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symptomatic primate and a primate in the clinical phase of disease after being orally infected 
with BSE that eventually developed a primate version of vCJD (Amorfix 2009). However, 
the EP-vCJD™ assay was unable to identify blood from a patient in the clinical stage of 
vCJD as positive for disease and development of the assay was terminated (Amorfix 2010). 
Another assay in development known as the misfolded protein diagnostic assay used a 
palindromic synthetic peptide ligand (Pronucleon™ ligands) that binds to PrP
Sc 
in the N-
terminal region and then the peptide undergoes a conformational change to a β-sheet coil 
formation. Through the seeded conformational change of further peptides, the signal is 
increased as each time two fluorophores attached to the peptides come together an emission 
maxima at 495nm is produced, a different wavelength to the emission produced from the α-
helix formation 378nm. This assay identified hamster brain tissue as positive for disease 3 
weeks after inoculation with 263K whereas standard antibody-based methods detected 
disease 9 weeks after inoculation (Grosset, Moskowitz et al. 2005). This assay was 
successful in identifying the presence of PrP
Sc
 from blood plasma samples of experimentally 
infected mice and primates, endemic scrapie in sheep and sCJD patients. All plasma samples 
were from cases in the clinical stage of disease but the assay was shown to be specific with 
no false positives identified in these small scale studies (Pan, Sethi et al. 2007). Despite the 
promise of this assay in TSE diagnostics, recent work with Pronucleon™ ligands has focused 
on the development of a diagnostic test for other neurodegenerative diseases such as 
Alzheimer‟s disease. More recently, a novel blood-based assay for the detection of PrP
Sc
 was 
shown to identify a 10
-10
 dilution of vCJD brain homogenate spiked into whole human blood. 
This assay uses a solid-state binding matrix of steel particles that are incubated in the blood 
sample overnight to bind PrP
Sc
. The beads are then isolated, denatured by boiling to remove 
any background PrP
C
 prior to detection of PrP
Sc
 with an anti-PrP monoclonal antibody in an 
ELISA format. Assessment of 190 whole blood samples identified 15 of 21 blood samples 
from vCJD patients but did not identify 27 sCJD patients or have any false positives from the 
normal control samples including 42 samples from other neurological disease samples 
(Edgeworth, Farmer et al. 2011). Thus the assay showed a 71% sensitivity and 100% 
specificity for vCJD (Edgeworth, Farmer et al. 2011) but whether this could become a valid 
high-throughput blood-based diagnostic test remains to be seen.  
Currently the developments of pre-mortem diagnostic tests are centred on detecting PrP
Sc
 
through either PK resistance or conformational differences to PrP
C
. However, as previously 
discussed (Section 1.2.3), PrP
Sc
 might not be a reliable marker of TSE infection with 





1.2.3) producing false negatives and PrP amyloid present detected in healthy mice (Piccardo, 
Manson et al. 2007) producing false positives.  
As an alternative approach not based on the presence of PrP
Sc
, differential protein profiling 
has been investigated to identify alternative proteins that are expressed differently in TSE 
infected and uninfected animals. The ideal multiple protein markers would be altered early in 
the disease process, present throughout the duration of the disease, in an easily accessible 
bodily fluid and not be present in other neurodegenerative diseases. Production of a „disease-
fingerprint‟ that allows for diagnosis based on the presence of multiple markers rather than 
one individual marker, would reduce the possibility of mis-diagnosis. The identification of 
one such disease biomarker, 14-3-3 protein allowed for the development of a differential 
diagnostic test that detects the presence of the 14-3-3 protein in the cerebrospinal fluid (CSF) 
of CJD patients and has been utilised in combination with clinical symptoms and 
electroencephalography readouts to present a differential diagnosis of sCJD from other 
dementias. The detection of 14-3-3 protein has 86% sensitivity for diagnosing sCJD 
(Chohan, Pennington et al. 2010). As the disease progresses, levels of different brain-derived 
proteins, such as 14-3-3, tau, S100b and neuron specific enolase increase in the CSF in CJD 
patients (Sanchez-Juan, Green et al. 2006). The detection of these proteins has been shown to 
be increased in sporadic CJD and familial CJD (caused by either E200K or V210I mutations) 
but in other familial TSE diseases, e.g. FFI and GSS, the levels of these brain-derived 
proteins remains low (Ladogana, Sanchez-Juan et al. 2009). Another recent study identified 
seven acute phase proteins that were up-regulated in plasma samples from sCJD patients 
compared to plasma samples from Alzheimer‟s patients and age-matched healthy controls 
that could be candidate plasma biomarkers for sCJD (Fratini, Principe et al. 2012). Three 
proteins were identified in mouse scrapie brain that were differentially regulated in 
comparison to an uninfected brain; up-regulation of Hsp/Cpn10, acyl co A binding protein 
and down-regulation of FK506 binding protein 12 (Barr, Watson et al. 2009). Proteomic 
profiling of scrapie-infected asymptomatic hamster CSF identified that biomarkers of prion 
infection could provide specificity of 72% and sensitivity of 73% but the researchers do not 
identify the biomarkers that differentiated the diseased from the normal CSF (Herbst, 
McIlwain et al. 2009).  Together these papers highlight that the identification of disease 
biomarkers other than PrP-res could be utilised to diagnose TSE disease. However, much 
more research needs to be performed to identify the biomarkers that are specific for TSE 
disease rather than other neurodegenerative diseases and are present in an easily accessible 
bodily fluid.  
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The development of a pre-mortem blood test would be invaluable to TSE diagnostics and 
blood screening programs. However if an initial screening test is developed a confirmatory 
test would also be required to confirm any positive samples identified. Further large-scale 
testing of human blood donations would raise many ethical issues. With no current treatment 
available, the benefit of informing a donor that they may develop a fatal, neurodegenerative 
disease is questionable but a positive donor would have to be prevented from further 
donations. The development of a pre-mortem test could prove beneficial to the agricultural 
world although a rapid field test would be ideal to identify disease cases. 
1.5. Development of amplification techniques for disease 
diagnosis 
Given the low levels of PrP-res in bodily fluids, techniques have been created that amplify 
amyloid fibrils of PrP
Sc
 to detectable levels and are currently being analysed for specificity 
and sensitivity levels for detection of various prion diseases. Although the prion hypothesis 




 is not known with 
certainty. The current theory for conversion is based on a seeded nucleation model where 
PrP
Sc
 acts as a template to seed the conversion of the normal protein (Kocisko, Come et al. 
1994). To further understand the conversion mechanism, the conversion of PrP
C
 to PrP-res 
was reproduced in vitro. The conversion of PrP
C
 to PrP-res was first replicated in vitro by 
Kocisko and colleagues who produced a [
35
S]-radiolabelled protease resistant fragment 
through incubation of [
35
S]-labelled recombinant hamster PrP with a purified PrP-res seed 
from a 263K infected hamster (Kocisko, Come et al. 1994). This simple assay, known as the 
cell free conversion assay has been shown to replicate the species and polymorphism barriers 
and strain properties of prions (Kirby, Birkett et al. 2003). However, this system was limited 
by the requirement of a greater than fifty-fold excess of substrate required and chaotropic 
agents such as guanidine hydrochloride required for a higher conversion efficiency (Horiuchi 
and Caughey 1999). These limitations were overcome when the PrP
C
 substrate was provided 
by a cell-lysate of Chinese hamster ovary cells transfected with PrP
C
. It was hypothesised 
that the cell-lysate provides a co-factor required for a more efficient conversion. Based on 
this theory, the ability of a 10% (w/v) brain homogenate to provide both the seed and the 
substrate for the cell-free conversion reaction was tested. Conversion of PrP
C
 to PrP-res 
occurred, showing the in vitro conversion reaction was successful (Saborio, Soto et al. 1999), 
however the assay was limited by the number of available converting units present on the 
PrP-res aggregates. The addition of sonication pulses periodically during the incubation 
period, to break up the PrP-res aggregates, therefore increasing the number of converting 
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units was shown to enhance amplification of the seed. This novel technique was termed the 
protein misfolding cyclic amplification (PMCA) (Saborio, Permanne et al. 2001)(Figure 
1-4).  
1.5.1.  Protein Misfolding Cyclic Amplification (PMCA) 
PMCA allows the amplification of misfolded proteins in a manner analogous to 
amplification of DNA through PCR. The presence of the healthy brain homogenate as 
substrate provides a high molar excess of PrP
C
 as well as any as yet unidentified cofactors. 
Both the seed and substrate are homogenised in PMCA conversion buffer, which contains 
0.5% triton-X 100 and 0.05% sodium dodecyl sulphate to help prevent protein insolubility 
and non-specific interactions. In the proof-of-concept experiments, PrP-res from scrapie-
infected hamster brain homogenate was amplified by PMCA with 97.4-98.7% of total PrP-
res being newly formed from the amplification process after five cycles, each consisting of 1 
hour incubation with 5 one second sonication pulses. Increasing the number of cycles, up to 
40 cycles, increased the levels of amplified PrP-res
 
(Saborio, Permanne et al. 2001). In order 
to reduce the level of operator input and possible contamination from using a single probe 
microsonicator that was immersed in each individual sample to provide the sonication pulse 
(Sarafoff, Bieschke et al. 2005), an automatic block sonicator was used. This adaptation, 
known as automated PMCA, allows for the sonication of all the tubes to occur at once 
without sample contact (Castilla, Saa et al. 2004) and for an indefinite number of cycles to 
be performed. 
After 140 cycles (each cycle consisting of 30 minutes incubation at 37°C with a 40 second 
sonication pulse at 60-80% potency), an amplification factor of 6,600 fold was observed with 
PrP-res detected at a 2x10
7
 dilution of seed into substrate (Castilla, Saa et al. 2005). 
However, the efficiency of amplification decreased after 150 cycles, equivalent to 75 hours 
of incubation, hypothesised to be caused by the negative effects of long incubation periods 
on the stability of the PrP
C
 substrate (Castilla, Saa et al. 2005). To overcome this limitation, 
the amplified product was diluted into fresh healthy brain homogenate substrate after each 
successive round of automated PMCA (Ryou and Mays 2008). The progression of PMCA to 
this “serial automated PMCA technique” (sPMCA) increased the efficiency and speed of the 
assay to detect 1 attogram of PrP-res within 3 weeks (Atarashi, Moore et al. 2007).  
Since its development, PMCA has been performed in different laboratories investigating 
prion diseases. The different laboratories have utilised different methods for increasing the 
efficiency. One method that used healthy mouse brain tissue that over-expressed mouse PrP
C
 
to provide the substrate PrP
C
 increased the amplification of PrP-res with detection of an 
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RML seed at a 2.4 x 10
-4
 dilution. In comparison sPMCA using a wild-type mouse brain 
homogenate substrate, with the same genetic background, failed to amplify PrP-res beyond 
2.7 x 10
-3
 fold dilution of the seed (Mays, Titlow et al. 2009). Another alternative 
enhancement of the PMCA technology was the addition of 1.59 or 2.38mm Teflon beads to 
the PMCA reaction mix. After a single PMCA round of 48 hours, PMCA could detect 263K 




 dilution whilst the addition of beads increased the sensitivity of one 
round to a 10
-6
 dilution of 263K (Gonzalez-Montalban, Makarava et al. 2011). Despite 
various methods for increasing the efficiency of PMCA, the technique remains variable 
between laboratories depending on seed, substrate, sonicator and methodology (Gonzalez-
Montalban, Makarava et al. 2011).   
A comparison of the biochemical, structural and infectious properties of in vitro PMCA-
derived PrP-res and the hamster 263K scrapie brain-derived PrP-res seed, was performed by 
Castilla and colleagues (Castilla, Saa et al. 2005) to confirm that the in vitro amplification 
product was faithfully replicating the in vivo conversion product. Biochemically, the 
differently derived PrP-res proteins had virtually identical patterns of PK resistance, were 
both highly insoluble in non-ionic detergents, sensitive to denaturation by chaotropic agents 
and had similar heat-resistance profiles (Castilla, Saa et al. 2005). Structurally, the in vitro 
derived PrP-res and brain-derived PrP-res secondary structures had high levels of ß-sheet 
content producing virtually identical secondary structures by Fourier transform infrared 
spectroscopy. The PMCA-derived PrP-res also maintains the ability to form aggregates 
similar to those present in natural TSE disease (Castilla, Saa et al. 2005). The amplification 
product from a serial PMCA reaction was shown to be infectious causing a clinical and 
pathological TSE disease, with a disease pattern similar to hamster 263K seed. An extended 
incubation period was observed indicating that infectivity levels were 10-100 times less than 
the brain-derived seed PrP-res (Castilla, Saa et al. 2005). As the PMCA assay has been 
adapted and improved, the in vitro derived PrP-res maintained brain-derived PrP-res 
infectivity levels in five different mouse strains (Castilla 2008). Although the in vitro 
PMCA-derived product has been shown to maintain the biochemical, structural and 
infectious strain-specific properties of the brain-derived PrP-res seed (Ryou and Mays 2008), 
recent work questions this statement and whether either a co-factor is required to maintain 
infectivity levels or the PMCA produces another mis-folded PrP-res form that does not 




Figure 1-4: Schematic representation of the mechanism of amplification within the PMCA. Image taken from 
Soto et al 2002 (Soto, Saborio et al. 2002). 
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The PMCA has been used to address specific questions to increase our understanding of TSE 
disease, through investigation of the species barrier phenomenon (Castilla 2008, Fernandez-
Borges, de Castro et al. 2009, Barria, Telling et al. 2011, Yoshioka, Imamura et al. 2011, 
Chianini, Fernández-Borges et al. 2012), investigation of the minimal co-factors required for 
conversion of PrP
C
 to PrP-res (Deleault, Geoghegan et al. 2005, Deleault, Harris et al. 2007, 
Geoghegan, Valdes et al. 2007, Deleault, Kascsak et al. 2010, Yokoyama, Takeuchi et al. 
2011), and the investigation of environmental PrP-res contamination from TSE-infected 
animals (Nichols, Pulford et al. 2009, Maddison, Baker et al. 2010, Saunders, Shikiya et al. 
2011). Other work has investigated the ability of the PMCA to become a diagnostic test.   
The ability of PMCA to become a diagnostic test has been hampered by a number of issues, 
including the source and availability of a brain homogenate substrate. However, this 
limitation has the potential to be overcome through the use of recombinant PrP as a 
substrate. The ability of recombinant PrP
C
 (recPrP), purified from either Escherichia coli 
cells or baculovirus infected insect cells, to act as the substrate has been successfully shown 
for the cell-free conversion assay (Iniguez, McKenzie et al. 2000, Kirby, Birkett et al. 2003) 
and has many advantages: it can be produced in large quantities with a high purity level; it 
can be easily mutated to investigate different mutations and polymorphisms and it can be 
synthetically tagged or labelled with probes to allow easy detection of substrate and PMCA-
derived PrP-res (Atarashi, Moore et al. 2007). Recombinant PrP
C
 produced from E. coli 
Rosetta cells was used successfully as the substrate for a PMCA amplification reaction 
described as recPrP-PMCA. A 0.1mg/ml recPrP concentration was required for this reaction 
with the addition of 0.05% SDS and 0.05% Triton-X 100 to the reaction mix to encourage 
the formation of recombinant PrP-res and delay the formation of spontaneous PrP-res 
(discussed later), (Atarashi, Moore et al. 2007). Recombinant PrP-PMCA allows the 
detection of 50 attograms of PrP-res
 
seed in two days, in a faster and simpler assay than 
standard PMCA. The recombinant PrP-PMCA derived PrP-res
 
has a similar PK-resistance 
pattern and secondary structure, shown by FTIR, as the hamster 263K PrP-res seed.  
Alternatively, research is ongoing into the ability of human platelets to support amplification 
of PrP-res. Human platelets that express PrP
C
 on the cell surface, were able to support 
amplification of a vCJD seed. A 100-fold increase in PrP
Sc
 signal, as determined by 
conformational dependent immunoassay, was observed from two out of three platelet 
batches (Jones, Peden et al. 2007), with variation due to the substrate efficiency. This 
variation was minimised with the pooling of donor platelets (all codon 129 MM) to provide a 
single uniform substrate that supported amplification, with a 4 log10 increase in PrP-res 
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detection after four serial rounds of PMCA, detecting PrP-res at a 10
-7
 dilution of vCJD brain 
(Jones, Peden et al. 2008). Although the production of substrate is a major consideration if 
the PMCA is to be utilised as a diagnostic technique to test for human prion disease, the 
majority of work with the PMCA technique to research these unusual diseases still utilises 
normal brain homogenate as the substrate.  
Further, the use of infected brain homogenate as a seed requires an invasive biopsy for pre-
mortem diagnosis. The use of the PMCA to identify the presence of PrP-res in bodily fluids, 
including blood could lead to the development of a pre-symptomatic screening assay or a 
confirmatory test, as well as providing an insight into disease pathogenesis. Utilising PMCA, 
PrP-res was first detected in the buffy coat of 16 out of 18 hamsters that were clinically 
affected with scrapie after 6 rounds (144 cycles each) with 89% sensitivity and 100% 
specificity (Castilla, Saa et al. 2005). However, detection of PrP-res in the blood of 
presymptomatic cases is more complicated because as with viruses, there appears to be 
„windows of opportunity‟ for detecting PrP-res. Detection was possible during the early 
stages of infection, perhaps due to peripheral prion replication in lymphoid tissues that 
occurs immediately after infection, but then the concentration drops below the detection limit 
until the symptomatic stage (Saa, Castilla et al. 2006). However, these data do not agree with 
experimental transfusion data from sheep infected with BSE, where infectivity was present 
throughout disease duration (McCutcheon, Alejo Blanco et al. 2011) The detection of PrP-
res in blood samples through PMCA, is further complicated by the apparent inhibitory nature 
of blood or plasma components on the amplification, with reports of a 50% reduction in 
amplification efficiency when mouse RML brain homogenate spiked whole blood was used 
as the PMCA seed (Tattum, Jones et al. 2010) with a brain homogenate substrate from mice 
that over-express PrP
C
. Four rounds of serial PMCA were required to detect PrP-res from 
whole blood of pre-symptomatic scrapie-infected sheep. Reliable PrP-res detection was only 
achieved at 140 days post inoculation, with symptoms developing at 148 days post 
inoculation, a time point that correlates with the increase in infectious titre in the brain 
(Thorne and Terry 2008) and could be related to the break-down of the blood-brain-barrier. 
In order to enhance the amplification efficiency of PrP-res from blood from scrapie infected 
sheep, poly(A)RNA was added to the reaction mix and increased detection up to 5000-fold 
(Thorne and Terry 2008). Through three rounds of PMCA, PrP-res was detected in the blood 
of sheep with terminal scrapie with the efficiency of the amplification limited by the 
genotype combination of seed and substrate. This limitation of amplification based on 
substrate genotype suggests that this technique could not be utilised in the field for testing 
although it does provide a technique for differential diagnostic between strains. Attempts to 
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overcome this limitation with combination of multiple genotypes into the substrate reduced 
the amplification efficiency (Terry 2010). The limitation of sheep genotype to support 
PMCA amplification of PrP-res was again observed when another bodily fluid, saliva from 
sheep was utilised to produce the seed for the PMCA reaction. Buccal cheek swabs were 
taken from an endemic scrapie flock and PrP-res concentrated with silicon dioxide for use as 
a PMCA seed. After three rounds of PMCA, PrP-res was detected in swabs from VRQ/VRQ 
sheep at 12 months of age with 83% positive. However, no PrP-res was detected from any 
other age groups or any ARR/ARR sheep present in the same flock with any further rounds 
producing an 8% false positive rate (Maddison, Rees et al. 2010). 
An alternative bodily fluid which could be used to seed the PMCA reaction is urine. Urine 
from clinically sick hamsters with 263K scrapie was used to seed serial PMCA with PrP-res 
detection after 7 serial rounds (14 days) in four out of five samples. With no control samples 
developing spontaneous PrP, the assay was 80% sensitive with 100% specificity and the 
PMCA product was shown to be infectious to hamsters with identical disease characteristics 
(Gonzalez-Romero, Barria et al. 2008). Other PMCA data on the detection of PrP-res in 
urine indicates that the level of PrP-res excreted in urine at the terminal stage of disease is 
increased compared to the level present pre-symptomatically although only two out of five 
hamsters were positive at terminal disease (Murayama, Yoshioka et al. 2007). Taken 
together with the absence of detectable PrP-res from human urine from vCJD and sCJD 
patients (Head, Kouverianou et al. 2005) these data suggest that pre-clinically urinary PrP-
res cannot be amplified to a detectable level by the PMCA technique and is therefore an 
unreliable indicator of TSE disease. Further bioassay of urine from sCJD cases in transgenic 
mice expressing human PrP did not detect any the presence of any infectivity, with no 
disease developing (Notari, Qing et al. 2012). 
Within the agricultural world, scrapie disease in sheep is a major animal welfare issue, along 
with the potential for maternal transmission, from subclinical or carrier-state mothers, who 
have a neuropathological changes but do not develop clinical symptoms within the animal‟s 
natural life-span. An initial study utilising the PMCA technique detected PrP-res in milk of 
92% clinically ill sheep and 78% of scrapie-exposed, clinically normal sheep, after 12 rounds 
of serial PMCA with each round lasting 24 hours (Maddison, Baker et al. 2009).  If PrP-res 
is present in bovine milk, albeit at low levels, this could have major implications for human 
health. To date, although the successful amplification of spiked PrP-res in bovine milk has 
been shown through PMCA (Gough, Baker et al. 2009), no data has been published showing 
amplification of PrP-res from bovine milk. However, the possibility of utilising milk as an 
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easily accessible PMCA seed could be used for detection of disease prior to the onset of 
symptoms, if the sensitivity of PMCA could be increased within a shorter time-scale.  
A major concern relating to PMCA is the observation of spontaneous PrP-res formation in 
un-seeded, substrate only samples. This was first reported by Soto‟s group who observed 
spontaneous protease-resistant bands, indistinguishable to PrP-res, in un-seeded samples 
after 10 rounds of serial PMCA (Saa, Castilla et al. 2006). Although unexplained, the initial 
hypothesis was that spontaneous appearance was either due to cross-contamination from 
seeded samples or de novo generation. Spontaneous PrP-res formation was also observed 
from purified hamster PrP
C
 that underwent 16 rounds of PMCA in the presence of 
poly(A)RNA in an prion-free laboratory and equipment (Deleault, Harris et al. 2007). These 
de novo formed proteinase K resistant molecules were able to seed further formation of PrP-
res molecules in vitro, were shown to be detergent insoluble and were infectious to hamsters 
producing scrapie upon inoculation  (Deleault, Harris et al. 2007). These data support the 
latter hypothesis, that a PrP
Sc
-like form has been formed in vitro. The addition of 
poly(A)RNA to enhance the amplification efficiency when detecting PrP-res from sheep 
blood, also resulted in spontaneous formation of PrP-res in samples containing substrate 
only, after 3 rounds of PMCA, complicating the interpretation of the results (Thorne and 
Terry 2008). In order to understand this spontaneous formation or de novo formation of PrP-
res from an un-seeded substrate Soto and colleagues performed 20 rounds of serial PMCA 
on un-seeded brain homogenate substrates from both hamster and mouse tissues. Under 
standard PMCA conditions (144 cycles), no spontaneous formation was detected. After 
extended serial PMCA rounds (240 cycles) a PrP-res band was produced that proved to be 
infectious to hamsters with novel disease characteristics (Barria, Mukherjee et al. 2009). The 
number of serial PMCA rounds required to produce the appearance of spontaneous PrP-res 
material varied between species and PrP-res was not detected with human brain homogenate 
substrate or transgenic mouse substrate expressing human PrP
C
. This result was unexpected, 
due to the occurrence of sporadic forms of CJD in the human population. It was 
hypothesised to be due to a lower propensity of human PrP
C
 to spontaneously misfold, but 
with extended human life spans may allow this spontaneous event to occasionally occur 
(Barria, Mukherjee et al. 2009). The formation of de novo PrP-res through PMCA allows for 
both the study of spontaneous disease as well as the potential fulfilment of the prion 
hypothesis with the production of a prion in vitro (Section 1.2.5). Whether the PMCA 
technique is the technique used to produce the de novo prion, in a reaction where cross-




Indeed, recent work by Agrimi and colleagues (Cosseddu, Nonno et al. 2011) has questioned 
the formation of de novo PrP-res material, with no spontaneous PrP-res produced when 
working meticulously under prion-free conditions, over eleven serial PMCA experiments. 
Spontaneous formation of PrP-res only occurred in PMCA experiments when a positive 
control was included in the experiment. Through several investigations, cross-contamination 
of the un-seeded samples with seed appeared to be occurring within the sonicator during the 
amplification reaction itself. The introduction of an alternative 0.5ml screw-cap vials to 
support amplification; completely prevented any cross-contamination compared to the 0.2ml 
thin-walled PCR tubes that are commonly used for PMCA work (Cosseddu, Nonno et al. 
2011). 
For PMCA to be utilised diagnostically or as a screening assay, the sensitivity and specificity 
of the PMCA would need to be increased, an appropriate seed and a reliable, easily obtained 
substrate identified, as well as a balance struck between the sensitivity levels and the 
formation of spontaneous formation of PrP-res. The use of PMCA as a diagnostic tool is still 
in the early stages of development and potentially has the ability to become the confirmatory 
test rather than the initial screening test.  
1.5.2.  Amyloid Seeding Assay 
As well as PMCA, another assay monitors an increase in amyloid formation as a potential 
diagnostic test for TSE disease. This amyloid seeding assay monitors the formation of 
amyloid from a recombinant PrP substrate using thioflavin T dye that fluoresces when bound 
to amyloid fibrils. The reactions were seeded with NaPTA precipitated PrP-res from scrapie-
infected mice or hamsters. After a 22 hour reaction, the assay was able to detect PrP-res from 
the femtogram concentration range from RML and 301V in mouse recombinant PrP and 
Sc237 in hamster recombinant PrP. The assay was also able to specifically detect PrP-res 
that had been NaPTA precipitated from a sCJD brain homogenate, whilst reactions seeded 
with Alzheimer disease samples remained negative (Colby, Zhang et al. 2007).  
1.5.3.  Quaking Induced Conversion Assay (QuIC) 
An alternative assay, the QuIC assay monitors the amplification of amyloid formation as 
indicative of TSE disease. The QuIC assay first detected PK-resistant PrP amyloid formed 
when recombinant PrP was seeded by a TSE-infected brain homogenate or CSF. The 
reaction was incubated at a temperature above 37°C with intermittent shaking, with the 
products detected by an immunoblot with an anti-PrP antibody. This assay has detected PrP-
res from reactions seeded with brain tissue and CSF from scrapie infected hamsters detecting 
PrP-res from an initial 1 femtogram level in an 18 hour reaction (Atarashi, Moore et al. 2007, 
33 
 
Atarashi, Wilham et al. 2008, Orrú, Wilham et al. 2009). Adaptation of the QuIC, in terms of 
temperature, incubation time and shaking sequence, allowed detection of PrP
Sc
 from both 
brain tissue and CSF from scrapie infected sheep utilising a hamster recombinant PrP 
substrate. Further this technique also detected PrP-res from reactions seeded with brain tissue 
from vCJD patients (Orrú, Wilham et al. 2009). Further development of this technique 
produced the real-time QuIC (RT-QuIC) assay that detects amyloid fibril formation of 
recombinant PrP seeded with PrP
Sc
, through measurement of thioflavin T fluorescence, a 
compound which increases fluorescence signal in the presence of amyloid (Atarashi, Satoh et 
al. 2011, Orrù, Hughson et al. 2012). The RT-QuIC was able to discriminate CSF samples 
from sCJD patients and non-CJD patients, with 80% sensitivity and 100% specificity 
(Atarashi, Satoh et al. 2011). Additionally, the RT-QuIC can be utilised as a research tool, 
investigating the differing levels of aggregated PrP
Sc
 present in the CSF of hamsters 
inoculated either intra-tongue or intra-cerebrally at different time points in disease. The 
results showed that the route of inoculation can have an impact on the stage of disease when 
the CSF becomes positive using RT-QuIC, an important finding if this assay was to be 
utilised for human diagnostic testing (Orrù, Hughson et al. 2012). Other research has shown 





produced from brain tissue from hamsters infected with 263K (Wilham, Orrú et al. 2010) but 
with results achieved in only 2 days. The RT-QuIC was assessed for its ability to detect 
brain-derived PrP
Sc
 from sCJD and vCJD cases. The results showed that sCJD PrP
Sc
 was 
efficiently detected with either a hamster recombinant PrP or a human recombinant PrP 
substrate. However, detection of vCJD PrP
Sc
 was less efficient with an increased lag time 
and slower conversion rate than the sCJD PrP
Sc 
despite equivalent amounts of PrP-res seed 
being utilised (Peden, McGuire et al. 2012). The RT-QuIC was trialled for the ability to 
detect the presence of PrP
Sc
 in the CSF from sCJD patients, utilising hamster recombinant 
PrP as a substrate. The results indicated that the assay was 91% sensitive and 98% specific 
for the diagnosis of sCJD. A conformational study of an additional cohort of sCJD samples 
and controls from other neurodegenerative diseases was assayed with the RT-QuIC resulting 
in 87% sensitivity and 100% specificity (McGuire, Peden et al. 2012). In order to adapt the 
RT-QuIC technique to allow detection of vCJD PrP
Sc 
spiked in blood plasma, PrP
Sc
 was first 
immunoprecipitated utilising mAb 15B3 that preferentially binds the abnormal diseased 
form of PrP
Sc
 (Korth, Stierli et al. 1997)(Section 1.4.1). The immunoprecipitated PrP
Sc
 was 
utilised to seed a RT-QuIC reaction with a chimeric hamster-sheep recombinant PrP 
substrate. After 24 hours of RT-QuIC, the substrate was removed and replaced with fresh 
substrate to improve the sensitivity. This adapted RT-QuIC known as enhanced QuIC 
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(eQuIC) has been shown to detect vCJD PrP
Sc
 spiked into plasma as well as PrP
Sc
 present 
naturally in the plasma from scrapie infected hamsters (Orru, Wilham et al. 2011) and has 
10
-5
 fold increase in sensitivity compared to the RT-QuIC.  
The QuIC has some advantages over the PMCA technique (Section 1.5.1) as it utilises 
recombinant PrP as a substrate that is a readily available and reproducible substrate and is 
based on a 96-well format that has the potential to become a high throughput assay. The RT-
QuIC and eQuIC have the potential to be utilised as both a diagnostic test and as a research 
tool to enhance our understanding of prion disease. Detection of an aggregated protein that 
seeds further aggregation would allow for the detection of both PK-resistant and PK-
sensitive forms of PrP
Sc
. Although a full understanding of the biochemistry behind this 
phenomenon is not known the eQuIC has promise as diagnostic amplification assay.  
1.6. Transgenic murine models of human P102L GSS disease 
All current disease diagnostics are based on the identification of PrP-res. However, an 
increasing amount of data has suggested that PrP-res may not be a suitable marker for all 
TSE disease cases. Indeed, data generated from murine transgenic models questions the 
relationship between PrP-res and TSE infectivity. A number of different transgenic murine 
models (Table 1-2) have been produced that model the P102L point mutation that is present 
in cases of GSS disease and have produced data that questions the relationship. The 
production and characteristics of a number of different transgenic lines modelling P102L 
GSS are described below: 
Transgenic lines MoPrP-P101L Tg174 and Tg196 
The first transgenic mice expressing murine PrP containing the P101L mutation were created  
by random insertion producing a transgenic mouse line that expressed mutated PrP
C
 at a 
level eight-fold higher than wild-type controls. These mice (Tg(GSSPrP)174) appeared 
healthy until approximately 166 days of age when ataxia, lethargy and rigidity developed. 
On pathological examination, vacuolation was observed in both grey and white matter, no 
amyloid plaques were observed but low levels of PrP-res were present upon immunoblot 
(Hsiao, Scott et al. 1990, Hsiao, Scott et al. 1991). Tg196 mice were also produced with 
expression of 9 copies of the mutated transgene (Hsiao, Scott et al. 1990) producing a 2-fold 
over-expression of the mutant PrP. Intra-cerebral inoculation of the brain tissue from 
spontaneous ill Tg(GSSPrP)174 animals, caused disease in 80% of Tg196 mice inoculated 
and 20% of hamsters inoculated, but did not cause disease in wild-type CD-1 mice 
inoculated (Hsiao, Groth et al. 1994). Tg196 mice were shown to develop spontaneous 
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disease aged between 400-600 days. Sub-passage of brain tissue from asymptomatic Tg196 
mice (aged 378 days) accelerated the onset of disease to occur earlier (at 260dpi) than the 
expected onset of spontaneous disease (Kaneko, Ball et al. 2000). Taken together, these data 
suggested the presence of the 101LL mutation is enough to cause spontaneous disease, 
similar to the occurrence of disease in human cases of P102L GSS disease. However, the 
absence of detectable PrP-res by immunoblot in both the spontaneously ill mice and recipient 
mice indicated that the disease does not exactly replicate the natural prion disease. Disease 
was also accelerated in Tg196 mice when inoculated with a synthetic peptide produced from 
residues 89-143 of PrP, containing the P101L mutation that was re-folded into a beta-sheet 
conformation prior to inoculation. In contrast, inoculation of the unfolded synthetic peptide 
failed to produce any disease (Kaneko, Ball et al. 2000). Further solid-state NMR studies 
identified that the P101L synthetic peptide had greater beta-sheet content than the same 
peptide without the mutation indicating the beta-sheet formation was necessary to accelerate 
neurodegeneration (Laws, Bitter et al. 2001). The accelerated disease in Tg196 could be sub-
passaged into further Tg196 mice with the PrP-res produced identical to the PrP-res 
produced spontaneously in Tg2866 mice that over-express 101L mutant PrP
C
 8-fold. 
Transgenic lines Tg(GSS)22, Tg(GSS)12, Tg(GSS)6 and Tg(GSS)2 
A further set of transgenic mice expressing 101L PrP were created; Tg(GSS)22, Tg(GSS)12, 
Tg(GSS)6 and Tg(GSS)2 that over-express P101L PrP
C
 12-, 6-, 3- and 0.5-fold compared to 
levels of PrP
C
 in wild-type mice (Nazor, Kuhn et al. 2005). All but Tg(GSS)2 mice 
developed spontaneous illness with spongiform degeneration, plaque deposits and reactive 
gliosis detected in the brain tissue when clinical disease was apparent. However, the brain 
homogenates from the spontaneously-ill mice did not contain PrP-res but disease-associated 
PrP
Sc
 was detected using a mAb specific for PrP
Sc
, 15B3 (Section 1.4.1) that indicated the 
presence of protease-sensitive PrP. Tissue from spontaneous ill mice did not transmit disease 
to wild-type mice or Tg(GSS)2 mice that express mutated PrP
C
 close to physiological levels. 
Inoculation of Tg(GSS)12 and Tg(GSS)22 mice with brain homogenates from spontaneously 
ill mice, accelerated the onset of the spontaneous disease caused by the over-expression of 
PrP
C
. Therefore, sub-passage of tissue from a spontaneous ill mouse acted to accelerate the 
development of the spontaneous disease rather than transmitting a bona fide TSE disease. 
PK-treatment of the brain homogenates prior to inoculation prevented the acceleration of 
disease, indicating that a sPrP
Sc
 form was inducing the disease acceleration (Nazor, Kuhn et 







An alternative mouse transgenic line was produced that expressed a chimeric human/murine 
PrP transgene containing the P101L mutation (Tg(MHu2M-P101L)Prnp
o/o
) at a 2-fold higher 
level than wild-type PrP
C
. These mice developed spontaneous disease, but a control 
transgenic line that expressed only human PrP
C
 with the P102L mutation at 4-8 fold higher 
than wild-type murine PrP
C
 expression on a Prnp
o/o
 background did not develop disease. 
Inoculation of the Tg(MHu2M-P101L)Prnp
o/o
 mice with a brain extract from a P102L GSS 
patient, produced disease ~100days earlier than the un-inoculated controls that developed the 
spontaneous disease (Telling, Scott et al. 1995).  
Transgenic lines Tg(MoPrP-101L)/2247, Tg(MoPrP-101L)/2866, Tg(MoPrP-
101L)/2862 
Tg(MoPrP-101L)2247/FVB, Tg(MoPrP-101L)2866/FVB and Tg(MoPrP-101L)2862/FVB 
transgenic lines were produced through microinjection of linearized DNA into FVB mice. 
Tg2247 and Tg2866 over-express mutant PrP
C
 8-fold whilst Tg2862 over-express mutant 
PrP
C
 32-fold compared to wild-type levels with all three lines developing spontaneous 
disease between 150 and 200 days of age. Transgenic mice that over-express wild-type PrP
C
 
at the same level as the P101L transgenic mutants (8-fold) did not develop spontaneous 
disease suggesting that the mutation rather than the over-expression of PrP
C
 was responsible 
for the spontaneous disease. Crossing the 101L transgenic line onto a Prnp
o/o 
background, 
resulted in all mice developing spontaneous illness within a narrow time range, indicating 
that the expression of wild-type PrP
C
 affects the progression of disease in Tg(MoPrP-P101L) 
mice with the presence of widespread PrP-res deposition. Further, producing a mouse line 
homozygous for the transgene reduced the average age of spontaneous disease to only 85 
days old (Telling, Haga et al. 1996).  
Tg27 and Tg33 
Other transgenic mice have been produced that express human PrP
C
 containing the P102L 
mutation (Asante, Gowland et al. 2009). These mice designated Tg27 and Tg33 have a 
mutant PrP
C
 expression level of three and one-and-a-half times greater respectively than the 
levels observed in an uninfected human brain. These mice do not develop spontaneous 
disease but transmission of human P102L GSS disease cases caused a rapid disease. 
Transmission of CJD cases, either sporadic, iatrogenic or variant resulted in extended 
incubation periods and incomplete attack rates although all Tg27 mice inoculated were 
positive for TSE disease by either immunohistochemistry or immunoblot (Asante, Gowland 
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et al. 2005) 
Table 1-2: PrP
C
 expression levels, development of spontaneous disease and transmissibility of 
spontaneous disease on sub-passage to other or the same mouse model of each transgenic GSS mouse 
model currently developed.  
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Gene-targeted transgenic model, 101LL 
In contrast to all these transgenic mouse models of GSS disease, in the mouse model utilised 
in this thesis, the 101L mutation was introduced into the endogenous murine PrP gene in 
129/Ola mice through gene-targeting (Manson, Jamieson et al. 1999). These knock-in 
transgenic mice express PrP
C
 at the same level as wild-type mice and do not develop 
spontaneous disease (Manson, Jamieson et al. 1999) and are therefore the murine model that 
most closely replicates the physiological expression of mutant PrP in people carrying the 
P102L mutation. Upon inoculation of the 101LL mice with different sources of TSE disease, 
altered incubation periods to disease were observed (Table 1-3). Murine scrapie strains and 
vCJD had extended incubation periods, with the exception of 301V, whilst inoculation with 
hamster and sheep inocula reduced incubation periods. When either human classical P102L 
GSS or hamster 263K was inoculated, little or no PrP-res was detectable in the brain tissue 
of the 101LL mice by standard biochemical techniques (Barron, Thomson et al. 2001, 
Barron, Campbell et al. 2007). The results from other transmissions including vCJD and 
ME7 indicated that there was not an inability of the 101L PrP
C
 to convert to PrP
Sc
 as PrP-res 
was detectable in these transmissions by the standard biochemical and immunohistochemical 
methods (Barron, Thomson et al. 2001). Further, the levels of PrP-res produced upon 
inoculation with different murine scrapie strains were similar to those observed in wild-type 
mice independent of the Prnp genotype, with the exception of ME7 and 22A which had 
lower levels of PrP-res present in the 101LL brain tissue. Further, the 101L mutation was 
shown to alter the vacuolar targeting of disease in a strain-dependent manner (Barron, 
Thomson et al. 2003).  
Further investigation was performed on 101LL mice that were infected with either human 
P102L GSS disease or hamster 263K scrapie, that produce a disease phenotype with little or 
no PrP-res present in the brain tissue. These mice developed a clinical TSE disease with 
vacuolar pathology and the presence of infectivity was confirmed through sub-passage of the 
brain homogenates into 101LL mice with shortened incubation periods.  Full titration 
bioassay of both 101LL/GSS and 101LL/263K brain tissue was perfomed and the titers of 




 IU/g (Barron, Campbell et al. 2007). In four out of five 
101LL/263K brain tissues analysed, no PrP-res was detected by standard PK and 
immunoblot, with a detection limit at 62.5µg/ml concentration of brain homogenate for the 
one 101LL/263K brain tissue that contained PrP-res. Two 101LL/GSS brain tissues were 
analysed with no PrP-res detected by the standard PK and immunoblot methodology. These 





 IU/g associated with a PrP-res detection limit at 31.3µg/ml concentration of brain 
homogenate. The absence of PrP-res from 101LL/GSS and 101LL/263K tissues was 
confirmed through immunoblotting using a number of different anti-PrP antibodies, 
including mAb 8H4, 7A12 and the polyclonal antibody 1B3 (Barron, Campbell et al. 2007). 
The possible presence of sPrP
Sc
 (Section 1.2.4) was investigated by a number of different 
techniques including limited or „cold‟ PK digestion, confromational dependent 
immunoassays and immunoprecipitation with PrP
Sc
-specifc motif grafted mAbs 89-112 and 
136-158 (Section 1.4.1). However, none of these assays identified the presence of a PK-
sensitive isoform of PrP
Sc
 in the 101LL/GSS and 101LL/263K brain tissues (Barron, 







(days±SEM) to disease in 
wild-type that express 
101PP 
Incubation period 
(days±SEM) to disease 
in 101LL mice 
Reference(s) 
Human/GSS 456±0 288±4 
(Manson, 








Jamieson et al. 
1999) 
Hamster/263K >600 464±18 
(Barron, 














Thomson et al. 
2001) 
Human/vCJD 373±8 556±12 
(Barron, 
































Thomson et al. 
2003) 
Table 1-3: Altered susceptibilities of 101LL mice upon inoculation with different species and strains 
of TSE disease.  
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1.7. Thesis Aims 
The prion hypothesis states that PrP
Sc
 acts as the infectious agent in TSE diseases of both 
humans and mammals. The level of PrP
Sc
 has been shown to correlate with infectivity titre 
and infectivity co-purifies with PrP
Sc 
in standard laboratory models of TSE disease
 
(McKinley, Bolton et al. 1983, Hilmert and Diringer 1984)(Section 1.2.1). Despite the 
wealth of data available to support the prion hypothesis, an increasing number of natural and 
experimental disease models develop TSE disease in the absence of detectable PrP-res 
(Section 1.2.3)(Lasmezas, Deslys et al. 1997). One such disease model is a murine 
transgenic model of GSS disease that contains the proline to leucine mutation associated 
with human GSS disease, inserted into the endogenous murine PrP at the equivalent codon 
(101). Upon intra-cerebral inoculation with either human GSS or hamster 263K brain 





 IU/g despite the absence of detectable PrP-res by standard biochemical and 
immunohistochemical techniques (Barron, Campbell et al. 2007). This thesis aims to utilise 
these unusual disease models to investigate the correlation between PrP-res and TSE 
infectivity through a number of different but inter-related aims: 
 
• To confirm the observation of little or no PrP-res in independent transmissions of these 
agents, human GSS and hamster 263K, in 101LL transgenic mice. 
 
• To characterise the levels of PrP-res and TSE infectivity present in the spleen tissue at 
terminal stage of disease in the above disease models.  
  
• To determine whether it is possible to amplify PrP-res and/or TSE infectivity using the in 
vitro amplification technique, PMCA from the low or absent levels present in the brain tissue 
of these disease models? 
 
• To identify the protein(s) or component(s) and the associated TSE infectivity levels of the 
target of the Seprion ligand (Microsens Biotechnologies) that identifies these tissues as 
positive for TSE disease, in the IDEXX HerdChek* assay. 
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2. Chapter 2 – Materials and Methods 
2.1. DNA extraction and genotyping of transgenic mice 
2.1.1. DNA extraction for pre-genotyping of uninfected mice 
DNA was extracted from mouse tissue samples, either tail pieces or ear punches, using the 
QIAGEN DNeasy tissue kit as per manufactures instructions. Briefly, the tissue was lysed 
overnight in buffer ATL and PK (final concentration 2mg/ml) at 55°C with agitation. A 
mixture of ethanol: buffer AL (1:1) was added and the sample volume transferred to a 
DNeasy mini spin column (Qiagen). Centrifugation for 1 minute at 13,2000rpm (Benchtop 
microcentrifuge) bound the DNA to the column and two wash steps with Buffer AW1 and 
Buffer AW2 respectively removed any contaminants. The DNA was then eluted in a final 
volume of 200µl or 100µl Buffer AE for tail and ear punches respectively by centrifugation 
and stored at 4°C 
2.1.2. DNA extraction for confirmation genotyping of TSE 
infected mice 
At the end of each experiment a piece of tail tissue (~1cm long) was taken post-mortem for 
conformational genotyping from each animal. DNA was extracted from the tail tissue using a 
phenol/chloroform extraction method to reduce the level of any infectivity present. Briefly, 
tissue was lysed in tissue lysis buffer (15mM sodium acetate, 1% SDS, 1mM Tris, pH8, 
1mM EDTA) with PK at 200µg/ml overnight at 37°C with agitation. The lysate was mixed 
with 600µl phenol: chloroform (1:1, pH8) and centrifuged at 13,000rpm for 5 minutes 
(Benchtop microcentrifuge). The aqueous supernatant, which contains the DNA, was 
transferred to a clean eppendorf tube and mixed with 20µl 3M sodium acetate and 600µl 
isopropanol. The sample was incubated at RT for 10 minutes before DNA was pelleted 
through centrifugation at 13,000rpm for 1 minute (Benchtop microcentrifuge). The pellet 
was washed in 70% ethanol and air dried before being re-suspended in 100µl dH2O. The 
DNA sample was stored at 4°C. 
2.1.3. Genotyping PrP transgenic mice 
Mice were genotyped through a process of genomic amplification by polymerase chain 
reaction (PCR) and restriction enzyme digestion to produce an expected banding pattern for 




Method One: Mouse genomic DNA (1-2µl) was added to a PCR reaction buffer prepared to 
final concentrations 1X PCR buffer (Invitrogen), 1.5mM MgCl2 (Invitrogen), 0.2mM dNTPs 
(Promega solution containing ATP, CTP, GTP and TTP), 2pmol/µl oligonucleotides 
A044<>A045 (A044 5‟ TCATCCCACGATCAGGAAGATGAG 3‟)(A045 5‟ 
ATGGCGAACCTTGGCTACTGGCTG 3‟), 2 units DNA Taq polymerase (Invitrogen). 
Optimised PCR conditions for amplification of the mouse DNA were performed on a T3000 
Thermo-cycler (Biometra).  Briefly conditions were 94°C for 3 minutes, followed by 30 
cycles of 94°C for 30 seconds, 62°C for 30 seconds and 72°C for 1 minute. A 10 minute 
incubation time at 72°C incubation completed the reaction before the sample was cooled to 
4°C. DNA was stored at 4°C. 
Method Two: Mouse genomic DNA (1.5µl) was amplified utilising the Type-IT Mutation 
Detect PCR Kit (QIAGEN). The PCR reaction buffer was prepared with 1X Type-IT 
mastermix, 0.3p/mol A044<>A045 oligos prepared to a total volume of 25µl with distilled 
water. Optimised PCR conditions that allowed for amplification of the mouse genomic DNA 
were performed on the T3000 Thermo-cycler (Biometra). Briefly incubation at 95°C for 5 
minutes was then followed by 35 cycles of 95° for 30 seconds, 60°C for 90 seconds, 72°C 
for 30 seconds, then 68°C for 10 minutes before being cooled to 4°C. DNA was stored at 
4°C. 
2.1.4. Restriction Enzyme Digest to identify PrP 101 leucine 
alleles. 
The amplified DNA sample was digested with restriction enzyme DdeI (Promega) which 
identifies the leucine containing allele 101L due to the presence of an extra restriction site 
(5‟ CˇTNA G 3‟) that is absent from proline allele 101P. The PCR product was digested with 
0.1U DdeI in the presence of 1X Buffer D (final concentrations 6mM TrisHCl, 6mM MgCl2, 
150mM NaCl and 1mM DTT) (Promega) and 0.1mg/ml BSA (Promega) at 37°C for a 
minimum of 3 hours. 
The digestion product was mixed with loading buffer (0.25% bromophenol blue, 0.25% 
xylene cyanol FF in 20% ficoll solution) and run on a 1.5% agarose gel in 1X TBE buffer 
(89mM Tris, 9mM boric acid and 3mM EDTA) containing ethidium bromide. When 
possible SYPRO SAFE (Invitrogen) was used as an alternative to ethidium bromide, 
included at 10% (v/v) concentration in the 1.5% agarose/TBE gel. Gel electrophoresis was 
performed at 100V for 1-2 hours in 1X TBE buffer. A 1kb ladder (Invitrogen) was used as a 
standard and a positive and negative control were performed for each reaction. The DNA 
carrying the 101L allele produced a band of 464 base pair length whilst the 101P produced a 
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band of 614 base pair. The DNA banding pattern was visualised under UV light and 
photographed (The Imager; Appligene® Oncor). 
2.2. Preparation of sterile TSE infected inocula 
The tissue sample was accurately weighed and homogenised in sterile saline (0.9% w/v) 
using a glass dounce homogeniser to prepare a 1% (w/v) homogenate. Each tissue 
homogenate underwent ten-fold dilutions in sterile saline (0.9% w/v) to provide the required 
dilutions for inocula (Table 2-1).  
2.3. Intra-cerebral inoculation of mice 
Mice were anaesthetised with 3% fluothane gas before inoculation. Twenty microlitres of 
each inoculum was inoculated into the right brain hemisphere of the mice using a 26G ⅜” 
needle, which had a needle guard to ensure the inoculum was injected into the right mid 
temporal cortex. Injected animals were observed for adverse reaction to the injection 
procedure. All experimental protocols were submitted to the Local Ethical Review 
Committee for approval before mice were inoculated. All experiments were performed under 
license and in accordance with the UK Home Office Regulations (Animals (Scientific 







Final dilution of 
homogenate 
inoculated  
754A-1A Human P102L GSS brain homogenate (Chapter 3) 10
-2
 














Murine 101LL/GSS brain and spleen and murine 









Murine 101LL/GSS, 101LL/263K and wt/79A PAD-
beads inocula (Section 2.29), (Section 6.2.4) 
1%, 1/10 and 1/1000. 
522Z-1L 
Murine 101LL/GSS, 101LL/263K and wt/79A PAD-
beads inoculums (Section 2.29), (Section 6.2.4) 
1% homogenate 




2.4. TSE clinical assessment 
Animals were scored weekly for clinical signs of TSE disease (Dickinson, Meikle et al. 
1968) by experienced personnel as „unaffected‟, „possibly affected‟ or „definitely affected‟ 
(Table 2-2). Clinical signs of TSE disease include ataxia, hind limb paralysis and hunching. 
Animals given three consecutive „definitely affected‟ scores or receiving a fourth „definitely 
scrapie‟ score within five weeks were culled as clinically positive. Animals were culled by 
cervical dislocation when either a clinical TSE disease or an inter-current illness was 
observed, in accordance with the Animals (Scientific Procedures) Act 1986. Brain, spleen 
and a piece of tail tissue were removed by excision. The brain tissue was cut sagittally to the 
right of the midline into two pieces for pathological examination (one was fixed in 10% 
formal saline for 2-5 days) or biochemical analysis (one half brain flash frozen in liquid 
nitrogen and stored at -80°C). Spleen tissues were initially taken for biochemical analysis 
and were flash frozen in liquid nitrogen, and then stored at -80°C. At a later date, the spleens 
were allowed to defrost at room temperature (15-20 minutes) and then fixed in formal saline 
for 2-5 days for pathological examination.   
Score Criteria 
1 Unaffected by TSE 
2 Likely to be affected 
+ Definitely affected 
g “2” plus ataxia 
G “+” plus ataxia 
X Scratched eyes 
0 Wet around anal region 




2.5.1. Sectioning of brain tissue 
The half brain tissue was fixed with 10% formal saline and treated with 98% formic acid for 
90 minutes. The tissue was sectioned and the resulting sections were embedded face-up in 
paraffin wax (Figure 2-1). The resulting blocks were trimmed of excess wax and the cutting 
surface re-hydrated and softened by placing face down on wet ice for a minimum of 1 hour. 
Sections (6µm) were cut (Microtome, Leica), and then floated onto the surface of a water 
bath (40°C) before being floated onto Superfrost-plus glass slides. Mounted slides were 
dried overnight at 37°C and then stored at room temperature until use. All tissue was kindly 
processed and sectioned by experienced personnel in accordance with University of 






Figure 2-1: Tissue was cut into five sections (A) and embedded in paraffin wax face up in the 
indicated layout (B).  
2.5.2. Sectioning of spleen tissue 
Spleens that were initially stored at -80°C were defrosted for 20 minutes at RT prior to 
fixation in 10% formal saline for a minimum of 48 hours. Spleen tissue was then treated with 
98% formic acid for 90 minutes and then embedded in paraffin wax. The resulting blocks 
were trimmed of excess wax and the cutting surface re-hydrated and softened by placing face 
down on wet ice for a minimum of 1 hour. Sections (6µm) were cut (Microtome), and then 
floated onto the surface of a water bath (40°C) before being floated onto Superfrost-plus 
glass slides. Mounted slides were dried at 37°C for a minimum of 48 hours and then stored at 
room temperature for immunohistochemical analysis (Section 2.8). Alternatively, sections 
were floated onto polyvinylidene fluoride (PVDF) membrane (Millipore, UK), dried at 37°C 
for a minimum of 48 hours and then stored at room temperature for immunoblot analysis 
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(Section 2.18). All tissue was kindly processed and sectioned by experienced personnel in 
accordance with University of Edinburgh Health and Safety policy. 
2.6. Haemotoxylin and Eosin Staining 
Tissue sections were stained with haemotoxylin and eosin (H&E) to allow for visualisation 
of the general morphology of the tissues for scoring and diagnosis of TSE disease. Staining 
was performed using an automated Leica XL staining machine that immersed the slides in 
the appropriate solution for the required time (Table 2-3). 
Solution Time 
Xylene 3 x 5 minutes 
99% industrial methylated spirit 
(IMS) 
2 x 2 minutes 
95% IMS 1 x 5 minutes 
Water 5 minutes 
Haematoxylin 3 minutes 
Water 2 x 3 minutes 
Scotts Tap Water (0.17M) 
magnesium sulphate, 0.04M 
sodium hydrogen carbonate) 
2 minutes 
Running water 5 minutes 
Eosin 1.5 minutes 
Running water 30 seconds 
70% IMS 30 seconds 
95% IMS 2 x 30 seconds 
99% IMS 2 x 1 minute 
Xylene/99% IMS 1 minute 
Xylene 3 x 3 minutes 
Table 2-3: Haematoxylin and Eosin staining procedure using automated Leica XL machine.  
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2.7. Scoring and Lesion profiles 
The TSE-related vacuolar pathology of the brains was analysed by experienced personnel 
according to a scoring system previously described (Fraser and Dickinson 1968). Within this 
system, 9 grey matter and 3 white matter areas (Table 2-4) were scored for the level of 
vacuolation with a range from 0 (no vacuolation) to 5 (vacuoles confluent). All mice from 
each experiment were scored and an average of a minimum of six scores per group were 
plotted to show the pattern of vacuolation as a lesion profile. 
 Grey Matter Area White Matter Area 
1 Medulla Cerebellar peduncle (CP) 
2 Cerebellum Decussation of superior CP 
3 Superior Colliculus Basal CP 
4 Hypothalamus  
5 Thalamus 
6 Hippocampus 
7 Paraterminal Body 
8 Retrospinal cortex 
9 Cingulate and motor cortex 
Table 2-4: Areas of brain scored for TSE-associated vacuolation.  
2.8. Immunohistochemical analysis of brain and spleen tissue 
sections.  
Staining of brain tissue and spleen tissue sections for PrP was performed through 
immunohistochemistry, which unless otherwise stated was performed at room temperature. 
Tissue sections were hydrated through immersion in 100% xylene, 99% alcohol, 95% 
alcohol, 70% alcohol and distilled water for 1 minute each. Sections were autoclaved for 15 
minutes at 121°C to expose the PrP epitopes. Epitope exposure was further enhanced 
through 5 minute incubation in 98% formic acid. Incubation for 10 minutes in 1% hydrogen 
peroxide in methanol quenched endogenous peroxidase activity. Sections then underwent 
three 5 minute washes in 0.2% BSA/PBS wash buffer before being blocked with 90μl of 
normal goat serum diluted in 0.2% BSA/PBS (3mg/ml) for 15 minutes. After another three 5 
minute washes in wash buffer, the sections were incubated overnight with 90μl of 
monoclonal 6H4 primary antibody (Prionics) diluted in wash buffer (0.5μg/ml). Control 
sections were incubated overnight with 90μl of normal mouse serum diluted in wash buffer 
(1.86μg/ml) but were otherwise treated identically. Unbound primary antibody was removed 
through three 5 minute washes in wash buffer before the sections were incubated with goat-
anti-mouse biotinylated secondary antibody (2μg/μl) (Jacksons) for 1 hour. Three 5 minute 
washes with wash buffer removed any unbound antibody. For immunhistochemical analysis 
of the brain tissues, the sections were then incubated with 90μl of Vectastain ABC Elite 
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vector kit (Vector Labs) for 30 minutes, to amplify the secondary antibody signal. Three 5 
minute washes in wash buffer were performed prior to the detection of antibody-bound PrP 
through 3-4 minutes incubation in diaminobenzidine (Sigma) diluted in PBS (0.61μg/ml), 
activated by hydrogen peroxide. For immunohistochemical analysis of the spleen tissues, 
after incubation in the secondary antibody, the sections were then incubated in 90µl Vector® 
Novared (Vector Labs) for a maximum of 10 minutes. Sections of both brain and spleen 
tissue were stained in haematoxylin for 1 minute and counter-stained in Scotts tap water 
(0.04M sodium bicarbonate, 0.17M magnesium sulphate) for 1 minute to stain the general 
morphology of the cell. Sections were dehydrated through immersion in 95% alcohol, 99% 
alcohol, 1:1 mix of 99% alcohol/100% xylene and 100% xylene.  Cover slips (22x22mm) 
were mounted onto the sections utilising Pertex mounting media (CellPath). PrP staining was 
observed by light microscopy (Nikon E800) and the sections were scored for differing levels 
of PrP deposition.  
2.9. Quantification of PrPSc deposition by immunohistochemistry 
for 101LL/GSS and 101LL/263K primary passage.  
Immunohistochemical analysis of mouse brain tissues using an anti-PrP antibody 6H4 
(Section 3.2.3) showed low levels of PrP deposition, which is characteristic of this model. A 
scoring system was developed to determine the varying levels of low deposition within this 
mouse model. For each tissue, four different brain areas; septum, thalamus/hippocampus, 
midbrain and medulla were scored for the level of deposition as per the scoring system 
(Table 2-5 and Figure 2-2).  
While this scoring system allows for differences to be observed between experimental mice, 
an overall score (Table 2-6) was allocated dependent on the total number of +‟s each tissue 
received to allow the experimental mice to be analysed in comparison to standard scrapie 
strains such as ME7. A standard scrapie strain that has large amounts of detectable PrP
Sc
 
would be expected to score 8-12 for the level of deposition. Indeed, the positive controls 
used for immunohistochemical analysis, an 87V-infected VM mouse were given an overall 





- No deposition detectable 
+ Trace amounts of deposition 
++ Clustering of a few aggregates or light diffuse staining 
+++ Moderate deposition levels with multiple aggregates and/or diffuse staining 
Table 2-5: Definition of each score level used to describe PrP
Sc
 deposition observed through 
immunohistochemistry.  
 
Figure 2-2: Different score levels observed in the midbrain (x20 magnification) to illustrate the 
scoring system. (A) score + C17211, (B) score ++ C17309 and (C) score +++ C17070.  





0 0 Negative for PrP deposition 
1 1 Single aggregate in one brain area 
2-3 2 Trace deposition in one or more brain areas 
4-5 3 
Trace deposition in one or more brain areas 
with moderate-significant deposition 
quantities in one brain area 
6-7 4 
Moderate deposition in more than one 
brain area 
8-12 5 Significant deposition in three brain areas 
Table 2-6: Overall score system based on the number of +‟s each brain received to allow comparison 




2.10. Preparation of 10% (w/v) brain homogenate 
Half mouse brains were taken by qualified staff, flash frozen in liquid nitrogen and stored at 
-80°C until required. Brain tissue was weighed and transferred to a clean, glass dounce 
homogeniser and homogenisation in the appropriate buffer (Table 2-7) or distilled water was 
carried out on ice. The homogenate was briefly centrifuged at 2000rpm (Benchtop 
microcentrifuge) for 2 minutes to remove cellular debris. The supernatant was collected, 
aliquoted and stored at -80°C until use.   
Buffer Final Concentrations 
NP40 lysis buffer 
0.01M sodium deoxycholate, 0.15M sodium 
chloride, 0.05M Tris.HCl, 0.5% NP40 
PMCA conversion buffer 
0.15M sodium chloride, 0.01% triton X-100, 
4mM EDTA, 1X PBS (130mM NaCl, 
2.7mM KCl, 10mM sodium phosphate, 
1.7mM potassium phosphate, 5mM EDTA). 
Table 2-7: Details of buffers utilised to prepare 10% (w/v) brain tissue homogenates. 
2.11. Standard Proteinase K (PK) digestion of brain 
homogenates 
The disease-associated protein has been shown to be partially resistant to proteinase K 
digestion whilst the normal cellular protein PrP
C
 is completely digested (Bolton, McKinley 
et al. 1982). To identify the presence of PrP-res, homogenates were digested with PK 
(Roche) at a final concentration of 50µg/ml (unless otherwise stated) for 1 hour at 37°C with 
agitation. After digestion, PMSF (Sigma) was added to a final concentration of 2mM to 
inhibit the PK digestion. SDS-PAGE and immunoblot was performed as described (Section 
2.19-2.21) to detect PrP-res.  
2.12. NaPTA precipitation of PrPSc from brain tissue 
homogenates 
Sodium phosphotungstic acid (NaPTA) precipitation has previously been shown to increase 
the sensitivity of immunoblotting for detection of PrP
Sc 
(Wadsworth, Joiner et al. 2001). A 
50µl aliquot from each 10% (w/v) brain homogenate, prepared in distilled water (Section 
2.10), was utilised for the selective precipitation of PrP
Sc
 with NaPTA. All incubations were 
carried out at 37°C with agitation. Magnesium chloride was added to the aliquot to a final 
concentration of 0.1mM and incubated for 15 minutes.  An equal volume of 4% Sarkosyl 
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(v/v) was added and incubated for 5 minutes. The sample was divided into two equal 
aliquots. To one aliquot, PK was added to a final concentration of 50µg/ml and incubated for 
1 hour. To the other aliquot, an equal volume of PMSF was added a final concentration of 
2mM and the aliquot was kept at 4°C for the hour. PK digestion was inhibited by the 
addition of PMSF, final concentration 2mM. PrP
Sc
 was selectively precipitated with the 
addition of NaPTA (pre-warmed to 37°C) to a final concentration of 0.3% (w/v) and 
incubated for 20 minutes. Samples were centrifuged for 30 minutes at 13,200rpm (Benchtop 
microcentrifuge) to pellet the precipitated PrP
Sc
. The pellet was re-suspended in 0.1% 
Sarkosyl (v/v) and 250mM EDTA to chelate any magnesium present. Samples were 
centrifuged for a further 30 minutes at 13,200rpm (Benchtop microcentrifuge) to produce the 
final PrP
Sc
 pellet, which was drained overnight at 4°C. The pellet was re-suspended in 15µl 
PBS. SDS-PAGE and immunoblot was performed as described (Section 2.19-2.21).  
2.13. Purification of scrapie-associated fibrils (SAF) from 
brain tissue 
The isolation of SAF was first performed through detergent insolubility and differential 
centrifugation from scrapie hamster brains (Hilmert and Diringer 1984). The technique has 
been optimised for isolation of SAF from mouse brains within our laboratory. Briefly, half 
mouse brain tissues were weighed and homogenised in brain lysis buffer (10% (w/v) 
Sarkosyl, 0.01M sodium dihydrogenphosphate) to a 10% (w/v) homogenate. Cell debris was 
pelleted at 11,700rpm for 20 minutes (Benchtop microcentrifuge). The supernatant was PK 
digested (final concentration 50µg/ml) for 1 hour at 37°C with agitation. PMSF was added 
(final concentration 2mM) to inhibit PK digestion. PK digested homogenates were ultra-
centrifuged at 70,000rpm for 2.5 hours at 10°C (Beckman TL100, Rotor) in poly-carbonate 
tubes (Beckman). The pellets, which contain the SAFs were air-dried overnight at 4°C and 
then re-suspended in 200µl PBS. Standard SDS-PAGE and immunoblot was performed 
(Section 2.19-2.21) to detect SAF.  
2.14. Detection of PK-sensitive PrPSc through cold PK 
digestion and deglycosylation from brain tissue homogenates 
Cold PK digestion is a limited PK digestion step performed on ice that has been shown to 
allow the detection of PK-sensitive forms of PrP
Sc
 (Tremblay, Ball et al. 2004, Nazor, Kuhn 
et al. 2005). Briefly, aliquots of the 10% (w/v) NP40 homogenates (Section 2.10) were 
incubated with 253µg/ml PK on ice for 1 hour. PK digestion was inhibited with the addition 
of PMSF, final concentration 0.1mM. Samples were deglycosylated with peptide N-
glycosidase F (PNGase F) (New England Biolabs) following manufacturer‟s instructions. 
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Briefly, after the addition of denaturing buffer, the samples were incubated at 100°C for 10 
minutes. Both G7 buffer (New England Biolabs) and NP40 buffer (New England Biolabs) 
were added and the samples vortexed. PNGase F was added to a final concentration of 
44units/µl and the samples incubated at 37°C with agitation for four hours. Samples were 
stored at -20°C until the NaPTA precipitation and/or SDS-PAGE and immunoblot could be 
performed, as described in sections 2.12 and 2.19-2.21 respectively.  
2.15. Conformational dependent immunoassay 
The conformational dependent immunoassay was adapted from the original protocol by 
Safar and colleagues (Safar, Wille et al. 1998). All incubation steps were performed at 37°C 
with agitation. Briefly, magnesium chloride was added to the starting homogenate to a final 
concentration of 0.1mM and incubated for 30 minutes at 37°C with agitation. An equal 
volume of 4% Sarkosyl (v/v) was added and incubated for 10 minutes. Pre-warmed NaPTA 
was added to a final concentration of 0.3% (w/v) and incubated for a minimum of three 
hours. The sample was divided into two equal aliquots and PrP
Sc
 pelleted through 
centrifugation for 30 minutes at 13,200rpm (Benchtop microcentrifuge). The pellets were re-
suspended in 0.1% (v/v) Sarkosyl and 250mM EDTA and stored overnight at 4°C. Samples 
were centrifuged at 13,200rpm for 30 minutes (Benchtop microcentrifuge) to pellet the PrP
Sc
. 
The pellets were re-suspended in either distilled water or 4M guanidine hydrochloride to 
provide the native and denatured sample respectively. The 4M guanidine hydrochloride 
samples were heat-denatured at 80°C for 6 minutes. A 96-well plate was pre-coated with 
200µl anti-PrP mAb FH11 (final concentration 1µg/ml per well) and stored overnight at 4°C. 
All further sandwich ELISA incubations were performed for 1 hour at room temperature 
with agitation. The plate was washed three times with DELFIA wash solution (Perkin Elmer) 
(DELFIA plate washer, Perkin Elmer) prior to incubation in 2% BSA/PBS blocking solution. 
The plate was again washed three times prior to loading of samples (diluted 1:20 in assay 
buffer (Perkin Elmer) in duplicate. After sample incubation, the plate was washed three 
times prior to the loading of the europium-labelled detector antibody 7A12, at a final 
concentration of 0.2ug/well. After detector antibody incubation, the plate was washed six 
times and incubated with enhancement solution (Perkin Elmer) for 5 minutes at room 
temperature. The fluorescent signal was counted using a time-resolved fluorometer (Wallac 
Victor
2
 1420 multilabel counter). The average of the duplicate wells and the resulting 
denatured to native ratio was then calculated. 
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2.16. NaPTA precipitation of PrPSc from spleen tissue 
NaPTA precipitation has previously been shown to increase the sensitivity of 
immunoblotting for detection of PrP
Sc 
from spleen tissues (Wadsworth, Joiner et al. 2001). 
Briefly, spleen tissues were homogenised to a 10% (w/v) homogenate in ice-cold 0.1M Tris 
(pH7.4) using a glass dounce homogeniser. The homogenates were centrifuged for 5 minutes 
at 1000rpm (Benchtop microcentrifuge) to remove the cellular debris. The supernatant was 
added to an equal volume of 2% (w/v) Sarkosyl in 0.1M Tris (pH7.4) and incubated at 37°C 
for 10 minutes with agitation. Each sample was divided into two equal aliquots, one aliquot 
was PK digested (50µg/ml) for 1 hour at 37°C with agitation, whilst the other aliquot was 
stored at 4°C during the incubation period. PMSF was added to each aliquot at a final 
concentration of 2mM to prevent further PK digestion. PrP
Sc
 was precipitated through the 
addition of pre-warmed NaPTA to a final concentration 0.3% (w/v) and incubation at 37°C 
for 30 minutes with agitation. Centrifugation at 14,000rpm (15,400g) for 30 minutes 
produced a protein pellet that contained precipitated PrP
Sc
. The pellets were washed with 
300µl 83mM EDTA, 0.1% (w/v) Sarkosyl, 0.1M Tris. Samples were centrifuged at 
14,000rpm (15,400g) for 30 minutes, the supernatant was discarded and the protein pellets 
dried upside-down overnight at 4°C. The pellets were re-suspended in the appropriate 
volume of tris-glycine sample buffer (Invitrogen) according to the weight of the starting 
tissue. Samples were denatured and run on an SDS-PAGE as described (Section 2.19-2.21).  
2.17. Isolation of scrapie associated fibrils from spleen tissue 
Enrichment of PrP
Sc
 through isolation of the scrapie associated fibrils from spleen tissue 
using detergent extraction and differential centrifugation was adapted from (Mohri, Farquhar 
et al. 1992). Briefly, spleen tissue was weighed and homogenised to a 10% (w/v) 
homogenate in potassium chloride (0.2M) utilising hand-held disposable homogenisers. 
Homogenates were centrifuged at 1600rpm, 2000g for 10 minutes (Benchtop 
microcentrifuge). The cellular debris pellet was discarded and the supernatant was 
transferred to TL.100.3 polyallomer tubes (Beckman) and centrifuged at 50,000rpm, 
100,000g for 30 minutes at 4°C in a Beckman TL-100 centrifuge. The resulting supernatant 
was discarded and the pellet re-suspended in 1ml Tris-HCl (100mM, pH7.4). PK digestion 
was performed at 50µg/ml at 37°C for 1 hour with agitation. PMSF was added to a final 
concentration of 7.6mM to inhibit further PK digestion. The addition of 2% (w/v) sarkosyl 
solution at equal volume to the supernatant and 2µl β-mercaptoehanol was added to allow 
detergent extraction with incubation continued at 37°C for 1 hour with agitation. The sample 
was overlaid onto a 200µl 20% sucrose/TrisHCl cushion in TL100.2 polyallomer centrifuge 
tubes (Beckman) that were centrifuged at 50,000rpm, 200,000g (Beckman TL-100) for 2 
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hours at 4°C. The pellet containing the isolated scrapie associated fibrils was re-suspended in 
tris-glycine sample buffer (Invitrogen), according to the starting weight of the tissue, 
utilising sonication if necessary. The supernatant produced would contain PrP
C
, if the sample 
has not been PK digested, which could be extracted by the addition of 20µl 100mM PMSF, 
20µl 100mM NEM and 4 times the volume of ice-cold methanol. Samples were incubated 
overnight at -20°C and then centrifuged at 3000rpm for 10 minutes in Beckman GS-6R. The 
resulting supernatant was discarded and the pellet re-suspended in tris-glycine sample buffer 
(Invitrogen) according to the starting weight of the tissue.  
2.18. PET-blot analysis of spleen tissue sections 
This process utilises PK digestion prior to immunostaining to specifically detect PK-resistant 
PrP
Sc 
and was adapted from the technique developed by Schulz-Schaeffer and colleagues for 
detection of PrP
Sc
 in spleen sections from paraffin-embedded spleen tissue (Schulz-
Schaeffer, Tschöke et al. 2000). Staining of spleen tissue sections for PrP
Sc
 was performed 
through an immunoblotting method, which was carried out at room temperature with gentle 
agitation, unless otherwise stated. PVDF tissue sections (Section 2.5.2) were hydrated 
through immersion twice in 100% xylene, 100% isopropanol, 95% isopropanol for 5 minutes 
each followed by a single immersion in 70% isopropanol, 50% isopropanol and 0.1% Tween 
20/distilled water for 5 minutes each. Sections were washed twice in TBS containing 0.1% 
Tween20 (0.1% TBST) for 5 minutes each before incubation overnight at 55°C in PK digest 
buffer containing 20µg/ml PK (Sigma) with gentle agitation. Sections were washed 3 times 
with 0.1% TBST before the sections were denatured with 3M guanidine isothiocyanate for 
10 minutes. After a further three 5 minute washes with 0.05% TBST, sections were blocked 
with 2% casein/0.1% TBST for 30 minutes. Sections were incubated with primary antibody 
1B3 (kindly provided by Karen Brown (Farquhar, Somerville et al. 1989)) diluted 1:4,000 in 
2% casein/0.1% TBST solution for 2 hours. After three 5 minute washes in 0.05% TBST, 
sections were incubated in alkaline phosphatase conjugated rabbit-anti-mouse secondary 
antibody (Jacksons) diluted 1:5,000 in 2% casein/TBS for 1 hour. Sections were washed 5 
times for 5 minutes each in 0.05% TBST. The antibody signal was developed with Nitro-
blue tetrazolium chloride- 5-bromo, 4-chloro, 3‟-ondolyphosphate P-toluidine salt 
(NBT/BCIP®) solution (Sigma) at pH9 for a maximum of 10 minutes. Sections were washed 
with distilled water, then 0.02M EDTA/TBS before being air-dried overnight. PrP
Sc
 specific 
staining was analysed by bright-field microscopy (Leica DMRB).  
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2.19. Protein sample denaturation and separation by SDS-
PAGE 
To allow for protein identification, proteins were separated according to their size by 
polyacrylamide gel electrophoresis (PAGE). All reagents and apparatus were sourced from 
Invitrogen.  Briefly, samples were prepared in Novex® Tris-Glycine SDS sample buffer in 
the presence of NuPAGE® sample reducing agent (final concentration 50mM dithiothreitol). 
Samples were denatured at 90°C for 20-30 minutes and then loaded onto a pre-cast Novex® 
12% Tris-Glycine Gels. Pre-stained standard markers (SeeBlue® and MagicMark™) were 
loaded into the appropriate wells according to manufacturer‟s instructions. The gel was 
inserted into a gel tank that was filled with SDS-PAGE running buffer (0.02M Tris, 0.19M 
glycine, 3.5mM SDS). Samples were loaded at a 10mg/ml concentration unless otherwise 
stated. The gel was run at 130V for 120 minutes. After the run was complete, the apparatus 
was dismantled and the gels were removed from the cassettes, ready for further use. 
2.20. Semi-dry transfer of separated proteins to a membrane 
The separated proteins were transferred to a polyvinylidene fluoride (PVDF) membrane 
(Millipore, UK) using a semi-dry blotter (BIO-RAD). The PVDF membrane was first 
washed in methanol for 30 seconds, washed with distilled water and immersed in transfer 
buffer (40mM glycine, 48mM tris, 1mM SDS and 20% methanol (v/v)). Each individual gel 
was placed in a sandwich of 6 pieces of filter paper (soaked in transfer buffer), PVDF 
membrane, polyacrylamide gel, filter paper (Figure 2-3) and placed inside a semi-dry blotter. 
Current was applied at 2mA/cm
2 
for 90 minutes, i.e. 250mA, limited to 25V for two gels that 
allowed the transfer of proteins to the membrane.  
 
Figure 2-3: Semi-dry blotting technique  
2.21. Immunodetection of PrP 
The PVDF membrane was blocked in 20ml 1% blocking solution (Roche) diluted in Tris 
buffered saline (TBS) pH7.5 (50mM Tris, 150mM sodium chloride) for 1 hour at RT with 
gentle agitation. The PVDF membrane was then incubated in primary antibody 8H4 (Sigma), 
unless otherwise stated, (0.1µg/ml) in 20ml 0.5% blocking solution (Roche) in TBS, 
overnight at 4°C with agitation. The membrane was washed twice for 10 minutes in 0.1% 
TBS Tween20 and then washed twice in 0.5% blocking solution for 10 minutes each. The 
membrane was then incubated in a horseradish-peroxidase conjugated rabbit anti mouse 
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(IgG) secondary antibody (Stratech Scientific) diluted to the appropriate concentration 
(0.02µg/ml – 0.04µg/ml) in 20-30ml 0.5% blocking solution in TBS for 1 hour at RT with 
agitation. The PVDF membrane was then washed 4 times in 0.1% TBS Tween20 for a 
minimum of 10 minutes per wash. The membrane was then incubated protein-side down in 
SuperSignal West Dura Chemiluminescent Solution (Thermo-Scientific) for 5 minutes and 
developed in the dark room onto X-ray film (Roche), exposed for 1, 3, 5 and 10 minutes. 
Alternatively, the blot was imaged using the Kodak Image Station 440CF. A list of primary 
anti-PrP antibodies used within this research project is provided in Appendix 1. 
2.21.1. Stripping of bound antibody from PVDF 
In order to re-probe a blot with secondary antibody only, PVDF membranes were stripped of 
the bound antibody using Western Blot Stripping Buffer (Invitrogen). All incubations were 
performed at RT with gentle agitation. Briefly, after probing, PVDF membranes were 
washed twice in TBS for 5 minutes each, washed twice in TBST for 15 minutes and washed 
twice for 5 minutes in TBS. The PVDF was incubated in Restore Western Blot Stripping 
Buffer (Invitrogen) for 1 hour. The PVDF was then incubated in fresh Restore Western Blot 
Stripping Buffer (Invitrogen) overnight. After overnight incubation, the PVDF was washed 
twice for 10 minutes in TBS, twice for 15 minutes in TBST and twice for 5 minutes in TBS. 
The PVDF was then blocked in 1% blocking solution (Roche) for 1 hour before incubation 
in the appropriate antibody was performed as described in section 2.21. 
2.22. Total protein visualisation (non-specific) 
2.22.1. Method One: Silver Staining 
Silver staining was utilised to detect all proteins present on a gel after SDS-PAGE (Section 
2.19) had been performed. Tris-glycine gels were removed from the cassette and fixed 
overnight in fixing solution (30% ethanol, 10% acetic acid) with gentle agitation at RT. The 
gels were then soaked for 1 hour in sensitising solution (30% ethanol, 0.02% (w/v) sodium 
thiosulphate, 0.8M sodium acetate, 0.5% glutardialdehyde) at RT with gentle agitation 
before four 15 minute washes in distilled water were performed. The gels were then soaked 
in silver stain solution (15mM silver nitrate, 0.1% formaldehyde) for 1 hour with gentle 
agitation at RT. The silver stain solution was removed, the gels washed twice with distilled 
water for precisely 1 minute each before the gel was soaked in developing solution (0.2M 
sodium carbonate, 0.04% formaldehyde) until the protein bands were visible, with a 
maximum time of 10 minutes. Gels were then stored in stopping solution (0.05M EDTA) 
until visualisation could be performed. Gels were scanned with an Epson Perfection V750 
Pro scanner.  
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2.22.2. Method Two: SYPRO RUBY (Invitrogen) 
SYPRO Ruby protein gel stain (Invitrogen) stains all proteins, including glycoproteins 
present on a gel after SDS-PAGE. After protein separation was performed by SDS-PAGE 
(Section 2.19), the tris-glycine gels were incubated in fixing solution (50% methanol, 7% 
acetic acid) for 30 minutes with gentle agitation at RT, repeated twice. The gels were then 
incubated overnight in SYPRO Ruby protein stain with gentle agitation at RT allowing the 
SYPRO Ruby stain to bind to the proteins present through non-covalent interactions with 
primary amines, especially lysine, arginine and histidine (Patton 2000). The gels were then 
washed in wash solution (10% methanol, 7% acetic acid) for 30 minutes at RT. Gels were 
then rinsed in distilled water and protein bands visualised under UV light and photographed 
(The Imager; Appligene® Oncor).  
2.22.3. Method Three: Coomassie Blue Staining 
Coomassie blue staining was utilised to stain SDS-PAGE gels after protein transfer to PVDF 
membrane to confirm that the protein transfer was successful and to stain 2D-PAGE gels 
(Section 2.27). The SDS-PAGE gel was incubated in coomassie blue solution (0.25% 
coomassie brilliant blue R-250 (Sigma), 50% methanol (v/v), 9% acetic acid (v/v)) for 1 
hour with agitation at RT. Incubation in the de-stain solution (23% ethanol (v/v), 7% acetic 
acid (v/v)) was performed overnight with agitation at RT to remove excess staining solution. 
If necessary, a further wash for up to 1 hour in de-stain solution was performed to allow 
clear visualisation of protein bands. Gels were either scanned with Epson Perfection V750 
Pro scanner or photographed with the Kodak Image Station 440CF. 
2.23. IDEXX HerdChek* Bovine Spongiform Encephalopathy 
Antigen Test Kit, EIA 
The IDEXX HerdChek* Bovine Spongiform Encephalopathy Antigen Test Kit is a 
commercially available antigen-capture enzyme immunoassay (EIA) that detects the 
abnormal prion protein. Manufacturer‟s instructions were followed and all reagents were 
provided with the kit. Briefly, tissue for analysis was weighed (0.30g maximum weight) and 
ribolysed (Precellys® 24) for 40 seconds at a max speed of 6.5m/s in a tissue-disruption tube 
in buffer provided to a 30% (w/v) homogenate concentration. Brain tissue homogenate 
(100µl) was mixed with working plate diluent (25µl) before being loaded in duplicate onto 
the antigen-capture plate. Positive and negative controls provided with the kit were also 
loaded in duplicate and the plate incubated at RT for 1 hour with gentle agitation (100-
300rpm) to allow for antigen-ligand binding. The wells were washed 6 times with wash 
solution 1 (Model 1575 Immunowash, BIO-RAD) to remove any unbound components. 
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Conditioning buffer (100µl) was added to each well and incubated for 10 minutes at RT 
without agitation to denature the homogenates. The wells were washed 3 times with wash 
solution 2 (Model 1575 Immunowash, BIO-RAD) then the prepared small-ruminant brain 
conjugate HRPO-conjugated anti-PrP antibody (100µl) was added to each well and the plate 
incubated at RT for an hour without agitation to allow antibody-antigen binding. The wells 
were washed 5 times with wash solution 2 (Model 1575 Immunowash, BIO-RAD), to 
remove any unbound antibody. A peroxidise substrate, TMB (100µl) was added to each well 
and incubated for 15 minutes at RT protected from light before hydrogen chloride (100µl) 
was added to inhibit the reaction. The sample absorbance was measured at 450nm and 
620nm utilising the Wallac Victor
2
 1420 multilabel counter, with the level of colour 
development related to the amount of antigen captured by the ligand. Any remaining tissue 
homogenate was aliquoted and frozen at -80°C for further analysis by other biochemical 
techniques. For analysis of spleen tissue, the tissue homogenate (100µl) was added to 50µl 
working plate diluent and the IDEXX performed as above with incubation periods extended; 
antigen capture was performed for 2.5-3 hours and the capture antibody, HRPO-conjugated 
anti-PrP antibody was incubated for 2 hours before washes and TMB incubation were 
performed as described. 
2.24. Protein Misfolding Cyclic Amplification (PMCA) 
2.24.1. Preparation of normal brain homogenate 
substrate for PMCA 
Whole mouse brains were taken post mortem, snap frozen in liquid nitrogen and stored at -
80°C until use. The brains were weighed and homogenized in glass dounce homogenisers on 
ice to 10% (w/v) in PMCA conversion buffer (Section 2.10). Cell debris was removed by 
centrifugation at 2000rpm (Benchtop microcentrifuge) for 45 seconds at 4°C. The resulting 
supernatant was either used directly or frozen at -80°C until use. When multiple brain 
homogenates were combined to provide the substrate, the homogenates were combined prior 
to removal of the cellular debris.  
2.24.2. Preparation of TSE infected brain homogenate 
seed for PMCA 
Whole or half brains were taken post mortem, snap frozen in liquid nitrogen and stored at -
80°C until use. The brain tissue was weighed and homogenized in glass dounce 
homogenisers on ice to 10% (w/v) in PMCA conversion buffer (Section 2.10) containing one 
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complete protease inhibitor tablet without EDTA (Roche) per 10ml buffer. Homogenates 
were aliquoted and stored at -80°C until use.  
2.24.3. Protein misfolding cyclic amplification  
PMCA was developed by Soto and colleagues (Saborio, Permanne et al. 2001) to allow the 
amplification of minute amounts of PrP
Sc
 seed. The TSE seed was diluted into the substrate 
to produce an appropriate dilution to undergo amplification. At this dilution, the PrP
Sc
 seed 
was just detectable by immunoblot. Aliquot(s) of each dilution were placed inside the 
sonicator bath in the appropriate holder. The remaining aliquot of each dilution was 
immediately frozen at -80°C to provide a sample prior to amplification for comparison of 
PrP-res levels. Negative control aliquot(s) of substrate only were included in each run to 
control for both spontaneous formation and cross contamination. The sonicator horn and bath 
(either Misonix 3000 or 4000) were placed inside an incubator set at 37°C. The samples 
were subjected to cycles of sonication pulses (of varying length and power) followed by a 30 
minute incubation period, over a period of either 24 or 48 hours. When the run was 
complete, samples were either analysed immediately or frozen at -80°C until analysis. 
Sample analysis was performed with PK digestion, SDS-PAGE and immunoblot (Sections 
2.11, 2.19-2.21 or 2.25). Three variations in PMCA methodologies were trialled, in three 
different laboratories with the variations between techniques shown below:  
Method One:  
Location The Roslin Institute, Edinburgh 
Sonicator Misonix 4000 
Sonication pulse length and power 40 seconds at variable sonication powers 
Holder 96-well Multiply-PCR plate half skirt (Sarstedt) 
Water bath  Static 
 
Method Two:  
Location Istituto Superiore di Sanità, Rome 
Sonicator Misonix 3000 
Sonication pulse length and power 20 seconds at 180-190W 
Holder Multiply safecup 100µl screwcap biosphere 
(Sarstedt) 





Location National CJD Research & Surveillance Unit, 
Edinburgh 
Sonicator Misonix 3000 or 4000 
Sonication pulse length and power 20 second pulse at 80% sonication power (~236W) 
Holder 0.2ml thin-walled PCR tubes 
Water bath  Static 
 
2.25. Alternative SDS-PAGE and immunoblot method to detect 
PrPSc in PMCA products (performed at NCJDRSU)  
The detection of PrP
Sc
 by immunoblotting was performed at the NCJDRSU as per protocols 
in place. Briefly, sample homogenates were PK digested at a final concentration 50µg/ml at 
37˚C for 1 hour. Pefabloc® (Roche) was added to a final concentration of 1mM to inhibit 
further PK digestion. Samples were diluted in NuPAGE LDS 4X sample buffer (Invitrogen) 
and denatured at 100˚C for 10 minutes. Proteins were then separated by gel-electrophoresis 
using NuPAGE® Novex® 10% Bis-Tris gels (Invitrogen) in NuPAGE 1X MES SDS 
running buffer (final concentrations: 50mM MES, 50mM Tris, 0.1% SDS, 1mM EDTA, 
)(Invitrogen) for 50 minutes at 200V. Proteins were transferred to a PVDF membrane 
(Millipore) using the NuPAGE® wet transfer system at 30V for 1 hour in 1X NuPAGE 
transfer buffer (final concentrations: 25mM bicine, 25mM bis-tris, 1mM EDTA, 0.05M 
chlorobutanol and 20% methanol)(Invitrogen). The PVDF membrane was blocked in 5% 
milk (Sainsbury‟s non-fat dried milk powder)/TBST overnight at 4˚C with gentle agitation. 
The membrane was washed with TBST prior to incubation in the primary antibody, diluted 
in TBST to the appropriate concentration (8H4, Sigma – 0.1µg/ml), (3F4, kindly provided by 
Mark Head – 1:25,000), for 1 hour at RT with gentle agitation. The membrane was washed 
three times in TBST for 2 minutes each and then incubated in horseradish-peroxidase 
conjugated rabbit-anti-mouse secondary antibody (kindly provided by Mark Head), diluted 
in TBST (1:50,000), for 1 hour at RT with gentle agitation. The membrane was briefly 
washed in TBST, prior to incubation with the chemiluminescent substrate (ECL plus, 
Amersham Biosciences). The blot was exposed to X-ray film for 1, 3 and 30 minutes. Films 




2.26. PAD-beads depletion of brain tissue homogenates 
utilising the Seprion ligand.  
Brain tissue was homogenised to 10-25% (w/v) in distilled water (Section 2.10). Following 
the manufacturer‟s protocol (Microsens Biotechnologies), an initial ten minute incubation 
step was performed at RT with sample homogenate (200µl), capture buffer (200µl), distilled 
water (400µl) and the Seprion PAD-reagent (100µl) to allow the binding of the target 
aggregate to the Seprion ligand. After the addition of PAD-beads (100µl), the sample was 
incubated for 30 minutes at RT with agitation to allow the Seprion ligand to bind to the 
magnetic beads. The beads were then captured using a magnetic rack (Invitrogen) and the 
depleted homogenate aliquoted for analysis. The beads were washed through re-suspension 
in wash buffer one, re-captured on the magnetic rack and the wash buffer removed and 
aliquoted. This process was repeated twice with wash buffer two, to improve the specificity 
of the assay by removing the normal unaggregated protein prior to elution of the target 
aggregate from the beads. The microtubes were then pulsed for 10 seconds at 13,200rpm 
(Bench-top microcentrifuge), placed back on the magnetic rack to allow re-capture the 
magnetic beads and allow the removal of the any remaining buffer. The beads were then re-
suspended in the appropriate elution buffer. Standard elution was performed with re-
suspension in 200µl tris-glycine sample buffer (Invitrogen), which was heated at 100°C for 
10 minutes. The beads were then re-captured on the magnetic rack and the eluate removed 
for analysis. Throughout this thesis, dh refers to the depleted homogenate, W refers to the 
wash buffer with the appropriate number associated, W without a number indicates that the 
wash buffers were combined to provide the sample analysed and E refers to the eluate from 





Figure 2-4: PAD-beads protocol with samples aliquoted from each stage indicated. Adapted from Microsens Biotechnologies. 
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2.27. Two Dimensional-PAGE (2D-PAGE) 
2D-PAGE separates proteins through two dimensions, firstly through isoelectric focusing 
and secondly by molecular weight (Gorg, Postel et al. 1988, Gorg, Obermaier et al. 2000). 
For 2D-PAGE, elution of the protein from the PAD-beads was performed through incubation 
in 200µl 0.5% SDS for 10 minutes at 100°C. To the 200µl eluate, 480µl methanol and 160µl 
chloroform was added and the sample mixed by vortexing. Distilled water (640µl) was 
added prior to centrifugation for 5 minutes at 13,000rpm (benchtop micro-centrifuge). The 
upper phase was removed with a small amount of upper phase left as the proteins were 
present between the two liquid phases. Further precipitation was performed through the 
addition of 300µl methanol and the sample mixed by vortexing. The proteins were pelleted 
by centrifugation for 10 minutes at 13,000rpm (Benchtop micro-centrifuge). The supernatant 
was removed and the pellets allowed to air dry prior to re-suspension in 30µl DeStreak 
Rehydration Buffer (GE Healthcare). 2D-PAGE was then performed under conditions 
previously optimised within the laboratories. Briefly 125µl DeStreak Rehydration Solution 
(GE Healthcare) containing 30µl precipitated eluate and 0.5% IPG buffer 3-10NL (GE 
HealthCare) was placed into the centre of a gel strip holder (Amersham Biosciences) and an 
Immobiline DryStrip pH3-10 NL, 7cm (GE Healthcare) was overlaid onto the sample. The 
Immobiline DryStrip was coated with 3ml Immobiline DryStrip cover fluid (GE Healthcare) 
and placed in the correct orientation on an Ettan™ IPGphor II™ to allow rehydration and 
isoelectric focusing through the settings described in Table 2-8. 
Step Voltage Mode Voltage (V) Time (Hrs) Volt-Hours (KVh) 
1. Step and Hold 500 1 0.5 
2. Gradient 1000 8 0.8 
3. Gradient 8000 3 13.5 
4. Step and Hold 8000 2 12.2-21.2 
Table 2-8: Conditions for rehydration and isoelectric focusing during 2D-PAGE. 
After rehydration and isoelectric focusing program was completed, the Immobiline Strip was 
removed and equilibrated in 10ml SDS equilibration buffer (75mM Tris-HCl, 6M Urea, 30% 
(v/v) Glycerol, 2% (w/v) SDS, 0.002% (w/v) bromophenol blue) containing 6.5µM DL-
dithiothreitol (Sigma) for 15 minutes with rotation. A second equilibration step was 
performed with 10ml SDS equilibration buffer containing 13.5µM iodoacetamide (Sigma) 
for 15 minutes with rotation. The Immobiline Strip was washed in SDS-PAGE running 
buffer (0.02M Tris pH7, 0.19M glycine, 3.5mM SDS) for 2 minutes with rotation. The 
Immobiline Strip was placed in the well of a pre-cast 4-20% tris-glycine ZOOM gel 
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(Invitrogen) with the negative end of the Immobiline Strip placed at the left-hand side of the 
gel. The Immobiline Strip was sealed in place with the addition of approximately 2ml 
agarose sealing solution (0.5% agarose in SDS-PAGE running buffer with a trace amount of 
bromophenol blue). The gel was run at 125V for 120 minutes with a Bio-Rad power pack 
and the gel removed from the cassette and incubated in coomassie blue stain (Section 2.22.3) 
to stain for separated proteins. Stained gels were photographed using the Kodak Image 
Station 440CF and analysed with Imagemaster 2D Platium Software Version 5.0. 
2.28. Surface-enhanced laser desorption/ionization (SELDI) 
The SELDI technique (Hutchens and Yip 1993)(Bio-Rad Laboratories), used for the analysis 
of proteins, has previously been optimised within our laboratories (Barr, Watson et al. 2009). 
The SELDI technique utilises time-of-flight mass spectrometry (TOF-MS) to measure the 
mass-to-charge (m/z) ratio of the peptides and proteins present on each spot of the 
ProteinChip® array that can hold up to 8 samples. The SELDI was utilised in this study to 
identify any proteomic differences between the PAD-beads components produced from a 
79A infected brain homogenate and a normal uninfected brain homogenate. Each component 
was methanol precipitated in the same manner as the inocula samples were prepared (Section 
2.28), to minimise contaminants and reduce the detergent concentration, with re-suspension 
of the pellet in 200µl PBS. The normal phase protein ProteinChip® NP20 array (Bio-Rad) 
contains silicon dioxide on the arrays that allows for the general binding of all proteins 
present in the sample via serine, threonine or lysine residues to the spot. Each spot on the 
ProteinChip® was activated with 2µl PBS and allowed to air dry prior to the addition of 2µl 
of the sample of interest. After the sample had air dried, two applications of 0.5µl matrix 
solution (sinapinic acid/50%acetonitrile/0.1% TFA) were applied to each array spot, which 
provided energy absorbing molecules within an organic solvent. The presence of the organic 
solvent dissolves the proteins into a solution with the energy absorbing molecules that then 
forms crude crystals after drying. The ProteinChip® NP20 array was then analysed on a 
ProteinChip® Enterprise system (Bio-Rad). Briefly, the SELDI fires a nitrogen laser at a 
spot on the ProteinChip® that ionizes the protein and induces a change of state from solid, 
crystalline phase into the gas phase. The charged gaseous proteins then „fly away‟ from a 
positively charged array within the time-of-flight assembly. A detector at the top of this 
assembly monitors the arrival of each charged protein with the resulting flight times 
dependent upon the mass of the protein, producing an accurate analysis of the mass (mass to 
charge ratio) of the protein. The arrays were read twice, once with a low laser power that 
focused on the 1-50kDa spectral range and again with a high laser power focused on the 1-
200kDa spectral range. Spectral data were collected using ProteinChip® DataManager 
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software with an average of 583 laser shots per array spot. Resultant data was processed 
using ProteinChip® DataManager software. The spectra were baseline corrected and the   
“Peak Wizard” function used to locate proteins in each spectrum.  
2.29. Methanol precipitation of inocula to determine the 
relationship between Seprion ligand target and TSE 
infectivity.  
The PAD-beads procedure was carried out according to the optimised conditions (Section 
2.26) and the dh, wash buffers and eluates collected. The wash buffers were combined into 
one sample, which alongside the dh and appropriate controls (described in section 6.2.4), 
were methanol precipitated to remove any harmful chemicals present in the buffers utilised 
during the separation. Methanol precipitation was carried out with the addition of 4x sample 
volume of ice cold methanol and incubated at -20°C overnight. The precipitated protein was 
pelleted through centrifugation at 3000g for 20 minutes (Beckman GS6R) and the resulting 
pellet re-suspended in 200µl sterile saline by pipetting, producing a sample at an equivalent 
concentration to the 10% (w/v) homogenate. The resulting re-suspension was diluted to 
produce a concentration equivalent to a 1% (w/v) homogenate to be utilised as inoculum. 
Inoculations were then performed as previously described (Section 2.3). 
Nomenculture  
Within this thesis, the following terms apply; 
PrP-res describes disease-associated PrP that is PK resistant,  
PrP
Sc
 describes for disease-associated PrP for which the PK-resistance is unknown.  
sPrP
Sc
 describes PK-sensitive PrP
Sc
. 
Unless otherwise stated, within this thesis wild-type mice are 129Ola mice.  
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3. Confirmation of extremely low levels or absence of PrP-res in 
the brain tissue from 101LL/GSS and 101LL/263K 
transmissions 
3.1. Introduction 
The prion hypothesis states that PrP
Sc
 acts as the infectious agent in TSE disease (Prusiner 
1982) and that its resistance to PK digestion is a defining feature, producing PrP-res. 
However, models exist where either PrP
Sc
 is present in the absence of transmissible 
infectivity (Yuan, Xiao et al. 2006, Piccardo, Manson et al. 2007) or infectivity is present 
despite the lack of detectable PrP-res
 
(Lasmezas, Deslys et al. 1997, Manson, Jamieson et al. 
1999, Race, Meade-White et al. 2002, Barron, Campbell et al. 2007). One example of the 
later scenario has been identified when a gene-targeted mouse model of GSS disease, with a 
point mutation from proline to leucine at codon 101 in murine PrP, was inoculated intra-
cerebrally with human P102L GSS disease brain homogenate (Manson, Jamieson et al. 
1999) or hamster 263K scrapie brain homogenate (Barron, Thomson et al. 2001). For both 
isolates, efficient TSE transmission occurs with clinical symptoms, including ataxia, hind 
limb paralysis and marked kyphosis with TSE-associated vacuolar pathology observed in the 
brain tissue. This was in contrast to transmission of these diseases to wild-type mice that 
results in incomplete attack rates and long incubation times, indicative of low transmission 
rates. Sub-passage of the 101LL/GSS and 101LL/263K brain tissue from mice that showed 
clinical signs of TSE disease with confirmed vacuolar pathology, to further 101LL mice, 
resulted in short incubation periods (120-160 days) to terminal disease, indicative of high 
infectivity titres (Manson, Jamieson et al. 1999). Indeed, further full titration bioassay of the 









IU/g tissue for 101LL/GSS and 101LL/263K transmissions respectively (Barron, 
Campbell et al. 2007). Despite the presence of a clinical TSE disease with associated 
vacuolar pathology and high infectivity levels, little or no PrP-res was detected in the brain 
tissue of terminal animals through conventional diagnostic laboratory techniques such as 
immunohistochemistry and immunoblotting. Thus this disease model questions the 
relationship between PrP-res and TSE infectivity. This chapter describes the techniques used 
to confirm the disease characteristics that were observed in previous transmissions were 
present in novel transmissions of human P102L GSS and hamster 263K into the 101LL mice 
performed to produce tissue for use in this thesis. 
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3.2. Results  
3.2.1. Short incubation periods are indicative of high titres of 
infectivity.  
Previous experiments performing transmissions of different isolates of P102L GSS disease 
(Figure 3-2) or hamster 263K brain homogenates (Figure 3-3) into the 101LL mouse model 
resulted in a clinical TSE disease with associated vacuolar pathology. Upon sub-passage into 
101LL mice, short average incubation periods to disease were observed with a clinical TSE 
disease present with associated vacuolar pathology (Manson, Jamieson et al. 1999, Barron, 
Thomson et al. 2001). Incubation periods to terminal disease give an indication of the 
infectivity levels within an inoculum sample, with short incubation periods being indicative 
of high infectivity titres (Manson, Jamieson et al. 1999). 
For this thesis, an isolate of the frontal cortex of brain tissue from a 45 year old female with 
pathologically confirmed GSS disease, with a P102L mutation (129MM) and detectable PrP-
res (Figure 3-1) was inoculated intra-cerebrally (Section 2.2, 2.3) into thirty-six 101LL mice. 
Thirty-five of the thirty-six mice developed clinical symptoms with confirmed vacuolar 
pathology between 233 and 281 days with an average incubation period of 265±3 days 
(Figure 3-2, Isolate E). A similar average incubation period, 279±5 days, was observed in a 
previous transmission of a different tissue sample from the same case (Figure 3-2, isolate E*) 
and from several other previous transmissions of isolates from unrelated P102L GSS cases 
(isolates A, B, D and D). 
Wild-type mice that have proline present at the 101 codon (101PP) have lower attack rates 
and extended incubation periods when inoculated with P102L GSS isolates. Transmission of 
the isolate E to twelve wild-type mice was performed although none of the mice displayed 
clinical signs of TSE disease, vacuolar pathology or the presence of PrP
Sc
 by 





Figure 3-1: PrP-res was present in P102L GSS brain used to provide the inoculum. Although no 
residual inoculum was available a different sample from the same brain (frontal cortex) area showed 
the presence of PrP-res. Samples loaded at 15mg/ml. Blot probed with mAb 3F4 and exposed for 30 
minutes.  
 
Figure 3-2: Average incubation periods of different isolates of P102L GSS into 101LL mice 
performed within the institute (A) P102L GSS (Manson, Jamieson et al. 1999), (B) P102L GSS 
(personal communication – Rona Barron), (C) P102L GSS (Vienna case) (personal communication – 
Rona Barron), (D) purified SAF from a P102L GSS with 21kDa PrP
Sc
 (Piccardo, Manson et al. 2007), 
(E and E*) frontal cortex homogenate from P102L GSS case from 45 year old female.   
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 For this thesis, thirty-six 101LL mice were inoculated intra-cerebrally with a hamster 263K 
scrapie brain homogenate (Sections 2.2, 2.3)(Figure 3-3, homogenate E). Twenty-six of the 
thirty-six mice developed clinical symptoms between 307 and 669 days with an average 
incubation period of 447±16 days (Figure 3-3, homogenate E). In experiments using five 
different hamster 263K brain homogenates (101PP genotype) all transmitted efficiently to 
the 101LL mouse model producing a clinical TSE disease with confirmed vacuolar 
pathology (Figure 3-3, homogenates A - D). 
Wild-type mice (101PP) were inoculated with the same hamster 263K brain homogenate 
(homogenate E), only three of twelve mice were culled due to clinical signs of TSE disease 
with a survival time of 447±118 days but no TSE vacuolar pathology was observed. 
Additionally, two of the twelve mice were scored positive for TSE-related vacuolation but 
did not display any clinical symptoms. The remaining seven mice did not display clinical 
signs of TSE disease or related vacuolar pathology and were therefore negative for TSE 
disease and remained healthy until 669 days post inoculation at which point the experiment 
ended.  
The average incubation periods to disease of 101LL/GSS, isolate E, and 101LL 263K, 
homogenate E, were similar to the incubation periods to disease previously observed with 
similar isolates of inocula. Although full sub-passage titration experiments were not 
performed on the tissues used in this thesis, it can be presumed that a similar infectivity titre 
would be present given the similar incubation periods to disease as the other primary 
transmissions that were fully titrated. Individual tissues from human P102L GSS isolate B 




































Hamster 263K in 101LL mice
 
Figure 3-3: Average incubation periods of five primary transmissions of different hamster 263K 
scrapie brain homogenates into 101LL mice performed within the institute (A), (B) (Barron, Thomson 
et al. 2001); (C), (D) personal communication, R. Barron and (E) performed to provide tissue for use 




3.2.2.  Lesion profiles show the expected strain profile. 
The production of lesion profiles (Section 1.1.5), based on the vacuolation score of nine 
different brain areas (Section 2.7) provides a specific pattern (Fraser and Dickinson 1968) 
that can be used to distinguish between different strains. The lesion profiles (Figure 3-4) 
produced from the transmission of each isolate of P102L GSS (identified in Figure 3-2) in 
101LL mice follow generally the same pattern varying in the severity of the vacuolation. 
The lesion profiles produced from the primary transmission of different brain tissue 
homogenates of hamster 263K scrapie into 101LL mice (identified in Figure 3-3) all show 
similar lesion profiles (Figure 3-5) indicating the same 263K strain has been transmitted in 
each case. The severity of vacuolation is the only variable observed, specifically in the 




Figure 3-4: Lesion profiles produced from the different isolates of P102L GSS inoculated into 101LL 
mice show a similar pattern with variable vacuolation scores (A). „Isolate E‟ used for this thesis has 
been transmitted twice producing identical lesion profiles shown on their own (B) for clarity. Profiles 
calculated from the mean scores of at least 6 individual animals per group. Details of the brain areas 
scored detailed in Table 2-4. Scoring was performed by experienced personnel. 
 
Figure 3-5: Lesion profile produced from the five different transmissions of hamster 263K brain 
homogenates into 101LL mice show a similar pattern with variable vacuolation scores. „Homogenate 
E‟ was transmitted to produce tissue for use within this thesis. Profiles calculated from the mean 
scores of at least 6 individual animals per group. Details of the brain areas scored detailed in Table 
2-4. Scoring was performed by experienced personnel. 
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3.2.3.  Quantification of low levels of PrPSc deposition by 
immunohistochemistry 
Of the thirty-six mice inoculated in the 101LL/GSS transmission, only thirty-two had brain 
tissue available for pathological and biochemical analysis (Table 3-1). Brain tissues were 
sectioned (Section 2.5.1) and subjected to immunohistochemical analysis (Section 2.8). 
Twenty-three brain sections were positive for PrP
Sc
 deposition at varying levels (Table 3-3), 
of which twenty showed clinical signs of TSE disease with confirmed vacuolar pathology 
and three showed clinical signs of TSE but did not have TSE related vacuolar pathology. 
Importantly, three mice showed clinical signs of TSE disease and were positive for vacuolar 
pathology; however no PrP
Sc
 was detected by immunohistochemistry. Three mice were 
scored clinically positive for TSE disease but were negative for both TSE-related vacuolar 
pathology and PrP
Sc
 deposition. Three brain tissues were damaged during post mortem and 
therefore a vacuolar pathology score was not determined due to tissue quality (Table 3-1).  
For the 101LL/263K transmission, thirty-three tissues were available for 
immunohistochemical analysis (Section 2.8), (Table 3-2), with eleven mice positive for the 
presence of PrP
Sc
 deposition. Of these eleven mice, ten showed clinical signs of TSE disease 
with confirmed vacuolar pathology. The remaining tissue that contained PrP
Sc
 deposition 
was positive for TSE-related vacuolation but had been culled due to an inter-current illness 
at 636 days post inoculation and was likely to be in the sub-clinical. Importantly, thirteen 
mice showed clinical signs of TSE disease with confirmed vacuolar pathology but did not 
have PrP
Sc
 detectable by immunohistochemistry. Of the remaining mice, three showed only 
clinical signs of TSE disease, one only showed vacuolar pathology whilst the other five mice 
were negative for clinical signs of disease and neuropathology (both vacuolar pathology and 
PrP
Sc
 deposition) (Table 3-2).  
For both 101LL/GSS (Table 3-3) and 101LL/263K (Table 3-4) transmissions, the level of 
PrP
Sc 
deposition in each brain area was scored and an overall deposition score given to each 
positive tissue (Section 2.9). The level of PrP
Sc
 deposition observed was similar to previous 
transmissions of the P102L GSS isolates into 101LL mice, showing low levels of PrP
Sc
 in 
comparison to the 87V/VM positive control (Figure 3-6). Although the numbers of mice 
positive for PrP
Sc
 deposition were greater in the 101LL/GSS transmission, the average 
overall scores indicated that the severity of PrP
Sc
 deposition was lower than those observed 
in the 101LL/263K transmission. However, the level of PrP
Sc
 deposition in the 101LL/263K 




Clinical TSE Vacuolar pathology PrP
Sc 
deposition by IHC Number of mice 
+ + + 20 
+ + - 3 
+ - + 3 
+ - - 3 
+ Unknown - 3 
Table 3-1:  Clinical, vacuolar pathology and immunohistochemistry (IHC) PrP
Sc 
deposition results for 
101LL/GSS transmission. The vacuolar pathology for 3 mice was unknown as a vacuolar pathology 
score could not be determined due to tissue quality. 
 
Clinical TSE Vacuolar pathology PrP
Sc
 deposition by IHC Number of mice 
+ + + 10 
+ + - 13 
- + + 1 
+ - - 3 
- + - 1 
- - - 5 
Table 3-2: Clinical, vacuolar pathology and immunohistochemistry (IHC) PrP
Sc 
deposition results for 








Septum Thalamus Midbrain Medulla 
C17006 - - + ++ 2 
C17007 - ++ + + 3 
C17046 - ++ ++ - 3 
C17048 - - - + 1 
C17057* - + + - 2 
C17068 - + - - 1 
C17069 - ++ - ++ 3 
C17070 - ++ +++ + 4 
C17132 + +++ + - 3 
C17133 - + ++ ++ 3 
C17134 - ++ +++ - 3 
C17161 - - - ++ 2 
C17162* - + - - 1 
C17180* - ++ - + 2 
C17181 - - - ++ 2 
C17189 - ++ ++ - 3 
C17201 - - - + 1 
C17210 - - + - 1 
C17211 - - + - 1 
C17218 - ++ - - 2 
C17264* - + - - 1 
C17308 - - - + 1 
C17309* - + ++ + 3 
Table 3-3: 101LL/GSS tissues that were scored positive for PrP
Sc
 deposition and the overall score 
given. BP numbers highlighted with an asterisk (*) indicate that the single deposition plaque was 




Figure 3-6: Little or no PrP
Sc
 deposition was observed in 101LL/GSS brain tissues through 
immunohistochemical analysis. Tissues were scored according to the level of PrP
Sc
 deposition 
(Section 2.9), (Table 3-3). For each tissue the hippocampus region is shown (x2 magnification) and 
the brain area(s) in which PrP
Sc
 was detected at x20 magnification (A) 87V/VM mouse brain was 
stained as a positive control. (B) Three tissues (C17160, C17060 and C17188) were from mice 
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clinically and pathologically positive for TSE disease but were scored zero, as no PrP
Sc
 deposition was 
detectable. (C and D) Two mice (C17048 and C17308) had a single aggregate present in the medulla 
and were given an overall score of 1. (E and F) Tissues that had trace amount of PrP
Sc
 deposition were 
given a score of 2 as shown in (E – C17218) thalamus and (F – C17161) medulla. (G and H) A score 
of 3 was given for moderate levels of deposition for this mouse model present in more than one brain 
area as shown in (G – C17132) thalamus and septum and (H – C17134) thalamus and midbrain.. 





Septum Thalamus Midbrain Medulla 
B48101 ++ +++ - - 3 
B48542 - + ++ - 2 
B48640 - +++ +++ - 4 
B48812 + +++ - ++ 4 
B49174 - + - - 1 
B49233 - - - ++ 2 
B49326 - ++ - ++ 3 
B49727 - ++ - ++ 3 
B50026 - ++ - - 2 
B50324 - ++ - - 2 
*B51317 - + ++ ++ 3 
Table 3-4: 101LL/263K tissues that were scored positive for PrP
Sc
 deposition by 





Figure 3-7: Little or no PrP
Sc
 deposition was observed in 101LL/263K brain tissues through 
immunohistochemical analysis. Tissues were scored according to the level of PrP
Sc
 deposition 
(Section 2.9), (Table 3-4). For each tissue the hippocampus region (X2) is shown and the brain area(s) 
in which PrP
Sc
 was detected (x20). (A) 87V/VM mouse brain was stained as a positive control. (B) 
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Three tissues (B47645, B48156, and B49098) were from mice clinically and pathologically positive 
for TSE disease but were scored zero, as no PrP
Sc
 deposition was detectable. (C) One tissue (B49174) 
had two single aggregates present in one brain area and was given a score of 1. (D – B50026 and E – 
B50324) Tissues that had trace amounts of PrP
Sc
 deposition in the thalamus were given a score of 2. 
(F and G) A score of 3 was given for moderate levels of deposition for this mouse model in more than 
one brain area as shown in (F – B49326) thalamus and medulla and (G – B49727) thalamus and 
medulla. Two tissues were scored at a level 4, with one tissue (H – B48812) shown with deposition in 
both the thalamus and medulla. Immunohistochemistry performed with mAb 6H4.  
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3.2.4.  Little or no PrP-res detectable through biochemical 
methods 
Previous transmissions of human P102L GSS disease or hamster 263K scrapie to 101LL 
mice showed low levels of PrP-res when standard biochemical techniques were performed 
(Manson, Jamieson et al. 1999, Barron, Campbell et al. 2007). Proteinase K digestion of 
tissue homogenate to detect the PK-resistant core of PrP
Sc
, PrP-res is used widely in prion 
research to diagnosis TSE disease. All brain tissues assessed throughout this chapter were 
from mice with a clinical TSE disease and confirmed vacuolar pathology.  
Analysis of four different 101LL/GSS brain tissues by standard PK digestion (Section 2.11) 
and immunoblot (Sections 2.19-2.21) confirmed little or no PrP-res
 
was present (Figure 3-8). 
No PrP-res was detected in two of the tissues (Figure 3-8, lanes 4 and 6) whilst faint bands 
indicative of low amounts of PrP-res were detected in the other two tissues (Figure 3-8 lanes 
2 and 8). Further confirmation of this disease phenotype was performed on brain tissue that 
was homogenised in distilled water (Section 2.10). Distilled water tissue homogenates were 
produced to provide tissue homogenates for use in various different experimental procedures 
described later in this thesis (Chapter 6). However, PK digestion did not consistently work 
efficiently (Figure 3-9), as PK-resistant bands were present in the tissues, that were subjected 
to PK digestion, but did not have the normal banding pattern expected of the PK-res core, 
PrP 27-30, and no clear band shift was observed between PrP
C
 in the undigested sample and 
PrP 27-30 produced from the PK digestion.  
It was hypothesised that inefficient PK digestion was caused by the absence of detergent 
from the homogenisation buffer. This hypothesis was tested with a 1:1 dilution of the 10% 
(w/v) distilled water homogenates in either 2X NP40 buffer or distilled water prior to PK 
digestion. The results (Figure 3-10) show that for efficient PK digestion to occur, the 
presence of a detergent, NP40 was required. This result was further confirmed through 
titration of PK activity on 101LL uninfected brain tissue homogenised in either NP40 buffer 
or distilled water. PrP
C
 was completely digested even at a PK concentration of only 20µg/ml 
in the NP40 homogenate, whilst in comparison a PK concentration of 100µg/ml only 
partially digested PrP
C





Figure 3-8: Low or undetectable levels of PrP-res in 101LL/GSS. Lanes 2, 4, 6 and 8 underwent PK 
digestion at 50μg/ml for 1hr at 37ºC; lanes 1, 3, 5 and 7 were untreated. BP numbers C17046 (lanes 
1+2), C17048 (lanes 3+4); C17059 (lanes 5+6); C17060 (lanes 7+8). Samples loaded at 10mg/ml. 
Blot probed with mAb 8H4 and exposed for 3 minutes.  
 
 
Figure 3-9: Presence of unusual banding pattern in PK digested 101LL/GSS tissues (lanes 2, 4, 6 and 
8). PK digestion appeared to be efficient in both the 79A tissue (lane 10) and the 101LL NBH (lane 
12). BP numbers C17068 (lanes 1+2), C17006 (lanes 3+4); C17180 (lanes 5+6); C17181 (lanes 7+8). 
All tissues were homogenised to 10% (w/v) distilled water. Samples loaded at 10mg/ml. Blot probed 




Figure 3-10: The presence of detergent (A) allows efficient PK digestion of PrP from the four 
101LL/GSS tissues (lanes 2, 4, 5, 8) as well as in the normal uninfected tissues (lanes 10, 12, and 14). 
In comparison, the same four 101LL/GSS homogenates diluted in distilled water (B) had inefficient 
PK digestion (lanes 2, 4, 5, and 8), whilst the normal brain homogenates were efficiently PK digested 
(lanes 10, 12 and 14). Two of the 101LL/GSS samples have low amounts of PrP-res present (lanes 4 
and 8) whilst the other two 101LL/GSS samples have no detectable PrP-res. BP numbers C17068 
(lanes 1+2), C17006 (lanes 3+4); C17180 (lanes 5+6); C17181 (lanes 7+8). Samples loaded at 
10mg/ml. Blot probed with mAb 8H4 and exposed for 5 minutes.  
 
 
Figure 3-11: Presence of detergent allows efficient PK digestion of 101LL normal brain homogenised 
in (A) NP40 buffer but not (B) distilled water homogenates. PK concentrations indicated were 
working concentrations of PK at µg/ml. Samples loaded at 10mg/ml. Blot probed with mAb 8H4 and 




A further complication of these results was due to the occasional presence of two bands, in 
the PK digested tissues, at a slightly higher molecular weight than is expected for PrP 
(Figure 3-9, lane 4 and lane 8). PK digestion is expected to digest all three glycoforms of 
PrP
C
 at an equal rate, therefore it would be unusual if only the di-glycosylated band was 
being digested but not the mono- or un-glycosylated band as the banding pattern would 
suggest. Taken together, the slightly higher molecular weight and the unusual banding 
pattern suggested that these bands were due to non-specific secondary antibody binding. This 
theory was confirmed through removal of the bound antibody (Section 2.21.1) and re-
probing with the secondary antibody only (Figure 3-12). The occasional appearance was 
hypothesised to be due to variation in the sample preparation and immunoblot procedure 
between different experiments and in order to minimise the appearance, the secondary 
antibody concentration used was reduced from 0.04µg/ml to 0.025µg/ml and incubated for a 
reduced time of 45 minutes.  
Through a combination of performing the PK digestion step in the presence of detergent and 
decreasing the secondary antibody concentration and the length of antibody incubation, the 
previously reported phenotype of little or no PrP-res (Figure 3-13) in both the 101LL/GSS 
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B: Immunoblot re-probed with secondary Ab only 
Lane  1   2    3   4  5   6        8  9 10 11 12  13 Lane  1   2    3   4  5   6       8   9  10 11 12 13
 
Figure 3-12: Doublet bands remained present when blot was re-probed with rabbit-anti-mouse 
secondary antibody (B) that were present during standard immunoblot (A) of 101LL/GSS brain 
homogenates prepared in NP40 buffer. Two 101LL/GSS homogenates were treated with varying PK 
concentrations (µg/ml). BP numbers C17057 (1) and C17069 (2). Samples loaded at 10mg/ml. Blot 
probed with mAb 8H4 and exposed for 5 minutes. 
 
 
Figure 3-13: Absence of PrP-res with standard PK digestion in (A) 101LL/GSS and (B) 101LL/263K 
homogenates. All tissues were homogenised in NP40 buffer and PK digested as standard. (A) 
101LL/GSS BP numbers C17006 (lanes 1+2), C17068 (lanes 3+4); C17180 (lanes 5+6); C17181 
(lanes 7+8). (B) 101LL/263K BP numbers B48813 (lanes 1+2), B48794 (lanes 3+4) and B49015 
(lanes 5+6). Samples loaded at 10mg/ml. Blot probed with mAb 8H4 and a decreased concentration of 
secondary antibody and exposed for 3 minutes.  
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In order to enhance the sensitivity of the detection of PrP-res, PrP-res was precipitated with 
NaPTA after proteinase K digestion. NaPTA precipitation is known to enrich for PrP
Sc
 
(Safar, Wille et al. 1998), leaving any remaining PrP
C
 present in the supernatant, and is 
commonly used in many detection techniques to concentrate PrP
Sc
 and increase the 
sensitivity level of detection. Brain homogenates were PK digested, precipitated with 
NaPTA (Section 2.12) and then immunoblotted as described (Section 2.19-2.21). The 
resulting immunoblot (Figure 3-14A) confirmed that there was a variation in the low level of 
PrP-res in four different 101LL/GSS brain homogenates that were from mice with a clinical 
TSE disease and vacuolar pathology and PrP
Sc
 deposition by immunohistochemistry (Table 
3-3). The second homogenate (Figure 3-14A, lane 4) contained the highest level of PrP-res
 
(IHC score 1), two other 101LL/GSS homogenates contained a detectable amount of PrP-res 
(A, lane 2 and 8), (IHC score 2) whilst one contained no detectable PrP-res (Figure 3-14, 
lane 6), (IHC score 2). However, in comparison, the level of PrP-res in the 101LL/GSS 
homogenates was less than that observed in the wild-type/79A homogenate included as a 
positive control (Figure 3-14A, lane 10). No PrP-res was detected in any of the four 
101LL/263K brain homogenates (Figure 3-14B) confirming the absence of detectable PrP
Sc
 
in these homogenates as shown by the immunohistochemical results.  
To further increase the sensitivity of detection of PrP-res, an alternative protocol involving 
PK digestion, detergent extraction and differential centrifugation as initially described by 
Merz and colleagues (Merz, Somerville et al. 1981) was utilised to purify the scrapie 
associated fibrils (SAF)(Section 2.13) from both a 101LL/GSS (IHC score 3), a 101LL/263K 
(IHC score 2), a wild-type/79A brain tissue and a negative control (101LL normal brain). 
The SAF pellet was re-suspended in PBS and loaded at three different wet weight tissue 
equivalent concentrations (Figure 3-15A); 0.6mg, 1.3mg and 1.9mg. The 79A SAF isolated 
PrP-res was clearly detectable at all three concentrations. PrP-res was detectable from the 
101LL/GSS SAF pellet loaded at wet tissue weight equivalents of 1.3mg and 1.9mg. The 
101LL/263K SAF pellet had detectable PrP-res loaded at the wet weight tissue equivalent of 
1.9mg, although at a much lower level than that observed from the 79A tissue. In 
comparison, no PrP-res was detected from a 101LL normal brain that underwent the SAF 
purification protocol. To further analyse the difference in levels of PrP-res detected, 
doubling dilutions of the SAF pellets were performed and immunoblotted (Figure 3-15B). 
The results showed that 79A PrP-res was detected clearly at a wet weight tissue equivalent of 
0.04mg whilst 101LL/GSS PrP-res was only detectable at a higher wet weight tissue 
equivalent of 0.95mg and 101LL/263K PrP-res was faintly detectable at a wet weight tissue 
equivalent of 0.48mg. This indicates the level of PrP-res present in the brain tissue of 
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101LL/GSS and 101LL/263K was at least 23x and 12x lower respectively than the levels of 
PrP-res present in the brain tissue of a wild-type mouse infected with 79A.  
 
 
Figure 3-14: Selective precipitation of PrP-res with NaPTA from (A) four 101LL/GSS homogenates 
(lanes 1-8) and (B) four 101LL/263K homogenates (lanes 1-8). Positive control wt/79A homogenate 
(lanes 9-10) and 101LL NBH (11-12) were included in both precipitations. NaPTA precipitation was 
carried out as described (Section 2.12) either with (lanes 2, 4, 6, 8, 10 and 12) or without (lanes 1, 
3,5,7,9 and 11) PK digestion prior to precipitation. (A) 101LL/GSS BP numbers C17006 (lanes 1+2), 
C17068 (lanes 3+4); C17180 (lanes 5+6); C17181 (lanes 7+8). (B) 101LL/263K BP numbers B47894 
(lanes 1+2), B48364 (lanes 3+4), B48813 (lanes 5+6) and B49015 (lanes 7+8). Samples loaded at wet 
tissue weight equivalent of 33mg. Blot probed with mAb 8H4 and exposed for 5 minutes. 
 
 
Figure 3-15: Low levels of PrP-res detected in 101LL/GSS and 101LL/263K tissues in comparison to 
a wild-type/79A tissue. Scrapie associated fibrils (SAF) were isolated by PK digestion, detergent 
solubilisation and differential centrifugation. Wet weight tissue equivalent (mg) shown for each lane. 
BP numbers 101LL/GSS C17189, 101LL/263K B50026 and wild-type/79A U7479. Internal 
immunoblot control of PrP
C
 (A- lane 13, B- lane 14) loaded at 10mg/ml. Blot probed with mAb 8H4 
and exposed for 10 minutes.  
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3.2.5.  Analysis of alternative forms of PrPSc 
Although the presence of PrP-res is commonly used as a diagnostic marker for TSE disease, 
the disease model described in this thesis do not have high levels of PrP-res detectable 
through conventional methods including immunohistochemistry and standard PK digestion 
followed by immunoblot. Alternative assays have been developed that allow the detection of 




) that detect PrP
Sc
 without the pre-requirement of PK 
digestion. The following assays were performed to determine if an alternative form of PrP
Sc
 
was present in this disease model that would account for the high levels of infectivity 
observed. 





 in their native and denatured states (Safar, Wille et al. 
1998, McCutcheon, Hunter et al. 2005), (Section 1.2.4). The detector antibody utilised, mAb 
7A12, is hypothesised to recognise PrP
C
 but has increased binding to PrP
Sc
 upon 
denaturation with guanidine hydrochloride, that exposes the epitope binding site in PrP
Sc
 
(Barron, Campbell et al. 2007). An increase in the ratio of the europium fluorescent signal 
produced in the denatured and native samples (d/n ratio) indicates the presence of PrP
Sc
. 
Brain tissue homogenates from 101LL/GSS and 101LL/263K were analysed by CDI 
(Section 2.15). The d/n ratios from the 101LL/GSS homogenates (Figure 3-16) remained at a 
low level (0.82-1.42) only slightly higher than the d/n ratio observed from the 101LL normal 
brain homogenate (0.61) but clearly different from the positive control homogenate, infected 
with 79A scrapie that produced a d/n ratio of 7.49 indicating the presence of PrP
Sc
. Similarly, 
the d/n ratios from the 101LL/263K homogenates (Figure 3-17) remained at a low level 
(1.03-1.09) again only slightly higher than the d/n ratio observed from the 101LL normal 
brain homogenate (0.86) whilst in contrast, the positive control homogenate, infected with 
79A scrapie produced a d/n ratio of 8.59 that indicates the presence of PrP
Sc
. Both the 
101LL/GSS and 101LL/263K homogenates have a d/n ratio similar to the negative cut-off 
(calculated as d/n ratio of 101LL NBH + 10%), therefore there was an absence of any form 
of misfolded PrP
Sc































Conformation Dependent Immunoassay on 101LL/GSS
 
Figure 3-16: Conformational dependent immunoassay analysis of levels of PrP
Sc
 in 101LL/GSS 
homogenates without PK digestion. 101LL/GSS homogenates (Samples 1-4) were similar to 101LL 
NBH (Sample 6), in comparison to the positive control, 79A infected homogenate (Sample 5). The 
negative cut-off (red line) was calculated at 0.67 (101LL NBH d/n ratio + 10%). BP numbers (1) 































Conformation Dependent Immunoassay on 101LL/263K
 
Figure 3-17: Conformational dependent immunoassay analysis of levels of PrP
Sc
 in 101LL/263K 
homogenates without PK digestion. 101LL/263K homogenates (Samples 1-4) were similar to 101LL 
NBH (Sample 6). In comparison to the positive control, 79A infected homogenate (Sample 5). The 
negative cut-off (red line) was calculated at 0.95 (101LL d/n ratio + 10%). BP numbers (1) B47894, 
(2) B48364, (3) B48813 and (4) B49015.  
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Limited or „cold‟ PK digestion has been used to detect sPrP
Sc
 from Tg196 mice (that over 
express 101L PrP
C
) inoculated with a 55-mer peptide. The „cold‟ PK digestion with NaPTA 
precipitation produced a 22-24kDa fragment that was suggested to be sPrP
Sc
 (Tremblay, Ball 
et al. 2004). Previous data using „cold‟ PK digestion and deglycosylation with peptide N-
glycosidase F (PNGase F) on 101LL/GSS and 101LL/263K tissues produced a 19kDa 
fragment that was also observed in the normal brain homogenates representing PrP
C
. In 





 (Barron, Campbell et al. 2007). Four 101LL/GSS tissue 
homogenates were „cold‟ PK digested and degylcosylated (Section 2.14), only two of the 
four 101LL/GSS tissues produced a 22kDa band at a much lower intensity than the ME7 and 
79A infected tissues (Figure 3-18A, lanes 1+2). Four 101LL/263K tissues were also „cold‟ 
PK digested and deglycosylated (Section 2.14), with no PrP-specific bands detected (Figure 
3-18B). Again this was in comparison to the 22kDa band that was detected in both the ME7 
and 79A tissues included as positive controls. In both experiments, the 19kDa band 
previously observed in 101LL uninfected tissues and 101LL/GSS and 101LL/263K 
experimental tissues (Barron, Campbell et al. 2007) was undetectable. It is hypothesised that 
the absence of the 19kDa band expected to be present in the experimental samples and 
uninfected controls was due to procedural differences.  
Overall, the biochemical analysis performed to detect both PrP-res and sPrP
Sc
 detected a low 
level of PrP-res in two 101LL/GSS tissues (C17006 and C17068), but no PrP-res was 
detectable in the other two 101LL/GSS tissues (C17180 and C17181) despite these all 
having a low level of PrP
Sc
 deposition by immunohistochemistry. The 101LL/263K tissues 
(B47894, B48364, B48813 and B49015) were all negative by immunohistochemistry and for 
each biochemical assay tested on these tissues. Only the precipitation of the SAF gave a 
positive result when performed on a different 101LL/263K brain tissue. However, the level 
of PrP-res identified by SAF purification was not sufficient to account for the high titres of 





Figure 3-18: Limited or „cold‟ PK digestion of (A) four 101LL/GSS homogenates (lanes 1-4) and (B) 
four 101LL/263K homogenates (lanes 1-4). In both (A) and (B), 79A homogenate (lane 5), ME7 
homogenate (lane 6) were included as a positive controls. A 101LL uninfected homogenates (lanes 7) 
was included as a negative control. Undigested 101LL NBH was loaded as immunoblot control (lane 
8). (A) 101LL/GSS BP numbers C17006 (lane 1), C17068 (lane 2); C17180 (lane 3); C17181 (lane 4). 
(B) 101LL/263K BP numbers B47894 (lane 1), B48364 (lane 2), B48813 (lane 3) and B49015 (lane 
4). Samples loaded at 10mg/ml and SDS-PAGE was run at 100V for 2 hours to allow visualisation of 
low molecular weight bands. Blot probed with mAb 8H4 and exposed for 5 minutes. 
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A commercially available diagnostic kit, the IDEXX HerdChek* kit, which detects the 
presence of protein aggregates, without the pre-requisite of PK digestion was used to 
determine if an aggregated form of PrP
 
was present in this disease model. The enzyme 
immunoassay kit utilises the Seprion ligand (Microsens Biotechnologies) and an anti-PrP 
antibody to identify tissues as positive for TSE disease. Both 101LL/GSS and 101LL/263K 
brain tissue homogenates were analysed following manufacturer‟s instructions optimised for 
use with mouse tissues (Section 2.22), and were deemed positive or negative for disease 
based on the calculation result of the absorbance readings at A450-A620. For both 
transmissions (Figure 3-19), the infected brain tissues were identified as positive for TSE 
disease utilising this kit and the associated Seprion ligand, indicating that an aggregated form 
of PrP was present in these tissues. For the 101LL/GSS tissues this positive result contrasts 
with the previous standard PK digestion result where no PrP-res was detected in any of the 
tissues (Figure 3-8), irrespective of whether PrP
Sc
 was detected by immunohistochemistry or 
not (Table 3-3). Of the 101LL/263K tissues positive with the IDEXX HerdChek* assay, the 
only other data available was from immunohistochemistry that identified small amounts of 
PrP
Sc
 deposition in B49233 and B49727 only (Table 3-4).   
Although not quantitative, a dilution series of a 101LL/GSS, 101LL/263K and wild-
type/79A brain tissue homogenates from 30% (w/v) homogenates to 0.003% (w/v) 
homogenates were taken through the IDEXX HerdChek* assay (Section 2.22) to provide an 
indication of the percentage of brain homogenate where this assay was no longer able to 
identify these tissues as positive for TSE disease. Both 101LL/GSS and 101LL/263K were 
identified as negative for TSE disease when a 0.1% (w/v) brain homogenate was analysed 
(Figure 3-20). In comparison, the wild-type/79A was identified as negative for TSE disease 
only at a 0.003% (w/v) brain homogenate concentration (Figure 3-20), indicating that the 
target of the assay was present at a greater concentration in the wild-type/79A homogenate 
























































Figure 3-19: IDEXX HerdChek* results of (A) 101LL/GSS tissues and (B) 101LL/263K tissues. 
IDEXX HerdChek* assay performed as per manufacturer‟s instructions and A450-A620 value calculated 
based on the average result from duplicate wells for each sample. Both the IDEXX positive and 
negative controls (red) were provided by the kit whilst a wild-type/79A tissue was included as an 


























Figure 3-20: 101LL/GSS (blue) and 101LL/263K (orange) homogenates were identified as negative 
at a higher brain homogenate percentage than the wild-type/79A (green) brain homogenate. IDEXX 
controls (red) were provided with the kit and negative cut-off (purple) calculated as per 




The prion hypothesis states that PrP
Sc
 acts as the infectious agent in TSE diseases. In TSE 
disease, the presence of either PrP
Sc
 detected by either immunohistochemistry or 
immunoblotting of PK digested homogenates to detect PrP-res, are often used to confirm 
disease. In both the 101LL/GSS and 101LL/263K mouse models described, the results from 
standard analytical techniques question the correlation between TSE infectivity and PrP
Sc
. 
The incubation periods observed upon inoculation of 101LL mice with either human GSS or 
hamster 263K of 265±3 or 447±16 days respectively, were similar to previous transmissions 
(Figure 3-2, Figure 3-3). (Barron, Campbell et al. 2007). Furthermore, the mice showed 
clinical signs of TSE disease with confirmed vacuolar pathology, yet upon 
immunohistochemical and biochemical analysis of brain tissue, extremely low levels or no 
PrP-res was detected.  The use of a subjective, semi-quantitative scoring system highlights 
the low levels of PrP
Sc
 detected through immunohistochemistry (Table 3-1, Table 3-2). 
Although the numbers of tissues positive for PrP
Sc
 deposition were greater in the 101LL/GSS 
transmission, the scores given were consistently lower in comparison to the scores given to 
the 101LL/263K tissues, however both sets of scores were low in comparison to the positive 
control, 87V/VM. Detection of PrP-res was assessed by three different biochemical 
techniques; standard PK digestion (Figure 3-8, Figure 3-13), NaPTA precipitation (Figure 
3-14) and the isolation of scrapie associated fibrils (Figure 3-15), with the later two 
techniques concentrating any PrP-res present. All three biochemical techniques demonstrated 
that although the levels of PrP-res were variable between tissues, there was a consistently 
lower level of PrP-res present in the brain tissue of 101LL/GSS and 101LL/263K than in the 
brain tissue of a wild-type mice infected with either 79A or ME7. The results (Figure 3-15) 
indicated the level of PrP-res present in the brain tissue of 101LL/GSS and 101LL/263K was 
at least 23x and 12x lower respectively than the levels of PrP-res present in the brain tissue 
of a wild-type mouse infected with 79A.  
In previous analysis of these disease models, the low levels of PrP-res have corresponded 









 IU/g respectively (Barron, Campbell et al. 2007). The data 
presented in this thesis identified low levels of PrP-res present with similar incubation 
periods to disease produced upon the primary passage of GSS and hamster 263K scrapie 
indicating the disease phenotype was replicated in these transmissions. Together these data 
are in contrast to the prion hypothesis where increasing levels of PrP-res are associated with 
increasing titres of infectivity (Prusiner 1982, McKinley, Bolton et al. 1983). Given the high 
titres of infectivity presumed to be associated with these tissues, PrP-res would be expected 
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to be at a level detectable by immunoblotting. Therefore these models question the 
relationship between PrP-res and infectivity.  
The inability of wild-type mice to succumb to disease when inoculated with human GSS 
disease and the low attack rate upon infection with hamster 263K scrapie indicates that the 
101L mutation causes an alteration in disease pathogenesis. Previous work has shown that 
the 101L PrP
C
 was able to convert to PrP-res, with PrP-res detectable by both 
immunohistochemistry and standard biochemical techniques, when 101LL mice were 
inoculated with vCJD or a sub-pass of 101LL/GSS brain tissue was performed (Barron, 
Thomson et al. 2001). Additionally, the occurrence of this unusual disease characteristic 
when either human GSS brain homogenate or hamster 263K scrapie was inoculated indicates 
that the absence of PrP-res was not a consequence of the species barrier or strain of inoculum 
alone. 
Given the absence of high levels of PrP-res, it is plausible that in these disease models, 
another form of PrP could be the infectious agent. Recently, research has shown that PrP-res 
might not be the sole component of the infectious agent, with the identification of alternative 
conformations of PrP
Sc
 and the isolation of PK-sensitive forms of PrP
Sc
 (Section 1.2.4). The 
CDI identifies conformationally different forms of PrP, without the pre-requisite for PK 
digestion. Instead detection is based on the effect of GdnHCl denaturation-based unmasking 
of epitopes hidden in PrP
Sc
. However, both the 101LL/GSS and 101LL/263K tissues 
produced d/n values that were similar to the negative cut-off value for each assay (Figure 
3-16, Figure 3-17), indicating that within these tissues, there was not a form of PrP that was 
unmasked by GdnHCl denaturation. Therefore this assay did not identify the presence of a 
form of misfolded PrP in these tissues that could account for the level of infectivity present.  
Previous work by others has shown that PK-sensitive forms of PrP
Sc
 were detected in over-
expressing transgenic mouse models of GSS disease (Tremblay, Ball et al. 2004) and in 
natural cases of P102L GSS disease (Monaco, Fiorini et al. 2012). A 22kDa band, 
representing de-glycosylated sPrP
Sc
, was produced upon limited or „cold‟ PK digestion of 
human GSS tissues and was detectable in samples where PrP-res 
 
was both present or absent 
(Monaco, Fiorini et al. 2012). In the studies shown here, the low level or absence of the 
22kDa band in the 101LL/GSS and 101LL/263K tissues (Figure 3-18) indicates that a PK-
sensitive form of PrP
Sc
, detectable by the limited or „cold‟ PK digestion technique, is not 
responsible for the levels of infectivity observed in these tissues. However, the possibility 
that other alternative techniques could detect an as yet unidentified form of PrP
Sc
 in the 
101LL/GSS and 101LL/263K tissues cannot be ruled out.  
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The IDEXX HerdChek* kit, an ELISA based assay without the requirement of PK digestion, 
identified all 101LL/GSS and 101LL/263K tissues as positive for TSE disease (Figure 3-19). 
This assay utilises the Seprion ligand, which captures aggregated protein that is detected by 
an anti-PrP detector antibody. The aggregated component or complex to which the Seprion 
ligand binds is currently unknown, although it is hypothesised to be a form of PrP given that 
it was detected by the anti-PrP detector antibody. Further investigation to identify the target 
of the Seprion ligand could potentially identify a form of aggregated PrP present in 
101LL/GSS and 101LL/263K tissues that is not detectable by standard techniques. The 
association between the Seprion ligand target and TSE infectivity within these disease 
models was further investigated within this thesis (Chapter 6).   
In summary, this study confirms that either extremely low levels of PrP-res or an absence of 
PrP-res was identified in the brain tissue of 101LL/GSS and 101LL/263K disease models. 
Any form of PrP
Sc
 that might be present in these tissues is sensitive to both standard and 
limited PK digestion, not unmasked by GdnHCl denaturation, but detectable by the Seprion 
ligand. Further investigation into both the identification of the infectious agent and the 
relationship between the different forms of PrP
Sc
 and infectivity will contribute to our 
understanding of this disease model and the relationship between PrP
Sc
 and infectivity. 
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4. Characterisation of the levels of PrP-res and TSE infectivity 
in 101LL/GSS and 101LL/263K spleen tissue 
4.1. Introduction 
Many TSE strains replicate in the lymphoreticular system (LRS) and in some cases 
replication in the LRS is required prior to neuroinvasion. The role of the spleen in TSE 
disease models has been widely investigated, with the level of involvement varying 
depending on host species and TSE strain. Studies conducted with mouse scrapie identified 
that levels of infectivity in the spleen initially increased upon infection until a plateau level 
was reached that was maintained for the disease duration (Rubenstein, Merz et al. 1991). 
Further, the spleen has been shown to contain levels of the infectious agent that were 100 to 
1000-fold less than in brain tissue in mouse scrapie disease, with the spleen also containing 
less PrP-res than brain tissue, at the end stage of disease (Rubenstein, Merz et al. 1991). A 
hamster 263K infected spleen contained 6 log10 units less infectivity and 5000 fold less PrP-
res than the brain tissue from the same hamster (Rubenstein, Merz et al. 1991). A previous 
study showed that the level of PrP-res was 200-300 fold less in the spleen than the brain of 
mice infected with a mouse-adapted strain of GSS originating from the Fukuoka-1 GSS case 
(Cervenakova, Yakovleva et al. 2003).  
The role of the spleen in the 101LL/GSS and 101LL/263K disease model has not previously 
been investigated, with research focusing on the brain tissue that contains high infectivity but 
little or no PrP-res. Extremely low levels or an absence of PrP-res in the brain tissue has 
been confirmed for tissues utilised in these studies (Chapter 3). This chapter describes the 
research to determine the level of PrP-res deposition and TSE infectivity present in the 
spleen tissue of 101LL/GSS and 101LL/263K disease models and to identify whether the 




4.2.1.  Biochemical detection of PrP-res in the spleen tissue 
from 101LL/GSS and 101LL/263K mice. 
The techniques that were utilised to detect the presence of PrP-res in the spleen were initially 
trialled on spleen tissue from wild-type mice infected with ME7 to ensure the techniques 
were efficient. Isolation of SAF from spleen tissue, was performed through detergent 
extraction and differential centrifuagation (Section 2.17). The presence of PrP was identified 
through immunoblotting as described (Section 2.19-2.21). The process of isolation of SAF 
from a wild-type/ME7 spleen tissue worked efficiently with PK digestion increasing the 
specificity of the isolation (Figure 4-1A).  
The SAF technique optimised with wild-type/ME7 infected tissue was then applied to the 
isolation of SAF from PK-digested spleens of 101LL/GSS infected mice. The results (Figure 
4-2) show that there was variation in the level of PrP-res present in the pellets between 
individual 101LL/GSS spleens but overall the level of PrP-res from the 101LL/GSS spleens 
was consistently lower than the level of PrP-res observed in wild-type/ME7 or wild-
type/79A spleens. However, the results (Figure 4-2) were complicated by the presence of 
PrP-specific bands in the supernatant that were unexpected due to the PK digestion step 
performed prior to the differential centrifugation. Through this technique, PrP-res should be 
pelleted, with PrP
C
 remaining in the supernatant. However, given that these samples were PK 
digested, no PrP should be present in the supernatant. In experiment one (Figure 4-2A) the 
results indicated that the PK digestion may not have worked efficiently whilst for 
experiments two and three (Figure 4-2B+C) it was hypothesised that the presence of PrP-
specific bands in the supernatants were due to inefficiency in the differential centrifugation 
to pellet all the PrP-res from the homogenate. This was confirmed by the results in (Figure 
4-2B) experiment two where the supernatant contains PrP-res with the expected band shift 
for PrP-res compared to PrP
C




Figure 4-1: PrP-res was present following isolation of SAF from a wild-type ME7 spleen both with 
(A) and without (B) PK digestion. Pellets were re-suspended tris-glycine sample buffer 




/10). Samples loaded 
at neat – 30mg, 1/5 – 6mg and 1/10 – 3mg wet weight tissue equivalents. Blot probed with mAb 8H4 
and exposed for 10 minutes.  
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Figure 4-2: Variation in the level of PrP-res that was present in the pellets (P) produced during SAF 
isolation from 101LL/GSS spleens in three repeat experiments alongside either wt/ME7 or wt/79A 
positive controls. Also PrP was present in supernatant (S) from each isolation. Experiment 1 and 2 




In order to clarify results, immunoblots were repeated with only the pellets produced from 
PK-digested 101LL/GSS spleen homogenates loaded alongside a pellet produced from the 
wild-type/ME7 positive control. The results confirmed there was variation in the level of 
PrP-res between individual spleens from 101LL/GSS mice (Figure 4-3). Based on the band 
intensity, the level of PrP-res appeared lower in three of the four 101LL/GSS spleens than 
that observed in wild-type/ME7 infected spleens (Figure 4-3). 
Although isolation of SAF is a recognised technique for purifying PrP-res, abnormal PrP can 
also be enriched by precipitation with sodium phosphotungstic acid (NaPTA). NaPTA 
precipitation (Section 2.16) was analysed for its ability to precipitate PrP-res present in the 
spleen homogenates of control wild-type/ME7 mice with an immunoblot detection method 
(Section 2.19-2.21). This technique enriches for PrP
Sc
 and allows detection of PrP-res from 
15µl of a 2.5% (w/v) wild-type/ME7 spleen homogenate (Figure 4-4, lane 6). The results 
show that a level of PrP
C
 was precipitated if the sample was not PK treated prior to 
precipitation (Figure 4-4, lanes 1, 3, 5 and 7). Low levels of PrP
C 
have previously been 
NaPTA precipitated from normal brain homogenates not subjected to PK digestion (personal 
communication, R. Barron) therefore all 101LL/GSS and 101LL/263K homogenates were 
PK digested prior to precipitation with NaPTA to allow for PrP-res levels to be assessed.  
PrP-res was present in all 101LL/GSS spleens (Figure 4-5) analysed by NaPTA precipitation 
except a spleen analysed in experiment one, lane 1 (BP Number C20435), which has a non-
specific band hypothesised to be IgG cross-reactivity with the secondary antibody (Section 
3.2.4, Figure 3-12). The result confirmed that the level of PrP-res in 101LL/GSS was 






Figure 4-3: Variation in the level of PrP-res isolated from 101LL/GSS spleens through purification of 
SAF. Only PK digested pellets have been shown for clarity with a tissue equivalent of 15mg loaded. 
Blot probed with mAb 8H4 and exposed for 5 minutes.  
 
Figure 4-4: NaPTA precipitated PrP-res from different concentrations of wild-type/ME7 spleen 
homogenates with a detection limit of a 2.5% (w/v) homogenate. Blot probed with mAb 8H4 and 
exposed for 5 minutes.  
 
Figure 4-5: Variation in the level of PrP-res in 101LL/GSS spleens confirmed through NaPTA 
precipitation in two repeat experiments. PrP
C
 loaded on each immunoblot (lane 5) as internal control. 
Blot probed with mAb 8H4 and exposed for 3 minutes. Tissue equivalent of 15mg loaded per well. 
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Initial trial experiments of the isolation of SAF from 101LL/263K spleen homogenates 
resulted in the same inefficiencies in concentration of the PrP-res through differential 
centrifugation (data not shown) as experienced with the 101LL/GSS spleen homogenates. 
Indeed, throughout the analysis of the 101LL/GSS spleen tissue, the NaPTA precipitation 
technique was more reliable and had a greater consistency between experiments than the 
technique for the isolation of the SAF. Therefore, analysis of 101LL/263K spleen 
homogenates was performed through NaPTA precipitation (Section 2.16) and were analysed 
by immunoblot (Section 2.19-2.21). The results (Figure 4-6) from the 101LL/263K spleen 
homogenates were similar to the results from the 101LL/GSS spleen with tissue-to-tissue 
variation present and the level of PrP-res was lower than that observed with the positive 
control wild-type/ME7 infected spleen. To assess the difference in the level of PrP-res in 
101LL/GSS and 101LL/263K spleens, doubling dilutions of the resulting pellet suspensions 
were analysed by immunoblot to allow an estimation of the difference in quantities of PrP-
res.  
The results (Figure 4-7A) show that PrP-res can be detected in the wild-type/ME7 spleen 
from a tissue equivalent of 2.5mg. The 101LL/GSS spleen homogenates (Figure 4-7A) 
showed a high variability between spleens examined with faint detection of PrP-res from 
C20501 at a tissue equivalent of 2.5mg (Figure 4-7, lane 3) but a stronger PrP-res signal 
from C20516 with detection from a tissue equivalent of 1.25mg (Figure 4-7, lane 8). In 
comparison, the 101LL/263K spleen homogenate clearly showed a lower PrP-res signal from 
the first two homogenates examined, B17511 and B2116 (Figure 4-7B). As a low signal was 
observed from both 101LL/263K spleens, an additional 101LL/263K spleen homogenate 
was diluted and immunoblotted to confirm the result was due to low levels of PrP-res in the 
spleen and not due to a possible inefficiency in the blotting procedure. The resulting 
immunoblot (Figure 4-7C) confirmed that a lower level of PrP-res was present in the 
101LL/263K spleen homogenate with PrP-res only detectable from a tissue equivalent of 






Figure 4-6: Variation in the level of PrP-res in 101LL/263K spleens. Each pellet produced from 
NaPTA precipitation was re-suspended in tris-glycine sample buffer (Invitrogen) at the tissue 
equivalent of 15mg. PrP
C
 loaded on each immunoblot (A - lane 5, B – lane 6) as internal control. Blot 
probed with mAb 8H4 and exposed for 5 minutes.  
 
Figure 4-7: A lower PrP-res concentration in 101LL/GSS (A) and 101LL/263K (B and C) spleen 
homogenates than in the wild-type/ME7 spleen homogenate included as a positive control. Each pellet 
produced from NaPTA precipitation was re-suspended in tris-glycine sample buffer (Invitrogen) at the 
tissue equivalent of 10mg when loaded neat (N). The re-suspended pellets underwent doubling 
dilutions (1-4) in further sample buffer to allow a comparison of concentration with tissue equivalent 
concentrations of 1 – 5mg, 2 – 2.5mg, 3 -1.25mg, 4 – 0.62mg and 5 – 0.31mg loaded. 
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Spleen tissues from 101LL/GSS and 101LL/263K mice were also analysed using the IDEXX 
HerdChek* assay (Section 2.22) that identifies the brain tissue from these mice as positive 
for TSE (Section 3.2.5). The spleen tissues were also identified as positive for TSE disease 
by this assay, with all 101LL/GSS spleen tissues saturating the assay (Figure 4-8A). The 
101LL/263K spleen tissues showed a variation in the absorbance readouts from the assay 
(Figure 4-8B) but were all identified as positive for TSE disease. Although the IDEXX 
HerdChek* assay is not quantitative, the lower absorbance readouts with the 101LL/263K 
spleens, compared to the 101LL/GSS spleens agrees with the results from the immunoblot 





















































Figure 4-8: All (A) 101LL/GSS and (B) 101LL/263K spleen tissues identified as positive for TSE 
disease utilising the IDEXX HerdChek* assay. IDEXX controls (red) provided by the kit and negative 
cut-off (purple) calculated as per manufacturer‟s instructions.  
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4.2.2.  Immunohistochemical detection of PrPSc in the spleen 
tissue from 101LL/GSS and 101LL/263K mice. 
Detection of PrP
Sc
 in 101LL/GSS and 101LL/263K spleen tissues was additionally assessed 
through immunohistochemical analysis with a range of anti-PrP antibodies. Unfortunately, 
due to experimental design, the only spleen tissue that was available for analysis had been 
flash frozen and stored at -80°C. For good immunohistochemical analysis, tissue should be 
fixed immediately after harvesting, as freezing damages the tissue architecture. As no other 
tissue was available, preliminary studies were performed to determine whether any data 
could be obtained from these tissues by immunohistochemistry. The tissues were de-frosted, 
fixed in 10% formal saline and treated with formic acid to produce sections for 
immunohistochemical analysis (Section 2.5.2). As the structure of the spleen was disrupted 
(Figure 4-9) the immunohistochemical analysis was not successful with high levels of non-
specific background staining (Figure 4-10). This result was observed for all four primary 
antibodies trialled; 6H4, 1B3, SAF32 and BC6 (Appendix 1), (data not shown).  
In an attempt to reduce this background staining, paraffin embedded tissue (PET) blots of the 
spleen sections were performed that allowed for PK digestion prior to probing with an anti-
PrP antibody (Section 2.18) to specifically detect PrP-res. Despite technical difficulties, PrP-
res deposition was identified in spleens from 101LL/GSS mice (Figure 4-11A+B). However, 
results from 101LL/263K and wild-type/ME7 controls could not be interpreted due to tissue 
damage (Figure 4-11C+D). However, these preliminary results indicate that PrP-res was 
present within the spleens and that this technique would be beneficial for future analysis 




Figure 4-9: Disruption of the spleen structure through tissue being flash frozen upon harvesting 
before being defrosted to be fixed in formal saline (C+D). In comparison tissue fixed in (A) 
acetone/periodate-lysine-paraformaldehyde (PLP) or (B) formal saline immediately upon harvesting 
have intact structures. H&E staining was performed as described (Section 2.6). Images were taken at 
x4 magnification on Nikon E800 microscope.  
 
Figure 4-10: High level of background staining with normal serum control on 101LL/263K and 
101LL/GSS spleen sections that underwent immunohistochemistry. Immunohistochemistry was 
performed as described (Section 2.8) with mAb 1B3 and normal rat serum controls. Images were 




Figure 4-11: PrP-res was detectable by PET-blots although tissue structure remained disrupted. 
Spleens were stored at -80°C and defrosted prior to fixation in formal saline. PET-blot analysis was 
performed as described (Section 2.18) with mAb 1B3. PrP-res staining shown as blue/black colour. 
Images were taken at x20 magnification on Leica DMRB microscope.  
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4.2.3.  High infectivity levels present in the spleen tissue from 
101LL/GSS and 101LL/263K mice. 
To determine the level of TSE infectivity present in the spleen tissue, sub-passage of brain 
and spleen tissue from two mice from each disease model, (101LL/GSS and 101LL/263K) 
was performed into 101LL mice (Section 2.2-2.3). Based on previous research in wild-type 
mouse models infected with ME7 or 139A (Rubenstein, Merz et al. 1991), it was 
hypothesised that infectivity titres in the spleen tissue would be 2-3log10 lower than the 
infectivity titre observed in the brain tissue. Utilising the data produced in previous titration 
studies from these disease models (Barron, Campbell et al. 2007) it was hypothesised that a 
10
-4
 dilution of the brain homogenate would have a 100% attack rate. Given the expected 2-3 







was predicted to allow the identification of differences in incubation 
periods and infectivity levels between the brain and spleen tissue. Inoculations were also 
performed with brain and spleen tissue from a wild-type/79A mouse into 129Ola mice to 
provide comparison data. Information on the end-point tissues utilised for inoculation and a 























101LL/GSS 754A-1A C17218 281 + + + (Score2) 
101LL/GSS 754A-1A C17188 274 + + - 
101LL/263K 522L-1D B48156 350 + + - 
101LL/263K 522L-1D B48157 350 + + - 
wt/79A 522U-1A U7484 133 + + Not Done 




Figure 4-12: Summary of the inoculations performed from each mouse with dilutions of inocula 
indicated and the related group size. 
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4.2.4.  Biochemical analysis of the residual inocula. 
The residual inocula (10
-2
 dilution) were analysed biochemically for the presence of PrP-res 
by standard PK digestion (Section 2.11) and immunoblotted (Section 2.19-2.21). The results 
(Figure 4-13) show that no PrP-res was detected in either of the 101LL/263K brain 
homogenates (Figure 4-13, lanes 4 and 6) and one of the 101LL/GSS brain homogenates, 
C17188 (Figure 4-13, lane 8). A low amount of PrP-res was detected in the other 
101LL/GSS brain homogenate, C17218 (Figure 4-13, lane 10), compared to the clear 
presence of PrP-res in the 79A brain homogenate (Figure 4-13, lane 2).  
Further analysis of the residual brain and spleen homogenate inocula was carried out through 
PK digestion followed by NaPTA precipitation of the homogenates (Section 2.12) to 
increase the sensitivity level of detection by immunoblot. PrP-res was detected in both 
101LL/GSS brain homogenates and 101LL/263K B48156 brain homogenate (Figure 4-14A). 
PrP-res was not detected in 101LL/263K, B48157 brain homogenate (Figure 4-14A, lane 3). 
PrP-res was detected in both 101LL/GSS spleen homogenates (Figure 4-14B). The presence 
of faint bands from the 101LL/263K B48157 spleen homogenate (Figure 4-14B, lane 2) 
were hypothesised to be caused by residual PrP
C
, indicating that the PK digestion was not 
fully efficient in this homogenate. Unfortunately no residual spleen homogenate was 
available from 101LL/263K B48156 for analysis by NaPTA precipitation. PrP-res was 
present in both wild-type/79A brain and spleen homogenates at a greater concentration than 
was observed for any of the 101LL/GSS or 101LL/263K residual homogenates. Thus the 
level of PrP-res in the 101LL/GSS and 101LL/263K inocula was lower than the level present 
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Figure 4-13: Little or no PrP-res detected from the 101LL/263K and 101LL/GSS residual brain 
homogenate inocula by standard PK digestion and immunoblot. PrP-res was present in 79A residual 
inocula (lane 2). PrP
C
 included as internal immunoblot control (lane 11). All samples loaded at a 
concentration of 1mg/ml. Blot probed with mAb 8H4 and exposed for 3 minutes.  
 
 
Figure 4-14: PrP-res present in all residual inocula from (A) brain and (B) spleen tissue with the 
exception of 101LL/263K B48157 (A – lane 3, B – lane 2) by PK digestion and NaPTA precipitation. 
No residual spleen homogenate was available for analysis from 101LL/263K B48156. PrP
C
 included 
as immunoblot control (B – lane 5). Wet weight tissue equivalent of 10mg loaded. Blot probed with 
mAb 8H4 and exposed for 5 minutes.  
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4.2.5.  Brain and spleen show equivalent levels of infectivity in 
101LL/GSS and 101LL/263K mice. 
Mice were scored for clinical disease and culled at a pre-determined clinical end-point of 
disease by experienced animal house staff (Section 2.4). Surprisingly, mice inoculated with 
each dilution of the spleen homogenates from 101LL/GSS and 101LL/263K had similar 
average incubation periods to disease as the equivalent dilutions of brain homogenates from 
the same mouse. No statistical differences (t-test, p-values, Table 4-2, Figure 4-15) were 
observed between the average incubation periods to disease at each dilution for both 
101LL/GSS and 101LL/263K. The two exceptions were 101LL/GSS C17188 (Figure 
4-15A), where inoculation of the spleen homogenate at 10
-3
 dilution produced significantly 
shorter incubation period to disease (p-value 8.3x10
-5
) than the equivalent dilution of the 
brain homogenate, and a statistically significant difference was observed for 101LL/GSS 
C17218 (Figure 4-15B) at the 10
-2
 dilution (p-value 5.6x10
-4
) only, with the brain 
homogenate producing a shorter incubation period than the spleen homogenate. These results 
were in comparison to the average incubation periods for the control wild-type/79A where 
the spleen homogenate produced extended average incubation periods to disease in 
comparison to the brain homogenate at all dilutions (Figure 4-15E). For the wild-type/79A, 
the average incubation period for the spleen tissue was 30-40 days longer than the average 
incubation period for the brain tissue, which was a statistically significant result (t-test, p-









Average incubation period 









 122±2 125±2 0.35 
10
-3














 146±3 148±3 0.65 
10
-4




 137±2 127±4 0.03 
10
-3
 145±7 145±4 0.99 
10
-4




 142±4 135±2 0.08 
10
-3
 161±11 157±4 0.65 
10
-4














 135±2 176±2 1.08x10
-8
 
Table 4-2: Similar incubation periods to disease were observed from brain and spleen homogenates 
from 101LL/GSS and 101LL/263K mice. In comparison significantly different incubation periods to 
disease were observed between brain and spleen homogenates from wild-type/79A mice. P-value 
calculated with student t-test.  
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Figure 4-15: Similar average incubation periods to disease were observed for brain and spleen 
transmissions from (A+B) 101LL/GSS (p-values C17188 0.32, 8.3x10
-5
 and 0.34; C17218 5.6x10
-4
, 






 groups respectively) and (D+E) 101LL/263K (p-values B48156 






 groups respectively)  tissues 













 groups respectively). 
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4.2.6.   Similar lesion profile patterns but different levels of 
vacuolation and PrP-res deposition dependent on tissue 
type inoculated. 
Lesion profiles (Section 1.1.5) can be utilised to distinguish between strains (Fraser and 
Dickinson 1968) and all mice underwent pathological analysis by experienced personnel to 
determine the level of TSE related vacuolar pathology to allow the production of lesion 
profiles (Section 2.7). Lesion profiles were produced from each dilution group for each 
tissue to determine if the same pattern was produced indicating the same strain of agent was 
replicated in the brain and spleen. Alternatively, a difference in lesion profiles could indicate 
that tissue-specific replication of different isolates was occurring, a phenomenon that has 
previously been described in different strains passaged in Tg338 mice (Béringue, Herzog et 
al. 2012).  
Each dilution of inoculum produced a similar lesion profile for each tissue inoculated (Figure 
4-16). In order to compare the lesion profiles, between the brain and spleen inoculated 
groups, lesion profiles were produced from all mice that were clinically and pathological 
positive for TSE disease from each tissue inocula (Figure 4-17). The lesion profiles produced 
from 101LL/GSS C17188 (Figure 4-17A) show that the mice inoculated with the brain tissue 
have a slightly lower vacuolation scores in the grey matter areas 4-7, however area 4, the 
hypothalamus had the greatest variation between scores, with the spleen tissue peaking with 
an average score of 2.7 whilst the average vacuolation score for the brain-inoculated mice 
was only 1.3. In comparison, for 101LL/GSS C17218 (Figure 4-17B), the lesion profiles 
produced from the brain and spleen inoculated mice follow the same pattern with no 
variation in the grey matter area. For both 101LL/GSS tissues utilised, the lesion profile 
produced for the white matter area showed higher levels of vacuolation from inoculation 
with the brain tissue compared to inoculation with the spleen tissue. For both 101LL/263K 
tissues, inoculation with brain tissue produced lower vacuolation scores at the hypothalamus 
(area 4). For 101LL/263K B48156 (Figure 4-17C), the difference in vacuolation scores in the 
hypothalamus was 1.8, the only grey matter area that had a difference greater than 0.6 
between the vacuolation scores. For 101LL/263K B48157 (Figure 4-17D), three grey matter 
brain areas, 4, 5 and 7; the hypothalamus, thalamus and paraterminal body, showed a greater 
level of vacuolation from inoculation with the spleen tissue compared to inoculation with the 
brain tissue, with the difference equal to or greater than one vacuolation score level. As with 
101LL/GSS tissues, the level of vacuolation in all three white matter areas scored in the 
101LL/263K mice was greater in the mice that received the brain tissue inocula compared to 
the mice that received the spleen tissue. The wild-type/79A disease model (Figure 4-17E), 
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produced similar vacuolation scores, with the spleen inocula producing a slightly lower 
vacuolation score for most grey matter areas. The only grey matter area that had a difference 
of one vacuolation score was area 8, the retrospinal cortex but the large error bars were 
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Figure 4-16: Lesion profiles produced from each dilution group inoculated from each tissue produce 
similar lesion profile patterns. Profiles calculated from the mean scores of at least 6 individual animals 
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Figure 4-17: Comparison of lesion profiles produced from each tissue inoculum using all mice that 
were clinically and pathologically positive for TSE disease from each tissue homogenate inoculum. 
Profiles calculated from the mean scores of at least 6 individual animals per group. Details of the brain 
areas scored detailed in Table 2-4. Scoring was performed by experienced personnel. 
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Further investigation of the strain properties produced from inoculation of brain and spleen 
homogenates was performed by immunohistochemical analysis of the brain tissue to 
determine the PrP
Sc
 deposition pattern (Section 2.8) from each inoculum. For the 
101LL/GSS sub-passage from both C17188 and C17218 brain and spleen, PrP
Sc
 deposition 
was targeted to the same areas with deposition mainly in the hippocampus/thalamus and the 
midbrain. In cases with heavier deposition, PrP
Sc
 was also observed in the medulla and 
occasionally the septum. The deposition observed was lighter in those mice inoculated with 
spleen homogenate (Figure 4-18B+D) compared to those inoculated with the brain 
homogenate (Figure 4-18A+C). From the sub-passage of 101LL/263K B48156 brain 
homogenate PrP
Sc
 deposition was targeted to the hippocampus with PrP
Sc
 aggregates present 
in the corpus callosum and in the midbrain (Figure 4-18E). The same brain areas were 
targeted with inoculation of the spleen homogenate with deposition also observed in the 
medulla (Figure 4-18F). PrP
Sc
 deposition produced from inoculation with brain homogenate 
from 101LL/263K B48157 targeted the hippocampus with PrP
Sc
 aggregates present in the 
corpus callosum, the midbrain and the septum (Figure 4-18G). Following inoculation of 
101LL/263K B48157 spleen homogenate, PrP
Sc
 deposition targeted the same areas as the 
brain homogenate as well as the medulla (Figure 4-18H). Immunohistochemical analysis of 
the PrP
Sc
 deposition from the sub-pass of the 79A homogenates was not successful with most 
sections identified as negative (data not shown). This result was in contrast to the results of 
the immunoblots (Figure 4-19) where PrP
Sc
 was present at high levels. The absence of PrP
Sc
 
deposition was hypothesised to be due to damage to the PrP
Sc
 during the pre-treatment steps 
prior to sectioning of the tissue, specifically the formic acid step. Previous research has 
shown that for certain strains, formic acid treatment of the tissues prior to fixation reduces 
the detection level of PrP
Sc
 (personal communication – A. Coghill), (Appendix 2) but health 
and safety regulations at The Roslin Institute require the tissue to be formic acid treated prior 
































H: 101LL/263K B48157 spleen homogenate
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Figure 4-18: Lighter PrP
Sc
 deposition observed from inoculation of (B) spleen homogenates 
compared to (A) brain homogenates from 101LL/GSS C17188 inocula and (D) spleen homogenates 
compared to (C) brain homogenates from 101LL/GSS C17218 inocula. No difference in PrP
Sc
 
deposition levels observed from inoculation of brain or spleen homogenates from (D, brain and E, 
spleen) 101LL/263K B48156 and (G, brain and H spleen) 101LL/263K B48157. The tissue and 
dilution inoculated are indicated on the left-hand side of each image. Two mice from each group are 
shown with their BP identification number and incubation period to disease (days post inoculation – 
dpi) indicated. The hippocampus section from each mouse is shown at x2 magnification followed by 
the brain area(s) in which deposition was identified at x20 magnification. If a brain area is not shown, 
no PrP
Sc




4.2.7.  Biochemical analysis of brain tissue produced from sub-
pass experiments. 
Biochemical analysis of the brain tissues collected from both the brain and spleen sub-
passage were performed to identify if PrP-res had replicated in the recipient brain tissue. 
Brain tissue was analysed through standard PK digestion (Section 2.11) and immunoblot 
(Section 2.19-2.21) with initial analysis performed on brain tissue harvested from mice 
inoculated with the 10
-2
 dilution of either the brain or spleen homogenate. Although there 
was a variation between animals, the results show that inoculation with the brain 
homogenate resulted in greater accumulation of PrP-res in the recipient brain compared to 
inoculation of the spleen homogenate for the 101LL/GSS and 101LL/263K B48156 tissues 
(Figure 4-19A-C). Variation between tissues was observed for 101LL/263K B48157 with a 
spleen-inoculated brain containing a similar level to the brain-inoculated brain (Figure 
4-19D) despite the absence of PrP-res from the residual inocula (Figure 4-14). In contrast, 
the level of PrP-res produced from inoculation with either the brain or spleen homogenate 
from wild-type/79A resulted in the production of a similar level of PrP-res in the recipient 
brain (Figure 4-19E).  
Further analysis of the same brain tissues was performed through NaPTA precipitation to 
determine if PrP-res was present in the brain homogenates that appeared to have no PrP-res 
by standard PK digestion. Brain tissues were PK digested and PrP-res precipitated with 
NaPTA (Section 2.12) and immunoblotted as previously described (Section 2.19-2.21). The 
NaPTA precipitation technique confirmed the results of the standard PK digestion, showing 
that for both the 101LL/GSS tissues and 101LL/263K B48156 tissue, inoculation with a 
brain homogenate resulted in a greater level of PrP-res in the recipient brain compared to 
inoculation with the spleen homogenate (Figure 4-20) whilst for 101LL/263K B48157 one of 
the spleen-inoculated brains (Figure 4-20, lane 3) contained a similar level of PrP-res to one 
of the brain-inoculated brains (Figure 4-20, lane 2). The positive control from wild-type/79A 
was included on both blots with an equal level of PrP-res detectable irrespective of the tissue 
inoculated. Thus the NaPTA precipitation technique confirmed the results of the standard PK 
digestion and indicated that the bands present in Figure 4-19 (Figure 4-19A, lanes 6 and 8, 
Figure 4-19B, lanes 6 and 8, Figure 4-19D lanes 2 and 8) were non-specific interaction 
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Inocula Br              Br Spl Spl -
D: 101LL/263K (B48157)
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Inocula Br              Br Spl Spl -
C: 101LL/263K (B48156)
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Figure 4-19: Variation in PrP-res level depending on the tissue source of the inoculum from (A) 
101LL/GSS C17188, (B) 101LL/GSS C17218, (C) 101LL/263K B48156 and (D) 101LL/263K 
B48157. A similar level of PrP-res was observed from inoculation with both brain and spleen 
homogenates from (E) wild-type/79A. Brain tissue from two individual mice that received each 
inoculum are shown on each blot. The tissue homogenate inoculated in each case is indicated above 
the individual blot. Samples loaded at 10mg/ml. PrP
C 
was included in each blot as an internal 
immunoblot control (lane 9). Blots probed with mAb 8H4 and exposed for 10 minutes.  
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Figure 4-20: Variation in PrP-res level in brain tissues depending on the tissue source of the 
homogenate that was inoculated from (A) 101LL/GSS (C17188 and C17218) and (B) 101LL/263K 
(B48157 and B48156). Wild-type/79A (U7484) (lanes 9-12) included on both gels as the positive 
control and PrP
C
 (lane 13) included as immunoblot control (10mg/ml). Samples loaded at wet tissue 
weight equivalent of 33mg. Blot probed with mAb 8H4 and exposed for 5 minutes.  
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To confirm if the different levels of PrP-res were due to the type of tissue inoculated rather 
than simply due to tissue-to-tissue variation, isolation of SAF (Section 2.13) was performed 
on a further group of brain tissues from the 10
-2
 dilution groups. The immunoblot (Section 
2.19-2.21) results (Figure 4-21A) show that for the 101LL/GSS tissues, PrP-res was present 
in the brain-inoculated tissue at both wet weight tissue equivalents loaded but PrP-res was 
only detected in the spleen-inoculated tissue at a wet weight tissue equivalent of 2.25mg 
indicating a lower concentration of PrP-res was present. The 101LL/263K tissues (Figure 
4-21B) show a greater variability between tissues with the spleen-inoculated tissue 
containing more PrP-res than the brain-inoculated tissue for B48156 with the opposite 
relationship observed for B48157 inoculated tissues. The positive control wild-type/79A 
(Figure 4-21) confirmed that the level of PrP-res was consistent in this disease model 
irrespective of the tissue inoculated.  
Brain tissues produced from inoculation of the 10
-3
 dilution groups were also analysed 
through standard PK digestion and immunoblotted (Section 2.11, 2.19-2.21). The 
101LL/GSS C17188, 101LL/263K B48156 and 101LL/263K B48157 10
-3
 inocula results 
(Figure 4-22A, C + D) also showed an increased concentration of PrP-res in tissues that had 
been inoculated with brain homogenates compared to those that were inoculated with spleen 
homogenates. No PrP-res was detected in tissues following inoculation with either the brain 
or spleen homogenate inocula from 101LL/GSS C17218 (Figure 4-22B), with the bands 
present hypothesised to be due to IgG cross-reactivity (Section 3.2.4, Figure 3-12). This 
cross-reactivity was also present in lane 6 of 101LL/263K B48156 blot (Figure 4-22B). The 
positive control wild-type/79A (Figure 4-22E) had a consistent level of PrP-res present, 
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Figure 4-21: Variation in SAF precipitated PrP-res levels in (A) 101LL/GSS dependent on the tissue 
source of the homogenate inoculated. Variation in (B) 101LL/263K was not as clearly based on 
homogenate inoculated. Isolation of SAF was performed as previously described (Section 2.13) and 
the resulting pellets were re-suspended in 200µl PBS. Two wet weight tissue equivalent 
concentrations were loaded from each sample, (1) 1.125mg and (2) 2.25mg. Wild-type/79A (U7484) 
(lanes 9-12) included on both gels as the positive control and PrP
C
 (lane 13) included as immunoblot 
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Figure 4-22: Variation in PrP-res level depending on the tissue source of the homogenate inoculated 
from (A) 101LL/GSS C17188, (C) 101LL/263K B48156 and (D) 101LL/263K B48157. No PrP-res 
detected in any tissue from (B) 101LL/GSS C17218 inoculations with the bands present in PK 
digested homogenates (lanes 2, 4, 6 and 8) hypothesised to be IgG cross-reactivity. A similar level of 
PrP-res was observed from inoculation with both tissue homogenates from (E) wild-type/79A. Two 
brain tissues were analysed from each group inoculated with the source of tissue inocula in each case 
indicated above the blot. Samples loaded at 10mg/ml. PrP
C
 was included in each blot as an internal 
immunoblot control (lane 9). Blots probed with mAb 8H4 and exposed for 5 minutes. 
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In order to confirm these results and assess the level of PrP
Sc
 using a different analytic 




 dilutions) that have been analysed by standard PK 
and NaPTA precipitation, were additionally examined using the conformational dependent 
immunoassay (Section 2.15) to determine if there was an increase in the presence of a 
misfolded conformation of PrP (Section 1.2.4). The results (Figure 4-23) indicated that there 
was a slight increase in misfolded PrP
Sc
 present in tissues from mice that had been inoculated 
with brain homogenate, compared to those inoculated with the spleen homogenate.  
 
Further analysis with the IDEXX HerdChek* assay (Section 2.22) identified the brain tissues 
produced from sub-passage of both the brain and spleen homogenates at a 10
-2
 dilution as 
positive for TSE (Figure 4-24). The result indicated that the assay reaches saturation level 
with all tissues irrespective of tissue homogenate inoculated, despite the absence of PrP-res 
by immunoblot (Figure 4-19, Figure 4-20, Figure 4-21) and absence of misfolded PrP by 
CDI (Figure 4-23A) in the tissues from mice inoculated with the spleen homogenate at the 
10
-2
 dilution.  
Overall, it was concluded that in 101LL/GSS sub-passages there was a greater level of PrP-
res detected in brain tissues harvested from mice inoculated with brain homogenate than 
those inoculated with spleen homogenate. However, the same relationship was not as 
apparent in the 101LL/263K sub-passages, with a higher variability observed in these 
tissues. This was in contrast to the wild-type/79A sub-passages that had similar levels of 
PrP-res in all brain tissues analysed irrespective of the homogenate utilised as inocula. These 
data indicate that the differences observed between brain and spleen inocula could be strain-
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Figure 4-23: Conformational dependent immunoassay analysis of levels of PrP
Sc
 in brain tissues 
produced from sub-passage experiments. Two brain tissues were analysed from each group inoculated 
with the different homogenates. The source of homogenate inoculated in each case indicated on the x-
axis. Tissue for analysis produced from inoculation of (A) 10
-2
 and (B) 10
-3
 dilutions. The negative 




































Figure 4-24: Brain tissues collected from sub-pass were positive with the IDEXX HerdChek* kit 
irrespective of the homogenate utilised as inoculum. IDEXX controls (red) provided by the kit and the 
negative cut-off (purple) calculated as per manufacturer‟s instructions. 
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4.2.8.  Biochemical analysis of spleen tissue produced from 
subpass 
Due to time-constraints of this project, only limited analysis of the spleen tissues produced 
from the sub-passage was performed. Initial analysis was performed through PK digestion, 
NaPTA precipitation and immunoblots (Section 2.16, 2.19-2.21) of the spleen homogenates. 
The results indicated that the levels of PrP-res present in the spleen tissue from the sub-
passage (Figure 4-25) were increased in comparison to the levels present in the primary 
tissue (Figure 4-14). Further for the positive control, wild-type/79A and the 101LL/263K 
spleens there was no obvious difference between the levels of PrP-res for each tissue type 
inoculated (Figure 4-25). The 101LL/GSS results (Figure 4-25) were harder to interpret with 
PrP-res definitely present in the spleen from the mouse inoculated with 101LL/GSS C17188 
brain tissue (Figure 4-25, lane 1). However, the bands present in the other 101LL/GSS 
spleens (Figure 4-25, lanes 2-4) do not have the banding pattern expected for PrP-res and 
could potentially be IgG cross-reactivity of the secondary antibody. Further work is required 
to confirm the presence of PrP-res in the 101LL/GSS spleens and the increase in the level of 
PrP-res present in 101LL/263K through analysis of an increased number of tissues, to 
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Figure 4-25: Presence of PrP-res in the majority of spleen tissues produced from the sub-passage with 
each strain of inocula, independent of the homogenate brain (Br) and spleen (Spl) inoculated. PK 
digestion and NaPTA precipitation of spleen tissue performed with a tissue equivalent of 20mg 




Previous research into the unusual disease phenotype identified in 101LL/GSS and 
101LL/263K mice was performed through analysis of the brain tissue. This project aimed to 
investigate the role of the spleen in disease by analysing both the levels of PrP-res and TSE 
infectivity present in spleens of infected mice at clinical end point. Initial biochemical 
analysis through NaPTA precipitation and isolation of SAF identified a detectable level of 
PrP-res in some but not all of the 101LL/GSS and 101LL/263K spleen tissues. For analysis 
of spleen tissue from 101LL/GSS infected mice, two techniques were trialled, isolation of 
SAF and NaPTA precipitation of PrP-res. Both techniques detected PrP-res from spleen 
tissues with the NaPTA precipitation technique proving more consistent in producing 
interpretable results. A semi-quantitative immunoblot was performed with the amount of 
PrP-res from spleen tissue estimated through doubling dilutions of NaPTA precipitated PrP-
res, to determine the minimum dilution at which PrP-res could be detected. For the 
101LL/GSS (Figure 4-7A), band intensity clearly indicates a lower level of PrP-res was 
present in the 101LL/GSS spleen tissues compared to the wild-type/ME7 positive control. 
The 101LL/263K spleen tissues (Figure 4-7B) also demonstrated a lower concentration of 
PrP-res, with PrP-res present when a tissue equivalent of 2.5mg was loaded whilst the wild-
type/ME7 spleen had PrP-res detectable from a tissue equivalent of 1.25mg, with an 
estimation of at least two times less PrP-res present in the 101LL/263K spleens compared to 
the wild-type/ME7 spleens. Overall the biochemical results show that although a variable 
level of PrP-res was present in the 101LL/GSS and 101LL/263K spleen tissues, the level of 
PrP-res was consistently lower than the level of PrP-res observed in a wild-type/ME7 spleen. 
Therefore, in this mouse model, extremely low levels or an absence of PrP-res in the brain 
tissues and a low but detectable level of PrP-res was present in the spleen tissue. This result 
contrasts with other studies that have shown the amount of PrP-res to be greater in the brain 
than in the spleen for wild-type mice infected with 139A or ME7 (Rubenstein, Merz et al. 
1991, Cervenakova, Yakovleva et al. 2003). 
Based on previous research, it was hypothesised that the infectivity levels in the spleen 
would be 2-3 log10 lower than the levels observed in the brain tissue (Rubenstein, Merz et al. 
1991). This was true for the wild-type mice infected with 79A which upon inoculation with 
the spleen homogenate had incubation periods to disease that were 30-40 days longer than 
those observed from the brain homogenate (Table 4-2). However, unexpectedly the 
incubation periods to disease after intra-cerebral inoculation of both 101LL/GSS and 
101LL/263K brain and spleen homogenates were similar (Figure 4-15). Although full 
titration studies are required to determine the exact titre of infectivity (ID50/g tissue) for each 
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tissue, these preliminary data indicated that an unexpectedly high level of infectivity was 
present in the spleen of this disease model at clinical end-point. Interestingly, the 
101LL/263K B48157 that did not contain any PrP-res in the brain and spleen inocula (Figure 
4-14) was able to transmit disease and produce PrP-res in recipient mice with the same 
incubation period (Figure 4-15) as 101LL/263K B48156 that did have detectable PrP-res in 
the residual brain homogenate inoculum (Figure 4-14). Further as both 101LL/GSS and 
101LL/263K were analysed in this study, it can be assumed that this unexpected result was 
not specifically due to the strain of TSE agent. The similarity in incubation periods observed 
for both tissue homogenates could be due to an effect of the 101L mutation on disease 
pathogenesis or TSE agent replication. To determine if the mutation in the host is the cause 
of this unexpected result, further studies are required in which a strain of mouse scrapie 
would be primary passaged in both wild-type and 101LL mice. A sub-passage from both 
brain and spleen tissue from clinical end-point wild-type and 101LL mice could then be 
performed to determine levels of infectivity in each tissue.  
In conclusion, following inoculation of 101LL mice with GSS or hamster 263K scrapie, the 
spleen was shown to contain low levels of PrP-res but sub-passage identified high levels of 
infectivity, similar to those in the brain. The spleen tissue therefore shows the same 
discrepancy between PrP-res and infectivity as the brain tissue in these disease models.  
Analysis of the brain tissue collected from the sub-passage experiments from both brain and 
spleen of 101LL/GSS and 101LL/263K infected mice indicates that for the majority of 
tissues, mice inoculated with 101LL/GSS brain homogenates have a higher level of PrP-res 
than mice inoculated with 101LL/GSS spleen homogenates. This was shown through both 
biochemical and immunohistochemical analysis, with no PrP-res detectable by immunoblot 
and less intense PrP
Sc
 staining present by immunohistochemistry for the spleen-inoculated 
mice. This indicates that the spleen PrP-res could potentially be a different form or variant 
that is unable to replicate as efficiently in the brain tissue. It is hypothesised that the agent is 
replicating in a tissue-specific manner but is required to adapt before it can produce 
detectable levels of PrP-res in the brain tissue. It has previously been hypothesised that TSE 
strains consist of a heterogeneous population of molecular phenotypes (Collinge and Clarke 
2007) that are selected under different cellular environments. The hypothesis of quasi-
species with variants that replicate preferentially in a specific tissue type with dependence on 
tissue-specific host factors has been shown in Tg338 mice with the spleen more  permissive 
to foreign prions than the brain when inoculated with either elk CWD tissue, Ha 263K or Ha 
Sc237 scrapie (Béringue, Herzog et al. 2012). These Tg338 mice were asymptomatic on 
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primary passage with accumulation of PrP-res present upon intra-cerebral sub-passage of the 
spleen but not the brain tissue (Béringue, Herzog et al. 2012). In the disease model presented 
in this thesis, perhaps the spleen allows the preferential replication of a sub-variant due to the 
tissue-specific conditions present. Upon sub-passage of the spleen tissue, the conditions were 
altered and therefore a lower level of replication of PrP-res was observed in the brain. Based 
on the biochemical data that identifies the presence of PrP-res in the primary passage spleen 
tissue and the high levels of infectivity indicated by the sub-passage study performed in 
these studies, it is hypothesised that the spleen replicates a variant of the agent that replicates 




5.  In vitro amplification of PrP-res from mouse tissues using 
the PMCA amplification assay. 
5.1. Introduction 
The protein misfolding cyclic amplification (PMCA) technique (Section 1.5.1) allows for 
amplification of minute levels of PrP-res to a level detectable by conventional methods such 
as immunoblotting. Through cycles of sonication and incubation, PrP-res is amplified, with 
the sonication pulse hypothesised to break up PrP-res aggregates, increasing the number of 
converting units, whilst the incubation period allows for the growth of the PrP-res 
aggregates. In proof-of-concept studies, hamster 263K scrapie was amplified with 97.4-
98.7% of PrP-res being newly generated (Saborio, Permanne et al. 2001) and automation of 
the technique reduced the manual input required and allowed for indefinite amplification 
(Castilla, Saa et al. 2004). The seed and substrate are provided by 10% (w/v) homogenates 
prepared from infected and uninfected brain tissue respectively (from the same species for a 
homologous reaction), with the PMCA PrP-res product maintaining the biochemical 
properties of the PrP-res seed (Castilla, Saa et al. 2005). The uninfected brain homogenate 
contains a high molar excess of PrP
C
 to provide the substrate for conversion. Since its initial 
development, PMCA has been widely used in TSE research to investigate the species barrier, 
the minimal components required for production of PrP-res, and has been investigated as a 
potential diagnostic assay (Section 1.5.1). PMCA has been shown to amplify PrP-res from a 
10
-28
 dilution of chandler scrapie seed in a mouse substrate with the presence of digitonin in 
the PMCA conversion buffer (Murayama, Yoshioka et al. 2007). Research has also shown 
that PrP-res can be amplified from vCJD seed diluted in a transgenic mouse substrate that 
expresses human PrP
C 
(Jones, Peden et al. 2007). The studies in this thesis aimed to assess if 
PrP-res and TSE infectivity could be amplified through the PMCA technique from 
101LL/263K and 101LL/P102L GSS mouse tissues that have extremely low levels of 
detectable PrP-res as determined by conventional biochemical techniques (Section 3.2.4). As 
the PMCA technique had not previously been performed at The Roslin Institute, the work 
detailed in this chapter identifies the difficulties encountered in developing a positive control 
that would show successful amplification from a well-characterised mouse strain that had 
high levels of PrP-res
 




5.2.1. Power of sonication 
The optimal power of sonication required for amplification of a seed varies between species 
and TSE strains, and is hypothesised to be due to different conformation and aggregation 
states of the seed (Soto, Anderes et al. 2005). The sonication pulse is thought to be required 
to efficiently break up the PrP-res aggregates thus increasing the number of converting units 
without damaging their converting activity (Saa, Castilla et al. 2005). The optimal conditions 
for amplification of mouse PrP-res using a mouse PrP
C
 substrate was investigated for two 
well-characterised laboratory strains, 79A and ME7. The seeds and substrates were prepared 
according to previous protocols (Section 2.24.1, 2.24.2) and each seed was serially diluted in 
wild-type (C57BL6) uninfected 10% (w/v) brain homogenate substrate to identify the 
dilution at which PrP-res was just detectable by immunoblotting (Section 2.19-2.21) prior to 




dilution of a 10% (w/v) brain 
homogenate respectively (Figure 5-1A and Figure 5-2A). Optimisation of the power of 
sonication was undertaken with a 10
-2
 dilution to allow clear visualisation of any 
amplification levels through immunoblotting. Seeds were diluted in a wild-type (C57BL6) 
substrate and PMCA was performed (Section 2.24.3, Method One) at a range of power 
settings, with the sonicator set at 40, 50, 60, 70, 80, 90 and 100% power. Each different 
power setting was performed with 1 round consisting of either 24 hours (48 cycles) or 48 
hours (96 cycles) before analysis of the reaction product through PK digestion (Section 2.11) 
and immunoblotting (Section 2.19-2.21) to detect any amplified PrP-res product.  
Amplification of ME7 was observed at a 40% sonication power after 24 hours (Figure 5-1B) 
and at a 50% sonication power, after 24 and 48 hours (Figure 5-1C). No amplification of the 
ME7 seed was observed from samples composed of combined multiple replicates that had 
undergone PMCA reactions for 24 hours with sonication pulses at 60-90% power (Figure 
5-1D). A PMCA reaction with a sonication pulse at 100% power was unable to produce 
amplification of the ME7 seed after either 24 or 48 hours (Figure 5-1E). 
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A: Prior to PMCA
Lane  1             2             3      4      5      6     7      8             9    10
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PK    +     +          +          +    +  
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Power  60         70          80          90            - - -
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PK   +        +         +         +         +        +    -








PK   +   +   +        +   +   +          -
PMCA   F    24   48          F    24   48           -
Lane  1            2            3            4             5           6      7 Lane  1     2     3           4    5     6             7
 
Figure 5-1:  Varying the power of sonication affected the amplification of an ME7 seed in a wild-type 
(C57BL6) substrate. Based on the detection level of PrP-res prior to amplification (A), a 10
-2
 dilution 
of seed into substrate was prepared and an aliquot frozen (F) to provide a reference sample for PrP-res 
levels prior to amplification. The remaining aliquots underwent PMCA for either 24 or 48 hours (as 
indicated), with 40 second sonication pulse at (B) 40% sonication, (C) 50% sonication, (D) 60%, 
70%, 80%, 90% sonication and (E) 100% sonication every 30 minutes. Duplicate PMCA samples 
were then combined, PK digested (40µg/ml 37°C, 1 hour) and immunoblotted. Samples loaded at 
10mg/ml. Blot probed with mAb 8H4 and exposed for 10 minutes.  
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Amplification of the 79A seed in a wild-type (C57BL6) substrate was observed after PMCA 
was performed for 24 and 48 hours with sonication pulses at 40%, 50% and 70% (Figure 
5-2B, C+D). Amplification of the 79A seed was also obtained in a wild-type substrate 
produced from an SV mouse that expresses the prnp
a
 mouse genotype (Section 1.1.4) 
(Figure 5-2D, lane 3) after both 24 and 48 hours. The addition of this wild-type substrate was 
to create a homologous reaction to control for effects of genetic background in the 
homogenate as the 79A seed was provided by brain tissue from a 79A infected SV mouse. 
Although the substrate provided by the SV mouse line was not examined at each power 
setting, the result was included as it illustrates substrate-to-substrate variation in the level of 
amplification. Further analysis of reaction products produced from the combination of 
multiple replicates that underwent PMCA at 60% and 70% sonication pulses for 24 hours 
showed very faint levels of amplification (Figure 5-2E, lanes 1 and 3) whilst PMCA with 
sonication pulses at 80% and 90% power did not support amplification of the 79A seed 
(Figure 5-2E, lanes 5 and 7). PMCA with a sonication pulse set at 100% power was difficult 
to interpret as the frozen sample without amplification showed an unexpected strong band. 
Further during the 100% sonication reaction, due to the increased oscillation of the water, the 
caps that sealed the wells of the 96-well plate were dislodged and the possibility of cross-
contamination could not be ruled out. Therefore, this power setting was not repeated again 
and the sonicator was decontaminated before further experiments were performed.  
The preliminary results confirm that individual TSE strains have different optimal levels of 
amplification. While amplification levels of an ME7 seed were greatest at lower sonication 
powers 40-50%, the 79A seed amplifies more efficiently over a range of sonication power, 
50-70%. To minimise substrate-to-substrate variation, the substrate utilised in future 
experiments was produced from the combination of at least three uninfected brain 
homogenates, combined prior to the centrifugation step that removes cellular debris during 
preparation. 
However, following successful amplification, further repetition of the settings showed 
inconsistent amplification levels and attempts to amplify the mouse PrP-res seed from higher 
dilutions of seed at the optimum sonication powers identified were complicated by the 
unexpected presence of protease resistant bands in the diluted samples prior to amplification 
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Figure 5-2: Effect of the varying power of sonication on the amplification of a 79A seed in a wild-type 
(C57BL6) substrate. Based on the detection level of PrP-res prior to amplification (A), a 10
-2
 dilution 
of seed into substrate was prepared and an aliquot frozen (F) to provide a reference sample prior to 
amplification. The remaining aliquots underwent PMCA for either 24 or 48 hours (as indicated), with 
40 second sonication pulses at either 40% sonication (B), 50% sonication (C), 70% (D), 60%, 70%, 
80%, 90% sonication (E) or 100% sonication (F) every 30 minutes. Duplicate PMCA samples were 
combined, treated with PK (40µg/ml 37°C, 1 hour), loaded at 10mg/ml and detected with anti-PrP 
antibody 8H4 with 10 minute exposure. 
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5.2.2. The role of digitonin in the PMCA conversion buffer 
Digitonin, a glycoside detergent has previously been shown to clarify the results of mouse 
PMCA reactions when included in the PMCA conversion buffer used to homogenise the 
substrates. Although digitonin does not enhance the amplification levels it acts to reduce the 
presence of PrP-res formation in mouse normal brain homogenate that can complicate the 
PMCA result and lead to false positives (Murayama, Yoshioka et al. 2007, Fujihara, Atarashi 
et al. 2009). In order to assess the role of digitonin, wild-type (C57BL6) healthy mouse 
brains were halved longitudinally, one half was homogenised in PMCA conversion buffer 
without digitonin whilst the other half was homogenised in PMCA conversion buffer 
containing 0.05% digitonin (Section 2.24.1). PMCA was performed as described (Section 
2.24.3, Method One) on 10
-2
 dilution of seeds diluted in substrate with or without the 
addition of digitonin. PMCA products were PK digested (Section 2.11) and immunoblotted 
(Sections 2.19-2.21).  
The results show that the addition of digitonin to the PMCA conversion buffer neither 
enhanced nor decreased the levels of amplification observed (Figure 5-3). The variation 
observed between substrates was similar to the level of variation detected within any PMCA 
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Figure 5-3: Addition of digitonin to the conversion buffer did not help to clarify PMCA results. The 
seeds (A) 79A seed and (B) ME7 seed were diluted, 10
-2
 into two wild-type (C57BL6) substrate 
tissues either with (+) or without (-) the addition of digitonin.  Frozen samples of 10% (w/v) seed 
(lane 9) and 10% (w/v) substrate (lane 10) were included as immunoblot controls. Experimental 
samples (lanes 1-8) underwent PMCA for either 24 or 48 hours (as indicated), with 40 second 
sonication pulses at ~110W (50%) power, every 30 minutes. PMCA products were PK digested 
(40µg/ml 37°C, 1 hour) and immunoblotted. Samples loaded at 10mg/ml. Blot probed with mAb 8H4 
and exposed for 30 minutes.  
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5.2.3. Influence of condition of substrate on amplification 
efficiency 
The ability of the substrate to support amplification may vary depending on the storage 
conditions used between tissue harvesting and homogenisation. Although the treatment of 
the substrate is dependent on the species used, different laboratories have developed different 
procedures for the preparation of substrate. For the previous experiments, the substrate was 
prepared as described in methods (Section 2.10) from brain tissue immediately frozen at -
80°C upon harvesting. This method was chosen as it has previously been shown to support 
amplification of PrP-res from a range of seeds (Jones, Peden et al. 2008, Jones, Wight et al. 
2009). Others (Terry 2010) have investigated whether the freeze-thawing the tissue affects 
the substrates ability to support amplification with the results indicating that sheep brain 
tissue was unable to support amplification of sheep scrapie after undergoing one freeze-thaw 
cycle (Terry 2010). Given the results from the assessment of the power of sonication results 
that showed ME7 and 79A amplified at different powers of sonication (Section 5.2.1), this 
experiment was performed with only the ME7 seed utilising a 50% power for the sonication 
pulses. To test the different efficiencies of frozen and fresh tissue, healthy wild-type 
(C57BL6) mouse brains were received from the animal house within 30 minutes of 
euthanization and homogenised in PMCA conversion buffer without undergoing a freeze-
thaw cycle (Section 2.24.1). The ME7 10% (w/v) homogenate seed was diluted to a 10
-2
 
dilution into both the freshly prepared homogenate and homogenate prepared from a frozen 
brain (homogenised in the same PMCA CB). Multiple replicates of the dilutions underwent 
PMCA as described in (Section 2.24.3, Method One) for either 24 or 48 hours. The reaction 
products were PK digested (Section 2.11) and analysed by immunoblot (Section 2.19-2.21) 
for levels of amplification. No amplification was observed in either the freshly prepared 
substrate or the frozen homogenate substrate prepared by the standard method with the level 
of PrP-res in the amplified samples similar to the level of PrP-res in the samples prior to 
amplification (Figure 5-4). The result indicated that the use of a freshly prepared substrate 
did not improve amplification efficiency. 
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A: Fresh substrate B: Frozen substrate
Lane 1    2    3     4    5    6     7 Lane 1    2   3   4    5    6     7
 
Figure 5-4: No difference in amplification efficiency at 10
-2
 dilution of seed utilising (A) fresh 
substrate or (B) frozen substrate that has undergone one freeze-thaw cycle. An ME7 seed was diluted 
10
-2
 into wild-type (C57BL6) substrates and an aliquot frozen (F) to provide a comparison sample for 
PrP-res levels prior to amplification. Mulitple replicates of the seed: substrate combinations 
underwent PMCA for either 24 or 48 hours (as indicated), with 40 second sonication pulses at ~110W 
(50%) power, every 30 minutes. PMCA products were combined and PK digested (40µg/ml 37°C, 1 
hour). Samples were loaded at 10mg/ml and immunoblotted as standard. Blot probed with mAb 8H4 
and exposed for 10 minutes. Inefficient transfer of gel to PVDF membrane occurred for blot (B) but 
other repeat PMCA reactions and immunoblots confirmed that no difference in amplification was 
achieved with a fresh substrate (data not shown).  
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5.2.4. Variable reproducibility of amplification levels between 
duplicate samples and repeat experiments. 
The current methodology (Section 2.24.3, Method One) utilises a 96-well plate, floated on 
the surface of the sonicator bath, to contain the samples. It was hypothesised that the 
different wells were receiving different levels of sonication energy thus affecting the levels 
of amplification between replicates dependent on the replicate position within the plate. Both 
wild-type (C57BL6) and 101LL substrates were tested for their ability to support 
amplification in the following experiments as different strains are known to have varying 
amplification efficiencies dependent on the different amino acid exchanges in the substrate 
PrP
C
 (Piening, Nonno et al. 2006) and the future aim of this research would require the 
amplification of a positive control in the 101LL substrate. To test the hypothesis, the ME7 
seed was diluted into either a wild-type (C57BL6) or 101LL substrate at a 10
-2
 final dilution 
and 6 replicates of each were placed in different wells and subjected to PMCA (40 seconds 
at 50% power) for either 24 or 48 hours.  PMCA reaction products were subjected to PK 
digestion (Section 2.11) and immunoblotted (Section 2.19-2.21) as standard. The results 
show that although the ME7 seed has been detected in the sample prior to amplification, 
amplification was still observed at varying levels across the replicates, with the highest level 
of amplification observed in replicates 9 and 10 of the wild-type (C57BL6) substrate (Figure 
5-5, lane 10-11). The results indicated a variability of amplification efficiencies between 
replicates in the 96-well plate.  
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A: ME7 seed: wt (C57BL6) substrate
20
30
PMCA   F     24  24  24  24  24   24  48  48   48  48  48   48       
Replicate   F      1    2    3     4    5     6     7    8     9   10   11  12           
Lane  1     2    3    4    5    6     7    8     9    10  11  12  13
B: ME7 seed: 101LL Substrate
20
30
PMCA   F     24  24  24  24   24   24  48  48   48  48  48   48       
Replicate   F      1    2    3     4     5     6     7    8     9   10   11  12           
Lane  1     2    3     4    5    6     7    8     9   10   11  12  13
 
Figure 5-5: Variation in the amplification level between replicates of ME7 seed in either (A) wild-
type (C57BL6) or (B) 101LL substrates. A 10
-2
 dilution of seed into substrate was prepared and an 
aliquot frozen (F) to provide a reference sample prior to amplification. The remaining replicates 
underwent PMCA for either 24 or 48 hours (as indicated), with 40 second sonication pulses at ~110W 
(50%), every 30 minutes. PMCA products were PK digested (40µg/ml 37°C, 1 hour), samples loaded 
at 10mg/ml and immunoblotted. Blot probed with mAb 8H4 and exposed for 5 minutes. 
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Other published protocols for the PMCA technique recommend the use of thin-walled PCR 
tubes to allow effective penetration of the sonication ultrasound waves to support 
amplification (Castilla, Saa et al. 2006). To analyse the efficiency of tubes compared to a 
PCR-plate, replicates of the seed and substrate combinations in 0.2ml thin-walled PCR tubes 
(Thermo-Scientific) were subjected to the same PMCA technique (Section 2.24.3, Method 
One). Both ME7 and 79A seeds were included in the reaction to determine if the thin-walled 
PCR tubes enhance amplification levels. PMCA products were PK digested (Section 2.11) 
and immunoblotted (Section 2.19-2.21) with the results (Figure 5-6) indicating that the thin-
walled PCR tubes supported amplification of each seed in both the wild-type (C57BL6) and 
101LL substrate. A level of variability between samples still remained although it was 
hypothesised that this would be impossible to prevent due to both random variation and 
variation due to sample location within the sonicator horn (Gonzalez-Montalban, Makarava 
et al. 2011). However, in further experiments performed with the thin-walled PCR tubes and 
identical settings did not support amplification of the seed from any higher dilutions of seed 
and provided variable amplification results with repeat experiments with the 10
-2
 dilution. 
Amplification was therefore not reproducible with three identical repeat experiments failing 





C: ME7 seed in wt (C57BL6) substrate
PMCA    F   24  24   24   24  48  48   48  48
Replicate   F      1    2    3     4    5     6     7    8
30
A: 79A seed in wt (C57BL6) substrate
PMCA    F    24  24   24   24   48   48  48  48
Replicate   F      1    2    3     4      5     6     7    8
16
Lane  1      2      3     4      5      6     7     8     9
30
B: 79A seed in 101LL substrate
PMCA    F    24  24   24   24   48  48  48  48
Replicate   F      1    2    3     4      5    6     7    8
16
Lane  1      2      3     4      5      6     7     8     9
30
16
D: ME7 seed in 101LL substrate
PMCA    F    24  24   24   24    48   48   48  48
Replicate   F      1    2    3     4        5    6     7    8
Lane  1      2       3     4       5      6      7      8     9
 
Figure 5-6: Thin-walled PCR tubes were able to support amplification of the seed: substrate 
combinations of (A) 79A seed into wild-type (C57BL6) substrate, (B) 79A seed into transgenic 
101LL mouse substrate, (C) ME7 seed into wild-type (C57BL6) and (D) ME7 seed into transgenic 
101LL mouse substrate. A 10
-2
 dilution of each seed: substrate combination was prepared and an 
aliquot frozen (F) to provide a reference sample prior to amplification. The remaining replicates 
underwent PMCA for either 24 or 48 hours (as indicated), with 40 second sonication pulses at ~110W 
(50%), every 30 minutes. PMCA products were PK digested (40µg/ml 37°C, 1 hour), samples loaded 
at 10mg/ml and immunoblotted. Blot probed with mAb 8H4 and exposed for 10 minutes. 
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5.2.5. Amplification of 79A and ME7 seeds at the Istituto 
Superiore di Sanità (ISS), Rome 
Given the lack of reproducible results, work was undertaken at the Istituto Superiore di 
Sanità, Rome (ISS) where the PMCA is used routinely and provides consistent, reproducible 
amplification results (Piening, Nonno et al. 2006). Experiments at the ISS mainly utilise the 
PMCA to amplify PrP-res from a bank vole scrapie seed in a normal bank vole brain 
homogenate substrate.  In vitro PMCA experiments conducted at the ISS have confirmed the 
in vivo result that bank voles were more susceptible than wild-type mice to natural sheep 
scrapie with the different susceptibilities shown through PMCA experiments to be due to two 
amino acid substitutions in PrP
C
, Y154N and S169N (Piening, Nonno et al. 2006, Agrimi, 
Nonno et al. 2008). This PMCA technique (Section 2.24.3, Method Two) consistently 
amplifies PrP-res from a bank vole scrapie seed in a bank vole substrate. Prior to 
amplification, PrP-res was only detected at a 10
-1
 dilution whilst after a single 48 hour 
PMCA reaction, PrP-res was detected up to a 10
-5
 dilution (personal communication – GM 
Cosseddu). These results were reliably reproduced with three identical reactions producing 
amplification to the same detection level (data not shown). The conditions that supported 
amplification of the bank vole seed were significantly different to those utilised for 
amplification of a mouse seed at The Roslin Institute (Table 5-1) that were initially obtained 
on advice from the NCJDRSU (M. Jones – personal communication) and the literature 
available on mouse PMCA.  
The ISS conditions and sonicator that support amplification of bank voles PrP-res were 
tested for their ability to support the amplification of the mouse seeds ME7 and 79A, in a 
mouse substrate. PMCA substrates were prepared from either wild-type (RIII) or 101LL 
healthy mouse brains (kindly provided by GM Cosseddu). At post mortem, brain tissue was 
perfused (PBS containing 0.5M EDTA), flash-frozen in liquid nitrogen, stored at -80°C until 
homogenisation in PMCA CB was performed. A minimum of three brain homogenates were 
combined for each genotype to avoid substrate-to-substrate variation. For each seed to 
substrate combination (ME7:101LL, ME7: RIII, 79A: 101LL, 79A: RIII and bank vole: bank 




 was prepared and 50µl aliquots were subjected to 
PMCA as per conditions utilised at the ISS with the Misonix 3000 (Table 5-1), (Section 
2.24.3, Method Two). As an additional control a dilution series of ME7 in the bank vole 





Technique/Information Istituto Superiore di Sanità, 
Rome 
The Roslin Institute, Roslin, 
Edinburgh 
Temperature 37°C 37°C 
Water Re-circulating at 37°C Stationary (Incubator at 37°C) 
Sonication 20 seconds at 180-190W 
(Misonix 3000) 
40 seconds at 165-170W 
(Misonix 4000) 
Incubation 30 minutes 29 minutes 20 seconds 
Tubes Multiply Safecup (Sarstedt) 
screw-cap 0.1ml 
Either PCR plate or 0.2ml 
PCR tubes with cap. 
Volume of sample 50µl 100µl 
Total time/Number of 
cycles 
48 hours/96 cycles Either 24 hours/48 cycles or 
48 hours/96 cycles 
PK digestion (working 
concentration) 
100µg/ml at 55°C for 1 hour 
at 900rpm 
20µg/ml at 37°C for 1 hour 
with agitation. 
Table 5-1: PMCA conditions utilised in the two different laboratories; ISS and Roslin Institute.  
 
The ME7 seed was faintly detectable at a 10
-2
 dilution in both mouse substrates prior to 
amplification and was detected at a 10
-3
 dilution after PMCA indicating that amplification 
had occurred (Figure 5-7A). The 79A seed was only detectable at a 10
-1
 dilution prior to 





 dilution in the wild-type (RIII) and 101LL substrates respectively indicating that 
amplification had occurred (Figure 5-7B). The internal control confirmed that the PMCA 
was successful with the bank vole PrP-res detected at a 10
-5
 dilution after amplification, 
compared to detection at only a 10
-1
 dilution prior to amplification (Figure 5-7C). The ME7 
seed was also diluted into bank vole substrate to provide an additional control and although 
this was a cross-species reaction, amplification was still achieved at one log dilution (Figure 
5-7C). No amplification was achieved in negative controls (Figure 5-8). Therefore the 
settings that support the amplification of bank vole PrP-res were also able to support the 





Figure 5-7: Amplification of both (A) ME7 and (B) 79A in both wild-type (RIII) and 101LL mouse 
substrates using ISS settings and equipment. (C) Bank vole scrapie was amplified from a bank vole 
substrate as the positive control reaction and ME7 amplified from the bank vole substrate as substrate 
control. A dilution series of each seed: substrate combination was produced and aliquots frozen to 
provide a comparison sample prior to amplification (-PMCA). PMCA products (+PMCA) were 
subjected to PMCA for 48 hours, with a 20 second sonication pulse at 180-190W every 30 minutes. 
PMCA products were digested with PK (100µg/ml 55°C, 1 hour), samples loaded at 5mg/ml, 




Figure 5-8: No spontaneous formation or contamination occurred in substrate only controls in the 
PMCA performed at the ISS. Lanes 1 and 2 contain 101LL substrate, lanes 3 and 4 contain wild-type 
(RIII) substrate, lanes 5 and 6 contain bank vole substrate only. PMCA products (lanes 1-6) were 
treated with PK (100µg/ml 55°C, 1 hour), samples loaded at 5mg/ml, detected with anti-PrP antibody 




5.2.6. ISS conditions performed on the Misonix 4000 at The 
Roslin Institute were unable to support amplification. 
The main difference between conditions utilised at the ISS and the conditions utilised at The 
Roslin Institute (Table 5-1) was the use of a re-circulating water bath to maintain the 
temperature at 37°C. Without the presence of the water pump to re-circulate the water, the 
temperature of the water within the water bath increases after each sonication pulse (Figure 
5-9), due to the heat energy released during the sonication pulses. It was hypothesised that 
the temperature increase over the reaction period could be inhibiting the conversion of PrP
C
 
to PrP-res, therefore reducing the amplification efficiency.  
 
 
Figure 5-9: Temperature increase in the water bath of the sonicator horn, after only 3 cycles (40 
second pulse, 30 minute incubation) of PMCA without the presence of a re-circulating water pump. 
160 
 
However, replication of the ISS conditions (Section 2.24.3, Method Two), including re-
circulating the water in the sonicator horn, using the Misonix 4000 sonicator present at the 
Roslin Institute did not support amplification of mouse PrP-res, in five repeat reactions (data 
not shown). The conditions were being replicated as closely as possible to those performed at 
the ISS that achieved amplification including the use of a re-circulating water bath. 
However, the perfusion of the brain tissue with 1M PBS/0.05M EDTA prior to dissection 
was identified as a remaining difference between the two laboratory techniques. Perfusion of 
the tissue minimises the presence of blood in the tissue that is known to be inhibitory to the 
amplification of PrP-res using PMCA (Saá, Castilla et al. 2005, Tattum, Jones et al. 2010). 
Wild-type (C57BL6) mouse brains from the Roslin Institute‟s mouse facility were therefore 
perfused and flash frozen in liquid nitrogen as performed at ISS. Three perfused brain tissues 
were homogenised in PMCA CB to a 10% (w/v) homogenate, combined and used as the 
perfused substrate to amplify either 79A or ME7 seeds. The seeds were also diluted in a non-
perfused substrate for comparison. All samples were subjected to PMCA under ISS 
conditions (Section 2.24.3, Method Two) with the products PK digested (Section 2.10) and 
immunoblotted (Section 2.19-2.21). Low levels of amplification were achieved with the 79A 
seed in both the non-perfused and perfused substrates (Figure 5-10A+B) whilst no 
amplification was achieved with the ME7 seed in either substrate. Neither seed obtained the 
amplification levels observed from the results obtained at the ISS. The absence of 
amplification of ME7 agrees with previous results that failed to detect amplification at higher 
powers of sonication (Figure 5-1). Similar results, with little or no amplification was 
achieved upon three repeat reactions of these conditions (data not shown) indicating that the 
use of a perfused substrate did not enhance the levels of amplification to those observed at 
the ISS.  
The absence of any increase in amplification, despite the use of settings that supported 
amplification of both seeds from high dilutions at the ISS, could have been due to a lower 
affinity of the primary antibody 8H4 for the reaction products. An alternative primary 
antibody, 7A12 was assessed to determine if antibody affinity was influencing the outcome 
observed. Samples from the perfusion experiment (Figure 5-10) were immunoblotted 
(Section 2.19-2.21) and probed with either mAb 8H4 or mAb 7A12. Both antibodies 
detected PrP-res at a 10
-1
 dilution of ME7 seed into substrate, prior to PMCA (Figure 5-11). 
After PMCA, PrP-res was only detected faintly at the 10
-1
 dilution with both antibodies 
(Figure 5-11), confirming that amplification was not achieved. The normal brain homogenate 
included as an immunoblot control (Figure 5-11, lanes 4+11) that was not subjected to 






Dilution -1  -2  -3  -4 -5      -1 -2 -3  -4 -5   NBH
F +PMCA
A: 79A seed into perfused substrate
Lane  1     2    3    4   5          6    7   8   9  10     11
20
30




B: 79A seed into non-perfused substrate
Lane 1   2    3    4   5       6    7    8    9    10  11   12
20
30
Dilution -1  -2  -3  -4 -5 -1 -2 -3  -4 -5  NBH
F +PMCA
C: ME7 seed into perfused substrate
Lane 1     2    3    4    5       6    7    8    9    10  11
20
30
Dilution -1  -2  -3  -4 -5      -1 -2 -3 -4  -5 NBH
F +PMCA
D: ME7 seed into non-perfused substrate
Lane 1     2    3    4    5       6    7    8    9    10  11  
Figure 5-10: Perfusion of substrate (A+C) did not enhance amplification of either (A) 79A or (C) ME7 
seed compared to amplification achieved with a non-perfused substrate (B+D) seeded with either (B) 
79A or (D) ME7 seed. A dilution series of each seed: substrate combination was produced and 
aliquots frozen to provide a comparison sample prior to amplification (F). PMCA products (+PMCA) 
were subjected to PMCA for 48 hours, with a 20 second sonication pulse at 180W-190W, every 30 
minutes. PMCA products were PK digested (20µg/ml 37°C, 1 hour) and immunoblotted. Samples 
loaded at 10mg/ml. Blot probed with mAb 8H4 and exposed for 10 minutes. 
Dilution -1-2 -3  NBH -1 -2-3           -1 -2 -3NBH-1 -2-3        -1-2 -3 NBH -1 -2-3       -1-2 -3 NBH -1 -2-3
PK  +  + +    - + + + +  + +   - +  + +       +  +  +  - +  +  +      +  + +   - +  + +  










Perfused Non-perfused Perfused Non-perfused
A: 8H4 primary antibody B: 7A12 primary antibody
PMCA
Substrate
Lane  1  2  3    4  5   6  7            8  9 10 11 12 13 14 1   2  3   4  5   6  7        8  9 10 11 12 13 14  
Figure 5-11: Both (A) mAb 8H4 and (B) mAb 7A12 primary antibodies produce the same 
amplification result indicating that mAb efficiency was not affecting the PMCA result. A dilution 
series of ME7 seed into substrate was produced and aliquots frozen to provide a comparison sample 
prior to amplification (F). PMCA products (+PMCA) were subjected to PMCA for 48 hours, with a 20 
second sonication pulse at 180-190W every 30 minutes. PMCA products were PK digested (20µg/ml 
37°C, 1 hour) and immunoblotted. Samples loaded at 10mg/ml. Image detected with exposure for 30 
seconds with the Kodak Image Station 440CF. 
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Despite repetition of the conditions that supported amplification in ISS, amplification was 
not consistently reproduced to the level of detection observed from the experiments 
performed at the ISS. To investigate if the inconsistency was specifically due to an inability 
of the Misonix 4000 used in this research project to support amplification, the ability of 
hamster 263K scrapie to amplify in the Misonix 4000 sonicator used for this research project 
was assessed.  
5.2.7. Amplification of hamster 263K scrapie 
PMCA was performed using a hamster 263K scrapie seed, with hamster normal brain 
homogenate providing the substrate. Hamster 263K scrapie has been shown to be easily 
amplifiable by others. Hamster scrapie was utilised to initially develop the PMCA technique 
(Saborio, Permanne et al. 2001) and is often used in PMCA experiments worldwide. A 
dilution series of hamster 263K scrapie was prepared in hamster normal brain substrate (non-
perfused) and subjected to PMCA, under settings that have previously shown amplification 
(Section 2.24.3, Method One). PMCA products were PK digested (Section 2.11) and 
immunoblotted (Section 2.19-2.21) with the results showing that prior to amplification, PrP-
res was detected faintly at 10
-2
 dilution of seed into substrate. After amplification, PrP-res 
was detected clearly at the 10
-2
 dilution and faintly at 10
-3
 dilution, indicating that a low level 
of amplification had occurred (Figure 5-12). The negative control (Figure 5-12, lane 11) was 
absent of PrP-res indicating neither contamination nor spontaneous formation of PrP-res had 
occurred.  
Although amplification of hamster 263K was observed, repetition of these PMCA settings on 
the 79A or ME7 mouse seed and wild-type mouse (C57BL6) substrate combinations, using 
the hamster 263K dilution series as a positive control, did not show amplification from four 
repeat reactions with inconsistency between repeat experiments (data not shown). Given that 
amplification was achieved at the ISS but the same conditions were unable to support 
amplification using the Misonix 4000 sonicator. It was hypothesised that an issue may exist 
with the efficiency of the sonicator at The Roslin Institute. Therefore in order to further 
investigate if the sonicator efficiency was affecting the PMCA results, the mouse ME7 and 
79A seeds and the hamster 263K seed and substrate combinations were tested in an 







Dilution -1 -2  -3 -4  -5   -1  -2 -3 -4  -5    S NBH
F +PMCA
Lane  1   2   3    4   5      6   7   8   9   10   11   12
 
Figure 5-12: Ability of the Misonix 4000 sonicator to support amplification of hamster 263K seed in 
hamster normal brain homogenate substrate. A dilution series of seed into substrate was produced and 
aliquots frozen to provide a comparison sample prior to amplification (F). PMCA products (+PMCA) 
were subjected to PMCA for 48 hours; with a 20 second sonication pulse at ~160W every 30 minutes. 
PMCA products were treated with PK (20µg/ml 37°C, 1 hour), samples loaded at 10mg/ml, detected 
with anti-PrP antibody 3F4 with exposure for 10 minutes. 
164 
 
5.2.8. Amplification of 79A and ME7 in a different PMCA 
sonicator at the NCJDRSU, Edinburgh. 
The PMCA machine present at the NCJDRSU has been shown to support amplification 
(Jones, Peden et al. 2007, Jones, Peden et al. 2008, Jones, Peden et al. 2011) of human PrP-
res from a variety of substrates. Experiments were undertaken at the NCJDRSU using mouse 
79A, mouse ME7 and hamster 263K seeds with the appropriate substrates (non-perfused) 
that were prepared at The Roslin Institute. A dilution series was produced from the hamster 
263K seed, the mouse ME7 and mouse 79A seed in the appropriate substrate, either hamster 
substrate or mouse wild-type (C57BL6) substrate. Samples underwent PMCA, in both the 
Misonix 3000 and the Misonix 4000 at the NCJDRSU, with sonication for 40 seconds at 
potency 8.5, settings that were utilised by the NCJDRSU personnel for amplification 
(personal communication – M. Jones). PMCA reaction products were PK digested and 
immunoblotted according to NCJDRSU laboratory protocols (Section 2.25). No 
amplification was observed in the experiments performed in either sonicator (data not 
shown). These experiments were conducted alongside a NCJDRSU experiment that provided 
a positive control for amplification showing that the PMCA was successful in amplifying 
PrP-res but the mouse and hamster experimental samples for this thesis were not amplified 
(data not shown).  
Further PMCA advice was provided by personnel experienced in the use of the PMCA at the 
NCJDRSU with alterations to the protocol, including rapidly defrosting the substrate, in 
water at room temperature and increasing the EDTA concentration of the substrate from 
4mM to 9mM (personal communication – M. Barria). A dilution series of hamster 263K and 
mouse 79A were prepared in the hamster substrate and in both wild-type (C57BL6) and 
101LL mouse substrate respectively with the adaptations described above included in the 
substrate preparation. An initial dilution of seed to substrate of one in forty was prepared and 
then underwent three doubling dilutions. An aliquot of each dilution was subjected to PMCA 
(Misonix 4000, 80% sonication pulses (~236W) for 40 seconds every 30 minutes for 48 
hours) along with a positive control of sCJD brain homogenate diluted in transgenic mouse 
brain that expresses human PrP with a PRNP codon 129 genotype of valine / valine. PMCA 
reaction products were PK digested and immunoblotted according to NCJDRSU laboratory 
protocols (Section 2.25).  
Prior to amplification, 79A PrP-res was detectable at a one in eighty dilution of seed into 
wild-type (C57BL6) substrate, whilst after amplification PrP-res was detectable at the higher 
dilution of one in three hundred and twenty, indicating that amplification had occurred 
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(Figure 5-13A). Although, PrP-res was detected at all dilutions prior to amplification for 
both the 79A seed diluted in the 101LL mouse substrate and the hamster 263K seed diluted 
in hamster substrate, amplification had occurred as there was an increase in band intensity of 
the sonication (S) samples (Figure 5-13B and Figure 5-13C). The sCJD seed has amplified at 
both dilutions although only faint amplification was observed at the one in twenty dilution 
and was hypothesised to be due to an imperfect immunoblot technique (Figure 5-13D). The 
negative controls show the formation of PrP-res within the 101LL substrate but not the wild-
type (C57BL6) substrate (Figure 5-13E).  
Although the presence of PrP-res in the unseeded negative control indicated the possibility of 
cross-contamination, the results show that both the hamster 263K seed and the mouse 79A 
seed amplified under these conditions. To further investigate these results, the settings were 
reproduced in the Misonix 4000 (Section 2.24.3, Method Three) that was to be used within 
this research project, without the sCJD positive control due to containment safety levels at 
The Roslin Institute. An increase in band intensity in samples after amplification suggested 
that amplification had been achieved (Figure 5-14). However, there is no clear band shift 
observed between the PrP
C
 band size (internal immunoblot control, Figure 5-14A-C, lane 13) 
and the PMCA reaction products that were expected to have a slightly lower molecular size 
due to PK digestion, that produces the protease-resistant core of PrP. In comparison, the 
amplification results shown in Figure 5-7 and Figure 5-13 have a clear band shift between 
the PrP
C
 immunoblot control and the amplified samples.  
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B: 79A seed into mouse 101LL substrate
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C: 263K seed into hamster substrate
Lane 1          2        3         4         5         6        7        8          9
F S F S







D: sCJD seed into transgenic 
HuPrP(VV) mouse substrate





Genotype LL WT LL
E: Negative controls
Lane 1     2     3   
Figure 5-13: Amplification of different seed: substrate combinations of (A) 79A into wild-type 
(C57BL6) mouse substrate, (B) 79A into 101LL mouse substrate, (C) 263K into hamster substrate and 
(D) sCJD seed into transgenic mice HuVV substrate. A dilution series of each combination was 
produced and aliquots frozen to provide a comparison sample prior to amplification (F). Negative 
controls (E) containing substrates only were also subjected to PMCA. PMCA products (S) were 
subjected to PMCA for 48 hours, with a 20 second sonication pulse at ~236W (80%) every 30 
minutes. PMCA products were treated with PK (50µg/ml 37°C, 1 hour), samples loaded at 43mg/ml 
and immunoblotted. Blots were probed with either (A+B+E) 8H4 antibody or (C+D) 3F4 antibody, 
with exposure for 30 minutes.  
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B: 79A seed in 101LL mouse substrate
Lane  1       2    3     4    5      6     7    8     9   10   11   12   13
F S F S F S F S
⅟40 ⅟40 ⅟80⅟80 ⅟160 ⅟160 ⅟320⅟320
F S F S




C: 263K seed in hamster substrate
Dilution
PMCA F
Lane  1     2    3     4     5     6     7    8     9   10   11   12   13
 
Figure 5-14: Possible amplification of PrP-res from each different seed: substrate combinations of (A) 
79A into wild-type (C57BL6) mouse substrate, (B) 79A into 101LL mouse substrate and (C) 263K 
into hamster substrate. A dilution series of each combination was produced and aliquots frozen to 
provide a comparison sample prior to amplification (F). PMCA products (S) were subjected to PMCA 
for 48 hours, with a 20 second sonication pulse at ~230-240W (80%) every 30 minutes. PMCA 
products were treated with PK (50µg/ml 37°C, 1 hour), samples loaded at 43mg/ml and 
immunoblotted. Blot probed with either mAb 8H4 (A+B) or mAb 3F4 (C) with exposure for 1 minute. 
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5.2.9. Accumulation of protease-resistant PrPC? 
To investigate if the results were true amplification of the PrP-res seed or accumulation of 
protease-resistant PrP
C
 that has been reported to occur in mouse PMCA reactions 
(Murayama, Yoshioka et al. 2007), an identical PMCA was performed with a 79A seed 
diluted in both wild-type (C57BL6) and 101LL substrates with negative controls of substrate 
only included under PMCA settings as described in method three (Section 2.24.3, Method 
Three). Hamster 263K was not included as a seed in this run, in order to simplify the analysis 
of the results.  
The resulting immunoblots (Figure 5-15) showed the presence of PK-resistant bands in the 
samples that contained unseeded mouse substrate only (Figure 5-15, lane 9, boxed). The 
banding pattern was similar to those observed in seeded samples. This suggested that the 
hypothesis that the bands observed were due to PrP
C
 that had accumulated a level of protease 
resistance was plausible, although this experiment could not rule out the possibility of cross-
contamination or a failure in the PK digestion. To rule out cross-contamination, a PMCA 
reaction was performed containing substrate only samples (no seed) under the same PMCA 
conditions (Section 2.24.3, Method Three). Multiple aliquots of both wild-type (C57BL6) 
and 101LL normal brain homogenate substrate were subjected to the PMCA reaction for 48 
hours, subjected to PK digestion (Section 2.11) at varying concentrations [50-200µg/ml PK] 
and then immunoblotted (Section 2.19-2.21).  
The results (Figure 5-16) show the detection of protease-resistant bands in substrate only 
samples at a PK concentration of 50µg/ml. These bands were not detectable in the substrate 
prior to amplification (F samples), confirming that the PK enzyme was efficiently digesting 
PrP
C
. The PMCA reaction products were probed with different primary antibodies to 
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Figure 5-15: Presence of protease-resistant PrP in both seeded and un-seeded samples. 79A seed 
diluted in either (A) wild-type (C57BL6) or (B) 101LL mouse substrate with a dilution series of each 
combination were produced and aliquots frozen to provide a comparison sample prior to amplification 
(F). PMCA products (S) were subjected to PMCA for 48 hours, with a 20 seconds sonication pulse at 
~230-240W (80%) potency every 30 minutes. PMCA products were treated with PK (50µg/ml 37°C, 
1 hour), samples loaded at 43mg/ml and immunoblotted. Blot probed with either mAb 8H4 with 
exposure for 10 minutes. 
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Figure 5-16: Presence of PK-resistant PrP in un-seeded substrate only samples that underwent PMCA. 
Aliquots of each substrate were frozen to provide a comparison sample prior to amplification (F). 
PMCA products (S) were subjected to PMCA for 48 hours, with a 20 second sonication pulse at ~230-
240W (80%) every 30 minutes. PMCA products were treated with PK (50µg/ml 37°C, 1 hour), loaded 




 The protease-resistant bands in the substrate only samples were not observed when the 
immunoblots were probed with different primary antibodies; 8H4, 6H4 and BC6 (Figure 
5-17), (Appendix 1). Although no bands were observed from the immunoblots probed with 
secondary antibody only (Figure 5-17, right hand side), other research experiments 
performed within this thesis, identified that the same doublet band was due to non-specific 
secondary antibody binding (Section 3.2.4, Figure 3-12). However, the PrP-res bands 
observed in Figure 5-15 had a different banding pattern to the doublet produced from non-
specific antibody binding and was hypothesised to be due to an alteration in the immunoblot 
procedure rather than non-specific antibody binding. In order to detect amplification in the 
seeded samples, the immunoblot procedure had been adapted with an increase in the 
concentration of sample loaded on the SDS-PAGE to 43mg/ml. This alteration was based on 
the protocol that successfully detected amplification of the seeds in a PMCA reaction 
performed at the NCJDRSU (Figure 5-13 and Section 2.25). The standard protocol used 
initially (Sections 5.2.1-5.2.7) loaded a lower concentration of 10mg/ml. This 4-fold increase 
in concentration loaded on the immunoblot was hypothesised to be the cause of the unusual 
PrP-res bands present in Figure 5-15. A PMCA reaction was performed as per settings 
described in method three (Section 2.24.3, Method Three) with a 79A seed diluted in a 
101LL substrate, to provide samples to test this hypothesis. PMCA products were PK 
digested (Section 2.11) and immunoblotted as per the initial standard protocol (Section 2.19-
2.21) and the alternative protocol (Section 2.25).  
Increasing the concentration of protein loaded to 43mg/ml in the adapted protocol (Figure 
5-18B) detected protease-resistant bands that were not detected when the standard protocol 
was performed with only 10mg/ml loaded (Figure 5-18A). The detection of these apparently 
protease-resistant bands, that were hypothesised to be due to PrP
C
 that developed a low level 
of protease resistance (Murayama, Yoshioka et al. 2007) detectable due to the increased 
concentration, complicated the interpretation of the amplification results. Based on these 
results, analysis continued with the standard protocol to detect amplification and enhance the 
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Figure 5-17: Absence of protease-resistant bands in un-seeded (A) 101LL and (B) wild-type (C57BL6) 
substrates when probed with alternative primary antibodies; 8H4, 6H4 and BC6. Aliquots of 
substrates were frozen to provide a comparison sample prior to amplification (F) and underwent 
PMCA (S) for 48 hours, with a 20 second sonication pulse at ~230-240W (80%) potency every 30 
minutes. PMCA products were treated with PK (at varying concentrations indicated, 37°C, 1 hour), 
samples loaded at 10mg/ml and immunoblotted. Blot probed with either mAb indicated with exposure 
for 3 minutes. mAb BC6 was kindly provided by Sandra McCutcheon.  
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Figure 5-18: Variation in sample concentration (A) 10mg/ml and (B) 43mg/ml of a 10% (w/v) brain 
homogenate loaded. Dilution series of 79A seed into 101LL transgenic mouse substrate were 
produced and aliquots frozen to provide a comparison sample prior to amplification (F). PMCA 
products (S) were subjected to PMCA for 48 hours, with a 20 second sonication pulse at ~230-240W 
(80%) every 30 minutes. PMCA products were treated with PK (50µg/ml 37°C, 1 hour), detected with 
8H4 antibody and exposed for 30 minutes. 
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5.2.10. Mouse PrP-res from 79A and ME7 amplified after 
multiple rounds of serial PMCA at University of 
Nottingham.  
To investigate if mouse PrP-res was able to amplify under serial PMCA conditions, aliquots 
of the prepared seeds, 79A and ME7, and substrates, 101LL and wild-type (C57BL6), were 
sent to collaborators at the University of Nottingham. Previously this research group has 
achieved the amplification of 301C mouse PrP-res seed using a wild-type VM Prnp
b
 mouse 
substrate (personal communication – K. Gough) through serial rounds of PMCA and have 
shown amplification of sheep scrapie from milk from clinical and sub-clinical sheep and 
environmental sources (Gough, Baker et al. 2009, Maddison, Baker et al. 2009, Maddison, 
Baker et al. 2010, Maddison, Rees et al. 2010, Taema, Maddison et al. 2011). The seed brain 
homogenates was diluted 1:100 into the substrate brain homogenates. Samples were placed 
in 0.2ml PCR tubes in triplicate and were placed inside the ultra-sonicator with a stationary 
water bath (Misonix 4000) at 37°C. Samples were subjected to 40 second sonication pulses 
at 200W every 30 minutes for 24 hours (1 PMCA round) after which the PMCA products 
were diluted 1 in 3 into fresh substrate and subjected to additional rounds of PMCA. A total 
of 9 PMCA rounds were performed and the analysis of the PMCA product from different 
rounds was performed through PK digestion and immunoblot to detect any PrP-res product.  
No clear amplification of either 79A or ME7 seed was obtained after 4 rounds of serial 
PMCA. After 5 serial rounds of PMCA, 79A had amplified in both substrates (Figure 
5-19A+C), whilst ME7 showed amplification after 7 rounds of serial PMCA (Figure 
5-19B+D). The substrate only negative control included in this experiment was prepared 
from an uninfected VM mouse brain that underwent the serial PMCA in the presence of 
Teflon beads, which have been shown to enhance amplification, as part of a parallel 
experiment. After the sixth round of serial PMCA, 19 of the 20 negative controls were 
positive for PrP-res (personal communication – K. Gough). However, as the negative 
controls were performed under different experimental conditions, they were not directly 
comparable. Aliquots of the seeds and the wild-type substrate that underwent amplification 
at the University of Nottingham were retained and underwent the serial PMCA protocol in 
the Misonix 4000 sonicator at the Roslin Institute utilised for this research project. No 
amplification was observed in two repeat experiments of serial PMCA with 6 rounds of 24 
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B: ME7 seed in wild-type (C57BL6) substrate































































































D: ME7 seed in 101LL substrate
 
Figure 5-19: Immunoblot results of serial PMCA on four seed: substrate combinations (A) 79A 
seed: wild-type (C57BL6) substrate, (B) ME7 seed: wild-type substrate (C57BL6), (C) 79A seed: 
101LL substrate and (D) ME7 seed: 101LL substrate performed by collaborators at the University of 
Nottingham. Each seed was diluted 1:100 into substrate and divided in triplicate samples to undergo 
PMCA. Serial PMCA was performed as described above (Section 5.2.10) and PMCA products from 
rounds/days 4, 5, 6, 7 and 9 were analysed. Internal immunoblot control (+) is provided by an ovine 
scrapie sample and (MM) provided molecular weight markers. Blots were probed with Sha31 primary 




5.2.11. PrP-res from different mouse strains did not 
amplify within the Misonix 4000 system.  
PMCA has been shown to support the amplification of mouse PrP-res from RML, 301C and 
Chandler strains with 66% of published research (up to December 2011) on mouse PMCA 
using these three strains, with the majority (41%) using RML. The relative lack of published 
data on the amplification ability of ME7 (2 papers, (Piening, Nonno et al. 2006, Castilla 
2008)) and 79A (1 paper, (Castilla 2008)) mouse strains, despite being two widely 
characterised laboratory strains, suggests there may be an inherent inability of these strains 
to amplify under standard PMCA conditions. Two other mouse strains, 139A and 22A were 




 substrate was used to keep the reaction homologous as both seeds were 
provided from Prnp
b
 tissues. PMCA was performed under conditions described in method 
three (Section 2.24.3, Method Three) to determine if PrP-res from alternative strains could 
be amplified. PMCA products were PK digested (Section 2.11) and immunoblotted (Section 
2.19-2.21). The results (Figure 5-20) showed that no amplification was achieved from either 
the 139A or 22A seed. This result was confirmed in two identical repeat experiments (data 
not shown). It was therefore hypothesised that mouse PrP-res required specific conditions to 
amplify that were not obtained with the Misonix 4000 sonicator.  
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Figure 5-20: Alternative strains (A) 139A and (B) 22A did not amplify in a wild-type (VM) mouse 
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 respectively) and three replicates of the negative controls (C – N1-N3) underwent PMCA with 
sonication at ~230-250W (80%) for 20 seconds every 30 minutes for a total of 48 hours. All samples 
were PK digested except the uninfected brain homogenate loaded as an internal immunoblot control in 
(A+B) lane 14 and (C) lane 4. Samples loaded at 10mg/ml. Blots probed with mAb 8H4 and exposed 




5.2.12. GSS and vCJD PrP-res were unable to amplify in a 
101LL murine substrate. 
Inoculation of GSS into 101LL mice produces a clinical TSE disease with extremely low 
levels of PrP-res detectable in the brain tissue. In contrast, inoculation of vCJD into 101LL 
mice resulted in a clinical TSE disease with an altered PrP-res deposition pattern compared 
to wild-type mice (Barron, Thomson et al. 2001). One of the aims of the PMCA studies in 
this thesis was to investigate whether the in vivo occurrence produced from these 
transmissions was replicated within the in vitro PMCA system, when these human seeds 
underwent PMCA with a 101LL murine substrate. This work was carried out at the 
appropriate safety levels for working with human tissue at the NCJDRSU.  
Fresh brain tissue samples were taken from the same cases that were used to produce the in 
vivo mouse transmission data (Section 3.2 and (Barron, Thomson et al. 2001)) and the 
presence of PrP-res was confirmed by immunoblotting (Section 2.25) and (Figure 5-21). The 
PMCA was set up with a positive control known to successfully amplify; vCJD seed in a 
transgenic mouse brain substrate that expresses human PrP with 129 MM genotype, under 
the conditions used. PMCA products were PK digested and immunoblotted, using the 
NCJDRSU method (Section 2.25).  
Despite the quality of the blots (Figure 5-22), neither seed GSS nor vCJD has amplified in 
the 101LL substrate. However, the positive control for the reaction (Figure 5-22C) showed 
amplification of the vCJD seed, as no PrP-res was detectable at any dilution prior to 
amplification. After PMCA, vCJD PrP-res was detected at a 1/10, 1/100 dilution and faintly 
at 1/1000 dilution of seed into substrate. This indicated that the PMCA was capable of 
supporting amplification but amplification of PrP-res from the GSS or vCJD seed in the 
101LL substrate was not observed. However, whether this lack of amplification was due to 
an inability of the 101LL substrate to support amplification or a replication of the in vivo 
result for 101LL/GSS transmission was observed cannot be determined. In vivo vCJD 
produces a clinical TSE disease in 101LL mice with PrP-res detectable therefore the 
hypothesis that there was an inability of the 101LL substrate to support amplification could 
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Figure 5-21: PrP-res detected in both GSS and vCJD brain homogenates used to seed PMCA. 






Dilution     1/10          1/100          1/1000 1/10,000 PrPC
PMCA  F   S   F   S   F   S   F   S    F
A: GSS seed in 101LL  substrate 




Dilution     1/10          1/100          1/1000 1/10,000 PrPC
PMCA  F   S   F   S   F   S   F   S    F
B: vCJD seed in 101LL  substrate 





Dilution     1/10          1/100          1/1000 1/10,000 PrPC
PMCA  F   S   F   S   F   S   F   S    F
C: vCJD seed in TgHu(MM)  substrate 
Lane 1    2    3    4    5    6    7    8     9    
 
Figure 5-22: PrP-res was not amplified from either (A) GSS or (B) vCJD seeds in 101LL substrate. 
Amplification of PrP-res from (C) vCJD seed TgHuMM substrate. A dilution series of each 
combination was produced and an aliquot of each dilution frozen to provide a sample prior to 
amplification (F). PMCA products (S) were subjected to PMCA for 48 hours, with 20 second 
sonication pulses, at 80% potency ~200W, every 30 minutes. PMCA products were treated with PK 
(50µg/ml 37°C, 1 hour), samples loaded at 25mg/ml, detected with either (A+B) 8H4 antibody or (C) 




5.3.1. Experimental Discussion 
Although the PMCA technique is widely used in prion research, optimisation of the 
amplification conditions is required for each species and strain utilised. The production of 
appropriate conditions to produce a reliable positive control prior to the amplification of 
experimental 101LL/GSS and 101LL/263K tissues proved to be a hindrance for this project. 
There are many components of the amplification system that require optimisation each of 
which will be discussed in further detail.  
Choice of seed as positive control 
The two seeds tested as the positive control for the amplification of PrP-res from mouse 
tissues were 79A and ME7, two common laboratory strains. These well-characterised strains 
were chosen as both contain large amounts of PrP-res, as shown by immunohistochemistry 
and immunoblot, and tissue from wild-type mice infected with either strain was readily 
available. Both seeds are known to be transmissible to both wild-type and 101LL mice in 
vivo to produce a clinical and pathological TSE disease albeit with an extended incubation 
period in the transgenic mice (Manson, Jamieson et al. 1999, Barron, Thomson et al. 2003). 
It was hypothesised that either seed would be suitable to use as a positive control for PMCA 
and would be amplifiable in both a wild-type and a 101LL substrate.  
Different species and strains have different optimal amplification conditions due to their 
different conformational stabilities and aggregation states. The power of the sonication pulse 
has to efficiently break-up the PrP aggregates, whilst still retaining their converting activity. 
Too strong a sonication pulse may damage the PrP aggregate, preventing its converting 
activity, and efficient amplification will not be achieved. In contrast, a weak sonication pulse 
would be inefficient in fragmenting the PrP aggregates, and the number of converting units 
would not increase sufficiently to allow efficient amplification of the seed (Saá, Castilla et 
al. 2005). The power of the sonication pulse has to maintain a fine balance between the 
number and size of converting units produced. The ME7 seed showed greater amplification 
levels at lower sonication power (40-50%) whilst 79A had greater amplification efficiency at 
a higher range of sonication powers (50-70%), (Section 5.2.1). Recent work has suggested 
that the conformational stability of the seed determines the fragmentation rate. PMCA 
performed with the addition of Teflon beads on hamster strains showed that strains with 
lower conformational stabilities (based on PK resistance to proteolysis in the presence of 
increasing concentrations of GdnHCl), Drowsy and 139A, had poorer amplification rates 
179 
 
compared to strains with higher conformational stability, Hyper and SSLOW that had greater 
amplification rates (Gonzalez-Montalban, Makarava et al. 2011).  Based on the data, it was 
hypothesised that ME7 has a lower conformational stability than 79A, explaining the 
different optimum sonication powers required for amplification.  
Other published work has utilised PMCA to differentiate between two TSE strains, ovine 
BSE and CH1641 ovine scrapie. CH1641 scrapie was unable to amplify, even after 10 serial 
rounds of PMCA whilst ovine BSE PrP-res was readily amplifiable after a single round of 
PMCA (Taema, Maddison et al. 2011). Whilst the preliminary results (Section 5.2.1) and 
results from other laboratories (Section 5.2.5, 5.2.8 and 5.2.10) indicate that both 79A and 
ME7 seed can support amplification, it occurred only sporadically and it appears that settings 
have to be precise to allow for amplification, such as those provided in section 5.2.5. The 
results from analysis of other mouse strains, 139A and 22A indicated that the Misonix 4000 
sonicator at The Roslin Institute was not able to reproducibly support amplification of mouse 
PrP-res and was unreliable in terms of power delivered between positions, cycles and repeat 
experiments. Further understanding of the ability of different strains to amplify and the 
conditions required to achieve amplification may increase our understanding of how TSE 
strains are produced in vivo.  
Condition of substrate 
The procedure utilised to prepare the substrate from the brain homogenates is critical for 
obtaining high levels of amplification (Castilla, Saa et al. 2005). Different handling 
procedures are required dependent on species, sonicator and PMCA technique. An increase 
in the number of freeze-thaw cycles that the substrate undergoes correlates with a decrease in 
the substrate‟s ability to support amplification (Castilla, Saa et al. 2004). Repeated freeze-
thawing of the substrate is thought to damage either the PrP
C
 or a co-factor component 
required for amplification. For initial experiments (Section 5.2.1), the substrate tissue went 
through one freeze-thaw cycle prior to homogenisation with the homogenate prepared fresh 
for each PMCA experiment, perhaps increasing the ability of the substrate to support 
amplification explaining the level of amplification observed when investigating the power of 
sonication, compared to the later experiments, in which upon advice, homogenates were 
aliquoted and frozen for use. Another variation between techniques is the perfusion of tissue 
that is to be used as the substrate. Perfusion of the tissue is used to minimise the inhibitory 
nature of blood on the amplification process, the same hypothesis behind increasing the 
concentration of the chelating agent EDTA in the substrate. Although no difference in the 
substrates ability to support amplification was observed between a perfused and a non-
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perfused substrate, this hypothesis could explain why amplification was observed when the 
EDTA concentration of the substrate was increased to 9mM (Section 5.2.8).  
5.3.2. Technical Discussion 
Although the PMCA is a widely utilised technique, our understanding of the conversion 
process remains hypothetical and is affected by many technical considerations, not all of 
which can be controlled. As discussed above, the power of the sonication pulse can be 
optimised for each seed and substrate combination. The incubation period is equally as 
important as it provides the optimum conditions for growth of the aggregate. As protein 
conformation is known to be sensitive to temperature denaturation (Colby and Prusiner 
2011), any variations in temperature could either support or inhibit growth of the aggregate. 
The optimum temperature to which the incubator is set is 37°C, with the water in the 
sonicator horn therefore expected to be maintained at 37°C. The sonication heat energy 
released with each pulse increases the temperature of the water (Figure 5-9) which could 
inhibit the growth of the aggregates. A re-circulating water bath can be introduced to the 
PMCA system to maintain a more constant temperature of 37°C. However, the huge amount 
of data showing amplification without re-circulating the water, questions whether the 37°C 
temperature is an exact requirement for the conversion process to occur for all species.  
The level of amplification additionally varies with the sonicator horn‟s ability to distribute 
the sonication energy evenly which decreases as the sonicator horn ages and corrodes. Each 
individual sonicator develops different corrosion patterns that affect amplification levels of 
samples in varying positions within the horn (Gonzalez-Montalban, Makarava et al. 2011). 
This variation is impossible to control and can only be monitored with the use of a positive 
control for amplification levels. It could be possible that the sonicator used for this research 
project was inefficient in dispersal of sonication energy, meaning a consistent positive 
control could not be produced. The ideal experiment to examine this possibility would be to 
test the amplification of a seed and substrate, prepared elsewhere, that are known to have 
high levels of amplification, e.g. human vCJD seed in human transgenic mouse substrate. 
Unfortunately, due to the containment levels required for human vCJD samples this could 
not be performed at The Roslin Institute. 
Although not all the technical considerations can be controlled, they can be optimised for 
amplification of different seed and substrate combinations. However, there was wide 
variation between the optimum conditions identified by different research groups. Each 
research group consulted throughout this project has developed different conditions that were 
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utilised to support amplification (Table 5-2). Each set of conditions was repeatedly tested in 
the Misonix 4000 utilised for this research project but no reproducible amplification was 
achieved. Attempts to identify which conditions were necessary to support amplification and 
which were personal preferences have complicated the optimisation of mouse PrP-res 
amplification within this research project.  
Amplification of mouse PrP-res was observed from some PMCA experiments performed in 
this thesis (Sections 5.2.1, 5.2.2, 5.2.4, 5.2.5, 5.2.8 and 5.2.10) indicating that conditions can 
be obtained to support amplification of ME7 and 79A seed. However, a consistent 
reproducible PMCA experimental protocol was not achieved, with only single experiments 
showing amplification. Major differences in experimental results were observed with 
detection of both seeds at a 10
-5
 dilution after a single 48 hour PMCA reaction using the 
Misonix 3000 at the ISS (Section 5.2.5). The increased level of amplification achieved at the 
ISS, was hypothesised to be due to either the stricter temperature maintenance due to the 
presence of the re-circulating water bath or due to the methods used to prepare the substrate. 
In comparison, five and seven serial PMCA reactions, each 24 hours long, were required to 
detect a 10
-2
 dilution of the 79A and ME7 seed respectively with the Misonix 4000 
performed at the University of Nottingham (Section 5.2.10).  
Variation between experimental techniques and the amplification levels achieved both 
between and within repeat PMCA experiments made the PMCA results complicated to 
interpret. The ability to achieve amplification with each of the different techniques raises 
some interesting questions; what is the conversion process that allows for amplification to 
occur? What are the important conditions that allow amplification and which conditions are 
perhaps not necessary? Further understanding and investigation into each of the different 
variations may provide an insight into how the amplification reaction occurs and increase our 
understanding of the conversion process. 
The conditions required to consistently amplify mouse ME7 and 79A PrP-res as a positive 
control for a PMCA reaction using the Misonix 4000 at The Roslin Institute were not 
identified despite trialling different powers of sonication, substrate preparation methods, and 
replicating the experimental conditions that have produced amplification in other 
laboratories. Different strains, 139A and 22A were also unable to amplify under the 
conditions tested, indicating that rather than it being a strain specific inability to reproducibly 
amplify, it was hypothesised that the mouse species requires very specific conditions to 
support amplification and that the Misonix 4000 was inefficient in consistently providing 
these conditions.  
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The overall aim of this project was to utilise the PMCA to investigate if PrP-res and TSE 
infectivity could be amplified from 101LL/P102L GSS and 101LL/263K tissues that have 
extremely low levels or no detectable PrP-res. If standard mouse scrapie strains were 
difficult to consistently amplify, amplifying PrP-res from these unusual tissues could either 
take many serial rounds of amplification, increasing the possibility of either cross-
contamination or spontaneous formation, or not be achievable. If the amplification of PrP-res 
from these experimental tissues was not achieved, it would be impossible to ascertain 
whether this was due to either the absence of initial seed or a failure to obtain the optimum 
























20 seconds at 
180-190W 
40 seconds at 80% 
~230W 
  40 seconds at 80% 
~236W 
20 seconds at 
200W 
Incubation 30 minutes 30 minutes 30 minutes 30 minutes 
Temperature 37°C 37°C 37°C 37°C 





frozen for use. 
Non-perfused, 
snap-frozen brain. 








through a syringe. 
PMCA 1x 48 hour round 1x 48 hour round 1x 48 hour round 











Volume  50µl 2x 100µl 100µl 3x 100µl 
Seed Species Bank vole Human Human Mouse 









mouse seed and 
substrate 
YES  NO YES YES 
Reproducible in 
Misonix 4000 
NO NO NO NO 
Reference(s)  
(Piening, Nonno 
et al. 2006, 
Cosseddu, Nonno 
et al. 2011) 
(Jones, Peden et 
al. 2007, Jones, 






K. Gough and B. 
Maddison) 
Table 5-2: Different conditions utilised by different laboratories consulted within this research project 
to perform PMCA.  
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6. Investigation into the identity of the Seprion ligand target 
and its relationship with TSE infectivity in the 101LL/GSS 
and 101LL/263K disease models.  
6.1. Introduction 
The majority of current TSE diagnostic tests rely on the presence of PrP
Sc
 in post-mortem 
tissues as indicative of TSE disease (Section 1.4.1). Many of these tests also rely on the 
proteinase K resistance of PrP-res to allow the differentiation between the abnormal and 
normal form of PrP. In 2004, research identified several polyionic compounds that were able 
to bind to abnormal, aggregated forms of proteins, present in protein misfolding diseases, in 
the presence of high amounts of the normal form of the protein (Lane, Stanley et al. 2003). 
These compounds were termed Seprion ligands (Microsens Biotechnologies, London) and 
were shown to detect abnormal, aggregated proteins from a number of different protein 
aggregation diseases including TSE diseases, Alzheimer‟s disease and Huntington‟s disease. 
A simple ELISA assay for the detection of TSE disease without the pre-requirement of PK 
digestion utilises the polyionic Seprion ligand as the capture agent in combination with a 
PrP-specific detector antibody. This ELISA kit was commercially available through IDEXX 
laboratories as the IDEXX HerdChek* and is an approved post-mortem test for BSE, scrapie 
and CWD by the World Organisation for Animal Health and is utilised worldwide (EFSA 
2005), (Section 1.4.1).  
The Seprion ligands have been utilised in a modification of this IDEXX HerdChek* assay to 
identify the presence of PrP
Sc
 in the blood of sheep clinically ill with either scrapie or BSE 
and sheep that were in the sub-clinical stage of scrapie disease (Terry, Howells et al. 2009), 
albeit at a lower sensitivity level compared to the PMCA assay (Castilla, Saa et al. 2005, 
Thorne and Terry 2008). Additionally, the Seprion ligands are available commercially in 
association with magnetic beads (PAD-beads, Microsens Biotechnologies) to allow the 
precipitation of PrP
Sc
 using magnetic separation. The captured aggregated protein can be 
detected through an immunoblot of the eluate probed with an anti-PrP mAb. The only 
reported use of the PAD-beads kit to date was the analysis of colostrum milk samples from 
28 BSE infected cattle that were positive for TSE disease with the Bio-Rad TeSeE ELISA 
(Section 1.4.1). These ELISA positive milk samples were analysed with the Seprion PAD-
beads/immunoblot system, and only 12 of the 28 samples produced bands on the 
immunoblot. However, these bands were still present when anti-PrP mAb 6H4 was omitted 
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from the immunoblot protocol indicating the bands were due to cross-reactivity with 
immunoglobulin‟s present in the colostrum samples (Everest, Thorne et al. 2006). 
The IDEXX HerdChek* assay identified the murine 101LL/GSS and 101LL/263K brain and 
spleen tissues as positive for TSE (Section 3.2.5 and 4.2.1). From these results, the question 
arises as to what the component(s) are that the Seprion ligand binds to identify both the 
101LL/GSS and 101LL/263K as positive for TSE disease, when it is known that there are 
extremely low levels of PrP-res
 
detectable by conventional methods in the brain tissue and 
lower concentrations of PrP-res present in the spleen tissue compared to standard scrapie 
models. The research described in this chapter aimed to utilise the PAD-beads kit that 
supplies the Seprion ligand in association with magnetic beads to identify the target protein 
aggregate(s) of the Seprion ligand within the 101LL/GSS and 101LL/263K brain tissue and 
determine if TSE infectivity co-purifies with the Seprion ligand target protein aggregate. 
Throughout this chapter, products from the PAD-beads procedure (Section 2.26) were PK 
digested when appropriate (Section 2.11) and immunoblotted (Section 2.19-2.21) as 
previously described.  
Nomenclature  
Within this chapter; dh refers to the depleted homogenate; W1, W2 and W2.2 refer to the 
three washes performed with wash buffer 1 or 2, W refers to a combination of all three wash 
buffers, E refers to the eluate and B refers to the beads re-suspended in tris-glycine sample 
buffer (Invitrogen) after primary elution in appropriate buffer. Figure 2-4 provides a 




6.2.1. Optimisation of PAD-beads technique 
Following the manufacturer‟s instructions for the PAD-beads kit (Section 2.26), PrP
Sc 
was 
isolated from a wild-type/79A homogenate as a positive control. A 101LL normal brain 
homogenate was also prepared following the protocol to provide a negative control. As 
expected, PrP
Sc
 was isolated from the 79A homogenate however unexpectedly PrP was also 
isolated from the 101LL normal brain homogenate (Figure 6-1).  
The high intensity of the PrP
Sc
 band present in 79A elute combined with the presence of 
residual PrP-res in the depleted homogenate lends to the hypothesis that the 25% (w/v) 
homogenate, recommended by the manufacturer, saturates the Seprion ligand, with any 
unbound PrP-res remaining in the depleted homogenate. To test this hypothesis, 25% (w/v) 
homogenate and 12.5% (w/v) homogenate aliquots of 79A and 101LL NBH both underwent 
the PAD-beads procedure. The immunoblot results (Figure 6-2) indicated that the use of a 
12.5% (w/v) homogenate allowed the removal of a higher percentage of the aggregated PrP 
from the homogenate, with less PrP-res remaining in the dh (Figure 6-2 – lane 7). Whilst 
also reducing background PrP binding as no PrP was observed in the eluate from the 101LL 










 eluted from (A) 79A brain homogenate and (B) 101LL normal brain 
homogenate respectively (lane 5). PrP-res was also present in dh from 79A homogenate (A - lane 2) 
and PrP
C
 was detected in the dh, prior to PK digestion (B – lane 1). No PrP
C
 or PrP-res was detected 
in the wash buffers (W) (lane 3+4). PAD-bead depletions performed as described (Section 2.26) with 
25% (w/v) homogenates and elution in 50µl volume tris-glycine sample buffer (Invitrogen). Samples 
loaded at 10mg/ml with 15µl eluate loaded. Blot probed with mAb 8H4 and exposed for 1 minute.  
 
 
Figure 6-2: Lower concentration of starting homogenate (12.5% (w/v)) reduces saturation of (A) 79A 
eluate and removes PrP
C
 from (B) 101LL normal brain elute. PAD-bead depletions performed as 
described (Section 2.26) with elution in 50µl volume tris-glycine sample buffer (Invitrogen). Samples 
loaded at 10mg/ml with 15µl eluate. Blot probed with mAb 8H4 and exposed for 1 minute. 
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Further preliminary experiments with the 10% (w/v) homogenate identified that a 
background binding of PrP from the uninfected brain homogenates was still present in the 
eluates (data not shown). The background level of PrP
 
detected in the eluate from an 
uninfected 101LL NBH was hypothesised to be due to the mutation producing mild 
aggregation of the normal protein, therefore allowing recognition by the Seprion ligand that 
detects aggregated protein. In order to determine whether the binding to the Seprion ligand 
was specifically due to aggregation properties of 101LL PrP, the background level of PrP 
binding from a 101LL NBH was compared to the level observed from a wild-type (C57BL6) 
NBH. PrP was present in the eluate from both the 101LL and wild-type (C57BL6) normal 
brain homogenate (Figure 6-3) indicating that the Seprion binding of 101LL PrP was not as a 
result of the mutation, but due to a level of background binding of non-aggregated protein. 
The absence of any protein in the null eluate (Figure 6-3, lane 12) indicated that the protein 
in both the 101LL and wild-type (C57BL6) eluate was specific for PrP. Whether the normal 
PrP
C
 protein binds to either the Seprion ligand or binds directly to the magnetic bead was not 
determined in this work, but would be interesting to determine, as PrP
C
 has previously been 
shown to bind to metal ions (Rana, Gnaneswari et al. 2009). Indeed as PrP
Sc
 has also been 
shown to have a high affinity for metal surfaces (Zobeley, Flechsig et al. 1999) it would be 
interesting to determine if there is a level of background binding of PrP
Sc
 to the magnetic 
beads.  
To further confirm that the Seprion ligand was indeed binding PrP
C
, homogenates were 
digested with PK (Section 2.11) prior to undergoing PAD-beads depletion (Section 2.26). 




 from the brain homogenates. Thus the absence 
of  PrP
C
  in the eluate, produced from both wild-type and 101LL NBH that were PK-digested 
prior to the PAD-beads depletion (Figure 6-4B), confirmed that the presence of PrP
C
 in the 
eluate was due to a low level of background binding of PrP
C
 from normal brain 
homogenates. In addition, the result indicated that the Seprion ligand can bind PrP-res from a 







 was present in the eluate from both 101LL NBH (lane 6) and wild-type NBH (lane 
9). PrP
Sc
 present in wt/79A eluate (lane 3) was included as a positive control. PrP null homogenate 
were included as a negative control and shows no PrP in the eluate (lane 12). PAD-bead depletions 
performed as described (Section 2.26) with elution in 50µl tris-glycine sample buffer (Invitrogen). 
Samples loaded at 10mg/ml with 15µl eluates loaded. Blot probed with mAb 8H4 and exposed for 1 
minute. 
 
PK 2 - +       - - -
PK 1 - - - +   +  
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Lane  1   2  3      4  5        6   7   8  9  10      11
Sample dh   E     dh E        dh    E   dh E
PK 2  - +  - - - - +   - - - -
PK 1  - - - +   +       - - - + +      -
(B) Uninfected homogenates
 
Figure 6-4: Proteinase K digestion of homogenates (PK1) prior to PAD-beads separation elutes PrP-
res from (A) the 79A homogenate, whilst PrP
C
 was no longer eluted from (B) the 101LL and wild-
type normal brain homogenates. PAD-bead depletions performed as described (Section 2.26) with 
elution in 50µl volume tris-glycine sample buffer (Invitrogen). Samples loaded at 10mg/ml with 15µl 
eluates loaded . Blot probed with mAb 8H4 and exposed for 30 seconds. 
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A variety of adaptations to the PAD-beads protocol were tested to determine which, if any, 
would minimise the background PrP
C
 binding. Preliminary results, described above were 
performed as per manufacturer‟s instructions with the adaptations summarised in Table 6-1. 
Briefly, the manufacturers protocol suggests elution in a 50µl volume (adaptation 1) which 
produces an eluate four times more concentrated that the starting homogenate, therefore an 
increased elution volume to 200µl (adaptation 2) was tested for the ability to lower the signal 
of PrP
C
 in the eluate by reducing the concentration present due to the increased elution 
volume. Additionally, the re-use of the eluate as the starting homogenate for a second PAD-
beads depletion (adaptation 3) and the addition of an extra wash step with a 20% sarkosyl 




The results (Figure 6-5) show that the optimal adaptation was to increase the elution to 200µl 
volume to reduce the PrP
C
 concentration. However, with extended exposures of the 
immunoblot, e.g. greater than 5 minutes, a background level of PrP
C
 was still observed in the 





bands were detected in the experimental eluate by immunoblot without the 
presence of PrP
C
 in the negative control normal brain homogenate.  
 
Number Adaptation Hypothesis 
1 As per manufacturer‟s protocol with 
elution in 50µl volume. 
N/A 
2 Increase elution volume to 200µl Dilutes the eluate four times to decrease 
PrP
C
 background signal. 
3 Eluate taken through second PAD-
beads depletion 
A second depletion will increase the 
specificity for the aggregated form. 
4 Addition of an extra wash step with 
20% Sarkosyl solution. 
Sarkosyl acts as a competition agent to 
minimise the PrP
C
 background binding. 
Table 6-1:  Summary of adaptations performed to reduce the presence of PrP
C




Figure 6-5: Presence of PrP
C
 in the eluate was minimised with an increased elution volume 
(adaptation 2 – lane 6) compared to the original smaller elute volume (adaptation 1 – lane 3). The 




 were reduced when elutes were taken through an additional PAD-
beads depletion (adaptation 3 – lane 9), whilst background PrP
C
 remained in the elution despite an 
additional wash step (adaptation 4 – lane 13). PAD-bead depletions performed as described (Section 
2.26), samples loaded at 10mg/ml with 15µl eluate loaded, and blot probed with mAb 8H4 and 
exposed for 30 seconds. 
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In immunoblots produced (Figure 6-3, Figure 6-5), a 60kDa band was present in dh, wash 
buffers and eluates that was unlikely to be related to the Seprion target as the 60kDa band 
was present when a PrP null homogenate was taken through the PAD-beads procedure 
(Figure 6-3 – lane 10-12). In order to identify the buffer or reagent that produced the 60kDa 
protein, a number of PAD-beads depletions were performed on both a 79A homogenate and 
a PrP null homogenate with each individual buffer or reagent in the PAD-beads protocol 
excluded in turn. The absence of the 60kDa band from the immunoblot (Figure 6-6) when 
the capture buffer was not included during the PAD-beads procedure, indicated that the 
60kDa band was due to a protein present in the capture buffer. Examination of the patent for 
the procedure (Lane, Stanley et al. 2010) indicated that the protein was bovine serum 
albumin, a component of the capture buffer included to act as a blocking agent to minimise 
non-specific interactions. Further, the PrP null blot (Figure 6-6B) shows a laddering effect 
that was hypothesised to be the breakdown of the bovine serum albumin. The presence of 
PrP
Sc
 in the eluate from the 79A homogenate depleted without the Seprion reagent indicated 
that a level of PrP
Sc
 binds directly to the beads. In comparison to the standard protocol 
(Figure 6-6A, lanes 1-3), a greater amount of PrP-res remained in the dh when the Seprion 
reagent was absent (Figure 6-6A, lane 7-8) from the procedure indicating that some PrP-res 
was captured by the beads but the majority that was eluted during the standard procedure 





Figure 6-6: Absence of the 60kDa band when the capture buffer (A – lane 4-6, B lanes -3-4) was not 
included in the PAD-beads protocol performed on both (A) 79A homogenate and (B) PrP null 
homogenate. The 60kDa band was present when all components were included (A – lane 1-3, B – lane 
1-2), PAD-beads protocol was performed without the Seprion reagent (A – lanes 7-9, B – lanes 5-6) or 
without the PAD-beads (A – lanes 10-11, B – lane 7). PrP
C
 included as internal immunoblot control 
(A – lane 12, B – lane 8). PAD-bead depletions performed as described (Section 2.26). Samples 
loaded at 10mg/ml with 15µl eluates loaded. Blot probed with mAb 8H4 and exposed for 1 minute. 
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One of the aims of this thesis was to determine the association of the Seprion ligand target 
with infectivity, through bioassay experiments. The above experiments were all performed 
with elution of the captured protein(s) from the magnetic beads by incubation at 100°C for 
10 minutes in tris-glycine sample buffer (Invitrogen) as recommended by the manufacturer‟s 
instructions, a process that would reduce any TSE infectivity levels due to the presence of 
SDS in the sample buffer and the denaturation process. If the infectivity levels associated 
with the captured protein(s) were to be analysed, the elution process must not affect TSE 
infectivity levels present, i.e. must not involve denaturing conditions such as high pH, high 
concentrations of SDS or high temperatures, all of which are known to reduce TSE 
infectivity levels (Prusiner, Groth et al. 1981, Kimberlin, Walker et al. 1983, Somerville, 
Oberthur et al. 2002). Several elution methods were tested using a 79A homogenate taken 
through the optimised PAD-beads protocol (Section 2.26) altering only the elution buffer and 
method. To determine if the elution method had been successful, the beads were re-
suspended in tris-glycine sample buffer (Invitrogen) and protein eluted as standard to detect 
if any captured protein had remained on the beads. The presence of PrP
Sc
 was utilised as 
indicative of the successful elution of the captured protein(s).  The captured protein, PrP
Sc
, 
was not present in the eluate when elution was performed with either Sarkosyl or TritonX-
100 detergent elution buffers but remained on the beads and was eluted using the standard 
protocol (Figure 6-7A). The captured protein, PrP
Sc
 was shown to remain on the beads after 
elution with either 50mM glycine or 10mM EDTA (Figure 6-7B). The captured protein, 
PrP
Sc
 was not detected in either the experimental eluate or the standard elute after elution 
with 0.5M NaOH or 5% sarkosyl (Figure 6-7B), with the hypothesis that the elution buffer or 
process degraded PrP
Sc
 presumably by hydrolysis. In contrast, the captured protein, PrP
Sc
 
was detected in the eluate after elution with 0.1M NaOH (Figure 6-7B). However, previous 
experimental evidence has shown that this elution method would affect TSE infectivity 
(Lemmer, Mielke et al. 2008) and therefore could not be utilised in bioassay.  
Given that the tris-glycine sample buffer (Invitrogen) efficiently eluted PrP
Sc
, it was 
suspected that this resulted from the presence of SDS within the sample buffer. Therefore a 
range of concentrations of SDS detergent were tested for their ability to elute the captured 
protein from the beads. Elutions were performed by incubation at 100°C for 10 minutes in 
varying concentrations of SDS buffer. After the eluate was collected, the beads were re-
suspended in tris-glycine sample buffer (Invitrogen) to determine whether elution of PrP
Sc
 
had occurred. The immunoblot results (Figure 6-8) indicated that although 0.25% SDS was 
too low a concentration to elute the captured protein from the beads; both 0.5% and 1% SDS 
concentrations were able to successfully elute the captured protein. At the highest 
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concentration of 2% SDS, the captured protein appeared in the eluate but at a much lower 
intensity than expected.  
Although a number of elution methods were able to elute PrP
Sc 
from the beads, none of the 
conditions were compatible with methods to determine TSE infectivity. However, it was 
hypothesised that if the Seprion ligand target was associated with the infectious agent, the 
levels of infectivity in the depleted homogenate would be reduced after depletion of the 
Seprion target. Therefore, bioassays of the depleted homogenate were performed (Section 





Figure 6-7: Different elution methods were analysed for their ability to elute the PrP
Sc
 from a 79A 
homogenate. PrP
Sc
 was only detected in the eluate (E) produced from a 0.1M NaOH elution method 
(Blot B – lane 5). PrP
Sc
, remained present in the standard elute from the beads (B) performed after all 
other experimental elution methods. In the case of elution with 5% Sarkosyl (Blot A – lane 3+4) and 
0.5M NaOH (Blot B – lane 7+8), PrP
Sc
 was not detected in either eluate. PAD-beads was performed 
as described (Section 2.26) with experimental elutions performed with agitation for 10 minutes at RT 
except those eluted using different concentrations of NaOH which were incubated for 10 minutes at 
100°C. Elution of the beads (B) was performed as standard. Samples (15µl) of each eluate loaded. 
Blot probed with mAb 8H4 and exposed for 3 minutes. 
 
 
Figure 6-8: The captured protein, PrP
Sc
, was present in the eluate from 2%, 1% and 0.5% SDS (lanes 
1, 3 and 5 respectively) but remained on the beads with a 0.25% SDS elution buffer (lane 8). PAD-
bead depletions were performed as described (Section 2.26) with elution performed with incubation 
for 10 minutes at 100°C. Samples (15µl) of each eluate loaded. Blot probed with mAb 8H4 and 
exposed for 3 minutes.  
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6.2.2. Identification of the aggregated protein that the Seprion 
ligand binds from 101LL/GSS and 101LL/263K brain 
homogenates.  
After optimisation of the technique to produce both positive 79A and negative 101LL NBH  
controls, 101LL/GSS and 101LL/263K brain tissue homogenates were used as starting 
homogenates for the PAD-bead depletions (Section 2.26). Throughout this analysis, starting 
10% (w/v) brain homogenates were produced from mice that were scored positive for TSE 
disease and TSE-associated vacuolar pathology (Section 2.10). Based on previous data 
(Figure 6-5), PAD-bead eluates were considered positive for disease-associated PrP
Sc
 only if 
PrP
Sc 
bands were detected in the experimental eluate by immunoblot, without the presence of 
PrP
C
 in the negative control normal brain eluate. Preliminary experiments with 101LL/GSS 
and 101LL/263K homogenates showed that after 1 minute exposure (Figure 6-9A) only the 
101LL/263K eluate was positive for PrP
Sc
. After 3 minutes exposure (Figure 6-9B), the 
101LL/GSS eluate contained PrP-specific bands, however, the 101LL NBH eluate contained 
PrP
C
 bands and therefore this result cannot be differentiated from background PrP
C
 binding.  
To further investigate the identity of the Seprion ligand target, 101LL/GSS, 101LL/263K, 
wild-type (SV)/79A and 101LL normal brain homogenates were taken through the PAD-
beads procedure (Section 2.26), with elution in 0.5% SDS. The resulting dhs, wash buffers 
and eluates produced during the PAD-bead depletions were analysed by a number of 
techniques in order to identify any protein differences between the experimental 
homogenates and the positive (wild-type/79A) and negative (101LL NBH) controls. After 
short exposure periods, PrP
Sc
 was present in the wild-type/79A eluate but absent from any of 
the other eluates (data not shown). Only after an extended exposure of 30 minutes (Figure 
6-10), was PrP
Sc
 present in the eluate from the 101LL/GSS and 101LL/263K homogenates 
indicating the PrP
Sc
 eluted from the these homogenates was at a lower concentration than the 
positive control homogenate. The 101LL NBH remained negative for PrP
C
, thus it was 
assumed the PrP present in the 101LL/GSS and 101LL/263K eluates was not due to 
background binding of PrP
C
. The presence of PrP
Sc
 in the standard elution from the beads 
(Figure 6-10D - lane 12), performed after the 0.5% SDS elution indicated that the 
concentration of PrP
Sc
 bound by the Seprion ligand from the wild-type/79A homogenate was 
greater than that observed in the eluate (Figure 6-10D – lane 11). No PrP remained on the 
beads from either the 101LL/GSS or the 101LL/263K homogenates. No PrP-res or PrP
C
 
were detected in any of the wash buffers produced from all the homogenates, despite being 





Figure 6-9: Detection of PrP in the eluate depends on exposure length, with short (A) 1 minute 
exposure showing no PrP bands in 101LL NBH eluate (lane 6) in comparison to (B) 3 minutes 
exposure that contains faint PrP bands in the 101LL NBH eluate (lane 6). PAD-beads depletion 
performed as described (Section 2.26). Samples loaded at 10mg/ml with 15µl eluate loaded. Blots 




Figure 6-10: Detection of PrP in the components produced during PAD-beads procedure from (A) 
101LL/GSS, (B) 101LL/263K, (C) 101LL NBH and (D) wild-type/79A homogenates. Individual 
identification numbers of mice shown in brackets. 10% (w/v) brain homogenate (lane 1-2) and dh 
(lane 3-4) were loaded at equal concentration (10mg/ml), whilst wash buffers (W1 lane 5-6, W2 lane 
7-8, W2.2 lane 9-10) were loaded at 3x the concentration (30mg/ml). PAD-bead depletions performed 
as described (Section 2.26). The eluate (E, lane 11) was produced by incubation at 100˚C in 0.5% 
SDS for 10 minutes; beads were then re-suspended in tris-glycine sample buffer (B, lane 12) to detect 
any remaining captured protein with 15µl eluates loaded. PrP
C
 loaded as internal immunoblot control 
(lane 13), (10mg/ml). Blot probed with mAb 8H4 and exposed for 30 minutes. 
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Whilst the immunoblot detection method utilised an anti-PrP antibody and therefore only 
detected PrP, another protein or component that is the target or complexes with the target of 
the Seprion ligand would not be identified. Therefore, analysis of the total protein present in 
the samples produced from the PAD-bead depletions was performed through two different 
methods; silver staining (Section 2.22.1) and SYPRO Ruby (Invitrogen) (Section 2.22.2) 
staining.  
Both total protein staining methods (Figure 6-11) produced similar protein patterns in dh, 
wash buffers and eluate from each homogenates. As expected, the dh contained a large 
number of proteins, similar to the NBH loaded as a staining control as any protein not 
targeted by the Seprion ligand would remain in the dh. In all four eluates, a number of 
protein bands were observed between 50kDa-64kDa, however these were thought to be non-
specific as they were present in all eluates, including the 101LL normal brain eluate and 
were hypothesised to be due to BSA, which has previously been shown to be present by 
immunoblot (Figure 6-6) and possible contamination with keratin. The wash 1 samples 
produced all contained a single protein at 64kDa, which was hypothesised to be BSA whilst 
the samples produced from the latter washes, wash 2 and wash 2.2 contained no protein 
bands. It is important to note that PrP would not be efficiently stained through the silver 
staining procedure as it does not efficiently stain glycoproteins but would be stained with the 
SYPRO Ruby staining procedure. Two different glycoprotein staining kits were also tested 
(ProQ Emerald Green (Invitrogen) and Krypton™ (Pierce)), but both required optimisation 
and due to time constraints within this project was not possible.  
In order to further analyse the protein composition of the different samples produced from 
the PAD-beads protocol, the samples produced from the depletion were analysed with the 
IDEXX HerdChek* assay (Section 2.22) to determine which components the Seprion ligand 
target was present in. Although the assay was not quantitative, the results (Figure 6-12) 
indicated that the wild-type/79A dh still contained enough of the Seprion target to saturate 
the assay (A450-A620 value 3.116) with a readout similar to the untreated 79A 10% (w/v) BH 
(A450-A620 value 2.962). In contrast, the readout from the 101LL/GSS dh (A450-A620 value 
0.748) was a quarter of the value of the readout for the 10% (w/v) untreated BH (A450-A620 
value 2.995), indicating that three quarters of the initial concentration of the Seprion target 
had been removed by the PAD-beads procedure. The readout from the 101LL/263K dh 
(A450-A620 value 1.487) was roughly half of the readout value from the 10% (w/v) BH (A450-
A620 value 3.125) indicating that at least a half of the initial concentration of the Seprion 
target had been depleted from the homogenate. Other than the wild-type/79A W1 sample, all 
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the samples produced from the washes were negative in this assay, with absorbance values 
below the negative cut-off value of 0.146. All the results from the eluates were also negative, 
which was unexpected, especially for the wild-type/79A control where it is known from the 
immunoblot results (Figure 6-10) that PrP
Sc 
was present. However the elution process of 
boiling in 0.5% SDS would denature and disaggregate the PrP
Sc
 present possibly preventing 
the binding of PrP
Sc
 to the Seprion ligand, which binds aggregated proteins. This theory 
could be confirmed by pre-treating a non-depleted 10% (w/v) brain homogenate containing 
0.5% SDS with incubation at 100°C for 10 minutes prior to the assay. Alternatively, the 
elution process could release the Seprion ligand and PrP
Sc
 target as a complex from the beads 





Figure 6-11: No identifiable difference were observed in total protein analysis of components 
produced during PAD-bead depletions utilising (A) silver staining and (B) SYPRO Ruby staining. 
Samples are produced from (1) wild-type/79A, (2) 101LL NBH, (3) 101LL/GSS and (4) 101LL/263K 
homogenates. Each gel contains NBH loaded as control (left gel, lane 10, and right gel lane 14) and 




























Figure 6-12: Seprion target remains present in dh produced during PAD-beads depletion of wild-
type/79A (green bars), 101LL/GSS (blue bars) and 101LL/263K (orange bars) homogenates with the 
IDEXX HerdChek* assay. The Seprion target was present in W1 from wild-type/79A homogenate but 
remains undetectable from any other wash buffer and the eluates. The non-depleted 10% (w/v) brain 
homogenate analysed were the same as were used as the starting material for the PAD-bead depletion 
and show high levels of the Seprion target as expected. IDEXX HerdChek* positive and negative 
controls (red bars) were provided with the kit.  
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6.2.3. Proteomic analysis to identify the aggregated protein(s) 
present in an infected and uninfected eluate.  
The immunoblots (Figure 6-10) and total protein stains (Figure 6-11) did not identify a clear 
protein difference between the experimental eluates; 101LL/GSS and 101LL/263K and the 
control eluates; wild-type/79A and 101LL NBH. Therefore, more detailed proteomic 
analysis of the protein(s) present in the eluates was required and it was hypothesised that the 
Seprion target protein or complex could be identified from comparison of a standard scrapie 
homogenate; wild-type/79A eluate, where PrP
Sc
 is present, compared to an eluate from an 
uninfected brain homogenate. If a protein or complex could be identified that was present in 
the positive control eluate but not the negative control eluate, then further analysis could 
identify if the same protein or complex was identifiable in the 101LL/GSS and 101LL/263K 
experimental homogenates and whether there was a difference in concentration of the 
Seprion target between the positive control and the experimental samples. Both a wild-
type(SV)/79A and a wild-type (SV) normal brain homogenate (of the same genetic 
background) were depleted with the PAD-beads as described previously (Section 2.26). As 
the previous total protein stains have shown high concentrations of proteins, serial dilutions 
of both the dh and eluates were separated by SDS-PAGE (Section 2.19) and total protein was 
stained with SYPRO ruby (Section 2.22.2). The results (Figure 6-13) show that no 
identifiable protein differences were identified between the infected and uninfected eluate.  
Further analysis of the proteomic differences between the 79A infected eluate and an 
uninfected eluate were performed through 2D-PAGE. 2D-PAGE separates the proteins 
present in a sample firstly on the basis of their isoelectric point and then by molecular weight 
through SDS-PAGE (Section 2.27). After initial analysis, it was determined that protein 
precipitation of the eluate by a methanol and chloroform precipitation technique (Section 
2.27) was required to optimise detection of proteins by 2D-PAGE. Preliminary results 
(Figure 6-14) have shown that the protein spots identified were slightly greater in number in 
the uninfected elute, (30 spots), than in the 79A infected eluate, (21 spots). Given that within 
in the normal brain homogenate the Seprion target should be absent, perhaps the increase in 
number of spots was due to a higher level of non-specific binding as the binding sites were 
not specifically occupied by an aggregated protein. However, in order to confirm that any 
variation observed was due to depletion with the Seprion ligand, it was determined that a 
minimum of 24 repeats of the experiment would be required to ensure any variation was not 
due to starting homogenate variation or technique variation (repeat groups four times to 
ensure differences were not due to sample variation, run experiments in triplicate to ensure 
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validity gives a minimum of 24 repeats). Unfortunately due to the timescales of this project, 
this number of experiments was not possible.  
 
Figure 6-13: No clear difference between total proteins in either (A) depleted homogenates or (B) 
eluates from a 79A infected homogenate and an uninfected normal brain homogenate. Gels were 
stained with SYPRO Ruby (Invitrogen), (Section 2.22.2).  
 
Figure 6-14: Unexpectedly, the uninfected eluate (B) contained more protein spots than the infected 
eluate (A). 2D-PAGE gels were stained with Coomassie blue (Section 2.22.3), imaged on a Kodak 
Image Station 440CF and analysed by Imagemaster 2D Platium Software Version 5.0.  
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The SELDI technique allows for identification of proteins utilising time-of-flight mass 
spectrometry (TOF-MS) and was utilised to provide analysis of the protein spectra produced 
from each PAD-beads component. Analysis of all the components produced from a PAD-
beads depletion of both a 79A infected and an uninfected normal brain homogenate was 
performed to help identify any protein peaks present. The dh, individual wash buffers and 
eluates underwent preliminary analysis on a normal-phase ProteinChip® array (Section 
2.28). Results (Figure 6-15) agreed with the previous immunoblot results (Figure 6-6) with a 
peak at 66kDa in all samples that corresponds to bovine serum albumin. The absence of any 
protein peaks from the uninfected eluate, including the bovine serum albumin peak, was 
hypothesised to be due to damage to the chip during preparation rather than absence of 
proteins from the eluate. Both the infected and uninfected depleted homogenates contained 
peaks at 33kDa and 22kDa which were also present in the infected eluate and the individual 
wash buffers (Figure 6-16). These peaks were hypothesised to be break-down products of 
bovine serum albumin similar to the BSA laddering effect previously observed on the 
immunoblot (Figure 6-6). The individual wash buffers were also analysed (Figure 6-16), 
with a variety of proteins present in wash one and the second wash buffer (W2.2). However, 
there was no measurable difference in the peaks from the washes produced during depletion 
of either an infected homogenate or uninfected homogenate.  
In conclusion, despite application of a number of different techniques, no clear difference 
between an infected 79A eluate and an uninfected eluate could be identified that could 





Figure 6-15: Protein spectra produced from analysis of (A+B) depleted homogenates and (C+D) 
eluate displayed by ProteinChip® software. Components produced from PAD-beads depletion of 
(A+C) 79A homogenate and (B+D) normal brain homogenate and analysed on an NP20 ProteinChip® 




Figure 6-16: Protein spectra produced from analysis of (A+B) wash buffer 1, (C+D) wash buffer 2 
and (E+F) wash buffer 2.2 displayed by ProteinChip® software. Components produced from PAD-
beads depletion of (A, C+E) 79A homogenate and (B, D+F) normal brain homogenate and analysed 
on an NP20 ProteinChip® by SELDI. Recombinant PrP (G) loaded as control. 
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6.2.4. Is TSE infectivity bound by the Seprion ligand? 
Single depletion 
In order to assess if the Seprion ligand target was associated with TSE infectivity, the 
original aim was to bioassay the eluate to determine the level of infectivity. However, as no 
elution method was identified that could elute the protein without affecting infectivity 
(Section 6.2.1), this was not possible. Therefore it was hypothesised that if the Seprion 
ligand target is the infectious agent, then the level of infectivity would decrease in the 
depleted homogenate produced from the PAD-beads depletion with the Seprion ligand. In 
order to determine if there was a reduction in infectivity in the depleted homogenate, the 
PAD-beads kit was utilised to perform a single depletion of the ligand target from 
101LL/GSS and 101LL/263K brain homogenates. A wild-type/79A homogenate was treated 
identically as a control for comparison. A 101LL NBH was taken through the PAD-beads 
procedure to provide a negative control to allow for biochemical analysis of inoculum. 
Homogenates (Table 6-2) underwent the optimised PAD-beads procedure (Section 2.26) and 
the dh, wash buffers and eluates were collected.  
The dh and combined wash buffers (W) were methanol precipitation (Section 2.29) with the 
resulting pellets re-suspended at an equivalent concentration to a 10% (w/v) homogenate. 
The dh and wash buffers were then inoculated intra-cerebrally at a concentration equivalent 
to 1% (w/v) homogenate.  The wash buffers were assayed for infectivity levels due to 
preliminary SELDI data that identified multiple protein peaks present in the wash buffers 
produced from a 79A PAD-beads experiment (Figure 6-17). The dh, W1 and W2‟s from a 
79A depletion and a NBH depletion were analysed on a normal-phase ProteinChip® array 
(Section 2.28) to identify the protein peaks present. The results (Figure 6-17) show multiple 
protein peaks present in both 79A wash buffers although at a lower concentration (based on 
the uA size of each individual peak) compared to the peaks observed in the 79A dh and 10% 
(w/v) homogenates. The wash buffers from the NBH do not show any obvious peaks, with 
the signal produced due to a background level. Therefore, the wash buffers were combined 
and methanol precipitated to produce inocula to determine if the infectious agent was 




Figure 6-17: Protein spectra produced from analysis of 79A and NBH depleted homogenates and 
wash buffers produced from a PAD-beads depletion displayed by ProteinChip® software. Samples 
analysed on an NP20 ProteinChip® by SELDI. 10% (w/v) homogenates included as controls. 
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To provide comparison infectivity data, non-depleted controls were prepared from the 10% 
(w/v) brain homogenate that was diluted to a 1% (w/v) homogenate. The 1% (w/v) 
homogenate was also further diluted 1/10 and 1/1000. The 1/10 dilution and 1/1000 dilution 
of the 1% (w/v) homogenate were methanol precipitated by the same methods as the 
experimental samples (Section 2.29) and re-suspended in sterile saline for inoculation. 
Together, the non-depleted, unclarified 1% (w/v) homogenate and the non-depleted, clarified 
(methanol precipitated) 1/10 and 1/1000 dilutions provided comparison infectivity data from 
a non-depleted sample to provide an estimation of the loss of infectivity. A summary of the 
different inocula prepared from each starting homogenate are provided in (Figure 6-18). 
These controls were performed for 101LL/GSS, 101LL/263K and wild-type/79A 
homogenates. A further control was prepared from only the wild-type/79A homogenate to 
demonstrate that any loss in infectivity observed was due to depletion with the Seprion 
ligand. The wild-type/79A homogenate was taken through the PAD-beads protocol (Section 
2.26) without the inclusion of the Seprion ligand. The resulting homogenate was methanol 
precipitated (Section 2.29) and inoculated at the equivalent concentration to the 1% (w/v) 
homogenate. If the Seprion ligand does bind the infectious agent and a decrease in infectivity 
is observed in the depleted homogenate, this control will show if the decrease was due to the 





















101LL/GSS 754A-1A C17308 303 + + +(Score1) 
101LL/263K 522L-1D B49174 428 + + +(Score1) 
Wt/79A 522U-1A U7535 134 + + Not Done 
101LL/GSS 754A-1A C17210 280 + + +(Score1) 
101LL/263K 522L-1D B48542 382 + + +(Score2) 
Wt/79A 522U-1A U7481 133 + + Not Done 
Table 6-2: Information on the each tissue utilised to provide the starting homogenate for the 
infectivity studies with the Seprion ligand. Incubation period to disease shown and the 
immunohistochemical (IHC) result (Data obtained from Table 3-3 and Table 3-4).  
 
Figure 6-18: Summary of the methods utilised to prepare the five different inoculums from each 
starting homogenate for inoculation to assess if the Seprion ligand depletes TSE infectivity from a 
single PAD-beads separation. Numbers of mice per group are indicated. Wild-type/79A control 
processed through the PAD-beads protocol without the Seprion ligand and then methanol precipitated 
not shown.  
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It was hypothesised that by depleting the Seprion target from the brain homogenates, the titre 
of infectivity would decrease and therefore an increase in incubation period would be 
observed for the dh if the Seprion target was the infectious agent. However, the immunoblot 
results of the inocula (Figure 6-19) show that in both the 79A controls, PrP-res was present 
in the dh before and after methanol precipitation. Therefore it was hypothesised that the 79A 
dh would remain infectious but the incubation period to disease may be extended, given that 
enough PrP-res was present in the eluate to be detectable by immunoblot.  
In the experimental samples (Figure 6-19A, B, E and F), no PrP-res was present in the dh, 
prior to methanol precipitation (Figure 6-19 - lane 2). The protein bands detected in the dh 
after methanol precipitation were not specific to the experimental samples as the same bands 
were present in the 101LL NBH samples. The methanol precipitation process was 
hypothesised to have caused a break-down of the bovine serum albumin that were then 
detected by cross-reactivity with the secondary antibody during the immunoblot procedure. 
This hypothesis was confirmed through probing a blot with secondary antibody only (data 
not shown). Although PrP
Sc
 was present in the eluate from the 79A controls (Figure 6-19C 
and G), a faint band was detectable in the eluate from the experimental samples but the 
protein identity remains unconfirmed as the molecular weight size was slightly different to 
that expected of PrP (Figure 6-19A, B, E and F). No background binding of PrP
C
 was 
observed in the 101LL NBH control samples (Figure 6-19D and H).  
Mice were genotyped prior to inoculation by DNA extraction from pieces of ear tissue to 
confirm the presence or absence of the 101LL mutation (Sections 2.1.1, 2.1.3 and 2.1.4). 
101LL/GSS and 101LL/263K inocula were injected intra-cerebrally into 101LL mice whilst 
the wild-type/79A inocula were injected intra-cerebrally into wild-type 129Ola mice that 
express PrP without the 101LL mutation (101PP). Inoculations were carried out as 
previously described (Section 2.3) and the animals monitored weekly for signs of TSE 






Figure 6-19: Immunoblot of PAD-beads inocula samples (A) 101LL/GSS, (B) 101LL/263K, (C) 
wt/79A, (D) 101LL NBH, (E) 101LL/GSS, (F) 101LL/263K, (G) wt/79A and (H) 101LL NBH. (A)- 
(D) and (E)-(H) immunoblots were performed together. PAD-beads inocula samples were analysed 
before and after methanol precipitation (meth ppt) and PK digested (PK) when appropriate for 
immunoblot results. Samples loaded at 10mg/ml and PrP
C
 (lane 8) was present as immunoblot control 




Mouse ID Number of Starting Homogenate: C17308 B49174 U7535 C17210 B48542 U7481 
TSE Strain: GSS 263K 79A GSS 263K 79A 
Recipient Genotype: 101LL 101LL 129Ola 101LL 101LL 129Ola 
Group numbers (number clinical positive/number 
inoculated) and Incubation Period (IP)(days±SEM) 
+ve/n IP +ve/n  IP +ve/n IP +ve/n IP +ve/n IP +ve/n IP 
Inoculum Sample ↓             
1% (w/v) Homogenate 6/6 120±2 6/6 181±4 6/6 132±3 6/6 119±3 5/6 129±3 6/6 135±3 
1/10 Dil. 1% (w/v) methanol precipitated. 3/6 176±0 3/6 260±19 5/6 155±8 3/6 218±38 4/6 224±13 6/6 154±3 
1/1000 dilution 1% (w/v) methanol precipitated. (survival 
time) 
0/6 (218) 0/6 (218) 0/6 (157) 0/6 (211) 0/6 (211) 0/6 (184) 
Combined wash buffers from PAD-beads separation, 
methanol precipitated. 
6/6 138±4 6/6 217±5 5/6 159±3 6/6 146±7 5/6 169±14 5/6 156±3 
Depleted homogenate from PAD-beads separation, 
methanol precipitated. 
6/8 134±6 7/8 227±14 8/8 148±2 8/8 127±4 8/8 136±5 6/8 133±0 
79A only control, PAD-beads performed without Seprion 
Reagent, methanol precipitated. 
        Control 6/6 133±0 
Table 6-3: Infectivity results from single depletion with Seprion ligand PAD-beads. Numbers positive for clinical disease in each group are indicated by numbers 




Surprisingly, the dh did not show a significant increase in incubation period to disease 
compared to the 1% (w/v) homogenate for 101LL/GSS C17210, 101LL/263K B48542 and 
wt/79A U7481 (p-values 0.20, 0.35, 0.29 respectively)(Table 6-3, Figure 6-20). The 
101LL/GSS C17308 had a significant difference with a p-value of 0.05, with the incubation 
period to disease from inoculation with the depleted homogenate 14 days longer than 
incubation period to disease from inoculated with the 1% (w/v) homogenate.  However, 
previous research has shown that a single log10 reduction in titre increases the incubation 
period of 101LL/GSS by approximately 20 days (personal communication – R. Barron), thus 
the 14 day increase in incubation period observed does not represent the loss of 1log10 in 
infectious titre. Results from the other wild-type/79A sample, U7535, showed that the dh had 
a  longer average incubation period of 148 days compared to the 1% (w/v) homogenate 
average incubation period of 132 days, indicating a significant difference in incubation 
period with a p-value of 0.001. Based on previous data (Section 4.2.3) a single log10 dilution 
of wild-type/79A increases the incubation period by 4-6 days, therefore the U7535 depleted 
homogenate has a decreased infectivity titre by between 2-4 log10. The 101LL/263K, 
B49174, showed that the dh had a longer average incubation period of 227 days compared to 
the 1% (w/v) homogenate average incubation period 181 days, indicating a significant 
difference in incubation period with a p-value of 0.01. Previous research has shown that a 
single log10 reduction in titre increases the incubation period of 101LL/263K by 
approximately 20 days (personal communication – R. Barron), therefore the 46 day increase 
in incubation period observed represents the loss of 2-3log10 in infectious titre. However, full 
titration studies would be required to accurately determine the difference in infectivity titre 
in these cases. Despite a significant difference observed for wild-type/79A U7535 and 
101LL/263K B49174, the other results (Figure 6-20), indicated that a single depletion with 
the Seprion ligand did not reduce the level of TSE infectivity in 101LL/GSS homogenates, 
101LL/263K homogenate B48542 or the wild-type/79A homogenate U7481 by a single log10 
dilution that would have been observable through an increase in incubation period. The dh 
incubation periods were longer than the 1% (w/v) homogenate, a result that was 
hypothesised to be due to the different processing of the two samples. The 1% (w/v) 
homogenate was non-depleted and un-clarified (did not undergo a methanol precipitation 
step) and therefore no loss in infectivity was observed. The clarification and methanol 
precipitation, that was required to remove contaminants, has previously been shown to 
reduce the level of infectivity (personal communication – R, Barron) and therefore the 1/10 
dilution of the 1% (w/v) homogenate that was clarified was expected to provide the more 
appropriate control sample. However, for both the 101LL/GSS and 101LL/263K the 
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methanol precipitated 1/10 dilution of the 1% (w/v) homogenate had an unexpectedly long 
incubation period to disease. It was hypothesised that a step during the methanol 
precipitation decreased the level of TSE infectivity. Based on the average incubation times 
that were observed for the dh‟s and for the 1/10 dilutions of the 1% (w/v) homogenates 
(Table 6-3), it was concluded that the 1/1000 dilution of the 1% (w/v) homogenate would not 
provide any enhancement of the infectivity results and was therefore culled with the 
respective survival times indicated (Table 6-3). 
The presence of TSE infectivity in the wash buffers from wild-type/79A, 101LL/GSS and 
101LL/263K was unexpected (Table 6-3, Figure 6-20), especially given the absence of 
detectable PrP-res by immunoblot in all wash buffer samples prior to and after methanol 
precipitation (Figure 6-19). Further analysis of wash buffers from an alternative experiment 
with the IDEXX HerdChek* assay (Figure 6-12) indicated that there was an absence of the 
Seprion target from the wash buffers. However, the bioassay result indicates that the TSE 
infectious agent was initially bound to the PAD-beads, the Seprion ligand or to the tube wall 
but was unbound during the wash procedure. The incubation periods to clinical disease for 
the wild-type/79A wash buffers were similar to the 1/10 dilution of the 1% (w/v) 79A 
homogenates (Figure 6-20) indicating that the levels of infectivity were approximately a 
single log dilution less than the 1% (w/v) homogenate. The incubation periods to disease for 
the 101LL/GSS and 101LL/263K wash buffers were shorter than the 1/10 dilution of the 1% 
(w/v) homogenate although due to the unexpected long incubation period of the later 








































































B: Comparison of 1% (w/v) homogenate and dh 







Figure 6-20: Average incubation periods to disease of each inoculum produced from each starting 
homogenate (A). Average incubation periods to disease of 1% (w/v) homogenate and depleted 
homogenates shown individually of comparison (B) with student‟s two-tailed t-test performed to 
identify statistical differences. The p-values were 101LL/GSS C17308 0.05, 101LL/263K B49174 




The lesion profiles produced from inoculation with from each 1% (w/v) homogenate, wash 
buffer and dh inoculum were compared to determine if the same strain was present in each 
sample (Section 1.1.5 and 2.7). For both 101LL/GSS tissues, the lesion profiles (Figure 
6-21A+D) produced from the three inoculas followed the same pattern although slightly 
different vacuolation scores were observed between C17308 and C17210 at area 4, the 
hypothalamus. For both 101LL/263K tissues (Figure 6-21B+E), the lesion profiles produced 
from the three inocula follow a similar pattern but the two tissues have produced different 
lesion profile patterns, with a higher level of vacuolation in B49174 (Figure 6-21B) in the 
grey matter brain areas numbered 3-7; super colliculus, hypothalamus, thalamus, 
hippocampus and paraterminal body. This was hypothesised to be due to the difference in 
incubation periods to disease for the B49174 inoculum that were extended in comparison to 
the B48542 incubation periods (Figure 6-20). The differences in lesion profiles between 
101LL/GSS and 101LL/263K tissues was expected as initial tissue was produced from 
primary transmission therefore a greater level of variability was expected as the strains were 
still adapting to a new host compared to the wild-type/79A tissues that were produced from 
passage of a cloned strain. For both wild-type/79A tissues, the lesion profiles (Figure 
6-21C+F) produced from each inoculum followed the same pattern. The similarity in lesion 
profiles between the 1% (w/v) homogenate, dh and wash buffers indicate there was no 
change in strain properties or selection of subtypes.  
Immunohistochemical analysis of brain sections (Section 2.8) from the 1% (w/v) 
homogenate, wash buffers and depleted homogenates show a similar PrP
Sc
 deposition pattern 
(Figure 6-22). The 101LL/GSS and 101LL/263K strains have the majority of deposition in 
the hippocampus and midbrain sections, although depending on the severity of PrP
Sc
 
deposition, occasional deposits were observed in the medulla or septum. Surprisingly, the 
101LL/GSS tissues inoculated with C17210 (Figure 6-22B) contained plaques in the corpus 
callosum that have previously been hypothesised to be seeded in 101LL mice following 
inoculation of amyloid aggregates (Piccardo, Manson et al. 2007, Jeffrey, McGovern et al. 
2012). Given that the Seprion ligand is known to bind protein aggregates, it was expected 
that these aggregates would have been preferentially depleted from the homogenate. The 
101LL/263K strains show similar patterns of deposition although inoculation with B49174 
(Figure 6-22C) resulted in a lower level of PrP
Sc
 deposition than B48542 (Figure 6-22D). 
The wild-type/79A immunohistochemistry showed extremely low levels of PrP
Sc
 deposition 
with the majority of sections identified as negative for PrP
Sc
 deposition (data not shown). As 
discussed previously (Section 4.2.2) this result was hypothesised to be due to the formic acid 
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treatment included as a health and safety step during the processing of these tissues 
(Appendix 2). 
In conclusion, a single depletion with the Seprion ligand, through magnetic separation, did 
not consistently alter TSE infectivity levels. However, the presence of PrP-res in the 79A 
depleted homogenate as shown by immunoblot (Figure 6-19) suggested that some TSE 
infectivity remained in the depleted homogenate following a single depletion. Indeed, to 
observe a single log10 depletion of infectivity, 90% of the PrP-res would have been required 
to be depleted. Therefore perhaps a single depletion did not remove enough of the PrP-res to 
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Figure 6-21: Lesion profiles produced from each group of 1% (w/v) homogenates, wash buffer and 
depleted homogenates inoculated from (A) 101LL/GSS C17308, (B) 101LL/263K B49174, (C) 
wt/79A U7535, (D) 101LL/GSS C17210, (E) 101LL/263K B48542 and (F) wt/79A U7481. Profiles 
calculated from the mean scores of at least 6 individual animals per group. Details of the brain areas 












 deposition targets similar brain areas independent of sample inoculated. 1% (w/v) 
homogenate, wash buffers and dh deposition are shown from (A) 101LL/GSS C17308, (B) 
101LL/GSS C17210, (C) 101LL/263K B49174 and (D) 101LL/263K B48542. Two mice are shown 
from each group with a picture of the hippocampus section (x2 magnification) shown with the 
identification number of the mouse underneath and the incubation period to disease indicated (days 
post inoculation (dpi)). The remaining pictures (x20 magnification) are of the brain areas where PrP
Sc
 




The infectivity data from the single depletions indicated that a single depletion did not 
consistently deplete an observable level of infectivity, i.e. greater than 1 log10 from the wild-
type/79A dh given the presence of PrP-res in the wild-type/79A dh by immunoblot (Figure 
6-19). Therefore it cannot be assumed that the experimental homogenates 101LL/GSS and 
101LL/263K were completely depleted of the Seprion ligand target. In order to assess the 
number of repeat depletions required to remove all PrP-res from a wild-type/79A dh, both a 
79A homogenate and a normal brain homogenate were taken through multiple depletions to 
identify the required number of depletions that would completely deplete a 79A homogenate 
of PrP-res. After each PAD-beads depletion (Section 2.26), the dh was methanol precipitated 
(Section 2.29) with the resulting pellets re-suspended in 200µl distilled water and utilised as 
the starting homogenate for the subsequent depletion. This process was repeated, with the 
homogenates taken through a total of 6 depletions.  
Following methanol precipitation each 79A multiple dh sample (Figure 6-23) displayed two 
bands on immunoblot following digestion with PK.  The intensity of the bands did not 
decrease with repeated depletions, and although thought to be either non-specific 
aggregation of PrP
C
 given the presence of the same bands in the NBH or break-down of the 
bovine serum albumin, the immunoblot analysis could not definitively determine the number 
of depletions required to completely remove PrP-res from the dh. However, PrP
Sc
 was 
present in the eluate from depletion 1, 2, 3 and 4 but not detected in the eluate from 
depletions 5 and 6, indicating that all the 79A PrP
Sc
 had been bound by the Seprion ligand 
during the previous depletions. The absence of detectable PrP
Sc
 from the fifth 79A eluate by 
immunoblot indicated that if this eluate was inoculated, a 2-3 log10 reduction in infectivity 




Figure 6-23: Presence of PK-resistant material in all PK digested dh from (A) repeat depletions of 
79A homogenate. Faint PrP
C
 bands are present in dh from (B) repeat depletions of 101LL NBH 
homogenates. Initial homogenate was taken through PAD-beads protocol (Depletion 1). This process 
was repeated a total of five times (Depletions 2-6). One fifth of each depleted homogenate re-
suspension was retained to provide the material for analysis by PK digestion. Depleted homogenates 
loaded at 10mg/ml with 15µl eluates loaded. Blot probed with mAb 8H4 and exposed for 3 minutes. 
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Based on this hypothesis the effect of performing multiple depletions with the Seprion ligand 
was assessed to determine if the level of TSE infectivity was reduced in the dh. A wild-
type/79A, a 101LL/GSS and a 101LL/263K homogenate (Table 6-4) were taken through five 
repeat depletions with the dh methanol precipitated between each depletion. After each 
depletion, a small aliquot (10µl) of the methanol precipitated dh was removed for 
biochemical analysis. The final dh was methanol precipitated, with the re-suspension 
equivalent to a 7.74% (w/v) homogenate that was diluted to the equivalent of a 1% (w/v) 
homogenate for inoculation. For each brain homogenate used in multiple depletions, an 
untreated 1% (w/v) homogenate and a non-depleted 1% (w/v) homogenate that underwent 
five methanol precipitations were also inoculated to provide comparison infectivity data 
(Figure 6-24). A 101LL NBH was handled identically to provide a negative control sample 
for biochemical analysis. A summary of inoculum are shown in Figure 6-24. 
Mice were genotyped prior to inoculation by DNA extraction from pieces of ear tissue to 
confirm the presence or absence of the 101LL mutation (Section 2.1). 101LL/GSS and 
101LL/263K inocula were injected intra-cerebrally into 101LL mice whilst the wild-
type/79A inocula were injected intra-cerebrally into wild-type 129Ola mice that express PrP 
without the 101LL mutation (101PP). Inoculations were carried out as previously described 























101LL/GSS 754A-1A C17134 262 + + 
+ (Score 
4) 
101LL/263K 522L-1B B21116 503 + + Not Done 
wt/79A 522U-1A U7745 141 + + Not Done 
Table 6-4: Information on the tissue used to provide the starting homogenate for infectivity studies 
with multiple depletions with the Seprion ligand. Incubation period to disease shown and the 
immunohistochemical (IHC) result (Data obtained from Table 3-3).  
 
 
Figure 6-24: Summary of the methods utilised to prepare the three different inocula from each 
homogenate for inoculation to assess if the Seprion ligand depletes TSE infectivity after five PAD-
beads separations. Numbers of mice per group are indicated.  
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The immunoblot results (Figure 6-25) show that PrP
Sc
 was present in eluate produced from 
the first depletion of the 79A homogenate and 101LL/GSS but not from any of the further 
depletions. PrP was detected only in the eluates produced from the first and second depletion 
of the 101LL/263K homogenate. Although these immunoblot results differed from the 
previous repeated depletions of 79A (Figure 6-23), the absence of detectable PrP
Sc
 in the 
fifth eluate by immunoblot, indicated that all PrP
Sc
 has been depleted from the homogenate 
and therefore it was expected that a difference in TSE infectivity levels would be observed 
between the 79A infected non-depleted five times methanol precipitated control and the five 
times dh upon bioassay. The absence of PrP
C
 in the dh from the fifth depletion (Figure 6-23) 
was unexpected and the non-depleted control, five times methanol precipitated control will 
provide vital data that will indicate if the processing of the samples with repeat methanol 
precipitations removed too much protein for infectivity to remain.  
However, if the Seprion ligand is depleting the infectious agent from the 101LL/GSS and 
101LL/263K homogenates, an increase in incubation period to disease could be expected for 
the five times dh, compared to the 1% (w/v) homogenate that underwent 5 methanol 
precipitations. The presence of PK-resistant bands in all the methanol precipitated, depleted 
homogenates that were PK digested, including the 101LL normal brain homogenate 
confirmed that the PK-resistant bands were not PrP-res but rather due to break-down of the 
bovine serum albumin similar to the peaks observed with the SELDI data (Figure 6-15, 
Figure 6-16). This hypothesis could be tested by immunoblot analysis of a PAD-beads 
depleted PrP null homogenate that has undergone repeat methanol precipitations to confirm 





Figure 6-25: Absence of PrP from the fifth depletion from each infected homogenate (A) 79A, (C) 
101LL/GSS and (D) 101LL/263K. PK-res bands are present in all dh after methanol precipitation 
including those from (B) 101LL NBH. Samples loaded at 10mg/ml with 15µl eluates loaded. Blot 
probed with mAb 8H4 and exposed for 10 minutes.  
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In order to confirm that the five times dhs were completely depleted of the Seprion ligand 
target, the residual inocula were analysed with the IDEXX HerdChek* assay that utilises the 
Seprion ligand as the capture agent. The results (Figure 6-26) show that the five times dhs 
from 101LL/GSS, 101LL/263K and wild-type/79A were all below the negative cut-off 
(calculated as per manufacturer‟s instructions) for the assay and indicated that the 
concentration of the Seprion ligand target was below the detection level of this assay. In 
contrast, both the 1% (w/v) homogenates and the five times methanol precipitated 
homogenates were positive in the assay and indicated that the Seprion ligand target was still 
present in these samples. However, the repeat methanol precipitations showed reduced 
absorbance readings in comparison to the untreated 1% (w/v) homogenate, suggesting that 
the repeated processing and methanol precipitation has either removed a small amount of the 
Seprion target or the repeat precipitation has altered the conformation of the Seprion target 
rendering it unrecognisable by either the Seprion ligand or the detector anti-PrP antibody.  
The 1% (w/v) inoculated groups for each species/strain developed disease with the expected 
incubation period for the untreated inoculas (Table 6-5, Figure 6-27). The incubation periods 
were compared between the non-depleted five-times methanol precipitated homogenate and 
the five-times depleted, methanol precipitated homogenate to determine if a decrease in 
infectivity was observed. The results (Table 6-5, Figure 6-27) from the multiple depletions 
bioassay indicate that a level of infectivity was depleted from the 101LL/GSS and wild-
type/79A homogenates but not for the 101LL/263K homogenates. For 101LL/GSS a 
significant difference of a 31 day increase in incubation period was observed between the 
five-times depleted, methanol precipitated and non-depleted five-times methanol precipitated 
homogenates. Previous research identified that a single log10 reduction in titre increased the 
incubation period of 101LL/GSS by approximately 20 days (personal communication – R. 
Barron). Therefore the difference in incubation period represents a loss of 1-2 log10 in 
infectious titre. For wild-type/79A the incubation period of the five-times depleted 
homogenate was increased by 43 days compared to the non-depleted five-times methanol 
precipitated homogenate. Based on previous data (Section 4.2.3) a single log10 dilution 
increases the incubation period by 4-6 days. Therefore the wild-type/79A had a decreased 
infectious titre by 7-10 log10. The 101LL/GSS and wild-type/79A results indicate that the 
Seprion ligand could potentially be binding the infectious agent. For 101LL/263K, both 
homogenates produced an average incubation period of 188 days, indicating that no 
difference in infectivity levels was present between the depleted and non-depleted five-times 
methanol precipitated homogenates. However, during preparation the 101LL/263K pellets 
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were the hardest to re-suspend and this experiment should be repeated before any 





































Figure 6-26: IDEXX HerdChek* analysis of the multiple depletions inocula did not identify the 
presence of the Seprion target in the five times dh. Inocula that underwent repeat methanol 
precipitation (meth ppt) are indicated. IDEXX controls (red) provided by the kit and the negative cut-




 Mouse ID Number of Starting 
Homogenate: 
C17134 B21116 U7745 
TSE Strain: GSS 263K 79A 
Recipient Genotype: 101LL 101LL 129Ola 
Group numbers (number clinical positive/number 
inoculated) and Incubation Period (IP)(days±SEM) 
+ve/n IP +ve/n IP +ve/n IP 
Inoculum  Sample ↓       
1% (w/v) homogenate 6/6 120±3 5/6 132±2 6/6 121±1 
1% (w/v) homogenate, 5x methanol 
precipitation 
6/6 139±7 5*/6 188±10 6/6 152±7 
Depleted homogenate from 5x depletions, 
methanol precipitated. 
7*/8 170±6 7/8 188±5 7*/8 195±5 
Table 6-5: Infectivity results from multiple depletions with Seprion ligand PAD-beads. Numbers 
positive in each group are indicated by numbers positive/number inoculated (+ve/n). Numbers with 
asterisk indicate that one mouse in the group is still alive. IP indicates average incubation period 
(days±SEM) to clinical disease, where disease has developed. Whilst for boxes marked (-), no clinical 
symptoms have developed to date. Data correct as of 30
th
 November 2012 with experiment ongoing 
and currently at 245 days post inoculation.  
 
 
Figure 6-27: Average incubation periods to disease from each inoculum from multiple depletions 
bioassay. Data correct as of 30
th
 November 2012 with experiment ongoing and currently at 245 days 
post inoculation. P-values calculated with student‟s t-test between five-times methanol precipitated 
and five-times depleted methanol precipitated groups as 4.7x10
-3
, 0.96 and 2.7x10
-4
 for 101LL/GSS, 




As a component of the IDEXX HerdChek* assay, the Seprion ligand identified both the 
101LL/GSS and 101LL/263K brain and spleen tissues as positive for TSE disease (Sections 
3.2.5 and 4.2.1). The availability of the Seprion ligand in association with magnetic beads 
allowed for further analysis of the 101LL/GSS and 101LL/263K brain tissues to identify the 
target of the Seprion ligand, that is thought to be a form of aggregated PrP, in a disease 
model where abundant PrP-res was not detectable and to determine the relationship of the 
Seprion ligand target with TSE infectivity.  
During the optimisation steps of the PAD-beads kit, PrP
C
 was detected in the eluate from a 
101LL normal brain homogenate utilising an immunoblot detection system. The presence of 
a background level of PrP
C
 binding from a wild-type normal brain homogenate indicated that 
the result was not due to the presence of the 101LL mutation but rather due to a low level of 
background binding of PrP
C
 to either the Seprion ligand or to the magnetic PAD-beads 





 bands were detected in the experimental eluate by immunoblot without the presence of 
PrP
C
 in the negative control normal brain homogenate that had been exposed to x-ray film 
for the same length of time. This cut-off level is similar to the negative cut-off value that 
would be set if the Seprion-isolated eluate was assessed by an in-house ELISA test. PrP 
specific-bands in the 101LL/GSS and 101LL/263K were detected in the eluates (Figure 6-9, 
Figure 6-10, Figure 6-25) that were not due to a background level of PrP
C
 binding, based on 
the negative control included in each round. Although it was shown previously that PK 
digestion of homogenates prior to depletion with the Seprion ligand would remove the 
background binding of PrP
C 
(Figure 6-4), PK digestion of 101LL/GSS and 101LL/263K 
samples was not performed, as it was hypothesised that PK digestion would also remove any 
sPrP
Sc
 potentially present in the 101LL/GSS and 101LL/263K homogenates that may be 
recognised by the Seprion ligand, complicating the interpretation of the results and the 
identification of the Seprion ligand target in these particular models of disease. 
The binding of the Seprion ligand to the target aggregated protein is through a polyionic 
interaction and requires the presence of an ionic surfactant such as triton-X 100 or Sarkosyl 
to completely inhibit any weak background binding of PrP
C 
(Everest, Thorne et al. 2006). 
Through examination of the patent (Lane, Stanley et al. 2010), it appears that the capture 
buffer is likely to be 20% (w/v) Sarkosyl, however an increase in the concentration of 
detergent in the reaction mixture could optimise the conditions to further minimise PrP
C
 
binding. It was further indicated in the patent that the Seprion ligand may have the ability to 
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bind both the aggregated protein and the non-aggregating form of the protein but that 
specificity for the aggregated protein is produced under conditions where N-lauryl sarcosine 
is utilised as the detergent competition agent, the pH is 8.2-8.6 and the salt concentration is 
less than 100mM. The specificity of the ligand is further increased through washes with N-
lauryl sarcosine present in the wash buffers as a competition agent for the lower affinity 
binding sites. It is hypothesised that these specific conditions were not exactly achieved; 
therefore a background level of PrP
C
 binding was observed to the Seprion ligand. The 
Seprion ligand as a component of the PAD-beads kit is advertised as specific for prion, β-
amyloid, tau, α-synuclein and huntingtin proteins in CJD, BSE, scrapie, CWD, Alzheimer‟s, 
Parkinson‟s and Huntington‟s disease tissues. The specificity of the Seprion ligand for 
aggregated protein indicates the binding of PrP
Sc
 is not specific due to the amino acid 
sequence but rather the conformation of the aggregated protein. Each strain of agent, is 
hypothesised to have a slightly different conformation of PrP
Sc
 resulting in different binding 
capacitates to the Seprion ligand.  
Through further examination of the patent, it was also ascertained that the Seprion ligand(s) 
are polyionic ligands such as pentosan polysulphate or dextran sulphate (Lane, Stanley et al. 
2010). It is thought that the initial 10 minute incubation period allows for the Seprion 
ligand(s) to bind the Seprion target. Although the mechanism of how the Seprion ligands 
bind the target aggregated protein remains unclear, it has been hypothesised that the 
polyionic ligands contain negative sulphate groups which bind to either pairs of positive 
amino acids, e.g. lysine and arginine, present in the aggregated protein or to the proteins 
polyhistidine metal binding sites (Lane, Stanley et al. 2010). 
In order to investigate if TSE infectivity was associated with the Seprion ligand target in 
101LL/GSS and 101LL/263K homogenates, a series of bioassays were set up. Ideally in 
order to determine the association of the Seprion ligand target and TSE infectivity, a 
bioassay would have been performed on the eluate produced during the depletion to 
determine if infectivity had been isolated using the Seprion ligand and magnetic beads. 
However, a method that would elute the Seprion target protein(s) from the beads without 
inactivating TSE infectivity was not identified (Figure 6-7, Figure 6-8). Additionally, the 
option of directly inoculating beads was complicated as incubation periods to disease would 
be altered due to the presence of the Seprion ligand, which is likely to be pentosan 
polysulphate. This polyionic compound, pentosan polysulphate, has previously been tested 
as a therapeutic agent for TSE disease and has been shown to lengthen incubation periods 
observed to disease in mouse models (Farquhar, Dickinson et al. 1999). Furthermore, direct 
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inoculation of the beads might have resulted in complications in the mice due to the 
introduction of particulate matter. Previous research with inoculation of particulate soil 
particles has resulted in hydrocephalus in the mice (personal communication – R. 
Somerville) and potentially inoculation of the beads would have the same affect. As a 
method to bioassay the eluate was not identified within the duration of these studies, the 
depleted homogenates were inoculated to determine if the Seprion ligand had depleted TSE 
infectivity through the binding and removal of Seprion target from the homogenate in a 
single depletion. 
Both the unclarified, untreated 1% (w/v) homogenate and the depleted homogenate had 
similar incubation periods to disease (Figure 6-20), with one wild-type/79A sample U7481 
showing only a 2 day difference in incubation period. Therefore, it was concluded that a 
single depletion with the Seprion ligand was not sufficient to consistently reduce the 
infectivity level. This was hypothesised to be due to saturation of the ligand, with the 
concentration of the ligand in a single depletion unable to completely deplete the infectious 
agent from the homogenate. Therefore to confirm if the Seprion ligand associates with the 
TSE infectious agent, a homogenate from each 101LL/GSS, 101LL/263K and wild-type/79A 
were depleted with the Seprion ligand in the PAD-beads kit five times to completely remove 
the presence of the Seprion ligand target from the depleted homogenate (Figure 6-25, Figure 
6-26). The results from the multiple depletions (Figure 6-27, Table 6-5) indicated a 
significant difference in incubation periods was observed for 101LL/GSS and wild-type/79A 
between the five-times methanol precipitated homogenate and the five-times depleted 
methanol precipitated homogenate. These results indicate that the Seprion ligand could be 
the infectious agent. However full titration studies are required to confirm the differences in 
infectious titre and the experiment should be repeated to confirm this hypothesis. 
The surprising result from the single depletion experiments was that the wash buffers 
produced similar or shorter incubation periods to disease in comparison to the 1/10 dilution 
of the 1% (w/v) homogenate (Table 6-3, Figure 6-20), despite the absence of detectable PrP-
res by immunoblot in both samples prior to and after methanol precipitation from all 
homogenates. Further total protein stains (Figure 6-13) of the wash buffers have not detected 
any protein present other than BSA present in W1 buffer. Although not the samples utilised 
for bioassay, Figure 6-12 shows that the wash buffers from a single PAD-beads depletion of 
101LL/GSS and 101LL/263K do not contain the target of the Seprion ligand at a level that 
could be detected by the IDEXX HerdChek* assay, indicating that perhaps the Seprion 
ligand target is not the infectious agent. The wild-type/79A W1 was identified positive, 
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albeit with a lower absorbance value compared to the absorbance values of the 79A starting 
10% (w/v) homogenate and dh values. Both the W2 and W2.2 from the wild-type/79A 
homogenate were below the negative cut-off value of the assay. However, as all three wash 
buffers were combined for bioassay, it is impossible to determine if there was a specific 
buffer that contains the TSE infectious agent or whether infectivity was present in each 
buffer. Overall, this leads to the hypothesis that significant amounts of the TSE infectious 
agent were initially bound to the Seprion ligand, PAD-beads or tube wall but was then 
dissociated during the wash stages. The absence of detectable PrP-res in the wash buffers by 
immunoblot (Figure 6-10), even when loaded at three times the normal concentration (at 
30mg/ml), especially in the wild-type/79A samples indicates that another form of the 
infectious agent might be present and adds to the evidence that questions the correlation 
between PrP-res and TSE infectivity.  
Overall, when investigated in these studies utilising the immunoblot detection method, the 
Seprion ligand does not appear to be as specific for abnormal aggregated proteins as initially 
thought, although conditions could be further optimised to increase specificity. Preliminary 
data collected indicates that the Seprion ligand binds a form of PrP from the 101LL/GSS and 
101LL/263K that is hypothesised to be either aggregated sPrP
Sc
 or PrP present in a complex 
with another aggregated component as the extremely low levels of PrP-res identified in the 
101LL/GSS and 101LL/263K brain tissues were not thought to be sufficient to produce a 
positive IDEXX HerdChek* result at the same level at wild-type/79A. Despite analysis using 
number of proteomics techniques, no proteomic differences were identified between an 
infected and uninfected eluate or dh at the sensitivity levels of the techniques performed and 
therefore the target of the Seprion ligand was not identified within these studies. Currently, 
the correlation between the Seprion ligand and TSE infectivity remains inconclusive until the 
five times depleted bioassay results are complete, although the presence of TSE infectivity in 
the wash buffers suggests that the Seprion ligand target may not be the infectious agent and 






In accordance with the prion hypothesis, the majority of TSE research focuses on the role of 
PrP
Sc
 in disease. The prion hypothesis proposes that PrP
Sc
 is the sole or main component of 
the infectious agent that converts the normal cellular isoform of PrP to the abnormal form 
during disease pathogenesis (Bolton, McKinley et al. 1982). PrP
Sc
 has previously been 
shown to correlate with TSE infectivity (McKinley, Bolton et al. 1983) and is distinguished 
from PrP
C
 based on its detergent insolubility and relative protease resistance (Prusiner, 
McKinley et al. 1981, McKinley, Bolton et al. 1983). However, recently data has shown that 
the PrP-res and TSE infectivity levels do not always correlate (Section 1.2.3). The disease 
models utilised in these studies have previously shown a discrepancy between TSE 
infectivity and PrP-res in which 101LL mice inoculated with either human P102L GSS or 





shown through full-titration sub-passage studies) despite the absence of detectable PrP-res
 
(Barron, Campbell et al. 2007). In this thesis, these specific disease models 101LL/GSS and 
101LL/263K were utilised to further investigate the relationship between PrP-res and TSE 
infectivity through a number of different experiments. Firstly, the levels of PrP-res in the 
brain and spleen tissue were analysed by a number of biochemical techniques and bioassay 
studies examined the levels of TSE infectivity present. Secondly, optimisation of the PMCA 
technique to amplify PrP-res from mouse tissues was assessed and thirdly, the relationship 
between TSE infectivity and the Seprion ligand (Microsens Biotechnologies) was 
investigated. Together these methods confirmed a discrepancy between PrP-res and TSE 
infectivity within these disease models.  
7.2. A disparity between PrPSc and TSE infectivity. 
Despite the wealth of data that supports PrP-res as a marker of TSE infectivity, an increasing 
number of experimental cases of TSE disease have been identified in which PrP-res was not 
detectable (Section 1.2.3). Indeed, infectivity in the absence of PrP-res has been shown in 
wild-type mice infected with BSE (Lasmezas, Deslys et al. 1997) and wild-type mice 
infected with hamster scrapie (Race, Meade-White et al. 2002). In both cases, sub-passage of 
the tissue confirmed the presence of TSE infectivity despite the absence of PrP-res. The 
disparity between PrP-res and infectivity has also been shown in cell culture models, where 
sub-cellular fractions enriched for either lipid rafts or endoplasmic reticulum/mitochondrial 
marker proteins had similar infectivity levels despite the lipid rafts fractions containing eight 
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times more PrP-res than the endoplasmic reticulum/mitochondrial fractions (Lewis, Haigh et 
al. 2012).  
Within this thesis extremely low levels or an absence of PrP-res was observed in the brain 
tissue through biochemical and immunohistochemical analysis of 101LL mice that showed 
clinical signs of TSE disease with associated vacuolar pathology when inoculated with GSS 
or hamster 263K. Sub-passage of brain tissue resulted in short incubation periods to clinical 
disease indicating that high titres of infectivity were present, with TSE vacuolar pathology 
and PrP-res deposition present in the recipient brains. The disparity between PrP-res and 
infectivity was also identified in the spleen tissue of the 101LL/GSS and 101LL/263K mice, 
with low PrP-res levels present compared to the levels of PrP-res in well-characterised 
standard strains. Transmission of spleen tissue containing low levels or an absence of PrP-res 
produced similar short incubation periods to disease as observed when transmission of the 
brain tissue from the same animal was performed, suggestive of similar high titres of 
infectivity although a full titration study is required to confirm infectivity levels. Both the 
brain and spleen tissue show a discrepancy between the levels of PrP-res and TSE 
infectivity. Therefore diagnostic tests that rely on the presence of PrP-res as indicative of 
TSE disease would identify the majority of TSE cases correctly but may mis-diagnose cases 
TSE with extremely low levels or an absence of PrP-res as negative. 
Other studies that question the relationship between PrP-res and TSE infectivity have shown 
the presence of PrP-res and PrP amyloid plaques in 101LL mice inoculated with material 
from a case of atypical P102L GSS (that shows only an 8kDa PrP-res band following PK 
digestion), despite no clinical signs, or disease associated neuropathological changes such as 
vacuolation being observed. The 101LL/8kDa GSS mouse tissue was shown to lack 
infectivity upon sub-passage with no TSE disease developing but PrP
Sc
 plaques were again 
produced in recipient 101LL mice (Piccardo, Manson et al. 2007). Research into these 
101LL/8kDa GSS mice showed that the PrP
Sc
 plaques were multi-centric, consisted of a 
single large core surrounded by several smaller satellite sub-units and were initiated by 
proto-fibrillar forms of PrP
Sc
 situated on oligodendroglia, astrocytes and neuritic cell 
membranes. The abnormal membrane pathology normally associated with PrP
Sc
 
accumulations in TSE disease (e.g. bizarre clathrin-coated vesicles and clefts of dendrites, 
spiral membrane invaginations, membrane microfolding) was not present in the 101LL/8kDa 
GSS mice, indicating a difference in pathogenesis (Jeffrey, McGovern et al. 2011). 
Therefore a diagnostic test that relies on the presence of PrP
Sc
 as indicative of TSE disease 
would identify these tissues incorrectly as positive for TSE disease. However, until a greater 
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understanding of the disease pathogenesis and the role of PrP
Sc
 in disease is understood, 
excluding any natural animal cases of this disease phenotype, of PrP
Sc
 without the presence 
of TSE infectivity, from the food chain remains the safest option. In terms of the 
development of human diagnostic screening, the identification of false positives has major 
ethical implications for informing patients incorrectly that they might develop a fatal 
neurodegenerative disease for which no treatment is currently available.  
Cases of TSE disease in the absence of PrP-res together with the presence of PrP
Sc
 without 
the associated disease symptoms or the presence of infectivity question the prion hypothesis 
that PrP
Sc
 is the sole component of the infectious agent (Bolton, McKinley et al. 1982, 
Prusiner 1982) and the reliability of diagnostic tests on the presence of PrP-res to identify 
cases of TSE disease.  
7.3. Is there a spectrum of infectious prions? 
7.3.1.  Protease sensitive forms of PrPSc 
To explain the discrepancies between PrP-res and infectivity that have been reported, it has 
been hypothesised that alternative forms of abnormal disease-associated PrP exist. These 
include protease-sensitive pathogenic forms of PrP
Sc
 that have been increasingly identified in 
both experimental and natural cases of TSE disease (Section 1.2.4). The CDI technique 
detected a proportion of PrP
Sc
 as PK-sensitive in hamster scrapie, sheep scrapie, mouse 
scrapie and vCJD and sCJD in humans (Safar, Wille et al. 1998, Safar, Geschwind et al. 
2005, Thackray, Hopkins et al. 2007, Thackray, Hopkins et al. 2007, Choi, Gröner et al. 
2011). The presence of sPrP
Sc
 has been described by different research groups in both animal 
(Tzaban, Friedlander et al. 2002, Tremblay, Ball et al. 2004, Pastrana, Sajnani et al. 2006, 
Cronier, Gros et al. 2008, Gambetti, Dong et al. 2008, D'Castro, Wenborn et al. 2010, 
Pirisinu, Di Bari et al. 2010, Zou, Puoti et al. 2010) and human TSE disease cases (Safar, 
Geschwind et al. 2005, Gambetti, Dong et al. 2008, Zou, Puoti et al. 2010, Choi, Gröner et 
al. 2011) alongside readily detectable PrP-res.  Further research on the isoforms of PrP
Sc
 
present in cases of P102L GSS identified the presence of a range of PrP
Sc
 conformers that 
were both resistant and sensitive to PK digestion originating from both wild-type and mutant 
PrP
C
 (Monaco, Fiorini et al. 2012) through cold or „limited‟ PK digestion. Infectivity 
analysis of a PK-sensitive fraction isolated from hamster 263K scrapie brain homogenates by 
ultra-centrifugation showed that the PK-sensitive fraction was infectious, with the same 
incubation period to clinical disease as the untreated PrP
Sc
 fraction (Sajnani, Silva et al. 
2012). Thus both human and animal TSE diseases have been shown to contain a broad 
spectrum of isoforms of PrP
Sc
, varying in both PK resistance and conformation.  
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Preliminary analysis of the 101LL/GSS and 101LL/263K brain tissues did not identify the 
presence of sPrP
Sc
 (Section 3.2.5) despite the use of techniques that identified sPrP
Sc
 in both 
P102L GSS cases and other murine models of GSS disease (Tremblay, Ball et al. 2004, 
Monaco, Fiorini et al. 2012). Therefore these studies have not identified sPrP
Sc
 or PrP-res in 
the 101LL/GSS or 101LL/263K brain tissues that would account for the high infectivity 
levels identified. Previous data has shown that the detergent insoluble pellet produced during 
a SAF preparation from 101LL/GSS and 101LL/263K brain contained the same level of TSE 
infectivity whether PK digestion was performed during the SAF preparation or not. 
Therefore these previous bioassay results indicated that in the 101LL/GSS and 101LL/263K 
disease models the infectious form present was resistant to PK digestion (R. Barron – 
personal communication) and not a form of sPrP
Sc
.  An unusual resistance pattern to PK 
digestion was observed in these studies (Section 3.2.4) when 101LL/GSS, 101LL/263K and 
101LL uninfected brain homogenates were prepared in distilled water rather than an NP40 
detergent buffer. This result suggests that a PrP form in 101LL mice was PK-sensitive in 
detergents but shows a level of increased PK resistance in the absence of detergents, with the 
molecular weight size indicating that the PrP form was an aggregated conformer of full 
length PrP.  
The role of the sPrP
Sc
 isoform in disease and whether it differs from PrP-res in conformation 
remains to be determined. One hypothesis is that sPrP
Sc
 is formed as an intermediate product 
during the conversion of PrP
C
 to PrP-res and could be either the sole infectious agent or a 
component of the infectivity within some disease cases. Indeed, patients with VPSPr and FFI 
succumb to disease prior to the accumulation of large quantities of PrP-res indicating that 
neuropathology occurred prior to abundant PrP-res formation and that another component is 
toxic and causes the neuropathology observed (Reder, Mednick et al. 1995, Gambetti, Dong 
et al. 2008).  One theory presented is that PrP-res is inert and that infectivity and thereby 
toxicity is present in smaller oligomeric PrP species produced as an intermediate on the 
conversion pathway (Collinge and Clarke 2007). Perhaps in the disease models presented 
within this thesis there is an as yet unidentified intermediate of PrP form that is the 






7.3.2.  Heterogeneous PrPSc populations 
Due to the recent identification of quasi-species present within individual cases of TSE 
disease in both humans and mammals analysis of all isoforms of PrP
Sc
 within a diseased 
tissue is required. In humans, the co-occurrence of both type 1 and type 2 PrP-res molecular 
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profiles has been identified in individuals with sCJD and vCJD (Head, Bunn et al. 2004, 
Yull, Ritchie et al. 2006). In experimental models, the presence of quasi-species with more 
than one form of PrP
Sc
 has been described in Tg338 mice inoculated with elk CWD, Ha 
263K or Ha Sc237 scrapie prions with tissue-specific replication of PrP
Sc
 (Béringue, Herzog 
et al. 2012). In cell-culture, the prions derived from infection of a neuroblastoma cell line, 
PK1, with 22L murine brain homogenate produced cell-derived prions that differed from the 
brain-derived prions in the cell panel assay indicating a heterogeneous population of prions 
was present in the murine infected brain homogenate with selection under specific cell 
culture conditions (Li, Browning et al. 2010). Taken together, these data indicate that PrP 
populations are biochemically heterogeneous with different sub-variants dominating under 
different environmental conditions or in different hosts.  
In the studies presented in this thesis, brain and spleen tissue from 101LL/GSS and 
101LL/263K was sub-passaged to compare infectivity levels in the different tissues. The 
biochemical and immunohistochemical analysis of the recipient mice (Section 4.2.7) of the 
101LL/GSS inoculum indicated that PrP-res deposition was lower in the brains of mice that 
received the spleen homogenate compared to those that received the brain homogenate 
indicating that a potentially heterogeneous population of PrP-res was present. The tissue-
specific conditions supported replication of different sub-variants that upon sub-passage 
showed different replication abilities; with the brain homogenate supporting replication of 
PrP-res to detectable levels whilst the spleen homogenate did not contain a variant that was 
able to support replication of PrP-res to a detectable level in the brain tissue.  
Although a tissue-specific difference in PrP-res deposition was observed for the 101LL/GSS 
disease case, the biochemical and immunohistochemical analysis of the 101LL/263K brain 
and spleen homogenate recipient mice did not show the same variation. The difference in 
results between the two strains could be hypothesised to be due to the differential 
involvement of the LRS in disease pathogenesis of each strain. Hamster 263K scrapie shows 
LRS involvement in its natural host, indicating that a sub-variant of the agent may be 
adapted to replicate in the splenic tissue-specific conditions. In comparison, no PrP-res has 
been detected in the spleen of human GSS cases including the case that was the source of the 
inocula for the primary transmission (Peden A – personal communication), suggesting the 
agent may not be adapted to splenic tissue conditions and therefore adaptation occurs within 
the mouse model utilised as the majority of mouse models have agent replication and PrP-res 
accumulation in the spleen tissue.   
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Although data have shown that different forms of PrP
Sc
 may exist within a single isolate 
whether all isoforms present are infectious remains unknown. A recent study, suggested that 
propagation occurs in two distinct stages, firstly, an exponential phase allows for an increase 
in infectivity levels that reach a plateau, followed by a second linear phase that produces a 
toxic species of PrP that is dependent on the PrP
C
 expression rate (Sandberg, Al-Doujaily et 
al. 2011). Therefore the authors proposed an uncoupling of infectivity and toxicity but still 
suggest a role for a toxic form of PrP, which could fit with the theory that there is a 
heterogeneous population of PrP
Sc
 forms where some but not all of the PrP
Sc
 forms are toxic. 
Given the increase in evidence of multiple isoforms of PrP
Sc
, diagnostic tests that do not rely 
on proteinase K digestion to differentiate between PrP-res and PrP
C
 may be more sensitive.  
If heterogeneous populations of disease-associated PrP forms are present, it is possible that 
within the 101LL/GSS and 101LL/263K disease models there are either multiple isoforms of 
PrP present that cause disease all of which are at too low a concentration for standard 
detection methods, or there is a single form of PrP that is the infectious agent that is not 
detectable by the majority of biochemical techniques currently available with the exception 
of the IDEXX HerdChek* assay.  
7.4. Is there a potential co-factor in infection or PrPSc replication? 
Given that disease cases have been identified in which PrP-res was absent (Section 1.2.3), 
another hypothesis is that a co-factor in association with PrP acts as the infectious agent 
(Manuelidis 2003, Manuelidis 2007). Indeed, the alternative hypotheses (Section 1.2.2), 
implicating a virus or virino propose that an as yet unidentified nucleic acid is the co-factor 
associated with PrP
Sc
 that encodes for the individual strain characteristics and mutates to 
allow adaptation to new hosts and conditions (Farquhar, Somerville et al. 1998). Another 
possible role for a co-factor that could be hypothesised is that the co-factor is required to act 
as either a catalyst or a stabiliser for PrP
Sc
 formation. The protein X hypothesis first proposed 
the potential role of a co-factor that binds to PrP
C
 and acts as a molecular chaperone to 
enable the conversion of the normal cellular form to PrP
Sc
 (Telling, Scott et al. 1995). 
Despite the identification of many cellular proteins that bind to PrP
C
 (Section 1.1.3), the 
identification of a protein X component, if there is one, is lacking. However protein X may 
not be a protein but rather another component that may act as a scaffold to allow conversion. 
Indeed, PMCA data has identified that the minimal components required to produce PrP
Sc 
from an unseeded recombinant PrP substrate was either poly(A)RNA (Deleault, Harris et al. 
2007) or an anionic lipid and RNA molecules (Wang, Wang et al. 2011). The PMCA derived 
products were shown to be infectious by bioassay but cross-contamination cannot be ruled 
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out as a source of the infectivity. More research is required to determine if a polyanion is 
required as a co-factor for the production of mis-folded PrP and/or infectivity. Recent 
promising research by Deleault et al (Deleault, Piro et al. 2012) has identified 
phosphatidylethanolamine (PE), as a co-factor that can support PrP
Sc
 propagation using PrP
C
 
molecules from a number of different animal species; hamster, mouse, vole and deer. This 
brain-derived co-factor molecule, PE, was able to support serial PMCA replication from 
recombinant PrP substrate and a purified PrP
Sc
 seed, producing an infectious seed after 18 
serial rounds that caused a clinical TSE disease upon inoculation into wild-type mice 
(Deleault, Piro et al. 2012). Other work suggests a role for glycosaminoglycans as co-factors 
specifically negatively charged sulphated polysaccharides that interact with the N-terminal 
of PrP
C
 although glycosaminoglycans have been shown to both stimulate and block PrP
Sc
 
formation (Vieira, Reynaldo et al. 2010). Whether a single component can act as a co-factor 
or multiple components can interchange and allow conversion remains to be determined but 
identification of any co-factor(s) present is important for a complete understanding of prion 
disease pathogenesis.  
In this study, attempts were made to identify the protein and/or co-factors that were 
associated with the target of the Seprion ligand through analysis of the eluate produced from 
PAD-beads depletion. This project focused on protein differences between an infected and 
uninfected eluate to identify the target of the Seprion ligand from a well-characterised 
standard strain. The absence of any identifiable protein differences between an infected and 
uninfected eluate (Section 6.2.3) indicates that any protein differences were at too low a 
level for detection by the total-protein analysis techniques performed or that the ligand target 
is associated with another macromolecule such as a nucleic acid or an RNA polyion 
(Deleault, Harris et al. 2007, Deleault, Piro et al. 2012) or a glycosaminoglycans such as 
heparin sulphate (Vieira, Reynaldo et al. 2010).  
7.5. Is PrP-res a reliable marker for TSE diagnostics? 
Based on the prion hypothesis and the resistance of PrP
Sc
 to PK digestion, the presence of 
PrP-res is currently diagnostic for TSE disease and identifies the majority of TSE disease 
cases. However, as shown within this thesis and in both natural and experimental diseases 
cases (Section 1.2.3) there can be a disparity between levels of PrP-res and the levels of 
infectivity. As infectivity can be present without the detection of PrP-res, the reliance of 
rapid post-mortem tests on the presence of this molecule indicates that some positive disease 
cases may be misdiagnosed as negative. Current tests for sheep scrapie, including the BIO-
RAD TeSeE western blot and ELISA kits were shown to have lower sensitivity for 
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identifying atypical scrapie disease cases compared to classical scrapie disease cases. Further 
the lymphoid tissues from atypical sheep scrapie cases have been shown to contain 
infectivity despite the absence of PrP-res
 
(Andreoletti, Orge et al. 2011), disease cases that 
would be mis-diagnosed if analysed with diagnostic tests that rely on the presence of PrP-res 
as indicative of disease.  
The presence of TSE infectivity in blood and blood products has been shown through both 
iatrogenic transmission of vCJD (Llewelyn, Hewitt et al. 2004, Peden, Head et al. 2004, 
Wroe, Pal et al. 2006, Peden, McCardle et al. 2010) and experimental transmission of sheep 
BSE through transfusion (McCutcheon, Alejo Blanco et al. 2011). However, the presence of 
PrP
Sc
 in the blood transfused was not analysed in this experimental model due to the known 
complications of detecting PrP-res from blood (Section 1.4.2). Despite the low levels of PrP-
res in blood, all clinically-relevant blood components have been shown to contain high levels 
of infectivity with a single transfusion from an infected donor capable of transmitting disease 
in the experimental sheep models (McCutcheon, Alejo Blanco et al. 2011, Andréoletti, 
Litaise et al. 2012, Lacroux, Vilette et al. 2012). These studies also indicated that infectivity 
was first detectable in blood of scrapie-infected sheep from 90 days post inoculation 
(Lacroux, Vilette et al. 2012) and detected as early as 27% of the incubation period for BSE-
infected sheep that were orally infected (McCutcheon, Alejo Blanco et al. 2011). Both 
experimental sheep models show that blood was infectious prior to the clinical onset of 
disease indicating the requirement of a blood screening assay for diagnosis of subclinical 
disease cases.  
A combined effect of the low levels of PrP-res and a high background of PrP
C
 limits the 
development of a blood test to identify PrP-res. Other tests that have targeted the abnormal, 
disease-associated form of PrP, including Amofix‟s epitope protection vCJD assay and a test 
based on the palindromic synthetic Pronucleon™ ligand were initially successful at detecting 
positive cases that were spiked with brain homogenate but ultimately were unable to detect 
disease cases from non-spiked blood samples from patients (Section 1.4.2). Given both the 
disparity between low levels of PrP-res despite the presence of infectivity and the inability of 
these tests to ultimately detect the disease-associated form of PrP in blood from non-spiked 
blood samples indicates that perhaps the infectious agent in blood may be another form of 
PrP that remains unidentified.  
Given the problems with detecting PrP-res and the disparity between PrP-res and TSE 
infectivity, there is a requirement for a more suitable marker of TSE infectivity for 
diagnostic testing in order to identify all cases of TSE disease, ideally during the non-
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symptomatic phase. The ideal marker would be in an easily accessible bodily fluid with 
detection incorporated into a TSE diagnostic test that is rapid, high-throughput, highly 
sensitive and specific and able to detect disease during the asymptomatic stage of disease as 
well as during the clinical stage of disease. Currently, the development of amplification tests 
that amplify the low levels of PrP-res in the blood and other bodily fluids to detectable levels 
or the detection of aggregated PrP have the most promise to be developed into diagnostic 
tests (Section 1.5).  
7.6. Can amplification of PrP-res by PMCA be diagnostic? 
When the studies described in this PhD were initiated, the PMCA technique was proposed as 
a diagnostic test (Castilla, Saa et al. 2006, Grassi, Maillet et al. 2008). Due to the low levels 
of PrP-res present in blood, the development of the PMCA amplification assay was seen as 
promising to amplify PrP-res to a detectable level. Despite a number of groups amplifying 
PrP-res from blood utilising the PMCA technique from different experimental models 
(Castilla, Saa et al. 2005, Saa, Castilla et al. 2006, Thorne and Terry 2008), development of a 
diagnostic PMCA assay was hindered due to the requirement of a normal brain homogenate 
substrate and problems with false positives and spontaneous formation of PrP-res in negative 
controls (Cosseddu, Nonno et al. 2011). These together with the technical variations 
observed between different laboratories, and varying efficiencies of different sonicators have 
delayed the production of a PMCA diagnostic test (Cosseddu, Nonno et al. 2011, Gonzalez-
Montalban, Makarava et al. 2011).  
However, the PMCA technique has become a hugely valuable research tool within the prion 





. The PMCA technique has been used to produce „synthetic prions‟ 
in vitro from either minimal components or recombinant PrP substrate, and if these were 
shown to be infectious would be definitive proof of the prion hypothesis (Deleault, Harris et 
al. 2007, Barria, Mukherjee et al. 2009, Kim, Cali et al. 2010, Wang, Wang et al. 2010). 
Although these in vitro derived prions are infectious, initial low levels of infectivity were 
observed (Kim, Cali et al. 2010, Makarava, Kovacs et al. 2010) or infectivity was produced 
from the combination of 50 reactions (Wang, Wang et al. 2010) questioning whether 
infectivity was replicated to a level similar to that observed in natural disease. Despite these 
promising results, the possibility of cross-contamination cannot be ruled out, especially when 
a recent study has shown that “de novo PrP-res formation” only occurred when a positive 
control was included in the PMCA reaction (Cosseddu, Nonno et al. 2011). Further the 
PMCA product has been shown to have 0.8 log10 lower infectivity level than brain-derived 
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material (Shikiya and Bartz 2011). This result implies that infectivity has not been replicated 
but rather a similar level maintained. Another study showed that the ratio of infectivity to 
PrP-res was much lower in PMCA-derived samples compared to brain-derived samples, 
indicating that a portion of PrP
Sc
 produced during the PMCA reaction might not be infectious 
(Klingeborn, Race et al. 2011).  
A full understanding of the mechanism of PrP-res amplification has not been achieved and 
how the conversion occurs within the test tube remains poorly understood. Indeed PMCA 
under standard conditions, (i.e. one round of 48 hours) has been shown to replicate the 
species barrier (Castilla 2008) and not produce any spontaneous formation of PrP-res 
(Barria, Mukherjee et al. 2009). It is only following extended rounds of serial PMCA that 
amplification can be achieved using extreme combinations of seed and substrate. For 
example, rabbit PrP can produce infectious PrP-res when seeded with murine scrapie and 
subjected to 7-13 rounds of PMCA, despite the fact that rabbits are resistant to TSE disease 
(Chianini, Fernández-Borges et al. 2012). Indeed researchers have shown that the production 
of the infectious synthetic strains required between 10-17 rounds of PMCA (Deleault, Harris 
et al. 2007, Barria, Mukherjee et al. 2009, Wang, Wang et al. 2010) increasing the risk of 
cross-contamination with the results then open to interpretation. Although the ability to 
amplify PrP-res in a cell-free system is a significant achievement and has proved invaluable 
for prion disease research, these results highlight a discrepancy between the levels of PrP-res 
and the levels of infectivity from the PMCA-derived material indicating that not all the PrP-
res formed is infectious. 
This thesis aimed to utilise the PMCA technique as a research tool to further understand the 
role of PrP-res in disease pathogenesis and to determine if PrP-res and/or TSE infectivity 
could be amplified from the 101LL/GSS and 101LL/263K tissues that contained little or no 
PrP-res to further investigate the correlation between PrP-res and infectivity (Chapter 5). 
However, the PMCA technique could not be optimised to produce consistent, reproducible 
amplification of PrP-res from standard mouse scrapie strains. Despite the wealth of data that 
exists from PMCA experiments, the majority of the rodent based PMCA research has 
focussed on investigations using hamster tissue rather than wild-type mouse tissue, in spite 
of the fact that mice are widely utilised model for TSE research. Indeed Weber et al (Weber, 
Giese et al. 2006) stated that the use of hamster tissue provides a more efficient and robust 
amplification than mouse tissue. Given that transgenic mouse models that express a different 
PrP
C
 species were able to support amplification (Jones, Peden et al. 2007), it is hypothesised 
that perhaps the conformation or stability of mouse PrP
C
 is altered compared to other species 
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that prevents consistent amplification from occurring unless precise technical conditions are 
achieved. The efficiency of PMCA varies both within experiments, due to the individual 
pattern of horn corrosion and distribution of the sonication energy, and between experiments 
depending on the age of the sonicator horn (Gonzalez-Montalban, Makarava et al. 2011) and 
it was concluded that the Misonix 4000 sonicator present at the Roslin Institute was 
inefficient at supporting reproducible amplification. The absence of a reproducible positive 
control with mouse tissues prevented the further analysis of the experimental 101LL/GSS 
and 101LL/263K homogenates. A recent paper (Saá, Sferrazza et al. 2012) utilised an 
enhanced PMCA technique with metal beads to show a strain-specific role of RNAs in PrP-
res amplification for mouse TSE strains. Initial data showed that all mouse strains assessed 
were able to amplify although ME7 showed the lowest conversion efficiency and the 79A 
strain showed a high level of conversion efficiency in the standard PMCA experiment with 
the presence of beads (Saá, Sferrazza et al. 2012), whether amplification of these strains was 
achieved in a PMCA reaction in the absence of beads would be interesting to ascertain. 
Further both ME7 and 79A strains were shown by Saa and colleagues (Saá, Sferrazza et al. 
2012) to have a high dependency on the presence of RNA for amplification to occur and it 
could be hypothesised that the production of the substrate during these studies failed to retain 
enough RNA to support amplification.  
7.7. Is aggregated PrP a reliable marker for disease? 
One commercially available diagnostic test, the IDEXX HerdChek* assay uses the Seprion 
ligand to capture a form of aggregated PrP (Lane, Stanley et al. 2003, S, A et al. 2004, 
Wilson, Lane et al. 2004) that is then detected with an anti-PrP antibody, without the 
requirement of PK digestion. This test is advantageous as it detects aggregated forms of PrP 
and may identify more cases of TSE disease than a test that relies on PK digestion. Indeed, 
the IDEXX HerdChek* kit has been shown to identify an atypical case of sheep scrapie that 
was not detected utilising the Prionics®-Check western small ruminant rapid test (Bozzetta, 
Nappi et al. 2011). Further this IDEXX HerdChek* assay was also shown to have the 
greatest sensitivity for classical cattle BSE compared to other rapid tests (Gray, Dudas et al. 
2011) and was shown to have the greatest sensitivity for all three of BSE types; classical-
BSE, atypical H-type and L-type BSE, in comparison to the PrioSTRIP (Prionics) and TeSeE 
ELISA (BIO-RAD) (Gray, Dudas et al. 2012). An adaptation of the IDEXX HerdChek* 
assay has been utilised to detect aggregated PrP
Sc
 in blood from 55% scrapie-affected and 
71% BSE-affected terminal sheep. However, the detection of aggregated PrP
Sc
 in blood from 
scrapie-affected sheep that were asymptomatic was intermittent indicating that PrP
Sc
 was not 
present in the blood throughout the entire disease period (Terry, Howells et al. 2009). 
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However, the IDEXX HerdChek* assay has identified healthy mice in which PrP amyloid 
plaques had been seeded as positive for TSE disease despite the absence of TSE infectivity 
(R. Barron – personal communication) producing a false positive.  
The IDEXX HerdChek* assay identified both the 101LL/GSS and 101LL/263K brain and 
spleen tissues as positive for TSE disease (Section 3.2.5 and 4.2.1). Other commercially 
available assays, such as the TeSeE Western blot assay (BIO-RAD) produced negative or 
borderline results for these unusual tissues (King, D – personal communication). This result 
indicates that within these tissues there is a form of PrP that is abnormal, presumably 
aggregated and therefore captured by the Seprion ligand. Although not quantitative, analysis 
of different concentrations of 101LL/GSS and 101LL/263K brain tissue homogenates with 
the IDEXX HerdChek* assay (Figure 3-20) indicated that the 101LL/GSS and 101LL/263K 
contain a lower level of the Seprion target than a wild-type/79A despite the high levels of 
infectivity present in both disease models.  
A single depletion (Section 6.2.4) of 101LL/GSS, 101LL/263K and wild-type/79A brain 
homogenates using the Seprion ligand in association with magnetic beads did not 
consistently reduce the level of infectivity in either the experimental 101LL/GSS and 
101LL/263K or the control wild-type/79A dh samples. The 101LL/GSS and 101LL/263K dh 
remained infectious despite the lack of detectable PrP by immunoblot in these inocula 
samples. Surprisingly, significant levels of infectivity were present in the wash buffers 
produced from the PAD-beads procedure from both the experimental and wild-type/79A 
samples, although no PrP was identified by immunoblots (Figure 6-19) and only low levels 
were present in the wild-type/79A wash buffer using the IDEXX HerdChek* assay. This 
suggests that the infectious agent was initially bound to either the Seprion reagent or the 
magnetic beads and then released during the wash periods. However, further work is 
required to determine the nature of the infectious agent within the wash buffers.  
To determine if the Seprion target is the infectious agent, multiple depletions (Section 6.2.4) 
were performed with the Seprion ligand in association with magnetic beads to ensure the 
Seprion target was completely removed from the dh. The hypothesis that was pursued was 
that if the aggregated form of PrP detected by the Seprion ligand was the TSE infectious 
agent, then the infectivity levels in the five times depleted methanol precipitated homogenate 
will decrease resulting in an observable increase in incubation period in comparison to the 
five times methanol precipitated control. Indeed results (Table 6-5, Figure 6-27) indicate that 
the multiple depletions with the Seprion ligand have reduced the level of infectivity in the 
depleted homogenate for 101LL/GSS and wild-type/79A but not 101LL/263K. Once this 
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hypothesis has been confirmed through further repeat bioassay experiments on more sample 
homogenates then further work can use more sensitive techniques to characterise the 
composition of the Seprion ligand target. This result highlights the Seprion ligand as an 
invaluable diagnostic agent, able to correctly identify disease cases that have extremely low 
levels of PrP-res and indicate that perhaps the detection of aggregated PrP could have greater 
diagnostic sensitivity.  
One other in vitro amplification assay that has shown promise as a diagnostic assay is the 
QuIC assay (Section 1.5.3) that has been optimised to detect amyloid formation in real-time 
through thioflavin T fluorescence (RT-QuIC) (Atarashi, Satoh et al. 2011). The detection of 
aggregates from sCJD clinical CSF specimens samples has been shown with 91% sensitivity 
and 98% specificity (McGuire, Peden et al. 2012). Analysis of the RT-QuIC reaction 
product, seeded with hamster 263K, has shown it to be PrP
Sc
-like with increased β-sheet 
content and a western blot profile with bands at 20, 18, 14 and 13kDa (Wilham, Orrú et al. 
2010).  The development of RT-QuIC is directed towards producing a clinical diagnostic test 
and detects an aggregated protein product, although the relationship of the seeding activity, 
the aggregated recombinant prion protein produced and infectivity remains unknown. 
Preliminary analysis using 101LL/GSS and 101LL/263K brain tissue as seeds in the RT-
QuIC assay indicated that aggregates formed at the same rate as ME7 aggregates with 




 dilutions of experimental and control 
brain homogenates (Janice Barr and James Alibhai – personal communication). Therefore 
there is probably an aggregate form of PrP present in the 101LL/GSS and 101LL/263K 
tissues that seeds amyloid formation in the RT-QuIC. These preliminary RT-QuIC data 
confirms the IDEXX HerdChek* result that there is an aggregated protein within the 
101LL/GSS and 101LL/263K tissues. It needs to be determined whether both assays are 
detecting the same aggregated isoform that is undetectable by other biochemical techniques 
and the role of the aggregated isoform has in disease.  
7.8. Summary of results 
Based on both previous data and the data presented in this thesis, it can be assumed that 
within the 101LL/GSS and 101LL/263K brain tissues there is a form of the TSE infectious 
agent that is PK-resistant, aggregated, detergent soluble and highly infectious that has not 
been identified by the conventional methods currently used. The analysis of brain and spleen 
tissues from these mice indicated that extremely low levels of PrP-res were present in these 
tissues but the level present was not sufficient to explain the high levels of infectivity 
observed, highlighting a discrepancy between PrP-res and infectivity. Although there was no 
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evidence of a previously identified alternative form of PrP, such as sPrP
Sc
 in these tissues, 
there may be another form of PrP that has avoided detection with the different techniques 
tested. The IDEXX HerdChek* assay that uses the Seprion ligand identified both the 
101LL/GSS and 101LL/263K tissues as positive for TSE disease. A single depletion of the 
brain homogenates with the Seprion ligand in association with magnetic beads was not 
enough to significantly reduce the levels of infectivity present. High levels of infectivity 
were present in the depleted homogenate despite the absence of PrP in the 101LL/GSS and 
101LL/263K depleted homogenates. Additionally, the presence of infectivity in the wash 
buffers produced from the single PAD-beads depletion was surprising and adds to the data 
that highlight a disparity between PrP-res and infectivity for both experimental homogenates 
101LL/GSS and 101LL/263K and the positive control wild-type/79A. Although the 
experiments examining the multiple PAD-beads depletions are still in progress, if the 
aggregate of PrP detected by the Seprion ligand corresponds to the infectious agent a 
decrease in incubation period to disease will be observed for the depleted homogenate. If 
significant levels of infectivity still remain following 5 rounds of depletion this would 
indicate that the aggregated form that is the target of the Seprion ligand is not the infectious 
agent in these disease models and would question the nature of the aggregated protein to 
which the Seprion ligand binds.  
7.9. Future Work 
In order to understand the relationship between PrP-res and TSE infectivity, further studies 
on these unique disease models 101LL/GSS and 101LL/263K may identify either a form of 
PrP or other molecular species that constitutes the infectious agent. Through analysis of the 
brain tissue the possible presence of a PK-sensitive isoform of PrP
Sc
 needs further 
investigation. Due to the recent increase in methodologies for the isolation of sPrP
Sc
, these 
methods could be performed, in combination with either cell culture or bioassay to determine 
if a level of infectivity is associated with a sPrP
Sc
 isoform. Further, it would be interesting to 
trial a PET-blot technique to determine if the minimal staining observed in the brain tissue 
by immunohistochemistry is indeed PrP-res.  
The main interest for future work focuses on the disparity of PrP-res and infectivity present 
in the spleen. The first experiments that need to be performed are a full titration to determine 
the level of TSE infectivity in the spleen tissue. Further, to confirm that this unusual 
phenomenon is not due to the 101LL mutation, the same strain of agent should be passaged 
in both 101LL and wild-type mice and then the spleen tissue sub-passaged to determine the 
levels of infectivity. During the initial studies to produce primary tissue for sub-passage, a 
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number of spleens could be immediately placed into formal saline for fixation to allow for 
immunohistochemical analysis to determine the regions of the spleen where PrP
Sc
 is present. 
Full quantification of the levels of PrP-res present in the primary spleen tissue also needs to 
be performed through both biochemical and PET-blot techniques. Further, it would be 
interesting to perform a time-course study to determine when PrP-res is present in the spleen 
and if it follows the pattern expected, of an early increase followed by a plateau. Analysis of 
the levels of infectivity through-out the time course would also be of interest to determine if 
the PrP-res and infectivity levels correlate.  
Given the recent paper by Saa and colleagues (Saá, Sferrazza et al. 2012) PMCA 
optimisation could be continued using the PMCA procedure with beads, determining the 
level of RNA present in the substrate and possibly optimising the substrate preparation 
methodology to retain as high a concentration of RNA as possible. If a reliable, reproducible 
positive control can be obtained, experiments could be performed to determine if PrP-res and 
TSE infectivity are amplifiable from a 101LL/GSS and 101LL/263K seeds. 
Further work will continue to investigate the identity of the Seprion ligand target through 
continuation of the preliminary assays performed within this study such as the 2D-PAGE and 
SELDI analysis along with other more sensitive proteomic techniques. Given that the 
multiple depletions bioassay result should determine the association of the Seprion ligand 
target with infectivity, work could concentrate on identifying the proteins or other 
components including DNAs or RNAs present in the eluates, initially from a standard 
scrapie brain homogenate compared to a normal brain homogenate. Further work could then 
identify and quantify the level of the Seprion ligand target in the 101LL/GSS and 
101LL/263K tissues. Furthermore, additional analysis of the eluates potentially through 
electron microscopy would help to determine the structure of the eluted aggregated protein. 
Further work is also required to investigate if a form of PrP-res is present in the combined 
wash buffers with more sensitive biochemical and proteomic techniques.  
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7.10. Conclusion statement 
Within the 101LL/GSS and 101LL/263K tissues there may be a sub-population of an 
aggregated form of PrP that is present at a low abundance that is beyond the detection limits 
of current standard biochemical and immunohistochemical techniques. These data presented 
in this thesis add to the wealth of data that suggest that PrP-res is not the sole component of 
the infectious agent within TSE diseases. Therefore the reliability of diagnostic tests on the 
presence of PrP-res might not detect all cases of TSE disease, possibly under estimating the 
level of TSE disease currently present in farm animals. Mis-diagnosis of TSE cases in the 
agricultural world could allow infected material to enter the human food chain, a major 
concern to human health throughout the UK. The disparity observed between PrP-res and 
infectivity, together with the knowledge that low levels of PrP-res are present in blood from 
infected individuals indicates that a more reliable disease marker for infectivity should be 
sought to improve the sensitivity and specificity of future human diagnostic techniques.  
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Appendix 1  
Table of primary anti-PrP antibodies used 
Antibody  Epitope(s) Reference 
8H4 145-220 (Li, Liu et al. 2000) 
6H4 143-151 (Korth, Stierli et al. 1997) 
7A12 90-145 (Li, Liu et al. 2000) 
FH11 54-58 (Thuring, van Keulen et al. 
2005) 
SAF32 59-89 (Féraudet, Morel et al. 2005) 
1B3 (polyclonal) 14-36, 83-102, 119-139, 
188-212 
(Farquhar, Somerville et al. 
1989) 
BC6 144-154 of sheep PrP Kindly provided by S. 
McCutcheon, RI 
3F4 (detects hamster and 
human PrP) 
109-112 of human PrP (Kascsak, Rubenstein et al. 
1987) 
SAF84 160-170 of hamster PrP Kindly provided by GM 
Cosseddu, ISS 








Figure 0-1: Loss of PrP
Sc
 staining by immunohistochemistry dependent upon pre-treatments 
performed prior to fixation in formal saline. (A and C) did not undergo any pre-treatment and 
therefore retained PrP
Sc
 staining whist both (B) that was pre-treated overnight with formic acid prior 
to fixation and (D) that was pre-treated with formic acid for 1.5 hours prior to fixation lost the ability 
to stain PrP
Sc





Agrimi, U., R. Nonno, G. Dell'Omo, M. A. Di Bari, M. Conte, B. Chiappini, E. Esposito, G. Di 
Guardo, O. Windl, G. Vaccari and H. P. Lipp (2008). "Prion protein amino acid determinants 
of differential susceptibility and molecular feature of prion strains in mice and voles." PLoS 
Pathog 4(7): e1000113. 
Amorfix. (2009). "Amorfix detects vCJD prions in blood from non-human primates."   
Retrieved 11.08.2012, 2012. 
Amorfix. (2009). "Amorfix test for vCJD achieves 100% specificity on 20,000 blood donations 
in France."   Retrieved 11.08.2012, 2012. 
Amorfix. (2010). "Corporate update on vCJD test development."   Retrieved 11.08.2012, 
2012. 
Andreoletti, O., L. Orge, S. L. Benestad, V. Beringue, C. Litaise, S. Simon, A. Le Dur, H. Laude, 
H. Simmons, S. Lugan, F. Corbiere, P. Costes, N. Morel, F. Schelcher and C. Lacroux (2011). 
"Atypical/Nor98 scrapie infectivity in sheep peripheral tissues." PLoS Pathog 7(2): 
e1001285. 
Andréoletti, O., P. Berthon, D. Marc, P. Sarradin, J. Grosclaude, L. van Keulen, F. Schelcher, 
J. M. Elsen and F. Lantier (2000). "Early accumulation of PrP(Sc) in gut-associated lymphoid 
and nervous tissues of susceptible sheep from a Romanov flock with natural scrapie." J Gen 
Virol 81(Pt 12): 3115-3126. 
Andréoletti, O., C. Litaise, H. Simmons, F. Corbière, S. Lugan, P. Costes, F. Schelcher, D. 
Vilette, J. Grassi and C. Lacroux (2012). "Highly efficient prion transmission by blood 
transfusion." PLoS Pathog 8(6): e1002782. 
Asante, E. A., I. Gowland, A. Grimshaw, J. M. Linehan, M. Smidak, R. Houghton, O. Osiguwa, 
A. Tomlinson, S. Joiner, S. Brandner, J. D. Wadsworth and J. Collinge (2009). "Absence of 
spontaneous disease and comparative prion susceptibility of transgenic mice expressing 
mutant human prion proteins." J Gen Virol 90(Pt 3): 546-558. 
Atarashi, R., R. A. Moore, V. L. Sim, A. G. Hughson, D. W. Dorward, H. A. Onwubiko, S. A. 
Priola and B. Caughey (2007). "Ultrasensitive detection of scrapie prion protein using 
seeded conversion of recombinant prion protein." Nat Methods 4(8): 645-650. 
Atarashi, R., K. Satoh, K. Sano, T. Fuse, N. Yamaguchi, D. Ishibashi, T. Matsubara, T. 
Nakagaki, H. Yamanaka, S. Shirabe, M. Yamada, H. Mizusawa, T. Kitamoto, G. Klug, A. 
McGlade, S. J. Collins and N. Nishida (2011). "Ultrasensitive human prion detection in 
cerebrospinal fluid by real-time quaking-induced conversion." Nat Med 17(2): 175-178. 
Atarashi, R., J. M. Wilham, L. Christensen, A. G. Hughson, R. A. Moore, L. M. Johnson, H. A. 
Onwubiko, S. A. Priola and B. Caughey (2008). "Simplified ultrasensitive prion detection by 
recombinant PrP conversion with shaking." Nat Methods 5(3): 211-212. 
Baker, H. F., L. W. Duchen, J. M. Jacobs and R. M. Ridley (1990). "Spongiform 
encephalopathy transmitted experimentally from Creutzfeldt-Jakob and familial 
Gerstmann-Sträussler-Scheinker diseases." Brain 113 ( Pt 6): 1891-1909. 
Barr, J. B., M. Watson, M. W. Head, J. W. Ironside, N. Harris, C. Hogarth, J. R. Fraser and R. 
Barron (2009). "Differential protein profiling as a potential multi -marker approach for TSE 
diagnosis." BMC Infect Dis 9(1): 188. 
Barria, M. A., A. Mukherjee, D. Gonzalez-Romero, R. Morales and C. Soto (2009). "De novo 
generation of infectious prions in vitro produces a new disease phenotype." PLoS Pathog 
5(5): e1000421. 
Barria, M. A., G. C. Telling, P. Gambetti, J. A. Mastrianni and C. Soto (2011). "Generation of a 




Barron, R. M., H. Baybutt, N. L. Tuzi, J. McCormack, D. King, R. C. Moore, D. W. Melton and 
J. C. Manson (2005). "Polymorphisms at codons 108 and 189 in murine PrP play distinct 
roles in the control of scrapie incubation time." J Gen Virol 86(Pt 3): 859-868. 
Barron, R. M., S. L. Campbell, D. King, A. Bellon, K. E. Chapman, R. A. Williamson and J. C. 
Manson (2007). "High titers of transmissible spongiform encephalopathy infectivity 
associated with extremely low levels of PrPSc in vivo." J Biol Chem 282(49): 35878-35886. 
Barron, R. M., V. Thomson, E. Jamieson, D. W. Melton, J. Ironside, R. Will and J. C. Manson 
(2001). "Changing a single amino acid in the N-terminus of murine PrP alters TSE incubation 
time across three species barriers." EMBO J 20(18): 5070-5078. 
Barron, R. M., V. Thomson, D. King, J. Shaw, D. W. Melton and J. C. Manson (2003). 
"Transmission of murine scrapie to P101L transgenic mice." J Gen Virol 84(Pt 11): 3165-
3172. 
Biasini, E., J. A. Turnbaugh, U. Unterberger and D. A. Harris (2011). "Prion protein at the 
crossroads of physiology and disease." Trends Neurosci. 
Bishop, M. T., P. Hart, L. Aitchison, H. N. Baybutt, C. Plinston, V. Thomson, N. L. Tuzi, M. W. 
Head, J. W. Ironside, R. G. Will and J. C. Manson (2006). "Predicting susceptibility and 
incubation time of human-to-human transmission of vCJD." Lancet Neurol 5(5): 393-398. 
Bolton, D. C., M. P. McKinley and S. B. Prusiner (1982). "Identification of a protein that 
purifies with the scrapie prion." Science 218(4579): 1309-1311. 
Bounhar, Y., Y. Zhang, C. G. Goodyer and A. LeBlanc (2001). "Prion protein protects human 
neurons against Bax-mediated apoptosis." J Biol Chem 276(42): 39145-39149. 
Bouzalas, I. G., F. Lortscher, C. I. Dovas, A. Oevermann, J. P. Langeveld, M. 
Papanastassopoulou, O. Papadopoulos, A. Zurbriggen and T. Seuberlich (2011). "Distinct 
proteinase K-resistant prion protein fragment in goats with no signs of disease in a classical 
scrapie outbreak." J Clin Microbiol 49(6): 2109-2115. 
Bozzetta, E., R. Nappi, S. Crudeli, D. Meloni, K. Varello, D. Loprevite, P. G. Melis, M. Mazza, 
S. Colussi, F. Ingravalle, G. Ru, R. Nonno and C. Ligios (2011). "Comparative performance of 
three TSE rapid tests for surveillance in healthy sheep affected by scrapie." J Virol Methods 
173(2): 161-168. 
Bruce, M. E., R. G. Will, J. W. Ironside, I. McConnell, D. Drummond, A. Suttie, L. McCardle, A. 
Chree, J. Hope, C. Birkett, S. Cousens, H. Fraser and C. J. Bostock (1997). "Transmissions to 
mice indicate that 'new variant' CJD is caused by the BSE agent." Nature 389(6650): 498-
501. 
Bueler, H., A. Aguzzi, A. Sailer, R. A. Greiner, P. Autenried, M. Aguet and C. Weissmann 
(1993). "Mice devoid of PrP are resistant to scrapie." Cell 73(7): 1339-1347. 
Buschmann, A., A. G. Biacabe, U. Ziegler, A. Bencsik, J. Y. Madec, G. Erhardt, G. Lühken, T. 
Baron and M. H. Groschup (2004). "Atypical scrapie cases in Germany and France are 
identified by discrepant reaction patterns in BSE rapid tests." J Virol Methods 117(1): 27-36. 
Béringue, V., L. Herzog, E. Jaumain, F. Reine, P. Sibille, A. Le Dur, J. L. Vilotte and H. Laude 
(2012). "Facilitated cross-species transmission of prions in extraneural tissue." Science 
335(6067): 472-475. 
Büeler, H., M. Fischer, Y. Lang, H. Bluethmann, H. P. Lipp, S. J. DeArmond, S. B. Prusiner, M. 
Aguet and C. Weissmann (1992). "Normal development and behaviour of mice lacking the 
neuronal cell-surface PrP protein." Nature 356(6370): 577-582. 
Carp, R. I., H. Meeker and E. Sersen (1997). "Scrapie strains retain their distinctive 
characteristics following passages of homogenates from different brain regions and 
spleen." J Gen Virol 78 ( Pt 1): 283-290. 
Castilla, J., Gonzalez-Romero, D., Saa. P., Morales, R., Castro. J. and Soto, P (2008). "Crossing 




Castilla, J., Morales, R., Saa, P., Barria, M., Gambetti, P. and Soto., C (2008). "Cell-free 
propagation of prion strains." The EMBO Journal: 1-10. 
Castilla, J., P. Saa, C. Hetz and C. Soto (2005). "In vitro generation of infectious scrapie 
prions." Cell 121(2): 195-206. 
Castilla, J., P. Saa, R. Morales, K. Abid, K. Maundrell and C. Soto (2006). "Protein misfolding 
cyclic amplification for diagnosis and prion propagation studies." Methods Enzymol 412: 3-
21. 
Castilla, J., P. Saa and C. Soto (2004). Cyclic amplification of prion protein misfolding. 
Techniques in prion research. L. S and G. J. Basel, Birkhauser Verlag: 198-213. 
Castilla, J., P. Saa and C. Soto (2004). Cyclic amplification of prion protein misfolding. 
Techniques in prion research. L. S and G. J. Basel, Birkhauser Verlag: 198-213. 
Castilla, J., P. Saa and C. Soto (2005). "Detection of prions in blood." Nat Med 11(9): 982-
985. 
Cervenakova, L., O. Yakovleva, C. McKenzie, S. Kolchinsky, L. McShane, W. N. Drohan and P. 
Brown (2003). "Similar levels of infectivity in the blood of mice infected with human-
derived vCJD and GSS strains of transmissible spongiform encephalopathy." Transfusion 
43(12): 1687-1694. 
Chianini, F., N. Fernández-Borges, E. Vidal, L. Gibbard, B. Pintado, J. de Castro, S. A. Priola, S. 
Hamilton, S. L. Eaton, J. Finlayson, Y. Pang, P. Steele, H. W. Reid, M. P. Dagleish and J. 
Castilla (2012). "Rabbits are not resistant to prion infection." Proc Natl Acad Sci U S A 
109(13): 5080-5085. 
Chiarini, L. B., A. R. Freitas, S. M. Zanata, R. R. Brentani, V. R. Martins and R. Linden (2002). 
"Cellular prion protein transduces neuroprotective signals." EMBO J 21(13): 3317-3326. 
Chohan, G., C. Pennington, J. M. Mackenzie, M. Andrews, D. Everington, R. G. Will, R. S. 
Knight and A. J. Green (2010). "The role of cerebrospinal fluid 14-3-3 and other proteins in 
the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review." J Neurol 
Neurosurg Psychiatry 81(11): 1243-1248. 
Choi, Y. P., A. Gröner, J. W. Ironside and M. W. Head (2011). "Comparison of the level, 
distribution and form of disease-associated prion protein in variant and sporadic 
Creutzfeldt-Jakob diseased brain using conformation-dependent immunoassay and 
Western blot." J Gen Virol 92(Pt 3): 727-732. 
Clarke, M. C. and D. A. Haig (1971). "Multiplication of scrapie agent in mouse spleen." Res 
Vet Sci 12(2): 195-197. 
Colby, D. W., K. Giles, G. Legname, H. Wille, I. V. Baskakov, S. J. Dearmond and S. B. Prusiner 
(2009). "Design and construction of diverse mammalian prion strains." Proc Natl Acad Sci U 
S A. 
Colby, D. W. and S. B. Prusiner (2011). "De novo generation of prion strains." Nat Rev 
Microbiol 9(11): 771-777. 
Colby, D. W., R. Wain, I. V. Baskakov, G. Legname, C. G. Palmer, H. O. Nguyen, A. Lemus, F. 
E. Cohen, S. J. DeArmond and S. B. Prusiner (2010). "Protease-sensitive synthetic prions." 
PLoS Pathog 6(1): e1000736. 
Colby, D. W., Q. Zhang, S. Wang, D. Groth, G. Legname, D. Riesner and S. B. Prusiner (2007). 
"Prion detection by an amyloid seeding assay." Proc Natl Acad Sci U S A 104(52): 20914-
20919. 
Collinge, J. and A. R. Clarke (2007). "A general model of prion strains and their 
pathogenicity." Science 318(5852): 930-936. 
Cosseddu, G. M., R. Nonno, G. Vaccari, C. Bucalossi, N. Fernandez-Borges, M. A. Di Bari, J. 
Castilla and U. Agrimi (2011). "Ultra-efficient PrP(Sc) amplification highlights potentialities 
and pitfalls of PMCA technology." PLoS Pathog 7(11): e1002370. 
258 
 
Coste, J., C. Prowse, R. Eglin, C. Fang and S. o. TSE (2009). "A report on transmissible 
spongiform encephalopathies and transfusion safety." Vox Sang 96(4): 284-291. 
Cronier, S., N. Gros, M. H. Tattum, G. S. Jackson, A. R. Clarke, J. Collinge and J. D. 
Wadsworth (2008). "Detection and characterization of proteinase K-sensitive disease-
related prion protein with thermolysin." Biochem J 416(2): 297-305. 
Cronier, S., H. Laude and J. M. Peyrin (2004). "Prions can infect primary cultured neurons 
and astrocytes and promote neuronal cell death." Proc Natl Acad Sci U S A 101(33): 12271-
12276. 
D'Castro, L., A. Wenborn, N. Gros, S. Joiner, S. Cronier, J. Collinge and J. D. Wadsworth 
(2010). "Isolation of proteinase K-sensitive prions using pronase E and phosphotungstic 
acid." PLoS One 5(12): e15679. 
Deleault, N. R., J. C. Geoghegan, K. Nishina, R. Kascsak, R. A. Williamson and S. Supattapone 
(2005). "Protease-resistant prion protein amplification reconstituted with partially purified 
substrates and synthetic polyanions." J Biol Chem 280(29): 26873-26879. 
Deleault, N. R., B. T. Harris, J. R. Rees and S. Supattapone (2007). "Formation of native 
prions from minimal components in vitro." Proc Natl Acad Sci U S A 104(23): 9741-9746. 
Deleault, N. R., R. Kascsak, J. C. Geoghegan and S. Supattapone (2010). "Species-dependent 
differences in cofactor utilization for formation of the protease-resistant prion protein in 
vitro." Biochemistry 49(18): 3928-3934. 
Deleault, N. R., J. R. Piro, D. J. Walsh, F. Wang, J. Ma, J. C. Geoghegan and S. Supattapone 
(2012). "Isolation of phosphatidylethanolamine as a solitary cofactor for prion formation in 
the absence of nucleic acids." Proc Natl Acad Sci U S A 109(22): 8546-8551. 
Dickinson, A. G. and H. Fraser (1969). "Genetical control of the concentration of ME7 
scrapie agent in mouse spleen." J Comp Pathol 79(3): 363-366. 
Dickinson, A. G. and V. M. Meikle (1971). "Host-genotype and agent effects in scrapie 
incubation: change in allelic interaction with different strains of agent." Mol Gen Genet 
112(1): 73-79. 
Dickinson, A. G., V. M. Meikle and H. Fraser (1968). "Identification of a gene which controls 
the incubation period of some strains of scrapie agent in mice." J Comp Pathol 78(3): 293-
299. 
Dickinson, A. G., V. M. Meikle and H. Fraser (1969). "Genetical control of the concentration 
of ME7 scrapie agent in the brain of mice." J Comp Pathol 79(1): 15-22. 
Edgeworth, J. A., M. Farmer, A. Sicilia, P. Tavares, J. Beck, T. Campbell, J. Lowe, S. Mead, P. 
Rudge, J. Collinge and G. S. Jackson (2011). "Detection of prion infection in variant 
Creutzfeldt-Jakob disease: a blood-based assay." Lancet 377(9764): 487-493. 
EFSA (2005). "Scientific Report of the European Food Safety authority on the Evaluation of 
Seven New Rapid post mortem BSE Tests." EFSA Journal 17: 1-13. 
EFSA (2007). Opinion of the Scientific Panel on Biological Hazards on a request from the 
European Commission on certain aspects related to the risk of Transmissible Spongiform 
Encephalopathies (TSEs) in ovine and caprine animals,. The EFSA Journal. 466: 1-10. 
EFSA (2012). Scientific Opinion on the evaluation of new TSE rapid tests submitted in the 
framework of the Commission Call for expression of interest 2007/S204-247339. EFSA 
Journal. 10: 2660. 
Everest, S. J., L. T. Thorne, J. A. Hawthorn, R. Jenkins, C. Hammersley, A. M. Ramsay, S. A. 
Hawkins, L. Venables, L. Flynn, R. Sayers, J. Kilpatrick, A. Sach, J. Hope and R. Jackman 
(2006). "No abnormal prion protein detected in the milk of cattle infected with the bovine 
spongiform encephalopathy agent." J Gen Virol 87(Pt 8): 2433-2441. 
Farquhar, C., A. Dickinson and M. Bruce (1999). "Prophylactic potential of pentosan 
polysulphate in transmissible spongiform encephalopathies." Lancet 353(9147): 117. 
259 
 
Farquhar, C. F., R. A. Somerville and M. E. Bruce (1998). "Straining the prion hypothesis." 
Nature 391(6665): 345-346. 
Farquhar, C. F., R. A. Somerville and L. A. Ritchie (1989). "Post-mortem immunodiagnosis of 
scrapie and bovine spongiform encephalopathy." J Virol Methods 24(1-2): 215-221. 
Fernandez-Borges, N., J. de Castro and J. Castilla (2009). "In vitro studies of the transmission 
barrier." Prion 3(4): 220-223. 
Fraser, H., K. L. Brown, K. Stewart, I. McConnell, P. McBride and A. Williams (1996). 
"Replication of scrapie in spleens of SCID mice follows reconstitution with wild-type mouse 
bone marrow." J Gen Virol 77 ( Pt 8): 1935-1940. 
Fraser, H. and A. G. Dickinson (1968). "The sequential development of the brain lesion of 
scrapie in three strains of mice." J Comp Pathol 78(3): 301-311. 
Fraser, H. and A. G. Dickinson (1970). "Pathogenesis of scrapie in the mouse: the role of the 
spleen." Nature 226(5244): 462-463. 
Fraser, H. and C. F. Farquhar (1987). "Ionising radiation has no influence on scrapie 
incubation period in mice." Vet Microbiol 13(3): 211-223. 
Fraser, J. R. (1996). "Infectivity in extraneural tissues following intraocular scrapie 
infection." J Gen Virol 77 ( Pt 10): 2663-2668. 
Fratini, F., S. Principe, M. Puopolo, A. Ladogana, A. Poleggi, P. Piscopo, G. Bruno, S. 
Castrechini, R. Pascone, A. Confaloni, L. Minghetti, F. Cardone, M. Pocchiari and M. 
Crescenzi (2012). "Increased levels of acute-phase inflammatory proteins in plasma of 
patients with sporadic CJD." Neurology. 
Fujihara, A., R. Atarashi, T. Fuse, K. Ubagai, T. Nakagaki, N. Yamaguchi, D. Ishibashi, S. 
Katamine and N. Nishida (2009). "Hyperefficient PrP Sc amplification of mouse-adapted BSE 
and scrapie strain by protein misfolding cyclic amplification technique." FEBS J 276(10): 
2841-2848. 
Féraudet, C., N. Morel, S. Simon, H. Volland, Y. Frobert, C. Créminon, D. Vilette, S. Lehmann 
and J. Grassi (2005). "Screening of 145 anti-PrP monoclonal antibodies for their capacity to 
inhibit PrPSc replication in infected cells." J Biol Chem 280(12): 11247-11258. 
Gambetti, P., Z. Dong, J. Yuan, X. Xiao, M. Zheng, A. Alshekhlee, R. Castellani, M. Cohen, M. 
A. Barria, D. Gonzalez-Romero, E. D. Belay, L. B. Schonberger, K. Marder, C. Harris, J. R. 
Burke, T. Montine, T. Wisniewski, D. W. Dickson, C. Soto, C. M. Hulette, J. A. Mastrianni, Q. 
Kong and W. Q. Zou (2008). "A novel human disease with abnormal prion protein sensitive 
to protease." Ann Neurol 63(6): 697-708. 
Gauczynski, S., J. M. Peyrin, S. Haïk, C. Leucht, C. Hundt, R. Rieger, S. Krasemann, J. P. 
Deslys, D. Dormont, C. I. Lasmézas and S. Weiss (2001). "The 37-kDa/67-kDa laminin 
receptor acts as the cell-surface receptor for the cellular prion protein." EMBO J 20(21): 
5863-5875. 
Gavier-Widén, D., M. J. Stack, T. Baron, A. Balachandran and M. Simmons (2005). "Diagnosis 
of transmissible spongiform encephalopathies in animals: a review." J Vet Diagn Invest 
17(6): 509-527. 
Geoghegan, J. C., P. A. Valdes, N. R. Orem, N. R. Deleault, R. A. Williamson, B. T. Harris and 
S. Supattapone (2007). "Selective incorporation of polyanionic molecules into hamster 
prions." J Biol Chem 282(50): 36341-36353. 
Goldmann, W. (2008). "PrP genetics in ruminant transmissible spongiform 
encephalopathies." Vet Res 39(4): 30. 
Gonzalez-Montalban, N., N. Makarava, V. G. Ostapchenko, R. Savtchenk, I. Alexeeva, R. G. 
Rohwer and I. V. Baskakov (2011). "Highly efficient protein misfolding cyclic amplification." 
PLoS Pathog 7(2): e1001277. 
260 
 
Gonzalez-Montalban, N., N. Makarava, R. Savtchenko and I. V. Baskakov (2011). 
"Relationship between conformational stability and amplification efficiency of prions." 
Biochemistry 50(37): 7933-7940. 
Gonzalez-Romero, D., M. A. Barria, P. Leon, R. Morales and C. Soto (2008). "Detection of 
infectious prions in urine." FEBS Lett 582(21-22): 3161-3166. 
Gorg, A., C. Obermaier, G. Boguth, A. Harder, B. Scheibe, R. Wildgruber and W. Weiss 
(2000). "The current state of two-dimensional electrophoresis with immobilized pH 
gradients." Electrophoresis 21(6): 1037-1053. 
Gorg, A., W. Postel and S. Gunther (1988). "The current state of two-dimensional 
electrophoresis with immobilized pH gradients." Electrophoresis 9(9): 531-546. 
Gough, K. C., C. A. Baker, M. Taema and B. C. Maddison (2009). "In vitro amplification of 
prions from milk in the detection of subclinical infections." Prion 3(4): 236-239. 
Graner, E., A. F. Mercadante, S. M. Zanata, O. V. Forlenza, A. L. Cabral, S. S. Veiga, M. A. 
Juliano, R. Roesler, R. Walz, A. Minetti, I. Izquierdo, V. R. Martins and R. R. Brentani (2000). 
"Cellular prion protein binds laminin and mediates neuritogenesis." Brain Res Mol Brain Res 
76(1): 85-92. 
Grassi, J., S. Maillet, S. Simon and N. Morel (2008). "Progress and limits of TSE diagnostic 
tools." Vet Res 39(4): 33. 
Gray, J. G., S. Dudas and S. Czub (2011). "A study on the analytical sensitivity of 6 BSE tests 
used by the Canadian BSE reference laboratory." PLoS One 6(3): e17633. 
Gray, J. G., S. Dudas, C. Graham and S. Czub (2012). "Performance analysis of rapid 
diagnostic tests on atypical bovine spongiform encephalopathy." J Vet Diagn Invest. 
Grosset, A., K. Moskowitz, C. Nelsen, T. Pan, E. Davidson and C. S. Orser (2005). "Rapid 
presymptomatic detection of PrPSc via conformationally responsive palindromic PrP 
peptides." Peptides 26(11): 2193-2200. 
Head, M. W., T. J. Bunn, M. T. Bishop, V. McLoughlin, S. Lowrie, C. S. McKimmie, M. C. 
Williams, L. McCardle, J. MacKenzie, R. Knight, R. G. Will and J. W. Ironside (2004). "Prion 
protein heterogeneity in sporadic but not variant Creutzfeldt-Jakob disease: UK cases 1991-
2002." Ann Neurol 55(6): 851-859. 
Head, M. W., E. Kouverianou, L. Taylor, A. Green and R. Knight (2005). "Evaluation of 
urinary PrPSc as a diagnostic test for sporadic, variant, and familial CJD." Neurology 64(10): 
1794-1796. 
Herbst, A., S. McIlwain, J. J. Schmidt, J. M. Aiken, C. D. Page and L. Li (2009). "Prion disease 
diagnosis by proteomic profiling." J Proteome Res 8(2): 1030-1036. 
Hilmert, H. and H. Diringer (1984). "A rapid and efficient method to enrich SAF-protein from 
scrapie brains of hamsters." Biosci Rep 4(2): 165-170. 
Horiuchi, M. and B. Caughey (1999). "Specific binding of normal prion protein to the scrapie 
form via a localized domain initiates its conversion to the protease-resistant state." EMBO J 
18(12): 3193-3203. 
Hsiao, K., M. Scott, D. Foster, S. J. DeArmond, D. Groth, H. Serban and S. B. Prusiner (1991). 
"Spontaneous neurodegeneration in transgenic mice with prion protein codon 101 proline--
--leucine substitution." Ann N Y Acad Sci 640: 166-170. 
Hsiao, K. K., D. Groth, M. Scott, S. L. Yang, H. Serban, D. Rapp, D. Foster, M. Torchia, S. J. 
Dearmond and S. B. Prusiner (1994). "Serial transmission in rodents of neurodegeneration 
from transgenic mice expressing mutant prion protein." Proc Natl Acad Sci U S A 91(19): 
9126-9130. 
Hsiao, K. K., M. Scott, D. Foster, D. F. Groth, S. J. DeArmond and S. B. Prusiner (1990). 




Hunter, N., J. Foster, A. Chong, S. McCutcheon, D. Parnham, S. Eaton, C. MacKenzie and F. 
Houston (2002). "Transmission of prion diseases by blood transfusion." J Gen Virol 83(Pt 
11): 2897-2905. 
Hunter, N., J. Hope, I. McConnell and A. G. Dickinson (1987). "Linkage of the scrapie-
associated fibril protein (PrP) gene and Sinc using congenic mice and restriction fragment 
length polymorphism analysis." J Gen Virol 68 ( Pt 10): 2711-2716. 
Hutchens and Yip (1993). "New desorption strategies for the mass spectrometry analysis of 
macromolecules." Rapid Communications in Mass Spectrometry 7(7): 576-580. 
Imran, M. and S. Mahmood (2011). "An overview of human prion diseases." Virol J 8: 559. 
Iniguez, V., D. McKenzie, J. Mirwald and J. Aiken (2000). "Strain-specific propagation of 
PrP(Sc) properties into baculovirus-expressed hamster PrP(C)." J Gen Virol 81(Pt 10): 2565-
2571. 
Jarrett, J. T. and P. T. Lansbury, Jr. (1993). "Seeding "one-dimensional crystallization" of 
amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?" Cell 73(6): 1055-
1058. 
Jeffrey, M., G. McGovern, E. V. Chambers, D. King, L. Gonzalez, J. C. Manson, B. Ghetti, P. 
Piccardo and R. M. Barron (2011). "Mechanism of PrP-Amyloid Formation in Mice Without 
Transmissible Spongiform Encephalopathy." Brain Pathol. 
Jeffrey, M., G. McGovern, E. V. Chambers, D. King, L. González, J. C. Manson, B. Ghetti, P. 
Piccardo and R. M. Barron (2012). "Mechanism of PrP-amyloid formation in mice without 
transmissible spongiform encephalopathy." Brain Pathol 22(1): 58-66. 
Jodoin, J., M. Misiewicz, P. Makhijani, P. N. Giannopoulos, J. Hammond, C. G. Goodyer and 
A. C. LeBlanc (2009). "Loss of anti-Bax function in Gerstmann-Straussler-Scheinker 
syndrome-associated prion protein mutants." PLoS One 4(8): e6647. 
Jones, M., A. H. Peden, M. W. Head and J. W. Ironside (2011). "The application of in vitro 
cell-free conversion systems to human prion diseases." Acta Neuropathol 121(1): 135-143. 
Jones, M., A. H. Peden, C. V. Prowse, A. Groner, J. C. Manson, M. L. Turner, J. W. Ironside, I. 
R. MacGregor and M. W. Head (2007). "In vitro amplification and detection of variant 
Creutzfeldt-Jakob disease PrPSc." J Pathol 213(1): 21-26. 
Jones, M., A. H. Peden, D. Wight, C. Prowse, I. Macgregor, J. Manson, M. Turner, J. W. 
Ironside and M. W. Head (2008). "Effects of human PrPSc type and PRNP genotype in an in-
vitro conversion assay." Neuroreport 19(18): 1783-1786. 
Jones, M., A. H. Peden, H. Yull, D. Wight, M. T. Bishop, C. V. Prowse, M. L. Turner, J. W. 
Ironside, I. R. Macgregor and M. W. Head (2008). "Human platelets as a substrate source 
for the in vitro amplification of the abnormal prion protein (PrP) associated with variant 
Creutzfeldt-Jakob disease." Transfusion. 
Jones, M., D. Wight, R. Barron, M. Jeffrey, J. Manson, C. Prowse, J. W. Ironside and M. W. 
Head (2009). "Molecular model of prion transmission to humans." Emerg Infect Dis 15(12): 
2013-2016. 
Jones, M., D. Wight, V. McLoughlin, K. Norrby, J. W. Ironside, J. G. Connolly, C. F. Farquhar, 
I. R. MacGregor and M. W. Head (2009). "An antibody to the aggregated synthetic prion 
protein peptide (PrP106-126) selectively recognizes disease-associated prion protein (PrP) 
from human brain specimens." Brain Pathol 19(2): 293-302. 
Kaneko, K., H. L. Ball, H. Wille, H. Zhang, D. Groth, M. Torchia, P. Tremblay, J. Safar, S. B. 
Prusiner, S. J. DeArmond, M. A. Baldwin and F. E. Cohen (2000). "A synthetic peptide 
initiates Gerstmann-Straussler-Scheinker (GSS) disease in transgenic mice." J Mol Biol 
295(4): 997-1007. 
Kascsak, R. J., R. Rubenstein, P. A. Merz, M. Tonna-DeMasi, R. Fersko, R. I. Carp, H. M. 
Wisniewski and H. Diringer (1987). "Mouse polyclonal and monoclonal antibody to scrapie-
associated fibril proteins." J Virol 61(12): 3688-3693. 
262 
 
Kim, C., T. Haldiman, Y. Cohen, W. Chen, J. Blevins, M. S. Sy, M. Cohen and J. G. Safar 
(2011). "Protease-sensitive conformers in broad spectrum of distinct PrPSc structures in 
sporadic Creutzfeldt-Jakob disease are indicator of progression rate." PLoS Pathog 7(9): 
e1002242. 
Kim, J. I., I. Cali, K. Surewicz, Q. Kong, G. J. Raymond, R. Atarashi, B. Race, L. Qing, P. 
Gambetti, B. Caughey and W. K. Surewicz (2010). "Mammalian prions generated from 
bacterially expressed prion protein in the absence of any mammalian cofactors." J Biol 
Chem 285(19): 14083-14087. 
Kimberlin, R. H. (1982). "Scrapie agent: prions or virinos?" Nature 297(5862): 107-108. 
Kimberlin, R. H. and C. A. Walker (1989). "The role of the spleen in the neuroinvasion of 
scrapie in mice." Virus Res 12(3): 201-211. 
Kimberlin, R. H., C. A. Walker, G. C. Millson, D. M. Taylor, P. A. Robertson, A. H. Tomlinson 
and A. G. Dickinson (1983). "Disinfection studies with two strains of mouse-passaged 
scrapie agent. Guidelines for Creutzfeldt-Jakob and related agents." J Neurol Sci 59(3): 355-
369. 
Kirby, L., C. R. Birkett, H. Rudyk, I. H. Gilbert and J. Hope (2003). "In vitro cell-free 
conversion of bacterial recombinant PrP to PrPres as a model for conversion." J Gen Virol 
84(Pt 4): 1013-1020. 
Klingeborn, M., B. Race, K. D. Meade-White and B. Chesebro (2011). "Lower specific 
infectivity of protease-resistant prion protein generated in cell-free reactions." Proc Natl 
Acad Sci U S A 108(48): E1244-1253. 
Kocisko, D. A., J. H. Come, S. A. Priola, B. Chesebro, G. J. Raymond, P. T. Lansbury and B. 
Caughey (1994). "Cell-free formation of protease-resistant prion protein." Nature 
370(6489): 471-474. 
Korth, C., B. Stierli, P. Streit, M. Moser, O. Schaller, R. Fischer, W. Schulz-Schaeffer, H. 
Kretzschmar, A. Raeber, U. Braun, F. Ehrensperger, S. Hornemann, R. Glockshuber, R. Riek, 
M. Billeter, K. Wuthrich and B. Oesch (1997). "Prion (PrPSc)-specific epitope defined by a 
monoclonal antibody." Nature 390(6655): 74-77. 
Lacroux, C., D. Vilette, N. Fernández-Borges, C. Litaise, S. Lugan, N. Morel, F. Corbière, S. 
Simon, H. Simmons, P. Costes, J. L. Weisbecker, I. Lantier, F. Lantier, F. Schelcher, J. Grassi, J. 
Castilla and O. Andréoletti (2012). "Prionemia and leukocyte-platelet-associated infectivity 
in sheep transmissible spongiform encephalopathy models." J Virol 86(4): 2056-2066. 
Ladogana, A., P. Sanchez-Juan, E. Mitrová, A. Green, N. Cuadrado-Corrales, R. Sánchez-
Valle, S. Koscova, A. Aguzzi, T. Sklaviadis, J. Kulczycki, J. Gawinecka, A. Saiz, M. Calero, C. M. 
van Duijn, M. Pocchiari, R. Knight and I. Zerr (2009). "Cerebrospinal fluid biomarkers in 
human genetic transmissible spongiform encephalopathies." J Neurol 256(10): 1620-1628. 
Lane, A., C. Stanley, S. Dealler and S. Wilson (2003). Polymeric Ligands with Specificity for 
Aggregated 
Prion Proteins. Clinical Chemistry. 49: 1774-1775. 
Lane, A., C. Stanley, S. Dealler and S. Wilson (2003). Polymeric Ligands with Specificity for 
Aggregated Prion Proteins. Clinical Chemistry. 
Lane, A., C. Stanley and S. Wilson (2010). Binding of pathological forms of prion proteins. 
United States, Microsens Biophage Limited. 
Lasmezas, C. I., J. P. Deslys, O. Robain, A. Jaegly, V. Beringue, J. M. Peyrin, J. G. Fournier, J. J. 
Hauw, J. Rossier and D. Dormont (1997). "Transmission of the BSE agent to mice in the 
absence of detectable abnormal prion protein." Science 275(5298): 402-405. 
Laws, D. D., H. M. Bitter, K. Liu, H. L. Ball, K. Kaneko, H. Wille, F. E. Cohen, S. B. Prusiner, A. 
Pines and D. E. Wemmer (2001). "Solid-state NMR studies of the secondary structure of a 
263 
 
mutant prion protein fragment of 55 residues that induces neurodegeneration." Proc Natl 
Acad Sci U S A 98(20): 11686-11690. 
Lee, C. C., L. T. Kuo, C. H. Wang, F. Scaravilli and S. F. An (2005). "Accumulation of prion 
protein in the peripheral nervous system in human prion diseases." J Neuropathol Exp 
Neurol 64(8): 716-721. 
Lefrère, J. J. and P. Hewitt (2009). "From mad cows to sensible blood transfusion: the risk of 
prion transmission by labile blood components in the United Kingdom and in France." 
Transfusion 49(4): 797-812. 
Legname, G., I. V. Baskakov, H. O. Nguyen, D. Riesner, F. E. Cohen, S. J. DeArmond and S. B. 
Prusiner (2004). "Synthetic mammalian prions." Science 305(5684): 673-676. 
Legname, G., H. O. Nguyen, I. V. Baskakov, F. E. Cohen, S. J. Dearmond and S. B. Prusiner 
(2005). "Strain-specified characteristics of mouse synthetic prions." Proc Natl Acad Sci U S A 
102(6): 2168-2173. 
Lemmer, K., M. Mielke, C. Kratzel, M. Joncic, M. Oezel, G. Pauli and M. Beekes (2008). 
"Decontamination of surgical instruments from prions. II. In vivo findings with a model 
system for testing the removal of scrapie infectivity from steel surfaces." J Gen Virol 89(Pt 
1): 348-358. 
Lewis, V., C. L. Haigh, C. L. Masters, A. F. Hill, V. A. Lawson and S. J. Collins (2012). "Prion 
subcellular fractionation reveals infectivity spectrum, with a high titre-low PrPres level 
disparity." Mol Neurodegener 7: 18. 
Li, J., S. Browning, S. P. Mahal, A. M. Oelschlegel and C. Weissmann (2010). "Darwinian 
evolution of prions in cell culture." Science 327(5967): 869-872. 
Li, R., T. Liu, B. S. Wong, T. Pan, M. Morillas, W. Swietnicki, K. O'Rourke, P. Gambetti, W. K. 
Surewicz and M. S. Sy (2000). "Identification of an epitope in the C terminus of normal prion 
protein whose expression is modulated by binding events in the N terminus." J Mol Biol 
301(3): 567-573. 
Liberski, P. P. (2012). "Gerstmann-Sträussler-Scheinker disease." Adv Exp Med Biol 724: 
128-137. 
Liberski, P. P. and H. Budka (2004). "Gerstmann-Sträussler-Scheinker disease. I. Human 
diseases." Folia Neuropathol 42 Suppl B: 120-140. 
Llewelyn, C. A., P. E. Hewitt, R. S. Knight, K. Amar, S. Cousens, J. Mackenzie and R. G. Will 
(2004). "Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion." 
Lancet 363(9407): 417-421. 
Maddison, B. C., C. A. Baker, H. C. Rees, L. A. Terry, L. Thorne, S. J. Bellworthy, G. C. 
Whitelam and K. C. Gough (2009). "Prions are secreted in milk from clinically normal 
scrapie-exposed sheep." J Virol 83(16): 8293-8296. 
Maddison, B. C., C. A. Baker, L. A. Terry, S. J. Bellworthy, L. Thorne, H. C. Rees and K. C. 
Gough (2010). "Environmental Sources of Scrapie Prions." J Virol. 
Maddison, B. C., H. C. Rees, C. A. Baker, M. Taema, S. J. Bellworthy, L. Thorne, L. A. Terry 
and K. C. Gough (2010). "Prions are secreted into the oral cavity in sheep with preclinical 
scrapie." J Infect Dis 201(11): 1672-1676. 
Mahal, S. P., C. A. Demczyk, E. W. Smith, P. C. Klohn and C. Weissmann (2008). "Assaying 
prions in cell culture: the standard scrapie cell assay (SSCA) and the scrapie cell assay in end 
point format (SCEPA)." Methods Mol Biol 459: 49-68. 
Makarava, N., G. G. Kovacs, O. Bocharova, R. Savtchenko, I. Alexeeva, H. Budka, R. G. 
Rohwer and I. V. Baskakov (2010). "Recombinant prion protein induces a new transmissible 
prion disease in wild-type animals." Acta Neuropathol 119(2): 177-187. 
Manson, J. C., A. R. Clarke, M. L. Hooper, L. Aitchison, I. McConnell and J. Hope (1994). 
"129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are 
developmentally normal." Mol Neurobiol 8(2-3): 121-127. 
264 
 
Manson, J. C., A. R. Clarke, P. A. McBride, I. McConnell and J. Hope (1994). "PrP gene 
dosage determines the timing but not the final intensity or distribution of lesions in scrapie 
pathology." Neurodegeneration 3(4): 331-340. 
Manson, J. C., E. Jamieson, H. Baybutt, N. L. Tuzi, R. Barron, I. McConnell, R. Somerville, J. 
Ironside, R. Will, M. S. Sy, D. W. Melton, J. Hope and C. Bostock (1999). "A single amino acid 
alteration (101L) introduced into murine PrP dramatically alters incubation time of 
transmissible spongiform encephalopathy." EMBO J 18(23): 6855-6864. 
Manuelidis, L. (2003). "Transmissible encephalopathies: speculations and realities." Viral 
Immunol 16(2): 123-139. 
Manuelidis, L. (2007). "A 25 nm virion is the likely cause of transmissible spongiform 
encephalopathies." J Cell Biochem 100(4): 897-915. 
Manuelidis, L. (2011). "Nuclease resistant circular DNAs copurify with infectivity in scrapie 
and CJD." J Neurovirol 17(2): 131-145. 
Masters, C. L., D. C. Gajdusek and C. J. Gibbs (1981). "Creutzfeldt-Jakob disease virus 
isolations from the Gerstmann-Sträussler syndrome with an analysis of the various forms of 
amyloid plaque deposition in the virus-induced spongiform encephalopathies." Brain 
104(3): 559-588. 
Mays, C. E., W. Titlow, T. Seward, G. C. Telling and C. Ryou (2009). "Enhancement of protein 
misfolding cyclic amplification by using concentrated cellular prion protein source." 
Biochem Biophys Res Commun 388(2): 306-310. 
McBride, P. A., W. J. Schulz-Schaeffer, M. Donaldson, M. Bruce, H. Diringer, H. A. 
Kretzschmar and M. Beekes (2001). "Early spread of scrapie from the gastrointestinal tract 
to the central nervous system involves autonomic fibers of the splanchnic and vagus 
nerves." J Virol 75(19): 9320-9327. 
McCulloch, L., K. L. Brown, B. M. Bradford, J. Hopkins, M. Bailey, K. Rajewsky, J. C. Manson 
and N. A. Mabbott (2011). "Follicular dendritic cell-specific prion protein (PrP) expression 
alone is sufficient to sustain prion infection in the spleen." PLoS Pathog 7(12): e1002402. 
McCutcheon, S., A. R. Alejo Blanco, E. F. Houston, C. de Wolf, B. C. Tan, A. Smith, M. H. 
Groschup, N. Hunter, V. S. Hornsey, I. R. MacGregor, C. V. Prowse, M. Turner and J. C. 
Manson (2011). "All clinically-relevant blood components transmit prion disease following a 
single blood transfusion: a sheep model of vCJD." PLoS One 6(8): e23169. 
McCutcheon, S., N. Hunter and F. Houston (2005). "Use of a new immunoassay to measure 
PrP Sc levels in scrapie-infected sheep brains reveals PrP genotype-specific differences." J 
Immunol Methods 298(1-2): 119-128. 
McGuire, L., A. Peden, C. Orru, J. Wilham, N. Appleford, G. Mallinson, M. Andrews, M. 
Head, B. Caughey, R. Will, R. Knight and A. Green (2012). "RT-QuIC analysis of cerebrospinal 
fluid in sporadic Creutzfeldt-Jakob disease." Annals of Neurology. 
McKinley, M. P., D. C. Bolton and S. B. Prusiner (1983). "A protease-resistant protein is a 
structural component of the scrapie prion." Cell 35(1): 57-62. 
Merz, P. A., R. A. Somerville, H. M. Wisniewski and K. Iqbal (1981). "Abnormal fibrils from 
scrapie-infected brain." Acta Neuropathol 54(1): 63-74. 
Millson, G. C., G. D. Hunter and R. H. Kimberlin (1976). "The physico-chemical nature of the 
scrapie agent." Front Biol 44: 243-266. 
Mohri, S., C. F. Farquhar, R. A. Somerville, M. Jeffrey, J. Foster and J. Hope (1992). 
"Immunodetection of a disease specific PrP fraction in scrapie-affected sheep and BSE-
affected cattle." Vet Rec 131(23): 537-539. 
Monaco, S., M. Fiorini, A. Farinazzo, S. Ferrari, M. Gelati, P. Piccardo, G. Zanusso and B. 
Ghetti (2012). "Allelic origin of protease-sensitive and protease-resistant prion protein 




Monaco, S., M. Fiorini, A. Farinazzo, S. Ferrari, M. Gelati, P. Piccardo, G. Zanusso and B. 
Ghetti (2012). "Allelic origin of protease-sensitive and protease-resistant prion protein 
isoforms in Gerstmann-Sträussler-Scheinker disease with the P102L mutation." PLoS One 
7(2): e32382. 
Moroncini, G., N. Kanu, L. Solforosi, G. Abalos, G. C. Telling, M. Head, J. Ironside, J. P. 
Brockes, D. R. Burton and R. A. Williamson (2004). "Motif-grafted antibodies containing the 
replicative interface of cellular PrP are specific for PrPSc." Proc Natl Acad Sci U S A 101(28): 
10404-10409. 
Murayama, Y., M. Yoshioka, H. Okada, M. Takata, T. Yokoyama and S. Mohri (2007). 
"Urinary excretion and blood level of prions in scrapie-infected hamsters." J Gen Virol 88(Pt 
10): 2890-2898. 
Murayama, Y., M. Yoshioka, T. Yokoyama, Y. Iwamaru, M. Imamura, K. Masujin, S. Yoshiba 
and S. Mohri (2007). "Efficient in vitro amplification of a mouse-adapted scrapie prion 
protein." Neurosci Lett 413(3): 270-273. 
Nazor, K. E., F. Kuhn, T. Seward, M. Green, D. Zwald, M. Purro, J. Schmid, K. Biffiger, A. M. 
Power, B. Oesch, A. J. Raeber and G. C. Telling (2005). "Immunodetection of disease-
associated mutant PrP, which accelerates disease in GSS transgenic mice." EMBO J 24(13): 
2472-2480. 
Nichols, T. A., B. Pulford, A. C. Wyckoff, C. Meyerett, B. Michel, K. Gertig, E. A. Hoover, J. E. 
Jewell, G. C. Telling and M. D. Zabel (2009). "Detection of protease-resistant cervid prion 
protein in water from a CWD-endemic area." Prion 3(3): 171-183. 
Notari, S., L. Qing, M. Pocchiari, A. Dagdanova, K. Hatcher, A. Dogterom, J. F. Groisman, I. B. 
Lumholtz, M. Puopolo, C. Lasmezas, S. G. Chen, Q. Kong and P. Gambetti (2012). "Assessing 
prion infectivity of human urine in sporadic Creutzfeldt-Jakob disease." Emerg Infect Dis 
18(1): 21-28. 
Orru, C. D., J. M. Wilham, L. D. Raymond, F. Kuhn, B. Schroeder, A. J. Raeber and B. Caughey 
(2011). "Prion disease blood test using immunoprecipitation and improved quaking-induced 
conversion." MBio 2(3). 
Orrù, C. D., A. G. Hughson, B. Race, G. J. Raymond and B. Caughey (2012). "Time course of 
prion seeding activity in cerebrospinal fluid of scrapie-infected hamsters after intratongue 
and intracerebral inoculations." J Clin Microbiol. 
Orrú, C. D., J. M. Wilham, A. G. Hughson, L. D. Raymond, K. L. McNally, A. Bossers, C. Ligios 
and B. Caughey (2009). "Human variant Creutzfeldt-Jakob disease and sheep scrapie 
PrP(res) detection using seeded conversion of recombinant prion protein." Protein Eng Des 
Sel 22(8): 515-521. 
Pan, K. M., M. Baldwin, J. Nguyen, M. Gasset, A. Serban, D. Groth, I. Mehlhorn, Z. Huang, R. 
J. Fletterick, F. E. Cohen and et al. (1993). "Conversion of alpha-helices into beta-sheets 
features in the formation of the scrapie prion proteins." Proc Natl Acad Sci U S A 90(23): 
10962-10966. 
Pan, T., J. Sethi, C. Nelsen, A. Rudolph, L. Cervenakova, P. Brown and C. S. Orser (2007). 
"Detection of misfolded prion protein in blood with conformationally sensitive peptides." 
Transfusion 47(8): 1418-1425. 
Parliament, E. (2001). REGULATION (EC) No 999/2001 OF THE EUROPEAN PARLIAMENT 
AND OF THE COUNCIL 
of 22 May 2001 laying down rules for the prevention, control and eradication of certain 
transmissible spongiform encephalopathies. L147/1. T. E. P. A. T. C. O. THE and E. UNION. 
Pastrana, M. A., G. Sajnani, B. Onisko, J. Castilla, R. Morales, C. Soto and J. R. Requena 
(2006). "Isolation and characterization of a proteinase K-sensitive PrPSc fraction." 
Biochemistry 45(51): 15710-15717. 
266 
 
Patton, W. F. (2000). "Making blind robots see: the synergy between fluorescent dyes and 
imaging devices in automated proteomics." Biotechniques 28(5): 944-948, 950-947. 
Peden, A., L. McCardle, M. W. Head, S. Love, H. J. Ward, S. N. Cousens, D. M. Keeling, C. M. 
Millar, F. G. Hill and J. W. Ironside (2010). "Variant CJD infection in the spleen of a 
neurologically asymptomatic UK adult patient with haemophilia." Haemophilia 16(2): 296-
304. 
Peden, A. H., M. W. Head, D. L. Ritchie, J. E. Bell and J. W. Ironside (2004). "Preclinical vCJD 
after blood transfusion in a PRNP codon 129 heterozygous patient." Lancet 364(9433): 527-
529. 
Peden, A. H., L. I. McGuire, N. E. Appleford, G. Mallinson, J. M. Wilham, C. D. Orrú, B. 
Caughey, J. W. Ironside, R. S. Knight, R. G. Will, A. J. Green and M. W. Head (2012). 
"Sensitive and specific detection of sporadic Creutzfeldt-Jakob disease brain prion protein 
using real-time quaking-induced conversion." J Gen Virol 93(Pt 2): 438-449. 
Piccardo, P., J. C. Manson, D. King, B. Ghetti and R. M. Barron (2007). "Accumulation of 
prion protein in the brain that is not associated with transmissible disease." Proc Natl Acad 
Sci U S A 104(11): 4712-4717. 
Piening, N., R. Nonno, M. Di Bari, S. Walter, O. Windl, U. Agrimi, H. A. Kretzschmar and U. 
Bertsch (2006). "Conversion efficiency of bank vole prion protein in vitro is determined by 
residues 155 and 170, but does not correlate with the high susceptibility of bank voles to 
sheep scrapie in vivo." J Biol Chem 281(14): 9373-9384. 
Pirisinu, L., M. Di Bari, S. Marcon, G. Vaccari, C. D'Agostino, P. Fazzi, E. Esposito, R. Galeno, J. 
Langeveld, U. Agrimi and R. Nonno (2010). "A new method for the characterization of 
strain-specific conformational stability of protease-sensitive and protease-resistant PrP." 
PLoS One 5(9): e12723. 
Prusiner, S. B. (1982). "Novel proteinaceous infectious particles cause scrapie." Science 
216(4542): 136-144. 
Prusiner, S. B., D. Groth, A. Serban, R. Koehler, D. Foster, M. Torchia, D. Burton, S. L. Yang 
and S. J. DeArmond (1993). "Ablation of the prion protein (PrP) gene in mice prevents 
scrapie and facilitates production of anti-PrP antibodies." Proc Natl Acad Sci U S A 90(22): 
10608-10612. 
Prusiner, S. B., D. F. Groth, M. P. McKinley, S. P. Cochran, K. A. Bowman and K. C. Kasper 
(1981). "Thiocyanate and hydroxyl ions inactivate the scrapie agent." Proc Natl Acad Sci U S 
A 78(7): 4606-4610. 
Prusiner, S. B., M. P. McKinley, D. F. Groth, K. A. Bowman, N. I. Mock, S. P. Cochran and F. R. 
Masiarz (1981). "Scrapie agent contains a hydrophobic protein." Proc Natl Acad Sci U S A 
78(11): 6675-6679. 
Race, B. L., K. D. Meade-White, A. Ward, J. Jewell, M. W. Miller, E. S. Williams, B. Chesebro 
and R. E. Race (2007). "Levels of abnormal prion protein in deer and elk with chronic 
wasting disease." Emerg Infect Dis 13(6): 824-830. 
Race, R., K. Meade-White, A. Raines, G. J. Raymond, B. Caughey and B. Chesebro (2002). 
"Subclinical scrapie infection in a resistant species: persistence, replication, and adaptation 
of infectivity during four passages." J Infect Dis 186 Suppl 2: S166-170. 
Raeber, A. J., F. Montrasio, I. Hegyi, R. Frigg, M. A. Klein, A. Aguzzi and C. Weissmann 
(2001). "Studies on prion replication in spleen." Dev Immunol 8(3-4): 291-304. 
Rana, A., D. Gnaneswari, S. Bansal and B. Kundu (2009). "Prion metal interaction: is prion 
pathogenesis a cause or a consequence of metal imbalance?" Chem Biol Interact 181(3): 
282-291. 
Reder, A. T., A. S. Mednick, P. Brown, J. P. Spire, E. Van Cauter, R. L. Wollmann, L. 
Cervenàkovà, L. G. Goldfarb, A. Garay and F. Ovsiew (1995). "Clinical and genetic studies of 
fatal familial insomnia." Neurology 45(6): 1068-1075. 
267 
 
Rieger, R., F. Edenhofer, C. I. Lasmézas and S. Weiss (1997). "The human 37-kDa laminin 
receptor precursor interacts with the prion protein in eukaryotic cells." Nat Med 3(12): 
1383-1388. 
Robinson, M. M., W. P. Cheevers, D. Burger and J. R. Gorham (1990). "Organ-specific 
modification of the dose-response relationship of scrapie infectivity." J Infect Dis 161(4): 
783-786. 
Rohwer, R. G. (1991). "The scrapie agent: "a virus by any other name"." Curr Top Microbiol 
Immunol 172: 195-232. 
Rubenstein, R., P. A. Merz, R. J. Kascsak, C. L. Scalici, M. C. Papini, R. I. Carp and R. H. 
Kimberlin (1991). "Scrapie-infected spleens: analysis of infectivity, scrapie-associated fibrils, 
and protease-resistant proteins." J Infect Dis 164(1): 29-35. 
Ryou, C. and C. E. Mays (2008). "Prion propagation in vitro: are we there yet?" Int J Med Sci 
5(6): 347-353. 
S, W., L. A, O. J and S. C (2004). "A protein-binding ligand system for prion disease 
detection." IVD Technology Beyond Clinical Diagnostics. 
Saa, P., J. Castilla and C. Soto (2005). "Cyclic amplification of protein misfolding and 
aggregation." Methods Mol Biol 299: 53-65. 
Saa, P., J. Castilla and C. Soto (2006). "Presymptomatic detection of prions in blood." 
Science 313(5783): 92-94. 
Saa, P., J. Castilla and C. Soto (2006). "Ultra-efficient replication of infectious prions by 
automated protein misfolding cyclic amplification." J Biol Chem 281(46): 35245-35252. 
Saborio, G. P., B. Permanne and C. Soto (2001). "Sensitive detection of pathological prion 
protein by cyclic amplification of protein misfolding." Nature 411(6839): 810-813. 
Saborio, G. P., C. Soto, R. J. Kascsak, E. Levy, R. Kascsak, D. A. Harris and B. Frangione (1999). 
"Cell-lysate conversion of prion protein into its protease-resistant isoform suggests the 
participation of a cellular chaperone." Biochem Biophys Res Commun 258(2): 470-475. 
Safar, J., H. Wille, V. Itri, D. Groth, H. Serban, M. Torchia, F. E. Cohen and S. B. Prusiner 
(1998). "Eight prion strains have PrP(Sc) molecules with different conformations." Nat Med 
4(10): 1157-1165. 
Safar, J. G., M. D. Geschwind, C. Deering, S. Didorenko, M. Sattavat, H. Sanchez, A. Serban, 
M. Vey, H. Baron, K. Giles, B. L. Miller, S. J. Dearmond and S. B. Prusiner (2005). "Diagnosis 
of human prion disease." Proc Natl Acad Sci U S A 102(9): 3501-3506. 
Safar, J. G., M. Scott, J. Monaghan, C. Deering, S. Didorenko, J. Vergara, H. Ball, G. Legname, 
E. Leclerc, L. Solforosi, H. Serban, D. Groth, D. R. Burton, S. B. Prusiner and R. A. Williamson 
(2002). "Measuring prions causing bovine spongiform encephalopathy or chronic wasting 
disease by immunoassays and transgenic mice." Nat Biotechnol 20(11): 1147-1150. 
Sajnani, G., C. J. Silva, A. Ramos, M. A. Pastrana, B. C. Onisko, M. L. Erickson, E. M. Antaki, I. 
Dynin, E. Vázquez-Fernández, C. J. Sigurdson, J. M. Carter and J. R. Requena (2012). "PK-
sensitive PrP is infectious and shares basic structural features with PK-resistant PrP." PLoS 
Pathog 8(3): e1002547. 
Sanchez-Juan, P., A. Green, A. Ladogana, N. Cuadrado-Corrales, R. Sáanchez-Valle, E. 
Mitrováa, K. Stoeck, T. Sklaviadis, J. Kulczycki, K. Hess, M. Bodemer, D. Slivarichová, A. Saiz, 
M. Calero, L. Ingrosso, R. Knight, A. C. Janssens, C. M. van Duijn and I. Zerr (2006). "CSF tests 
in the differential diagnosis of Creutzfeldt-Jakob disease." Neurology 67(4): 637-643. 
Sandberg, M. K., H. Al-Doujaily, B. Sharps, A. R. Clarke and J. Collinge (2011). "Prion 
propagation and toxicity in vivo occur in two distinct mechanistic phases." Nature 
470(7335): 540-542. 
Santuccione, A., V. Sytnyk, I. Leshchyns'ka and M. Schachner (2005). "Prion protein recruits 
its neuronal receptor NCAM to lipid rafts to activate p59fyn and to enhance neurite 
outgrowth." J Cell Biol 169(2): 341-354. 
268 
 
Sarafoff, N. I., J. Bieschke, A. Giese, P. Weber, U. Bertsch and H. A. Kretzschmar (2005). 
"Automated PrPres amplification using indirect sonication." J Biochem Biophys Methods 
63(3): 213-221. 
Saunders, S. E., R. A. Shikiya, K. Langenfeld, S. L. Bartelt-Hunt and J. C. Bartz (2011). 
"Replication efficiency of soil-bound prions varies with soil type." J Virol 85(11): 5476-5482. 
Saá, P., J. Castilla and C. Soto (2005). "Cyclic amplification of protein misfolding and 
aggregation." Methods Mol Biol 299: 53-65. 
Saá, P., G. F. Sferrazza, G. Ottenberg, A. M. Oelschlegel, K. Dorsey and C. I. Lasmézas (2012). 
"Strain-Specific Role of RNAs in Prion Replication." J Virol. 
Schulz-Schaeffer, W. J., S. Tschöke, N. Kranefuss, W. Dröse, D. Hause-Reitner, A. Giese, M. 
H. Groschup and H. A. Kretzschmar (2000). "The paraffin-embedded tissue blot detects 
PrP(Sc) early in the incubation time in prion diseases." Am J Pathol 156(1): 51-56. 
Scott, M., D. Foster, C. Mirenda, D. Serban, F. Coufal, M. Wälchli, M. Torchia, D. Groth, G. 
Carlson, S. J. DeArmond, D. Westaway and S. B. Prusiner (1989). "Transgenic mice 
expressing hamster prion protein produce species-specific scrapie infectivity and amyloid 
plaques." Cell 59(5): 847-857. 
Shikiya, R. A. and J. C. Bartz (2011). "In vitro generation of high-titer prions." J Virol 85(24): 
13439-13442. 
Somerville, R. A., C. R. Birkett, C. F. Farquhar, N. Hunter, W. Goldmann, J. Dornan, D. 
Grover, R. M. Hennion, C. Percy, J. Foster and M. Jeffrey (1997). "Immunodetection of PrPSc 
in spleens of some scrapie-infected sheep but not BSE-infected cows." J Gen Virol 78 ( Pt 9): 
2389-2396. 
Somerville, R. A., R. C. Oberthur, U. Havekost, F. MacDonald, D. M. Taylor and A. G. 
Dickinson (2002). "Characterization of thermodynamic diversity between transmissible 
spongiform encephalopathy agent strains and its theoretical implications." J Biol Chem 
277(13): 11084-11089. 
Soto, C., L. Anderes, S. Suardi, F. Cardone, J. Castilla, M. J. Frossard, S. Peano, P. Saa, L. 
Limido, M. Carbonatto, J. Ironside, J. M. Torres, M. Pocchiari and F. Tagliavini (2005). "Pre-
symptomatic detection of prions by cyclic amplification of protein misfolding." FEBS Lett 
579(3): 638-642. 
Soto, C. and J. Castilla (2004). "The controversial protein-only hypothesis of prion 
propagation." Nat Med 10 Suppl: S63-67. 
Soto, C., G. P. Saborio and L. Anderes (2002). "Cyclic amplification of protein misfolding: 
application to prion-related disorders and beyond." Trends Neurosci 25(8): 390-394. 
Stahl, N., M. A. Baldwin, D. B. Teplow, L. Hood, B. W. Gibson, A. L. Burlingame and S. B. 
Prusiner (1993). "Structural studies of the scrapie prion protein using mass spectrometry 
and amino acid sequencing." Biochemistry 32(8): 1991-2002. 
Stahl, N., D. R. Borchelt, K. Hsiao and S. B. Prusiner (1987). "Scrapie prion protein contains a 
phosphatidylinositol glycolipid." Cell 51(2): 229-240. 
Supattapone, S. (2010). "Biochemistry. What makes a prion infectious?" Science 327(5969): 
1091-1092. 
Taema, M. M., B. C. Maddison, L. Thorne, K. Bishop, J. Owen, N. Hunter, C. A. Baker, L. A. 
Terry and K. C. Gough (2011). "Differentiating Ovine BSE from CH1641 Scrapie by Serial 
Protein Misfolding Cyclic Amplification." Mol Biotechnol. 
Tateishi, J., T. Kitamoto, H. Hashiguchi and H. Shii (1988). "Gerstmann-Sträussler-Scheinker 
disease: immunohistological and experimental studies." Ann Neurol 24(1): 35-40. 
Tateishi, J., M. Ohta, M. Koga, Y. Sato and Y. Kuroiwa (1979). "Transmission of chronic 




Tateishi, J., Y. Sato, M. Koga, H. Doi and M. Ohta (1980). "Experimental transmission of 
human subacute spongiform encephalopathy to small rodents. I. Clinical and histological 
observations." Acta Neuropathol 51(2): 127-134. 
Tattum, M. H., S. Jones, S. Pal, J. Collinge and G. S. Jackson (2010). "Discrimination between 
prion-infected and normal blood samples by protein misfolding cyclic amplification." 
Transfusion 50(5): 996-1002. 
Telling, G. C., T. Haga, M. Torchia, P. Tremblay, S. J. DeArmond and S. B. Prusiner (1996). 
"Interactions between wild-type and mutant prion proteins modulate neurodegeneration in 
transgenic mice." Genes Dev 10(14): 1736-1750. 
Telling, G. C., M. Scott, J. Mastrianni, R. Gabizon, M. Torchia, F. E. Cohen, S. J. DeArmond 
and S. B. Prusiner (1995). "Prion propagation in mice expressing human and chimeric PrP 
transgenes implicates the interaction of cellular PrP with another protein." Cell 83(1): 79-
90. 
Terry, L. A. (2010). "Defra - Research Project Final Report - A blood test for TSEs." 
Terry, L. A. (2010). "Defra - Research Project Final Report - A blood test for TSEs. ." 
Terry, L. A., L. Howells, J. Hawthorn, J. C. Edwards, S. J. Moore, S. J. Bellworthy, H. Simmons, 
S. Lizano, L. Estey, V. Leathers and S. J. Everest (2009). "Detection of PrPsc in blood from 
sheep infected with the scrapie and bovine spongiform encephalopathy agents." J Virol 
83(23): 12552-12558. 
Thackray, A. M., L. Hopkins and R. Bujdoso (2007). "Proteinase K-sensitive disease-
associated ovine prion protein revealed by conformation-dependent immunoassay." 
Biochem J 401(2): 475-483. 
Thackray, A. M., L. Hopkins, M. A. Klein and R. Bujdoso (2007). "Mouse-adapted ovine 
scrapie prion strains are characterized by different conformers of PrPSc." J Virol 81(22): 
12119-12127. 
Thorne, L. and L. A. Terry (2008). "In vitro amplification of PrPSc derived from the brain and 
blood of sheep infected with scrapie." J Gen Virol 89(Pt 12): 3177-3184. 
Thuring, C. M., L. J. van Keulen, J. P. Langeveld, M. E. Vromans, F. G. van Zijderveld and T. 
Sweeney (2005). "Immunohistochemical distinction between preclinical bovine spongiform 
encephalopathy and scrapie infection in sheep." J Comp Pathol 132(1): 59-69. 
Tixador, P., L. Herzog, F. Reine, E. Jaumain, J. Chapuis, A. Le Dur, H. Laude and V. Beringue 
(2010). "The physical relationship between infectivity and prion protein aggregates is strain-
dependent." PLoS Pathog 6(4): e1000859. 
Tremblay, P., H. L. Ball, K. Kaneko, D. Groth, R. S. Hegde, F. E. Cohen, S. J. DeArmond, S. B. 
Prusiner and J. G. Safar (2004). "Mutant PrPSc conformers induced by a synthetic peptide 
and several prion strains." J Virol 78(4): 2088-2099. 
Tzaban, S., G. Friedlander, O. Schonberger, L. Horonchik, Y. Yedidia, G. Shaked, R. Gabizon 
and A. Taraboulos (2002). "Protease-sensitive scrapie prion protein in aggregates of 
heterogeneous sizes." Biochemistry 41(42): 12868-12875. 
Vieira, T. C., D. P. Reynaldo, M. P. Gomes, M. S. Almeida, Y. Cordeiro and J. L. Silva (2010). 
"Heparin Binding by Murine Recombinant Prion Protein Leads to Transient Aggregation and 
Formation of RNA-Resistant Species." J Am Chem Soc. 
Wadsworth, J. D., S. Joiner, A. F. Hill, T. A. Campbell, M. Desbruslais, P. J. Luthert and J. 
Collinge (2001). "Tissue distribution of protease resistant prion protein in variant 
Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay." Lancet 358(9277): 
171-180. 
Wang, F., X. Wang and J. Ma (2011). "Conversion of bacterially expressed recombinant 
prion protein." Methods 53(3): 208-213. 
Wang, F., X. Wang, C. G. Yuan and J. Ma (2010). "Generating a prion with bacterially 
expressed recombinant prion protein." Science 327(5969): 1132-1135. 
270 
 
Weber, P., A. Giese, N. Piening, G. Mitteregger, A. Thomzig, M. Beekes and H. A. 
Kretzschmar (2006). "Cell-free formation of misfolded prion protein with authentic prion 
infectivity." Proc Natl Acad Sci U S A 103(43): 15818-15823. 
Westaway, D., S. J. DeArmond, J. Cayetano-Canlas, D. Groth, D. Foster, S. L. Yang, M. 
Torchia, G. A. Carlson and S. B. Prusiner (1994). "Degeneration of skeletal muscle, 
peripheral nerves, and the central nervous system in transgenic mice overexpressing wild-
type prion proteins." Cell 76(1): 117-129. 
Westergard, L., H. M. Christensen and D. A. Harris (2007). "The cellular prion protein 
(PrP(C)): its physiological function and role in disease." Biochim Biophys Acta 1772(6): 629-
644. 
Wilham, J. M., C. D. Orrú, R. A. Bessen, R. Atarashi, K. Sano, B. Race, K. D. Meade-White, L. 
M. Taubner, A. Timmes and B. Caughey (2010). "Rapid end-point quantitation of prion 
seeding activity with sensitivity comparable to bioassays." PLoS Pathog 6(12): e1001217. 
Wilson, S., A. Lane, J. Oliver and C. Stanley (2004). "A protein-binding ligand system for 
prion disease detection." IVD Technology Beyond Clinical Diagnostics. 
Working Group, O. B. S. S. w. R. t. V. C.-J. D., vCJD (2009). "Report of the Working Group 
'Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)': 
Statement on the Development and Implementation of Test Systems Suitable for the 
Screening of Blood Donors for vCJD - Dated September 17, 2008." Transfus Med Hemother 
36(1): 79-93. 
Wroe, S. J., S. Pal, D. Siddique, H. Hyare, R. Macfarlane, S. Joiner, J. M. Linehan, S. Brandner, 
J. D. Wadsworth, P. Hewitt and J. Collinge (2006). "Clinical presentation and pre-mortem 
diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case 
report." Lancet 368(9552): 2061-2067. 
Yokoyama, T., A. Takeuchi, M. Yamamoto, T. Kitamoto, J. W. Ironside and M. Morita (2011). 
"Heparin enhances the cell-protein misfolding cyclic amplification efficiency of variant 
Creutzfeldt-Jakob disease." Neurosci Lett 498(2): 119-123. 
Yoshioka, M., M. Imamura, H. Okada, N. Shimozaki, Y. Murayama, T. Yokoyama and S. 
Mohri (2011). "Sc237 hamster PrPSc and Sc237-derived mouse PrPSc generated by 
interspecies in vitro amplification exhibit distinct pathological and biochemical properties in 
tga20 transgenic mice." Microbiol Immunol 55(5): 331-340. 
Yuan, J., X. Xiao, J. McGeehan, Z. Dong, I. Cali, H. Fujioka, Q. Kong, G. Kneale, P. Gambetti 
and W. Q. Zou (2006). "Insoluble aggregates and protease-resistant conformers of prion 
protein in uninfected human brains." J Biol Chem 281(46): 34848-34858. 
Yull, H. M., D. L. Ritchie, J. P. Langeveld, F. G. van Zijderveld, M. E. Bruce, J. W. Ironside and 
M. W. Head (2006). "Detection of type 1 prion protein in variant Creutzfeldt-Jakob disease." 
Am J Pathol 168(1): 151-157. 
Zanata, S. M., M. H. Lopes, A. F. Mercadante, G. N. Hajj, L. B. Chiarini, R. Nomizo, A. R. 
Freitas, A. L. Cabral, K. S. Lee, M. A. Juliano, E. de Oliveira, S. G. Jachieri, A. Burlingame, L. 
Huang, R. Linden, R. R. Brentani and V. R. Martins (2002). "Stress-inducible protein 1 is a cell 
surface ligand for cellular prion that triggers neuroprotection." EMBO J 21(13): 3307-3316. 
Zobeley, E., E. Flechsig, A. Cozzio, M. Enari and C. Weissmann (1999). "Infectivity of scrapie 
prions bound to a stainless steel surface." Mol Med 5(4): 240-243. 
Zomosa-Signoret, V., J. D. Arnaud, P. Fontes, M. T. Alvarez-Martinez and J. P. Liautard 
(2008). "Physiological role of the cellular prion protein." Vet Res 39(4): 9. 
Zou, W. Q., G. Puoti, X. Xiao, J. Yuan, L. Qing, I. Cali, M. Shimoji, J. P. Langeveld, R. Castellani, 
S. Notari, B. Crain, R. E. Schmidt, M. Geschwind, S. J. Dearmond, N. J. Cairns, D. Dickson, L. 
Honig, J. M. Torres, J. Mastrianni, S. Capellari, G. Giaccone, E. D. Belay, L. B. Schonberger, 
M. Cohen, G. Perry, Q. Kong, P. Parchi, F. Tagliavini and P. Gambetti (2010). "Variably 
271 
 
protease-sensitive prionopathy: a new sporadic disease of the prion protein." Ann Neurol 
68(2): 162-172. 
 
 
